genome_id	genome_name	organism_name	taxon_id	genome_status	strain	serovar	biovar	pathovar	mlst	other_typing	culture_collection	type_strain	completion_date	publication	bioproject_accession	biosample_accession	assembly_accession	genbank_accessions	refseq_accessions	sequencing_centers	sequencing_status	sequencing_platform	sequencing_depth	assembly_method	chromosomes	plasmids	contigs	sequences	genome_length	gc_content	patric_cds	brc1_cds	refseq_cds	isolation_site	isolation_source	isolation_comments	collection_date	isolation_country	geographic_location	latitude	longitude	altitude	depth	other_environmental	host_name	host_gender	host_age	host_health	body_sample_site	body_sample_subsite	other_clinical	antimicrobial_resistance	antimicrobial_resistance_evidence	gram_stain	cell_shape	motility	sporulation	temperature_range	optimal_temperature	salinity	oxygen_requirement	habitat	disease	comments	additional_metadata
1314.547	Streptococcus pyogenes		1314	Plasmid									2016-07-26T00:00:00Z	8093174				X66468			Plasmid					1.0	1		19203	34.39	25		21.0																																
1314.540	Streptococcus pyogenes		1314	Plasmid									2016-07-26T00:00:00Z	8093174				AY357120			Plasmid					1.0	1		28975	34.76	38		35.0																																
1210041.3	Streptococcus pyogenes 06BA18369	Streptococcus pyogenes 06BA18369	1210041	WGS					MLST.Streptococcus_pyogenes.579				2013-05-10T00:00:00Z		PRJNA170537	SAMN02470879	GCA_000390225.1	APMZ00000000	-	Northern Antibiotic Resistance Partnership	WGS	454	25.0x	Newbler v. 1.1.03.24	0.0	0.0	47		1813404	38.4	1825		0.0		skin and soft tissue infection	isolated from a mixed skin and soft tissue infection	2006	Canada	Canada: Saskatchewan						Human, Homo sapiens									Positive										Genome sequencing of Staphylococcus aureus and Streptococcus pyogenes co-isolated from a mixed skin and soft tissue infection.	
1314.4070	Streptococcus pyogenes 1004		1314	Complete	1004				MLST.Streptococcus_pyogenes.530				2023-03-21T00:00:00Z		PRJNA943101	SAMN33707422		CP119678				Illumina HiSeq; Oxford Nanopore GridION	130.0x	SPAdes v. 3	1.0	0.0	1		1842099	38.30196	1798		1706.0		skin		2008	India	India: Chandigarh						Homo sapiens																				sample_type:Pure culture
1314.4068	Streptococcus pyogenes 1039		1314	Complete	1039								2023-03-20T00:00:00Z		PRJNA942480	SAMN33693461		CP119597				Illumina HiSeq; Oxford Nanopore GridION	130.0x	SPAdes v. 3	1.0	0.0	1		1856557	38.30591	1827		1734.0		throat		2008	India	India: Chandigarh						Homo sapiens																				sample_type:Pure culture
1314.4067	Streptococcus pyogenes 1042		1314	Complete	1042				MLST.Streptococcus_pyogenes.530				2023-03-20T00:00:00Z		PRJNA942488	SAMN33693473		CP119598				Illumina HiSeq; Oxford Nanopore GridION	130.0x	SPAdes v. 3	1.0	0.0	1		1853582	38.259544	1809		1719.0		Skin sample		2000/2008	India	India: Chandigarh						Homo sapiens																				sample_type:Pure culture
1314.4071	Streptococcus pyogenes 1044		1314	Complete	1044				MLST.Streptococcus_pyogenes.28				2023-04-10T00:00:00Z		PRJNA951075	SAMN34032715		CP121250				Illumina HiSeq; Oxford Nanopore	150.0x	SPAdes v. 3	1.0	0.0	1		2008188	38.50257	2090		1980.0		Skin sample		2002/2007	India	India: Chandigarh						Homo sapiens																				sample_type:Pure culture
1314.3939	Streptococcus pyogenes 1095		1314	Complete	1095				MLST.Streptococcus_pyogenes.530	genotype:emm1-2			2023-01-30T00:00:00Z		PRJNA925705	SAMN32807490		CP116457				Illumina HiSeq; Oxford Nanopore GridION	150.0x	SPAdes v. 3	1.0	0.0	1		1854315	38.254448	1813		1718.0		Invasive		2008	India	India: Chandigarh																										sample_type:Pure cultured organism;biomaterial_provider:PGIMER
1314.4069	Streptococcus pyogenes 1133		1314	Complete	1133								2023-03-20T00:00:00Z		PRJNA943128	SAMN33709030		CP119599				Illumina HiSeq; Oxford Nanopore GridION	300.0x	SPAdes v. 3	1.0	0.0	1		1916409	38.30555	1884		1785.0		throat		2008	India	India: Chandigarh						Homo sapiens																				sample_type:Pure culture
1314.134	Streptococcus pyogenes 1E1		1314	Complete	1E1				MLST.Streptococcus_pyogenes.178				2014-11-05T00:00:00Z	-	PRJNA238987	SAMN02649402	GCA_000772245.1	CP007241.1	NZ_CP007241.1	University Rennes1	Complete	Illumina		CLC Genomics workbench v. 6.5.1	1.0		1		1796152	38.48	1732		1652.0		Hospital		2009	France	France:Brittany						Human, Homo sapiens									Positive	Cocci	No	No							Sequence analysis of a non-clonal type emm44 S. pyogenes.	
1314.3899	Streptococcus pyogenes 21/M49		1314	WGS	21/M49				MLST.Streptococcus_pyogenes.433				2022-11-19T00:00:00Z		PRJNA901290	SAMN31710621		JAPIVB000000000				Illumina	39.0x	SPAdes v. 3.13.0	0.0	0.0	28		1844013	38.13357	1869		1780.0		blood		2005	USA	USA: Atlanta						Homo sapiens			Sepsis																	collected_by:Bernard Beale
1314.3322	Streptococcus pyogenes 21SPY7071		1314	Complete	21SPY7071				MLST.Streptococcus_pyogenes.46	genotype:emm 21			2022-05-17T00:00:00Z		PRJNA835576	SAMN28104815	GCA_023380045.1	CP097251			Complete	Illumina HiSeq	728.0x	SOAPdenovo v. 2.04	1.0	0.0	1		1910967	38.514427	1939		1842.0		cerebral abscess pus		2021-12-09	China	China: Hangzhou						Homo sapiens	female	2 years and 3 months	cerebral abscess			host_description:She had a small abscess in the skin of the left lower limb and his mother squeezed the pus out of the abscess about 12 days before the onset of the disease.;host_disease_outcome:Recovery;host_disease_stage:Acute stage;host_health_state:Had decreased muscle strength in the left limbs;host_subject_id:Medical record ID was 65146224														collected_by:Hua CZ, Shen ZP, Zhou MM, Hu WL, Shu Q
1314.3302	Streptococcus pyogenes 52SS1		1314	Complete	52SS1				MLST.Streptococcus_pyogenes.37				2022-04-11T00:00:00Z		PRJNA820333	SAMN26993930	GCA_022869745.1	CP094944			Complete	Illumina NovaSeq	100.0x	SPAdes v. May2021	1.0	0.0	1		1860753	38.372498	1917		1812.0		oropharynx			Saudi Arabia	Saudi Arabia						Homo sapiens			pharyngitis																	collected_by:Galal Esmail and Badr AlDawood
1314.3900	Streptococcus pyogenes 7/M49		1314	WGS	7/M49	M49			MLST.Streptococcus_pyogenes.433				2022-11-19T00:00:00Z		PRJNA901279	SAMN31710600		JAPIVA000000000				Illumina	57.0x	SPAdes v. 3.13.0	0.0	0.0	27		1889533	38.04575	1912		1820.0		blood		2003	USA	USA: Atlanta						Homo sapiens			Sepsis																	collected_by:Bernard Beale
1314.132	Streptococcus pyogenes 7F7		1314	Complete	7F7				MLST.Streptococcus_pyogenes.5				2014-10-20T00:00:00Z	-	PRJNA238516	SAMN02644974	GCA_000767505.1	CP007240.1	NZ_CP007240.1	University Rennes1	Complete	Illumina		CLC Genomics workbench v. 6.5.1	1.0		1		1709790	38.6	1635		1550.0				2011	France	France: Brittany						Human, Homo sapiens									Positive	Cocci	No	No							new clonal spread of S.pyogenes emm83 among homeless persons in Brittany	
1314.3902	Streptococcus pyogenes A13000833		1314	WGS	A13000833				MLST.Streptococcus_pyogenes.36				2022-12-09T00:00:00Z		PRJNA808899	SAMN26135081		JAKUVR000000000				Illumina MiSeq	69.62x	SPAdes v. 3.13.0	0.0	0.0	35		1791139	38.359398	1822		1721.0		blood		2013-01-01	Denmark	Denmark: Copenhagen						Homo sapiens			Infective endocarditis																	collected_by:Rigshospitalet
1314.3901	Streptococcus pyogenes A16000451		1314	WGS	A16000451				MLST.Streptococcus_pyogenes.46				2022-12-09T00:00:00Z		PRJNA808899	SAMN26135082		JAKUVQ000000000				Illumina MiSeq	46.02x	SPAdes v. 3.13.0	0.0	0.0	45		1853807	38.29723	1990		1891.0		blood		2016-01-01	Denmark	Denmark: Copenhagen						Homo sapiens			Infective endocarditis																	collected_by:Rigshospitalet
1235829.3	Streptococcus pyogenes A20	Streptococcus pyogenes A20	1235829	Complete	A20				MLST.Streptococcus_pyogenes.28				2012-10-22T00:00:00Z		PRJNA175952	SAMN02603640	GCA_000307535.1	CP003901.1	NC_018936.1	National Cheng Kung University	Complete			1	1.0	0.0	1		1837281	38.54	1834		1828.0		Necrotizing fasciitis patient	isolated from a Necrotizing fasciitis patient in Tainan Provincial Hospital, ROC		Taiwan	Tainan Provincial Hospital ROC						Human, Homo sapiens									Positive	Cocci								Necrotizing faciitis	A clinical strain was isolated from a Necrotizing fasciitis patient in Tainan Provincial Hospital, ROC.  We want to know this strain's virulence factors, and how they are regulated.	
562016.3	Streptococcus pyogenes AA216		562016	WGS	AA216				MLST.Streptococcus_pyogenes.120				2014-09-25T00:00:00Z	-	PRJNA31299	SAMN00000666	GCA_000758075.1	JRLJ00000000	-	University of Maryland IGS	WGS	454; Sanger	32.13x	Celera Assembler v. 5.0			35		1839747	38.58	1827		1857.0		skin			Australia	Australia						Human, Homo sapiens									Positive	Cocci	No		Mesophilic			Facultative	HostAssociated	Wide range of opportunistic infections	 Streptococcus pyogenes AA216. This strain is being sequenced for comparative genome analysis.	
562018.3	Streptococcus pyogenes AA472		562018	WGS	AA472				MLST.Streptococcus_pyogenes.115				2014-09-25T00:00:00Z	-	PRJNA31311	SAMN00000677	GCA_000758125.1	JRLK00000000	-	University of Maryland IGS	WGS	454	26.13x	Newbler v. 1.1.03.24			32		1733604	38.37	1726		1731.0		skin			Australia	Australia						Human, Homo sapiens									Negative	Cocci	No		Mesophilic			Facultative	Multiple	Wide range of opportunistic infections	 Streptococcus pyogenes AA472. This strain is being sequenced for comparative genome analysis.	
1438987.3	Streptococcus pyogenes ABC020004984		1438987	WGS	ABC020004984				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233211	SAMN02567560	GCA_000630225.1	JJGE00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			15		1875140	38.6	1886		1844.0				2002	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438988.3	Streptococcus pyogenes ABC020005405		1438988	WGS	ABC020005405				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233212	SAMN02567561	GCA_000630205.1	JJGD00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1849489	38.6	1801		1741.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438989.3	Streptococcus pyogenes ABC020005716		1438989	WGS	ABC020005716				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233104	SAMN02567453	GCA_000628325.1	JJKE00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1829911	38.5	1823		1760.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438990.3	Streptococcus pyogenes ABC020005773		1438990	WGS	ABC020005773				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233105	SAMN02567454	GCA_000628345.1	JJKF00000000	-	Broad Institute	WGS	Illumina	98.0x	allpaths v. R48559			36		1873543	38.5	1899		1869.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438991.3	Streptococcus pyogenes ABC020005887		1438991	WGS	ABC020005887				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233106	SAMN02567455	GCA_000630945.1	JJHO00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			4		1827388	38.4	1829		1766.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438993.3	Streptococcus pyogenes ABC020006103		1438993	WGS	ABC020006103				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233108	SAMN02567457	GCA_000630925.1	JJHN00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1866034	38.6	1874		1825.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438994.3	Streptococcus pyogenes ABC020006298		1438994	WGS	ABC020006298				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233213	SAMN02567562	GCA_000630185.1	JJGC00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			4		1851690	38.5	1867		1818.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438995.3	Streptococcus pyogenes ABC020006309		1438995	WGS	ABC020006309				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233214	SAMN02567563	GCA_000630165.1	JJGB00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			6		1793372	38.5	1734		1682.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438996.3	Streptococcus pyogenes ABC020006345		1438996	WGS	ABC020006345				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233109	SAMN02567458	GCA_000628365.1	JJKG00000000	-	Broad Institute	WGS	Illumina	127.0x	allpaths v. R48559			2		1829889	38.5	1821		1761.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438997.3	Streptococcus pyogenes ABC020006715		1438997	WGS	ABC020006715				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233110	SAMN02567459	GCA_000628385.1	JJKH00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1830836	38.5	1817		1758.0				2002	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1438999.3	Streptococcus pyogenes ABC020007794		1438999	WGS	ABC020007794				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233216	SAMN02567565	GCA_000630145.1	JJGA00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			7		1805573	38.6	1731		1680.0				1998	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439000.3	Streptococcus pyogenes ABC020009156		1439000	WGS	ABC020009156				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233217	SAMN02567566	GCA_000630125.1	JJFZ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			9		1816296	38.6	1744		1697.0				1999	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439001.3	Streptococcus pyogenes ABC020010041		1439001	WGS	ABC020010041				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233218	SAMN02567567	GCA_000630105.1	JJFY00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			6		1791433	38.5	1726		1681.0				1999	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439002.3	Streptococcus pyogenes ABC020013256		1439002	WGS	ABC020013256				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233219	SAMN02567568	GCA_000628665.1	JJKV00000000	-	Broad Institute	WGS	Illumina	130.0x	allpaths v. R48559			2		1830843	38.5	1813		1757.0				2002	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439004.3	Streptococcus pyogenes ABC020013551		1439004	WGS	ABC020013551								2014-04-14T00:00:00Z	-	PRJNA233221	SAMN02567570	GCA_000630085.1	JJFX00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1895230	38.5	1933		1882.0				2002	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439006.3	Streptococcus pyogenes ABC020013952		1439006	WGS	ABC020013952				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233111	SAMN02567460	GCA_000630905.1	JJHM00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			7		1816797	38.4	1790		1741.0				2002	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439008.3	Streptococcus pyogenes ABC020014529		1439008	WGS	ABC020014529				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233112	SAMN02567461	GCA_000630885.1	JJHL00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			6		1816344	38.4	1778		1726.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439010.3	Streptococcus pyogenes ABC020014690		1439010	WGS	ABC020014690				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233224	SAMN02567573	GCA_000630065.1	JJFW00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			7		1821830	38.4	1792		1740.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439011.3	Streptococcus pyogenes ABC020014764		1439011	WGS	ABC020014764				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233114	SAMN02567463	GCA_000628405.1	JJKI00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1835785	38.5	1823		1761.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439012.3	Streptococcus pyogenes ABC020014897		1439012	WGS	ABC020014897				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233115	SAMN02567464	GCA_000630865.1	JJHK00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			10		1871907	38.6	1889		1842.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439013.3	Streptococcus pyogenes ABC020014925		1439013	WGS	ABC020014925				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233116	SAMN02567465	GCA_000630845.1	JJHJ00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			9		1863283	38.5	1888		1843.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439014.3	Streptococcus pyogenes ABC020015277		1439014	WGS	ABC020015277				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233225	SAMN02567574	GCA_000630045.1	JJFV00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1777734	38.4	1728		1679.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439015.3	Streptococcus pyogenes ABC020015285		1439015	WGS	ABC020015285				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233226	SAMN02567575	GCA_000630025.1	JJFU00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			7		1871962	38.4	1854		1803.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439016.3	Streptococcus pyogenes ABC020015292		1439016	WGS	ABC020015292				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233227	SAMN02567576	GCA_000630005.1	JJFT00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			3		1893954	38.5	1930		1879.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439017.3	Streptococcus pyogenes ABC020015294		1439017	WGS	ABC020015294				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233228	SAMN02567577	GCA_000629985.1	JJFS00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			3		1830564	38.5	1824		1760.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439026.3	Streptococcus pyogenes ABC020016937		1439026	WGS	ABC020016937				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233235	SAMN02567584	GCA_000629965.1	JJFR00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1810772	38.4	1791		1740.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439027.3	Streptococcus pyogenes ABC020017280		1439027	WGS	ABC020017280				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233236	SAMN02567585	GCA_000628685.1	JJKW00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			7		1806630	38.5	1744		1691.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439028.3	Streptococcus pyogenes ABC020017526		1439028	WGS	ABC020017526				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233119	SAMN02567468	GCA_000630825.1	JJHI00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1817117	38.5	1815		1760.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439029.3	Streptococcus pyogenes ABC020017774		1439029	WGS	ABC020017774				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233237	SAMN02567586	GCA_000628705.1	JJKX00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1831294	38.5	1818		1759.0				2003	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439033.3	Streptococcus pyogenes ABC020021452		1439033	WGS	ABC020021452				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233241	SAMN02567590	GCA_000628725.1	JJKY00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1829872	38.5	1822		1761.0				2000	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439042.3	Streptococcus pyogenes ABC020025676		1439042	WGS	ABC020025676				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233245	SAMN02567594	GCA_000629945.1	JJFQ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			3		1898709	38.6	1930		1879.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439043.3	Streptococcus pyogenes ABC020026287		1439043	WGS	ABC020026287				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233125	SAMN02567474	GCA_000630805.1	JJHH00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			6		1869575	38.6	1889		1835.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439047.3	Streptococcus pyogenes ABC020026799		1439047	WGS	ABC020026799				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233128	SAMN02567477	GCA_000630785.1	JJHG00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			10		1866994	38.6	1877		1827.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439048.3	Streptococcus pyogenes ABC020026946		1439048	WGS	ABC020026946				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233247	SAMN02567596	GCA_000629925.1	JJFP00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			6		1824218	38.4	1805		1748.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439055.3	Streptococcus pyogenes ABC020029706		1439055	WGS	ABC020029706				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233005	SAMN02567354	GCA_000631565.1	JJIT00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			5		1762179	38.6	1681		1626.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439056.3	Streptococcus pyogenes ABC020029711		1439056	WGS	ABC020029711				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233132	SAMN02567481	GCA_000630765.1	JJHF00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			5		1830352	38.5	1826		1759.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439057.3	Streptococcus pyogenes ABC020029793		1439057	WGS	ABC020029793				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233133	SAMN02567482	GCA_000630745.1	JJHE00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			4		1822019	38.4	1795		1742.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439059.3	Streptococcus pyogenes ABC020030020		1439059	WGS	ABC020030020				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233135	SAMN02567484	GCA_000628425.1	JJKJ00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1829833	38.5	1822		1763.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439060.3	Streptococcus pyogenes ABC020030063		1439060	WGS	ABC020030063				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233070	SAMN02567419	GCA_000631225.1	JJIC00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			12		1843473	38.5	1880		1830.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439064.3	Streptococcus pyogenes ABC020030925		1439064	WGS	ABC020030925				MLST.Streptococcus_pyogenes.182				2014-04-14T00:00:00Z	-	PRJNA233137	SAMN02567486	GCA_000630725.1	JJHD00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			6		1734820	38.4	1690		1647.0				2004	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439066.3	Streptococcus pyogenes ABC020031290		1439066	WGS	ABC020031290								2014-04-14T00:00:00Z	-	PRJNA233138	SAMN02567487	GCA_000630705.1	JJHC00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			3		1790097	38.4	1744		1686.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439067.3	Streptococcus pyogenes ABC020031898		1439067	WGS	ABC020031898				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233254	SAMN02567603	GCA_000629905.1	JJFO00000000	-	Broad Institute	WGS	Illumina	126.0x	allpaths v. R48559			9		1817740	38.6	1745		1700.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439068.3	Streptococcus pyogenes ABC020032057		1439068	WGS	ABC020032057				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233139	SAMN02567488	GCA_000628445.1	JJKK00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			6		1827505	38.4	1846		1789.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439070.3	Streptococcus pyogenes ABC020032182		1439070	WGS	ABC020032182				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233140	SAMN02567489	GCA_000630685.1	JJHB00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			8		1852913	38.6	1874		1826.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439071.3	Streptococcus pyogenes ABC020032183		1439071	WGS	ABC020032183				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233256	SAMN02567605	GCA_000629885.1	JJFN00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			7		1784699	38.5	1731		1683.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439072.3	Streptococcus pyogenes ABC020032186		1439072	WGS	ABC020032186				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233007	SAMN02567356	GCA_000631525.1	JJIR00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			14		1802732	38.5	1753		1704.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439073.3	Streptococcus pyogenes ABC020032523		1439073	WGS	ABC020032523				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233141	SAMN02567490	GCA_000630665.1	JJHA00000000	-	Broad Institute	WGS	Illumina	118.0x	allpaths v. R48559			9		1860370	38.6	1805		1751.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439074.3	Streptococcus pyogenes ABC020032535		1439074	WGS	ABC020032535				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233142	SAMN02567491	GCA_000628465.1	JJKL00000000	-	Broad Institute	WGS	Illumina	130.0x	allpaths v. R48559			2		1835851	38.5	1822		1761.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439075.3	Streptococcus pyogenes ABC020033020		1439075	WGS	ABC020033020				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233071	SAMN02567420	GCA_000631205.1	JJIB00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			10		1811069	38.5	1814		1768.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439076.3	Streptococcus pyogenes ABC020033193		1439076	WGS	ABC020033193				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233143	SAMN02567492	GCA_000630645.1	JJGZ00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			9		1810394	38.6	1745		1698.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439077.3	Streptococcus pyogenes ABC020033233		1439077	WGS	ABC020033233				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233006	SAMN02567355	GCA_000631545.1	JJIS00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1821264	38.4	1791		1741.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439079.3	Streptococcus pyogenes ABC020033799		1439079	WGS	ABC020033799				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233145	SAMN02567494	GCA_000630625.1	JJGY00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1785794	38.5	1735		1684.0				2005	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439080.3	Streptococcus pyogenes ABC020033919		1439080	WGS	ABC020033919				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233008	SAMN02567357	GCA_000631505.1	JJIQ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			6		1806019	38.6	1731		1685.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439090.3	Streptococcus pyogenes ABC020035427		1439090	WGS	ABC020035427				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233259	SAMN02567608	GCA_000629865.1	JJFM00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			7		1815310	38.4	1795		1741.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439091.3	Streptococcus pyogenes ABC020035446		1439091	WGS	ABC020035446				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233009	SAMN02567358	GCA_000631485.1	JJIP00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1784290	38.5	1740		1688.0				2006	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439095.3	Streptococcus pyogenes ABC020037542		1439095	WGS	ABC020037542				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233010	SAMN02567359	GCA_000631465.1	JJIO00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1827634	38.4	1830		1770.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439106.3	Streptococcus pyogenes ABC020038544		1439106	WGS	ABC020038544				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232984	SAMN02567333	GCA_000631825.1	JJJG00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			9		1828798	38.5	1795		1745.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439107.3	Streptococcus pyogenes ABC020038545		1439107	WGS	ABC020038545				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233155	SAMN02567504	GCA_000628485.1	JJKM00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			2		1831176	38.4	1821		1758.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439109.3	Streptococcus pyogenes ABC020038558		1439109	WGS	ABC020038558				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233156	SAMN02567505	GCA_000630605.1	JJGX00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			4		1824565	38.7	1812		1758.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439111.3	Streptococcus pyogenes ABC020039031		1439111	WGS	ABC020039031				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233013	SAMN02567362	GCA_000631445.1	JJIN00000000	-	Broad Institute	WGS	Illumina	130.0x	allpaths v. R48559			8		1816504	38.4	1794		1742.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439115.3	Streptococcus pyogenes ABC020039391		1439115	WGS	ABC020039391				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233158	SAMN02567507	GCA_000630585.1	JJGW00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			9		1795474	38.4	1754		1706.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439118.3	Streptococcus pyogenes ABC020040643		1439118	WGS	ABC020040643				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232986	SAMN02567335	GCA_000631805.1	JJJF00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			7		1775487	38.4	1730		1682.0				2007	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439120.3	Streptococcus pyogenes ABC020041397		1439120	WGS	ABC020041397				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233270	SAMN02567619	GCA_000628745.1	JJKZ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1829828	38.5	1821		1759.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439122.3	Streptococcus pyogenes ABC020041424		1439122	WGS	ABC020041424				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233059	SAMN02567408	GCA_000631365.1	JJIJ00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			10		1730598	38.6	1691		1641.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439123.3	Streptococcus pyogenes ABC020043540		1439123	WGS	ABC020043540				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233075	SAMN02567424	GCA_000631185.1	JJIA00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			12		1853311	38.5	1880		1835.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439127.3	Streptococcus pyogenes ABC020044010		1439127	WGS	ABC020044010				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233273	SAMN02567622	GCA_000629845.1	JJFL00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			5		1815949	38.6	1809		1757.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439132.3	Streptococcus pyogenes ABC020044173		1439132	WGS	ABC020044173				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233163	SAMN02567512	GCA_000630565.1	JJGV00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			5		1835237	38.4	1852		1789.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439133.3	Streptococcus pyogenes ABC020044188		1439133	WGS	ABC020044188				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233164	SAMN02567513	GCA_000630545.1	JJGU00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			15		1903783	38.5	1961		1913.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439134.3	Streptococcus pyogenes ABC020044193		1439134	WGS	ABC020044193				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233165	SAMN02567514	GCA_000630525.1	JJGT00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			9		1826704	38.6	1815		1766.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439135.3	Streptococcus pyogenes ABC020044203		1439135	WGS	ABC020044203				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233081	SAMN02567430	GCA_000631105.1	JJHW00000000	-	Broad Institute	WGS	Illumina	138.0x	allpaths v. R48559			8		1829973	38.6	1815		1766.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439136.3	Streptococcus pyogenes ABC020044412		1439136	WGS	ABC020044412				MLST.Streptococcus_pyogenes.406				2014-04-14T00:00:00Z	-	PRJNA233275	SAMN02567624	GCA_000629825.1	JJFK00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			3		1893319	38.5	1927		1878.0				2001	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439137.3	Streptococcus pyogenes ABC020046158		1439137	WGS	ABC020046158				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232994	SAMN02567343	GCA_000631725.1	JJJB00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			12		1897159	38.3	1865		1807.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439139.3	Streptococcus pyogenes ABC020046230		1439139	WGS	ABC020046230								2014-04-14T00:00:00Z	-	PRJNA232974	SAMN02567323	GCA_000631965.1	JJJN00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			10		1588778	38.2	1558		1520.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus;genome length too small	
1439141.3	Streptococcus pyogenes ABC020046264		1439141	WGS	ABC020046264				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233166	SAMN02567515	GCA_000630505.1	JJGS00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			6		1828011	38.5	1791		1741.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439144.3	Streptococcus pyogenes ABC020046470		1439144	WGS	ABC020046470				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233167	SAMN02567516	GCA_000630485.1	JJGR00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1824663	38.5	1815		1757.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439146.3	Streptococcus pyogenes ABC020046534		1439146	WGS	ABC020046534				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232996	SAMN02567345	GCA_000631685.1	JJIZ00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1809471	38.4	1793		1737.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439147.3	Streptococcus pyogenes ABC020046559		1439147	WGS	ABC020046559				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232995	SAMN02567344	GCA_000631705.1	JJJA00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			7		1827496	38.5	1800		1744.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439149.3	Streptococcus pyogenes ABC020046589		1439149	WGS	ABC020046589				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233276	SAMN02567625	GCA_000628765.1	JJLA00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			5		1798083	38.4	1808		1759.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439150.3	Streptococcus pyogenes ABC020046688		1439150	WGS	ABC020046688				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233277	SAMN02567626	GCA_000628785.1	JJLB00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			2		1831185	38.4	1829		1765.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439151.3	Streptococcus pyogenes ABC020046986		1439151	WGS	ABC020046986				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233278	SAMN02567627	GCA_000628805.1	JJLC00000000	-	Broad Institute	WGS	Illumina	129.0x	allpaths v. R48559			2		1829890	38.5	1823		1761.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439152.3	Streptococcus pyogenes ABC020047076		1439152	WGS	ABC020047076				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233094	SAMN02567443	GCA_000631025.1	JJHS00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			8		1900389	38.5	1944		1898.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439153.3	Streptococcus pyogenes ABC020047086		1439153	WGS	ABC020047086				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232975	SAMN02567324	GCA_000631945.1	JJJM00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			9		1789096	38.5	1735		1684.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439157.3	Streptococcus pyogenes ABC020047328		1439157	WGS	ABC020047328				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233279	SAMN02567628	GCA_000628825.1	JJLD00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			2		1855605	38.5	1868		1819.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439158.3	Streptococcus pyogenes ABC020047395		1439158	WGS	ABC020047395				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233280	SAMN02567629	GCA_000629805.1	JJFJ00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			8		1872167	38.5	1895		1846.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439159.3	Streptococcus pyogenes ABC020047506		1439159	WGS	ABC020047506								2014-04-14T00:00:00Z	-	PRJNA232976	SAMN02567325	GCA_000631925.1	JJJL00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			4		1807122	38.4	1743		1685.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439161.3	Streptococcus pyogenes ABC020047619		1439161	WGS	ABC020047619				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233095	SAMN02567444	GCA_000631005.1	JJHR00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1851068	38.5	1880		1826.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439162.3	Streptococcus pyogenes ABC020047635		1439162	WGS	ABC020047635				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232977	SAMN02567326	GCA_000631905.1	JJJK00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			7		1811587	38.4	1795		1739.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439163.3	Streptococcus pyogenes ABC020047925		1439163	WGS	ABC020047925				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233281	SAMN02567630	GCA_000629785.1	JJFI00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			3		1832226	38.5	1827		1763.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439165.3	Streptococcus pyogenes ABC020047955		1439165	WGS	ABC020047955				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233016	SAMN02567365	GCA_000628025.1	JJJP00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			2		1829785	38.5	1825		1760.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439167.3	Streptococcus pyogenes ABC020047959		1439167	WGS	ABC020047959				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233282	SAMN02567631	GCA_000629765.1	JJFH00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			8		1806062	38.5	1818		1765.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439168.3	Streptococcus pyogenes ABC020047977		1439168	WGS	ABC020047977				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233039	SAMN02567388	GCA_000628185.1	JJJX00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			7		1875350	38.5	1874		1816.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439169.3	Streptococcus pyogenes ABC020047993		1439169	WGS	ABC020047993				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233171	SAMN02567520	GCA_000630465.1	JJGQ00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			12		1775816	38.4	1757		1700.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439170.3	Streptococcus pyogenes ABC020048184		1439170	WGS	ABC020048184				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233283	SAMN02567632	GCA_000629745.1	JJFG00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			9		1794791	38.5	1733		1685.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439176.3	Streptococcus pyogenes ABC020048262		1439176	WGS	ABC020048262				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232997	SAMN02567346	GCA_000631665.1	JJIY00000000	-	Broad Institute	WGS	Illumina	129.0x	allpaths v. R48559			7		1785192	38.4	1732		1685.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439178.3	Streptococcus pyogenes ABC020048387		1439178	WGS	ABC020048387				MLST.Streptococcus_pyogenes.897				2014-04-14T00:00:00Z	-	PRJNA233040	SAMN02567389	GCA_000628205.1	JJJY00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			2		1832495	38.5	1827		1760.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439180.3	Streptococcus pyogenes ABC020048395		1439180	WGS	ABC020048395				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233173	SAMN02567522	GCA_000630445.1	JJGP00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			10		1870676	38.6	1913		1856.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439181.3	Streptococcus pyogenes ABC020048503		1439181	WGS	ABC020048503				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233018	SAMN02567367	GCA_000628045.1	JJJQ00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1832502	38.5	1821		1758.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439182.3	Streptococcus pyogenes ABC020048541		1439182	WGS	ABC020048541				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233284	SAMN02567633	GCA_000629725.1	JJFF00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			13		1869641	38.5	1922		1871.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439183.3	Streptococcus pyogenes ABC020048543		1439183	WGS	ABC020048543				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233174	SAMN02567523	GCA_000630425.1	JJGO00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			8		1754041	38.5	1678		1628.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439185.3	Streptococcus pyogenes ABC020048606		1439185	WGS	ABC020048606				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233175	SAMN02567524	GCA_000628505.1	JJKN00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			5		1814741	38.4	1790		1737.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439187.3	Streptococcus pyogenes ABC020048885		1439187	WGS	ABC020048885				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233062	SAMN02567411	GCA_000631345.1	JJII00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1750064	38.6	1712		1661.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439188.3	Streptococcus pyogenes ABC020049250		1439188	WGS	ABC020049250				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233177	SAMN02567526	GCA_000630405.1	JJGN00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			3		1829953	38.5	1822		1759.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439190.3	Streptococcus pyogenes ABC020049540		1439190	WGS	ABC020049540				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233063	SAMN02567412	GCA_000631325.1	JJIH00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			4		1814379	38.5	1811		1760.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439191.3	Streptococcus pyogenes ABC020049545		1439191	WGS	ABC020049545				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233019	SAMN02567368	GCA_000628065.1	JJJR00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1831340	38.5	1815		1758.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439192.3	Streptococcus pyogenes ABC020050193		1439192	WGS	ABC020050193				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233285	SAMN02567634	GCA_000628845.1	JJLE00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			2		1831362	38.5	1818		1760.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439193.3	Streptococcus pyogenes ABC020050731		1439193	WGS	ABC020050731				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233179	SAMN02567528	GCA_000630385.1	JJGM00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			7		1775222	38.4	1731		1678.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439194.3	Streptococcus pyogenes ABC020050818		1439194	WGS	ABC020050818				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233180	SAMN02567529	GCA_000628525.1	JJKO00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			2		1812453	38.5	1817		1768.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439196.3	Streptococcus pyogenes ABC020051161		1439196	WGS	ABC020051161				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233042	SAMN02567391	GCA_000631405.1	JJIL00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			4		1830702	38.5	1818		1758.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439197.3	Streptococcus pyogenes ABC020051269		1439197	WGS	ABC020051269				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233286	SAMN02567635	GCA_000628865.1	JJLF00000000	-	Broad Institute	WGS	Illumina	98.0x	allpaths v. R48559			15		1794401	38.5	1805		1764.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439204.3	Streptococcus pyogenes ABC020052023		1439204	WGS	ABC020052023				MLST.Streptococcus_pyogenes.315				2014-04-14T00:00:00Z	-	PRJNA233287	SAMN02567636	GCA_000628885.1	JJLG00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			2		1892750	38.5	1925		1875.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439205.3	Streptococcus pyogenes ABC020052203		1439205	WGS	ABC020052203				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233182	SAMN02567531	GCA_000630365.1	JJGL00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			8		1812487	38.4	1789		1742.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439207.3	Streptococcus pyogenes ABC020052211		1439207	WGS	ABC020052211				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232989	SAMN02567338	GCA_000628005.1	JJJO00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1799977	38.6	1733		1684.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439208.3	Streptococcus pyogenes ABC020052216		1439208	WGS	ABC020052216				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233183	SAMN02567532	GCA_000630345.1	JJGK00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			6		1820573	38.5	1779		1728.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439209.3	Streptococcus pyogenes ABC020052218		1439209	WGS	ABC020052218								2014-04-14T00:00:00Z	-	PRJNA233184	SAMN02567533	GCA_000628545.1	JJKP00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1825805	38.5	1813		1755.0				2008	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439210.3	Streptococcus pyogenes ABC020052291		1439210	WGS	ABC020052291				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233288	SAMN02567637	GCA_000629705.1	JJFE00000000	-	Broad Institute	WGS	Illumina	106.0x	allpaths v. R48559			4		1828891	38.5	1818		1760.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439211.3	Streptococcus pyogenes ABC020052309		1439211	WGS	ABC020052309				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233023	SAMN02567372	GCA_000628085.1	JJJS00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			2		1831353	38.5	1821		1758.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439212.3	Streptococcus pyogenes ABC020052313		1439212	WGS	ABC020052313				MLST.Streptococcus_pyogenes.858				2014-04-14T00:00:00Z	-	PRJNA233024	SAMN02567373	GCA_000628105.1	JJJT00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1831416	38.5	1821		1758.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439213.3	Streptococcus pyogenes ABC020052375		1439213	WGS	ABC020052375				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233185	SAMN02567534	GCA_000628565.1	JJKQ00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1832524	38.5	1823		1763.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439214.3	Streptococcus pyogenes ABC020052378		1439214	WGS	ABC020052378				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233077	SAMN02567426	GCA_000631165.1	JJHZ00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			10		1864567	38.5	1897		1839.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439215.3	Streptococcus pyogenes ABC020052420		1439215	WGS	ABC020052420				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233186	SAMN02567535	GCA_000630325.1	JJGJ00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			8		1863382	38.6	1886		1836.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439216.3	Streptococcus pyogenes ABC020052497		1439216	WGS	ABC020052497				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233100	SAMN02567449	GCA_000630985.1	JJHQ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			12		1882502	38.5	1918		1872.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439217.3	Streptococcus pyogenes ABC020052519		1439217	WGS	ABC020052519				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233064	SAMN02567413	GCA_000631305.1	JJIG00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			10		1848857	38.5	1893		1838.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439218.3	Streptococcus pyogenes ABC020052543		1439218	WGS	ABC020052543				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233289	SAMN02567638	GCA_000629685.1	JJFD00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			3		1829953	38.5	1821		1758.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439219.3	Streptococcus pyogenes ABC020052553		1439219	WGS	ABC020052553				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233187	SAMN02567536	GCA_000628585.1	JJKR00000000	-	Broad Institute	WGS	Illumina	128.0x	allpaths v. R48559			2		1829957	38.5	1821		1760.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439220.3	Streptococcus pyogenes ABC020052558		1439220	WGS	ABC020052558				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233290	SAMN02567639	GCA_000629665.1	JJFC00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			8		1901458	38.6	1944		1899.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439221.3	Streptococcus pyogenes ABC020052877		1439221	WGS	ABC020052877				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233188	SAMN02567537	GCA_000628605.1	JJKS00000000	-	Broad Institute	WGS	Illumina	130.0x	allpaths v. R48559			6		1835054	38.4	1855		1789.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439223.3	Streptococcus pyogenes ABC020052898		1439223	WGS	ABC020052898				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233041	SAMN02567390	GCA_000628225.1	JJJZ00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1832587	38.5	1824		1763.0				2009	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439224.3	Streptococcus pyogenes ABC020052980		1439224	WGS	ABC020052980				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233026	SAMN02567375	GCA_000628125.1	JJJU00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1831353	38.5	1821		1758.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439225.3	Streptococcus pyogenes ABC020053060		1439225	WGS	ABC020053060				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232990	SAMN02567339	GCA_000631785.1	JJJE00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			9		1842261	38.3	1779		1723.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439228.3	Streptococcus pyogenes ABC020053240		1439228	WGS	ABC020053240				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233065	SAMN02567414	GCA_000631285.1	JJIF00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			9		1820395	38.5	1822		1781.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439229.3	Streptococcus pyogenes ABC020053250		1439229	WGS	ABC020053250				MLST.Streptococcus_pyogenes.897				2014-04-14T00:00:00Z	-	PRJNA233044	SAMN02567393	GCA_000628245.1	JJKA00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1831357	38.5	1824		1759.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439236.3	Streptococcus pyogenes ABC020054184		1439236	WGS	ABC020054184				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232991	SAMN02567340	GCA_000631765.1	JJJD00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			9		1813017	38.4	1789		1744.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439243.3	Streptococcus pyogenes ABC020054871		1439243	WGS	ABC020054871				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233193	SAMN02567542	GCA_000630305.1	JJGI00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			4		1787652	38.5	1730		1681.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439245.3	Streptococcus pyogenes ABC020054955		1439245	WGS	ABC020054955				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233194	SAMN02567543	GCA_000630285.1	JJGH00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			9		1890479	38.5	1914		1875.0				2010	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439246.3	Streptococcus pyogenes ABC020054973		1439246	WGS	ABC020054973				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233294	SAMN02567643	GCA_000629645.1	JJFB00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1821620	38.4	1791		1744.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439258.3	Streptococcus pyogenes ABC020055897		1439258	WGS	ABC020055897				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233067	SAMN02567416	GCA_000631265.1	JJIE00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			11		1899691	38.4	1969		1918.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439259.3	Streptococcus pyogenes ABC020056020		1439259	WGS	ABC020056020				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233031	SAMN02567380	GCA_000631425.1	JJIM00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			3		1836558	38.5	1822		1760.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439260.3	Streptococcus pyogenes ABC020056060		1439260	WGS	ABC020056060				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233089	SAMN02567438	GCA_000631085.1	JJHV00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			8		1800428	38.5	1813		1758.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439261.3	Streptococcus pyogenes ABC020056064		1439261	WGS	ABC020056064				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233068	SAMN02567417	GCA_000631245.1	JJID00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			16		1853612	38.4	1898		1853.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439262.3	Streptococcus pyogenes ABC020056068		1439262	WGS	ABC020056068				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233049	SAMN02567398	GCA_000628265.1	JJKB00000000	-	Broad Institute	WGS	Illumina	131.0x	allpaths v. R48559			2		1833762	38.5	1827		1765.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439264.3	Streptococcus pyogenes ABC020056181		1439264	WGS	ABC020056181				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233201	SAMN02567550	GCA_000628625.1	JJKT00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1832593	38.5	1817		1761.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439268.3	Streptococcus pyogenes ABC020056765		1439268	WGS	ABC020056765				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233032	SAMN02567381	GCA_000628145.1	JJJV00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			2		1833524	38.5	1819		1762.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439271.3	Streptococcus pyogenes ABC020056794		1439271	WGS	ABC020056794				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232999	SAMN02567348	GCA_000631645.1	JJIX00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			7		1820200	38.5	1779		1727.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439272.3	Streptococcus pyogenes ABC020056883		1439272	WGS	ABC020056883				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233203	SAMN02567552	GCA_000628645.1	JJKU00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			6		1776358	38.4	1761		1701.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439273.3	Streptococcus pyogenes ABC020056884		1439273	WGS	ABC020056884				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232980	SAMN02567329	GCA_000631885.1	JJJJ00000000	-	Broad Institute	WGS	Illumina	135.0x	allpaths v. R48559			11		1821902	38.4	1790		1747.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439274.3	Streptococcus pyogenes ABC020056885		1439274	WGS	ABC020056885				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233204	SAMN02567553	GCA_000630265.1	JJGG00000000	-	Broad Institute	WGS	Illumina	99.0x	allpaths v. R48559			5		1828000	38.5	1815		1761.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439275.3	Streptococcus pyogenes ABC020056891		1439275	WGS	ABC020056891				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233090	SAMN02567439	GCA_000631065.1	JJHU00000000	-	Broad Institute	WGS	Illumina	136.0x	allpaths v. R48559			3		1896845	38.6	1933		1886.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439276.3	Streptococcus pyogenes ABC020056894		1439276	WGS	ABC020056894				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232981	SAMN02567330	GCA_000631865.1	JJJI00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			13		1770941	38.5	1697		1653.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439277.3	Streptococcus pyogenes ABC020056898		1439277	WGS	ABC020056898				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233091	SAMN02567440	GCA_000631045.1	JJHT00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			4		1894452	38.5	1930		1883.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439283.3	Streptococcus pyogenes ABC020057168		1439283	WGS	ABC020057168				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233078	SAMN02567427	GCA_000631145.1	JJHY00000000	-	Broad Institute	WGS	Illumina	161.0x	allpaths v. R48559			22		1858511	38.5	1883		1843.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439284.3	Streptococcus pyogenes ABC020057192		1439284	WGS	ABC020057192				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233102	SAMN02567451	GCA_000630965.1	JJHP00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1894511	38.5	1933		1881.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439285.3	Streptococcus pyogenes ABC020057288		1439285	WGS	ABC020057288				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233052	SAMN02567401	GCA_000631385.1	JJIK00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			4		1795281	38.4	1795		1728.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439286.3	Streptococcus pyogenes ABC020057442		1439286	WGS	ABC020057442				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233036	SAMN02567385	GCA_000628165.1	JJJW00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1832504	38.5	1827		1763.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439287.3	Streptococcus pyogenes ABC020057449		1439287	WGS	ABC020057449				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233079	SAMN02567428	GCA_000631125.1	JJHX00000000	-	Broad Institute	WGS	Illumina	137.0x	allpaths v. R48559			7		1807448	38.5	1816		1758.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439288.3	Streptococcus pyogenes ABC020058759		1439288	WGS	ABC020058759								2014-04-14T00:00:00Z	-	PRJNA233205	SAMN02567554	GCA_000630245.1	JJGF00000000	-	Broad Institute	WGS	Illumina	132.0x	allpaths v. R48559			4		1832937	38.5	1797		1746.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439289.3	Streptococcus pyogenes ABC020059502		1439289	WGS	ABC020059502				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233053	SAMN02567402	GCA_000628285.1	JJKC00000000	-	Broad Institute	WGS	Illumina	113.0x	allpaths v. R48559			2		1829776	38.5	1821		1758.0				2011	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439294.3	Streptococcus pyogenes ABC020060220		1439294	WGS	ABC020060220				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233001	SAMN02567350	GCA_000631625.1	JJIW00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			4		1823115	38.4	1796		1742.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439299.3	Streptococcus pyogenes ABC020060777		1439299	WGS	ABC020060777				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232982	SAMN02567331	GCA_000631845.1	JJJH00000000	-	Broad Institute	WGS	Illumina	128.0x	allpaths v. R48559			9		1799184	38.5	1744		1690.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439300.3	Streptococcus pyogenes ABC020060793		1439300	WGS	ABC020060793				MLST.Streptococcus_pyogenes.15				2014-04-14T00:00:00Z	-	PRJNA233301	SAMN02567650	GCA_000629625.1	JJFA00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			13		1874115	38.6	1889		1846.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439303.3	Streptococcus pyogenes ABC020061424		1439303	WGS	ABC020061424				MLST.Streptococcus_pyogenes.28				2014-04-14T00:00:00Z	-	PRJNA233057	SAMN02567406	GCA_000628305.1	JJKD00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			2		1831300	38.5	1827		1761.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439309.3	Streptococcus pyogenes ABC020062474		1439309	WGS	ABC020062474				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233003	SAMN02567352	GCA_000631605.1	JJIV00000000	-	Broad Institute	WGS	Illumina	134.0x	allpaths v. R48559			6		1818825	38.4	1797		1741.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439310.3	Streptococcus pyogenes ABC020062601		1439310	WGS	ABC020062601				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA233004	SAMN02567353	GCA_000631585.1	JJIU00000000	-	Broad Institute	WGS	Illumina	130.0x	allpaths v. R48559			9		1800419	38.5	1752		1697.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
1439314.3	Streptococcus pyogenes ABC020064181		1439314	WGS	ABC020064181				MLST.Streptococcus_pyogenes.36				2014-04-14T00:00:00Z	-	PRJNA232993	SAMN02567342	GCA_000631745.1	JJJC00000000	-	Broad Institute	WGS	Illumina	133.0x	allpaths v. R48559			9		1827557	38.5	1777		1736.0				2012	USA	United States						Human, Homo sapiens																			Group A Streptococcus	
864568.3	Streptococcus pyogenes ATCC 10782	Streptococcus pyogenes ATCC 10782	864568	WGS	ATCC 10782				MLST.Streptococcus_pyogenes.66		ATCC 10782, CIP 56.61  		2010-08-24T00:00:00Z		PRJNA50517	SAMN00189880	GCA_000146715.1	AEEO00000000	NZ_AEEO00000000	Baylor College of Medicine	WGS	454	33x	Newbler Assembler v. 2.3-10192009	0.0	0.0	29		1917082	36.84	1984		1943.0			Nose and throat; Rheumatic fever patient									Human, Homo sapiens				Airways; Nasal										-					Reference genome for the Human Microbiome Project	
487215.4	Streptococcus pyogenes Alab49	Streptococcus pyogenes Alab49	487215	Complete	Alab49				MLST.Streptococcus_pyogenes.11				2011-10-07T00:00:00Z	21949075	PRJNA162171	SAMN02603353	GCA_000230295.1	CP003068.1	NC_017596.1	Institute for Genome Sciences	Complete	ABI 3730xl		Celera Assembler	1.0	0.0	1		1827308	38.58	1809		1773.0		impetigo lesion		1986	USA	USA: Alabama						Human, Homo sapiens																		Impetigo	Genome sequencing of a skin specialist strain of Streptococcus pyogenes.	
1213458.3	Streptococcus pyogenes BJCYGAS15	Streptococcus pyogenes BJCYGAS15	1213458	WGS	BJCYGAS15				MLST.Streptococcus_pyogenes.36				2012-08-14T00:00:00Z	23045496	PRJNA171138	SAMN02469371	GCA_000290575.1	ALKD00000000	-	State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People???s Republic of China	WGS	Illumina HiSeq	232.0x	SOAPdenovo v. 1.06	0.0	0.0	50		1848733	38.3	1836		0.0		a patient with scarlatina	isolated from a patient with scarlatina	2011	China	China						Human, Homo sapiens			scarlatina						Positive	Cocci	No	No						Scarlet fever	This strain is also known as group A streptococci (GAS). This was isolated from a patient with scarlatina.	
1123316.3	Streptococcus pyogenes DSM 20565	Streptococcus pyogenes DSM 20565	1123316	WGS	DSM 20565				MLST.Streptococcus_pyogenes.28		DSM Z	Yes	2013-07-09T00:00:00Z		PRJNA188899	SAMN02440590	GCA_000421785.1	ATXR00000000	-	DOE Joint Genome Institute	WGS	Illumina HiSeq 2000	Unknown	Unknown program v. before 2013-04-04	0.0	0.0	31		1858737	38.3	1900		0.0																															Genomic Encyclopedia of Type Strains, Phase I: one thousand microbial genomes (KMG) project. The goal of the Genomic Encyclopedia of Bacteria and Archaea (GEBA) initiative is to sequence genomes to fill phylogenetic gaps, generating reference genomes for every major and minor group of bacteria and archaea.  Currently sequenced genomes have provided highly uneven coverage of the type strain material present in public culture collections.  The Microbial Earth Project is an initiative of the Microbial Genomics Program of the DOE Joint Genome Institute that focuses on 1000 Type strains from the DSMZ and ATCC repositories.	
1314.3684	Streptococcus pyogenes ERR5094905_bin.4_metaWRAP_v1.3_MAG		1314	WGS	ERR5094905_bin.4_metaWRAP_v1.3_MAG								2022-10-18T00:00:00Z		PRJEB56417	SAMEA111477208	GCA_947072525.1	CAMTII000000000			WGS				0.0	0.0	65		1888760	39.734745	1838				fish gut metagenome			Poland	Poland																										
1115825.3	Streptococcus pyogenes GA03455	Streptococcus pyogenes GA03455	1115825	WGS	GA03455				MLST.Streptococcus_pyogenes.11		 		2013-11-25T00:00:00Z		PRJNA78633	SAMN02436398	GCA_000499125.1	AWTY00000000	-	J. Craig Venter Institute	WGS	454	36x	Newbler v. 2.6	0.0	0.0	55		1771950	38.4	1848		1842.0																															-;many frameshifted proteins	
1115828.3	Streptococcus pyogenes GA03747	Streptococcus pyogenes GA03747	1115828	WGS	GA03747				MLST.Streptococcus_pyogenes.44		 		2013-11-25T00:00:00Z		PRJNA78639	SAMN02436402	GCA_000499145.1	AWUB00000000	-	J. Craig Venter Institute	WGS	454	33x	Newbler v. 2.6	0.0	0.0	52		1857708	38.3	1918		1915.0																															-	
1115826.3	Streptococcus pyogenes GA03799	Streptococcus pyogenes GA03799	1115826	WGS	GA03799				MLST.Streptococcus_pyogenes.126		 		2013-11-25T00:00:00Z		PRJNA78635	SAMN02436565	GCA_000499225.1	AWTZ00000000	-	J. Craig Venter Institute	WGS	454	22x	Newbler v. 2.6	0.0	0.0	39		1724252	38.3	1760		1745.0																															-;many frameshifted proteins	
1115824.3	Streptococcus pyogenes GA03805	Streptococcus pyogenes GA03805	1115824	WGS	GA03805				MLST.Streptococcus_pyogenes.4		 		2013-10-25T00:00:00Z		PRJNA78631	SAMN02436404	GCA_000483625.1	AWTL00000000	-	J. Craig Venter Institute	WGS	454	37x	Newbler v. 2.6	0.0	0.0	44		1779653	38.3	1806		1806.0																															-	
1115816.3	Streptococcus pyogenes GA06023	Streptococcus pyogenes GA06023	1115816	WGS	GA06023				MLST.Streptococcus_pyogenes.3		 		2013-09-19T00:00:00Z		PRJNA78615	SAMN00828760	GCA_000468795.1	AWPJ00000000	-	J. Craig Venter Institute	WGS	454	20x	Newbler v. 2.6	0.0	0.0	420		1971420	38.9	2045		2280.0																															-;many frameshifted proteins	
1115830.3	Streptococcus pyogenes GA16797	Streptococcus pyogenes GA16797	1115830	WGS	GA16797				MLST.Streptococcus_pyogenes.624		 		2013-11-25T00:00:00Z		PRJNA78643	SAMN02436566	GCA_000499165.1	AWUD00000000	-	J. Craig Venter Institute	WGS	454	36x	Newbler v. 2.6	0.0	0.0	44		1750043	38.3	1747		1742.0																															-	
1115815.3	Streptococcus pyogenes GA19681	Streptococcus pyogenes GA19681	1115815	WGS	GA19681				MLST.Streptococcus_pyogenes.382				2013-08-22T00:00:00Z		PRJNA78613	SAMN00828761	GCA_000454125.1	AVCE00000000	-	J. Craig Venter Institute	WGS	454	23x	Newbler v. 2.6	0.0	0.0	119		1833306	38.4	2002		2018.0																															-;many frameshifted proteins	
1115818.3	Streptococcus pyogenes GA19700	Streptococcus pyogenes GA19700	1115818	WGS	GA19700				MLST.Streptococcus_pyogenes.382		 		2013-10-25T00:00:00Z		PRJNA78619	SAMN02436481	GCA_000483525.1	AWTF00000000	-	J. Craig Venter Institute	WGS	454	12x	Newbler v. 2.6	0.0	0.0	196		1942425	39.9	1978		2086.0																															-;many frameshifted proteins	
1115829.3	Streptococcus pyogenes GA19702	Streptococcus pyogenes GA19702	1115829	WGS	GA19702				MLST.Streptococcus_pyogenes.63		 		2013-11-25T00:00:00Z		PRJNA78641	SAMN02436399	GCA_000499265.1	AWUC00000000	-	J. Craig Venter Institute	WGS	454	53x	Newbler v. 2.6	0.0	0.0	35		1898927	38.3	1874		1869.0																															-	
1115821.3	Streptococcus pyogenes GA40056	Streptococcus pyogenes GA40056	1115821	WGS	GA40056						 		2013-10-25T00:00:00Z		PRJNA78625	SAMN02436403	GCA_000483565.1	AWTI00000000	-	J. Craig Venter Institute	WGS	454	36x	Newbler v. 2.6	0.0	0.0	45		1822867	38.2	1896		1893.0																															-;many frameshifted proteins	
1115823.3	Streptococcus pyogenes GA40377	Streptococcus pyogenes GA40377	1115823	WGS	GA40377				MLST.Streptococcus_pyogenes.456		 		2013-10-25T00:00:00Z		PRJNA78629	SAMN02436564	GCA_000483605.1	AWTK00000000	-	J. Craig Venter Institute	WGS	454	30x	Newbler v. 2.6	0.0	0.0	40		1855692	38.2	1904		1900.0																															-	
1115817.3	Streptococcus pyogenes GA40468	Streptococcus pyogenes GA40468	1115817	WGS	GA40468				MLST.Streptococcus_pyogenes.99		 		2013-10-25T00:00:00Z		PRJNA78617	SAMN02436563	GCA_000483505.1	AWTE00000000	-	J. Craig Venter Institute	WGS	454	19x	Newbler v. 2.6	0.0	0.0	212		1880495	38.4	2075		2187.0																															-;many frameshifted proteins	
1115814.3	Streptococcus pyogenes GA40634	Streptococcus pyogenes GA40634	1115814	WGS	GA40634				MLST.Streptococcus_pyogenes.39				2013-08-05T00:00:00Z		PRJNA78611	SAMN00828756	GCA_000444015.1	AURU00000000	-	J. Craig Venter Institute	WGS	454	28x	Newbler v. 2.6	0.0	0.0	49		1844370	38.3	1935		1922.0																															-;many frameshifted proteins	
1115827.3	Streptococcus pyogenes GA40884	Streptococcus pyogenes GA40884	1115827	WGS	GA40884				MLST.Streptococcus_pyogenes.176		 		2013-11-25T00:00:00Z		PRJNA78637	SAMN02436405	GCA_000499245.1	AWUA00000000	-	J. Craig Venter Institute	WGS	454	33x	Newbler v. 2.6	0.0	0.0	28		1831915	38.2	1833		1815.0																															-	
1115819.3	Streptococcus pyogenes GA41039	Streptococcus pyogenes GA41039	1115819	WGS	GA41039				MLST.Streptococcus_pyogenes.37		 		2013-10-25T00:00:00Z		PRJNA78621	SAMN02436478	GCA_000483545.1	AWTG00000000	-	J. Craig Venter Institute	WGS	454	33x	Newbler v. 2.6	0.0	0.0	50		1782667	38.4	1899		1886.0																															-;many frameshifted proteins	
1115812.3	Streptococcus pyogenes GA41046	Streptococcus pyogenes GA41046	1115812	WGS	GA41046				MLST.Streptococcus_pyogenes.55		 		2013-09-19T00:00:00Z		PRJNA78607	SAMN00828758	GCA_000468875.1	AWWB00000000	-	J. Craig Venter Institute	WGS	454	31x	Newbler v. 2.6	0.0	0.0	32		1859441	38.4	1944		1932.0																															-;many frameshifted proteins	
1115820.3	Streptococcus pyogenes GA41208	Streptococcus pyogenes GA41208	1115820	WGS	GA41208				MLST.Streptococcus_pyogenes.37		 		2013-10-25T00:00:00Z		PRJNA78623	SAMN02436479	GCA_000483645.1	AWTH00000000	-	J. Craig Venter Institute	WGS	454	38x	Newbler v. 2.6	0.0	0.0	45		1782156	38.4	1885		1866.0																															-;many frameshifted proteins	
1115813.3	Streptococcus pyogenes GA41345	Streptococcus pyogenes GA41345	1115813	WGS	GA41345				MLST.Streptococcus_pyogenes.28				2013-08-05T00:00:00Z		PRJNA78609	SAMN00828759	GCA_000444035.1	AUOY00000000	-	J. Craig Venter Institute	WGS	454	14x	Newbler v. 2.6	0.0	0.0	110		1791042	38.4	1919		1935.0																															-;many frameshifted proteins	
1115822.3	Streptococcus pyogenes GA41394	Streptococcus pyogenes GA41394	1115822	WGS	GA41394						 		2013-10-25T00:00:00Z		PRJNA78627	SAMN02436480	GCA_000483585.1	AWTJ00000000	-	J. Craig Venter Institute	WGS	454	48x	Newbler v. 2.6	0.0	0.0	44		1797373	38.4	1837		1822.0																															-	
1048264.3	Streptococcus pyogenes HKU QMH11M0907901		1048264	Complete	HKU QMH11M0907901				MLST.Streptococcus_pyogenes.36				2012-05-18T00:00:00Z		PRJNA68183	SAMN02471172	GCF_000275625.1	AFRY00000000		Department of Microbiology, The University of Hong Kong	Complete	454 GS FLX titanium	48x	Newbler v. 2.5.3	1.0		1		1908100	38.45	1909		1865.0		blood from scarlet fever outbreak		2011	China	China: Hong Kong						Human, Homo sapiens																			Clinical use of next generation sequencing for rapid identification of useful genomic signatures in the complete genome of an epidemic strain of emm12 Streptococcus pyogenes causing scarlet fever and bacteremia in Hong Kong. Bacteremic strain from a patient with scarlet fever in Hong Kong. Gram positive cocci in chains, beta-hemolytic on horse blood agar, bacitracin susceptible, Lancefield Group A antigen positive. The Vitek ID bionumber profile was 51043230001 which had a confidence level of 99% in its identification as Streptococcus pyogenes. Resistant to erythromycin, clindamycin and tetracycline but susceptible to penicillin G, ciprofloxacin, levofloxacin, rifampicin and vancomycin. Emm typing: emm12. MLST: ST36.	
1314.133	Streptococcus pyogenes HKU360		1314	Complete	HKU360	serovar M12			MLST.Streptococcus_pyogenes.36				2014-11-05T00:00:00Z	-	PRJNA257934	SAMN02980885	GCA_000772185.1	CP009612.1	NZ_CP009612.1	University of Queensland	Complete	PacBio	141x	HGAP v. 2.1.0	1.0		1		1944537	38.46	1923		1846.0																															Complete genome of scarlet fever-associated serotype M12 Streptococcus pyogenes strain HKU360	
1214224.3	Streptococcus pyogenes HLJGAS12011	Streptococcus pyogenes HLJGAS12011	1214224	WGS	HLJGAS12011				MLST.Streptococcus_pyogenes.36				2012-08-14T00:00:00Z	23045496	PRJNA171209	SAMN02469372	GCA_000290595.1	ALKE00000000	-	State Key Laboratory for Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People???s Republic of China	WGS	Illumina HiSeq	241.0x	SOAPdenovo v. 1.06	0.0	0.0	38		1894759	38.3	1891		0.0		a patient with scarlatina	isolated from a patient with scarlatina in Helongjiang, China, 2011	2011	China	China: Heilongjiang						Human, Homo sapiens			scarlatina						Positive	Cocci	No	No						Scarlet fever	"""This strain is also known as group A streptococci (GAS). This was isolated from a patient with scarlatina in Helongjiang, China, 2011."""	
1336746.3	Streptococcus pyogenes HSC5	Streptococcus pyogenes HSC5	1336746	Complete	HSC5	serovar HSC5			MLST.Streptococcus_pyogenes.84				2013-07-11T00:00:00Z		PRJNA205050	SAMN02604317	GCA_000422045.1	CP006366.1	NC_021807.1	Washington University in St Louis	Complete	454; Illumina	220X	SeqMan NGen v. 4.0.0	1.0	0.0	1		1818351	38.5	1812		1744.0																					Positive	Cocci	No	No							The complete genome sequence of Streptococcus pyogenes emm14 serotype HSC5. This strain is a robust producer of the cysteine protease SpeB and is capable of producing infection in several different animal models.	
1150773.3	Streptococcus pyogenes JRS4		1150773	Complete	JRS4	serovar emm6			MLST.Streptococcus_pyogenes.37				2015-06-02T00:00:00Z		PRJNA283215	SAMN03610013	GCF_001014285.1	CP011414	NZ_CP011414.1	Washington University School of Medicine	Complete	454; Illumina	167	Newbler v. 2.5.3; DNASTAR SeqMan NGen	1.0		1		1811968	38.63	1811		1671.0				1971								Human, Homo sapiens			Rheumatic fever-associated											C					We report the complete genome assemblies of the group A Streptococcus pyogenes serotype emm6 strains D471 and its streptomycin-resistant derivative JRS4. Both of these well studied laboratory strains have been extensively characterized over the past three decades and have been instrumental in the discovery of multiple aspects of streptococcal pathogenesis.	collected_by:Rockefeller University Lancefield Collection
1150773.4	Streptococcus pyogenes JRS4		1150773	Complete	JRS4				MLST.Streptococcus_pyogenes.37				2015-04-04T00:00:00Z		PRJDB114		GCF_001547715.1	AP012335	NZ_AP012335.1	Tokyo Medical and Dental University	Complete	Sanger; Roche 454	150x	Newbler v. 2.5.1; Phrap v. 1.090518;	1.0		1		1811124	38.64	1886		1890.0																					Positive	Cocci	No							Pharyngitis	Complete genome sequence of the highly invasive Streptococcus pyogenes JRS4	
1207470.4	Streptococcus pyogenes M1 476	Streptococcus pyogenes M1 476	1207470	Complete	476				MLST.Streptococcus_pyogenes.28		 		2012-07-14T00:00:00Z	22965090	PRJDB141		GCA_000349925.2	AP012491.1	NC_020540.1	National Center for Global Health and Medicine	Complete	ABI3730xl, Roche 454, Illumina MiSeq	20x	GS De Novo Assembler v. 2.6	1.0	0.0	1		1831079	38.5	1929		1849.0		streptococcal toxic shock syndrome case (STSS) during pregnancy	isolated from a streptococcal toxic shock syndrome case (STSS) during pregnancy	1994								Human, Homo sapiens	female																	Toxic shock syndrome	We report the completely annotated genome sequence of Streptococcus pyogens M1 476 isolated from a streptococcal toxic shock syndrome case (STSS) during pregnancy. The genome sequence will provide new insights into the underlying mechanisms to cause STSS	
160490.10	Streptococcus pyogenes M1 GAS	Streptococcus pyogenes M1 GAS	160490	Complete	M1 GAS				MLST.Streptococcus_pyogenes.28				2001-04-11T00:00:00Z	11296296	PRJNA269	SAMN02604089	GCA_000006785.2	AE004092	NC_002737	University of Oklahoma	Complete				1.0	0.0	1		1852441	38.5	1919		1697.0		patient with a wound infection	isolated from a patient with a wound infection									Human, Homo sapiens			wound infection						+	Coccus	No	No	Mesophilic	30-35	Non-halophilic	Facultative	Host-associated		 Streptococcus pyogenes strain M1 GAS. This strain is also known as group A streptococci (GAS). This organism is a strict human pathogen that was isolated from a patient with a wound infection.	
1314.131	Streptococcus pyogenes M23ND		1314	Complete	M23ND				MLST.Streptococcus_pyogenes.160				2014-09-22T00:00:00Z	25225265	PRJNA248257	SAMN02800743	GCA_000756485.1	CP008695.1	NZ_CP008695.1	University of Notre Dame	Complete	454; Illumina	200x	velvet v. 1.0.18	1.0		1		1846477	38.61	1856		1842.0				2012-02-02	Japan	Japan						Human, Homo sapiens																			Streptococcus pyogenes is a pathogenic bacterial with versatile host infection phenotypes. The whole genome sequencing will help us to further understand its virulence mechanism and discover potential therapeutic targets.	
1314.4230	Streptococcus pyogenes M28PF1		1314	WGS	M28PF1				MLST.Streptococcus_pyogenes.52				2023-05-30T00:00:00Z	37104252	PRJNA926803	SAMN32884764		JAQMHW000000000				Illumina	48.0x	Velvet v. february 2020	0.0	0.0	31		1861621	38.202084	1892				female with post partum endometritis		2009	France	France						Homo sapiens	female		post partum endometritis																	collected_by:CNR strepto
294934.5	Streptococcus pyogenes M49 591	Streptococcus pyogenes M49 591	294934	WGS	M49 591	serovar M49			MLST.Streptococcus_pyogenes.29				2004-12-23T00:00:00Z		PRJNA13286	SAMN02469731	GCA_000167435.1	AAFV00000000	NZ_AAFV00000000	Department of Medical Microbiology and Hospital Hygiene, University Hospital Rostock, Germany	WGS				0.0	0.0	295		1327684	38.3	1432		1364.0		patient with a skin infection	isolated from a patient with a skin infection									Human, Homo sapiens			skin infection						+	Coccus	No	No	Mesophilic	-	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes strain M49 591. This strain is a serotype M49 strain isolated from a patient with a skin infection. ;genome length too small	
370552.6	Streptococcus pyogenes MGAS10270		370552	WGS					MLST.Streptococcus_pyogenes.63				2015-06-19T00:00:00Z		PRJEB9637	SAMEA3460950	GCF_001182065.1	CVUH00000000		URMITE	WGS						22		1948513	38.2	1979																																	Streptococcus pyogenes was isolated from blood in a sick patient	
370552.4	Streptococcus pyogenes MGAS10270	Streptococcus pyogenes MGAS10270	370552	Complete	MGAS10270				MLST.Streptococcus_pyogenes.55				2006-05-04T00:00:00Z	16636287	PRJNA16364		GCA_000013505.1	CP000260	NC_008022	Lab of Human Bacterial Pathogenesis|Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Laboratory of Human Bacterial Pathogenesis, USA, Hamilton	Complete				1.0	0.0	1		1928252	38.4	2024		1986.0																					+	Coccus	No	No	Mesophilic	-	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes MGAS10270.This strain is being sequenced for comparative genome analysis.	
286636.3	Streptococcus pyogenes MGAS10394	Streptococcus pyogenes MGAS10394	286636	Complete	MGAS10394	serovar M6			MLST.Streptococcus_pyogenes.382				2004-07-24T00:00:00Z	15272401	PRJNA12469	SAMN02603497	GCA_000011665.1	CP000003	NC_006086	Lab of Human Bacterial Pathogenesis	Complete				1.0	0.0	1		1899877	38.7	1960		1886.0		child with pharyngitis	This strain is a serotype M6 isolate cultured from a child with pharyngitis in private elementary school in Pennsilvania.		USA	Pennsilvania						Human, Homo sapiens									+	Coccus	No	No	Mesophilic	35	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes strain MGAS10394. This strain is a serotype M6 isolate cultured from a child with pharyngitis in private elementary school in Pennsilvania. The strain contains the mefA gene encoding macrolide resistance and shown to be resistant to erythromycin, and has a chromosomal field-inversion gel-electrophoresis pattern characteristic of the serotype M6 clone causing disease on the territory of USA. It has been deposited at the American Type Culture Collection (accession no. BAA-946).	
370554.4	Streptococcus pyogenes MGAS10750	Streptococcus pyogenes MGAS10750	370554	Complete	MGAS10750				MLST.Streptococcus_pyogenes.1072				2006-05-04T00:00:00Z	16636287	PRJNA16366	SAMN02603504	GCA_000013545.1	CP000262	NC_008024	Lab of Human Bacterial Pathogenesis|Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Laboratory of Human Bacterial Pathogenesis, USA, Hamilton	Complete				1.0	0.0	1		1937111	38.3	2030		1979.0																					+	Coccus	No	No	Mesophilic	-	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes MGAS10750.This strain is being sequenced for comparative genome analysis.	
530008.3	Streptococcus pyogenes MGAS10870		530008	Complete	MGAS10870				MLST.Streptococcus_pyogenes.15				2023-02-27T00:00:00Z		PRJNA36553	SAMN00013012		CP067090				Illumina MiSeq; PacBio	100.0x	CLC Genomics Workbench v. 20	1.0	0.0	1		1863912	38.602146	1903		1799.0																																
798300.3	Streptococcus pyogenes MGAS15252	Streptococcus pyogenes MGAS15252	798300	Complete	MGAS15252				MLST.Streptococcus_pyogenes.172		 		2012-03-01T00:00:00Z		PRJNA49669	SAMN02603944	GCA_000250905.1	CP003116.1	NC_017040.1	The Methodist Hospital Research Institute	Complete				1.0	0.0	1		1750832	38.5	1690		1662.0																															Streptococcus pyogenes MGAS15252.Causative agent of an epidemic of group A Streptococcus human invasive infections.	
1010840.4	Streptococcus pyogenes MGAS1882	Streptococcus pyogenes MGAS1882	1010840	Complete	MGAS1882				MLST.Streptococcus_pyogenes.172		NR-33708		2012-03-01T00:00:00Z		PRJNA66081	SAMN02603945	GCA_000250925.1	CP003121.1	NC_017053.1	The Methodist Hospital Research Institute	Complete	454; Illumina			1.0	0.0	1		1781029	38.0	1727		0.0				1960	USA							Human, Homo sapiens																	Host		-	
370553.4	Streptococcus pyogenes MGAS2096	Streptococcus pyogenes MGAS2096	370553	Complete	MGAS2096				MLST.Streptococcus_pyogenes.36				2006-05-04T00:00:00Z	16636287	PRJNA16365	SAMN02603503	GCA_000013525.1	CP000261	NC_008023	Lab of Human Bacterial Pathogenesis|Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Laboratory of Human Bacterial Pathogenesis, USA, Hamilton	Complete				1.0	0.0	1		1860355	38.7	1953		1898.0																					+	Coccus	No	No	Mesophilic	-	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes MGAS2096.This strain is being sequenced for comparative genome analysis.;many frameshifted proteins	
561522.3	Streptococcus pyogenes MGAS2111		561522	WGS	MGAS2111				MLST.Streptococcus_pyogenes.14				2014-09-25T00:00:00Z	-	PRJNA31303	SAMN00000656	GCA_000758065.1	JRLI00000000	-	University of Maryland IGS	WGS	454; Sanger	33.72x	Celera Assembler v. 5.0			126		2019649	38.96	2109		2203.0		blood			USA	United States						Human, Homo sapiens									Positive	Cocci	No		Mesophilic			Facultative	Multiple	Wide range of opportunistic infections	 Streptococcus pyogenes MGAS2111. This strain will be sequenced for comparative genome analysis.;many frameshifted proteins	
1314.3321	Streptococcus pyogenes MGAS270		1314	Complete	MGAS270				MLST.Streptococcus_pyogenes.82				2022-05-09T00:00:00Z		PRJNA494557	SAMN17127784	GCA_023278205.1	CP066541			Complete	Illumina MiSeq; Oxford Nanopore GridION	210.0x	Unicycler v. 0.4.6	1.0	0.0	1		1800518	38.565792	1775		1675.0		Not collected		1986	USA	USA:Minnesota						Homo sapiens			Invasive																	collected_by:JMMusser
198466.3	Streptococcus pyogenes MGAS315	Streptococcus pyogenes MGAS315	198466	Complete	MGAS315	serovar M3			MLST.Streptococcus_pyogenes.15				2002-07-18T00:00:00Z	12122206	PRJNA311	SAMN02603496	GCA_000007425.1	AE014074	NC_004070	Lab of Human Bacterial Pathogenesis	Complete				1.0	0.0	1		1900521	38.6	2010		1865.0																					+	Coccus	No	No	Mesophilic	30-35	Non-halophilic	Facultative	Host-associated		 Streptococcus pyogenes strain MGAS315. This strain is a serotype M3 strain.	
293653.4	Streptococcus pyogenes MGAS5005	Streptococcus pyogenes MGAS5005	293653	Complete	MGAS5005				MLST.Streptococcus_pyogenes.28				2005-08-05T00:00:00Z		PRJNA13888	SAMN02603500	GCA_000011765.2	CP000017	NC_007297	Lab of Human Bacterial Pathogenesis|PathoGenesis Corporation	Complete				1.0	0.0	1		1838554	38.5	1931		1865.0		invasive case	isolated from an invasive case in Ontario		Canada	Ontario															+	Coccus	No	No	Mesophilic	35	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes strain MGAS5005. This strain is an M1 serotype and was isolated from an invasive case in Ontario.	
319701.6	Streptococcus pyogenes MGAS6180	Streptococcus pyogenes MGAS6180	319701	Complete	MGAS6180				MLST.Streptococcus_pyogenes.52				2005-08-04T00:00:00Z		PRJNA13887	SAMN02603499	GCA_000012165.1	CP000056	NC_007296	Lab of Human Bacterial Pathogenesis|PathoGenesis Corporation	Complete				1.0	0.0	1		1897573	38.4	1956		1894.0		invasive disease	isolated from an invasive disease in Texas in 1998 and is an M28 serotype	1998	USA	Texas															+	Coccus	No	No	Mesophilic	35	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes strain MGAS6180. This strain was isolated from an invasive disease in Texas in 1998 and is an M28 serotype.	
186103.3	Streptococcus pyogenes MGAS8232	Streptococcus pyogenes MGAS8232	186103	Complete	MGAS8232	serovar M18			MLST.Streptococcus_pyogenes.42				2002-03-28T00:00:00Z	11917108,12122206	PRJNA286	SAMN02603495	GCA_000007285.1	AE009949	NC_003485	Lab of Human Bacterial Pathogenesis	Complete				1.0	0.0	1		1895017	38.5	2007		1839.0																					+	Coccus	No	No	Mesophilic	30-35	Non-halophilic	Facultative	Host-associated		 Streptococcus pyogenes strain MGAS8232. This strain is a serotype M18 strain often associated with acute rheumatic fever outbreaks in the USA.	
1314.3937	Streptococcus pyogenes MGAS8232_WT		1314	WGS	MGAS8232_WT				MLST.Streptococcus_pyogenes.42				2023-01-25T00:00:00Z	36449535	PRJNA825546	SAMN27522080		JALKIP000000000				Illumina MiSeq	100x	SPAdes v. 3.15.1	0.0	0.0	76		1848374	38.365955	1972		1855.0		not collected		not collected	Canada	Canada: London						Not collected																				sample_type:Laboratory culture
1314.3938	Streptococcus pyogenes MGAS8232_dhasA		1314	WGS	MGAS8232_dhasA				MLST.Streptococcus_pyogenes.42				2023-01-25T00:00:00Z	36449535	PRJNA825546	SAMN27522081		JALKIO000000000				Illumina MiSeq	100x	SPAdes v. 3.15.1	0.0	0.0	84		1846252	38.368435	1974		1857.0		not collected		not collected	Canada	Canada: London						Not collected																				sample_type:Laboratory culture
370551.4	Streptococcus pyogenes MGAS9429	Streptococcus pyogenes MGAS9429	370551	Complete	MGAS9429				MLST.Streptococcus_pyogenes.36				2006-05-04T00:00:00Z	16636287	PRJNA16363	SAMN02603501	GCA_000013485.1	CP000259	NC_008021	Lab of Human Bacterial Pathogenesis|Rocky Mountain Laboratories, National Institute of Allergy and Infectious Disease, National Institutes of Health, Laboratory of Human Bacterial Pathogenesis, USA, Hamilton	Complete				1.0	0.0	1		1836467	38.5	1893		1877.0																					+	Coccus	No	No	Mesophilic	-	Non-halophilic	Facultative	Host-associated		Streptococcus pyogenes MGAS9429.This strain is being sequenced for comparative genome analysis.	
1314.3189	Streptococcus pyogenes MIN-191		1314	WGS	MIN-191				MLST.Streptococcus_pyogenes.341				2022-01-13T00:00:00Z		PRJNA769286	SAMN22108526	GCA_021461125.1	JAJBIL000000000			WGS	Illumina MiSeq; Oxford Nanopore MinION	100x	unicycler v. v0.4.9	0.0	0.0	32		1755483	38.409203	1782		1688.0				2019-10-02	United Kingdom	United Kingdom						Homo sapiens																				sample_type:whole organism
1314.3202	Streptococcus pyogenes MSPY1		1314	Duplicate	MSPY1				MLST.Streptococcus_pyogenes.101				2021-10-13T00:00:00Z		PRJNA657283	SAMN15824174	GCA_020483265.1	JACSDN000000000			WGS	Illumina MiSeq	480x	Unicycler v. 0.4.6	0.0	0.0	16		1706687	38.37587	1677		1589.0		wound		2018	USA	USA: Houston						Homo sapiens			SSTI																	collected_by:UTHSC, BCM
1314.3895	Streptococcus pyogenes MUMCMC1953		1314	WGS	MUMCMC1953				MLST.Streptococcus_pyogenes.36	genotype:ST36			2018-01-10T00:00:00Z		PRJNA386535	SAMN07244089		NIYX00000000				Ion_Torrent_PGM	115x	SPAdes v. 5.0.0.1	0.0	0.0	49		1838519	38.397263	1921		1817.0		Biological Sample		Apr-2017	India	India: Mumbai						Homo sapiens		3.5years	Fever, Throat pain																	
1314.3897	Streptococcus pyogenes MUMCMC261		1314	WGS	MUMCMC261				MLST.Streptococcus_pyogenes.36	genotype:ST36			2018-01-10T00:00:00Z		PRJNA386535	SAMN07244086		NIYZ00000000				Ion_Torrent_PGM	129x	SPAdes v. 5.0.0.1	0.0	0.0	53		1730845	38.491894	1787		1696.0		Biological Sample		Apr-2017	India	India: Mumbai						Homo sapiens		2years	Fever, Throat pain																	
1314.3896	Streptococcus pyogenes MUMCMC433		1314	WGS	MUMCMC433				MLST.Streptococcus_pyogenes.55	genotype:ST55			2018-01-10T00:00:00Z		PRJNA386535	SAMN07244087		NIYY00000000				Ion_Torrent_PGM	121x	SPAdes v. 5.0.0.1	0.0	0.0	33		1862366	38.31105	1952		1845.0		Biological Sample		Apr-2017	India	India: Mumbai						Homo sapiens		5.5years	Fever, Throat pain																	
1138874.3	Streptococcus pyogenes NS88.2	Streptococcus pyogenes NS88.2	1138874	WGS	NS88.2				MLST.Streptococcus_pyogenes.205				2012-03-02T00:00:00Z		PRJEA84331	SAMEA2272718	GCA_000263315.1	CAHN00000000	-	University of Wollongong	WGS				0.0	0.0	298		1720933	38.5	1666		1659.0																															-	
1138874.5	Streptococcus pyogenes NS88.2		1138874	WGS	NS88.2	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864282	GCA_900990815.1	CAAILU000000000		SC	WGS						14		1753865	38.3808	1759		1672.0		sterile site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
471876.6	Streptococcus pyogenes NZ131	Streptococcus pyogenes NZ131	471876	Complete	NZ131	serovar M49							2008-10-16T00:00:00Z	18820018	PRJNA20707	SAMN02604236	GCA_000018125.1	CP000829	NC_011375	University of Oklahoma Health Sciences Center|University of Oklahoma's Advanced Center for Genome Technology	Complete				1.0	0.0	1		1815785	38.6	1876		1700.0		patient with acute glomerulonephritis	isolated from a patient with acute glomerulonephritis									Human, Homo sapiens			acute glomerulonephritis						+	Coccus	No	No	Mesophilic	-		Facultative	Host-associated		Streptococcus pyogenes NZ131. This strain is a serotype M49 strain isolated from a patient with acute glomerulonephritis. This strain will be used for comparative analysis.	
1314.3301	Streptococcus pyogenes PartK-Spyogenes-RM8376		1314	Complete	PartK-Spyogenes-RM8376				MLST.Streptococcus_pyogenes.28		ATCC:12344		2022-04-11T00:00:00Z		PRJNA605254	SAMN14078802	GCA_022869605.1	CP064364			Complete	Illumina; PacBio	2580x	Flye v. 2.5; Pilon v. 1.23	1.0	0.0	1		1914863	38.503223	1982		1862.0																																collected_by:ATCC -> NIST
1314.3244	Streptococcus pyogenes SHZ-1		1314	Complete	SHZ-1				MLST.Streptococcus_pyogenes.15				2022-03-07T00:00:00Z		PRJNA718134	SAMN18523098	GCA_022494495.1	CP072523			Complete	Illumina; Oxford Nanopore	200.0x	Unicycler v. 1.0	1.0	0.0	1		1819973	38.615135	1837		1736.0		Secretion		2018-09-06	China	China						Homo sapiens																				sample_type:Culture
1390076.3	Streptococcus pyogenes SP1-LAU	Streptococcus pyogenes SP1-LAU	1390076	WGS	SP1-LAU				MLST.Streptococcus_pyogenes.36		 		2013-11-25T00:00:00Z		PRJNA215875	SAMN02470233	GCA_000498895.1	AYPA00000000	-	Lebanese American University	WGS	Illumina MiSeq	355.0x	A5 v. 20130627	0.0	0.0	155		1925871	38.4	1920		0.0		throat		2010	Lebanon	Lebanon: Byblos						Human, Homo sapiens				throat					Positive	Cocci			Mesophilic	37C			HostAssociated		S. Pyogenes SP1-LAU WGS	
1390084.3	Streptococcus pyogenes SP10-LAU		1390084	WGS	SP10-LAU				MLST.Streptococcus_pyogenes.167				2014-04-28T00:00:00Z	24831139	PRJNA215886	SAMN02741846	GCA_000648895.1	AWPG00000000	-	Lebanese American University	WGS	Illumina MiSeq	469.0x	A5 v. 20130627			12		1771196	38.3	1743		0.0		throat		2011	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP10-LAU WGS	
1314.3942	Streptococcus pyogenes SP1380		1314	Complete	SP1380				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783172		CP060269				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1883075	38.527515	1907		1808.0		throat		2019	Australia	Australia						Homo sapiens			scarlet fever																	collected_by:Gold Coast University Hospital
1314.3945	Streptococcus pyogenes SP1384		1314	Complete	SP1384				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783173		CP060270				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1837261	38.534534	1841		1741.0		throat		2019	Australia	Australia						Homo sapiens			scarlet fever																	collected_by:Gold Coast University Hospital
1314.3943	Streptococcus pyogenes SP1426		1314	Complete	SP1426				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783174		CP060268				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1872024	38.506878	1893		1791.0		throat		2019	Australia	Australia						Homo sapiens			scarlet fever																	
1314.3940	Streptococcus pyogenes SP1448		1314	Complete	SP1448				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783175		CP060267				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1837335	38.53576	1834		1741.0		blood		2019	Australia	Australia						Homo sapiens			invasive disease																	
1314.3941	Streptococcus pyogenes SP1450		1314	Complete	SP1450				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783176		CP060266				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1831250	38.498512	1838		1741.0		blood		2019	Australia	Australia						Homo sapiens			invasive disease																	
1314.3944	Streptococcus pyogenes SP1451		1314	Complete	SP1451				MLST.Streptococcus_pyogenes.28				2023-02-01T00:00:00Z		PRJNA656382	SAMN15783177		CP060265				Oxford Nanopore	100x	Unicycler v. 0.4.7	1.0	0.0	1		1902947	38.423878	1913		1808.0		blood		2019	Australia	Australia						Homo sapiens			invasive disease																	
1390077.3	Streptococcus pyogenes SP2-LAU		1390077	WGS	SP2-LAU				MLST.Streptococcus_pyogenes.304				2014-04-28T00:00:00Z	24831139	PRJNA215877	SAMN02741843	GCA_000648775.1	AWOZ00000000	-	Lebanese American University	WGS	Illumina MiSeq	345.0x	A5 v. 20130627			29		1727943	38.3	1669		0.0		pus		2010	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP2-LAU WGS	
1390078.3	Streptococcus pyogenes SP3-LAU		1390078	WGS	SP3-LAU				MLST.Streptococcus_pyogenes.101				2014-04-28T00:00:00Z	24831139	PRJNA215878	SAMN02741841	GCA_000648795.1	AWPA00000000	-	Lebanese American University	WGS	Illumina MiSeq	275.0x	A5 v. 20130627			21		1745842	38.4	1716		0.0		throat swab		2010	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP3-LAU WGS	
1390079.3	Streptococcus pyogenes SP4-LAU		1390079	WGS	SP4-LAU				MLST.Streptococcus_pyogenes.52				2014-04-28T00:00:00Z	24831139	PRJNA215879	SAMN02741839	GCA_000648815.1	AWPB00000000	-	Lebanese American University	WGS	Illumina MiSeq	206.0x	A5 v. 20130627			28		1906369	38.2	1919		0.0		throat swab		2010	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci									S. pyogenes SP4-LAU	
1390080.3	Streptococcus pyogenes SP5-LAU		1390080	WGS	SP5-LAU				MLST.Streptococcus_pyogenes.28				2014-04-28T00:00:00Z	24831139	PRJNA215882	SAMN02741844	GCA_000648835.1	AWPC00000000	-	Lebanese American University	WGS	Illumina MiSeq	206.0x	A5 v. 20130627			26		1813544	38.4	1822		0.0		pus		2011	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP5-LAU WGS	
1390081.3	Streptococcus pyogenes SP6-LAU		1390081	WGS	SP6-LAU				MLST.Streptococcus_pyogenes.101				2014-04-28T00:00:00Z	24831139	PRJNA215883	SAMN02741840	GCA_000648855.1	AWPD00000000	-	Lebanese American University	WGS	Illumina MiSeq	85.0x	A5 v. 20130627			19		1733546	38.4	1694		0.0		throat		2011	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP6-LAU WGS	
1390082.3	Streptococcus pyogenes SP7-LAU		1390082	WGS	SP7-LAU				MLST.Streptococcus_pyogenes.46				2014-04-28T00:00:00Z	24831139	PRJNA215884	SAMN02741842	GCA_000648875.1	AWPE00000000	-	Lebanese American University	WGS	Illumina MiSeq	388.0x	A5 v. 20130627			158		1953601	38.4	1943		0.0		throat		2011	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP7-LAU WGS	
1390083.3	Streptococcus pyogenes SP8-LAU		1390083	WGS	SP8-LAU				MLST.Streptococcus_pyogenes.109				2014-04-28T00:00:00Z	24831139	PRJNA215885	SAMN02741845	GCA_000648715.1	AWPF00000000	-	Lebanese American University	WGS	Illumina MiSeq	307.0x	A5 v. 20130627			186		1917411	38.4	1867		0.0		throat		2011	Lebanon	Lebanon: Byblos						Human, Homo sapiens									Positive	Cocci			Mesophilic	37C			HostAssociated		S. pyogenes SP8-LAU WGS	
1314.3691	Streptococcus pyogenes SRR17635788_bin.1_metaWRAP_v1.3_MAG		1314	WGS	SRR17635788_bin.1_metaWRAP_v1.3_MAG				MLST.Streptococcus_pyogenes.458				2022-11-04T00:00:00Z		PRJEB56771	SAMEA111539312	GCA_947252695.1	CAMXVO000000000			WGS				0.0	0.0	37		1815876	38.17232	1872				vaginal metagenome		2008-01-01	USA	USA																										
562017.3	Streptococcus pyogenes SS1447		562017	WGS	SS1447				MLST.Streptococcus_pyogenes.109				2014-09-25T00:00:00Z	-	PRJNA31301	SAMN00000654	GCA_000758085.1	JRLL00000000	-	University of Maryland IGS	WGS	454; Sanger	26.23x	Celera Assembler v. 5.0			88		1915158	38.56	1867		1932.0		blood			United Kingdom	United Kingdom						Human, Homo sapiens									Positive	Cocci	No		Mesophilic			Facultative	Multiple	Wide range of infections	 Streptococcus pyogenes SS1447. This strain is being sequenced for comparative genome analysis.	
193567.3	Streptococcus pyogenes SSI-1	Streptococcus pyogenes SSI-1	193567	Complete	SSI-1	serovar M3			MLST.Streptococcus_pyogenes.15				2003-06-12T00:00:00Z	12799345	PRJNA301		GCA_000011285.1	BA000034	NC_004606	Osaka Univ.	Complete				1.0	0.0	1		1894275	38.6	2009		1861.0		toxic-shock patient	isolated from a toxic-shock patient in Japan and often associated with severe invasive infections, necrotizing fasciitis, and death		Japan	Japan						Human, Homo sapiens									+	Coccus	No	No	Mesophilic	30-35	Non-halophilic	Facultative	Host-associated		 Streptococcus pyogenes strain SSI-1. This strain is a serotype M3 strain that was isolated from a toxic-shock patient in Japan and often associated with severe invasive infections, necrotizing fasciitis, and death.	
1437008.3	Streptococcus pyogenes STAB1102		1437008	Complete	STAB1102				MLST.Streptococcus_pyogenes.5				2014-07-22T00:00:00Z	-	PRJNA231786	SAMN03081522	GCA_000732345.1	CP007023.1	-	Service Bacteriologie CHU Pontchaillou	Complete	Illumina	2,400x	CLC Genomics workbench v. 6.5.1	1.0		1		1709442	38.6	1624		1582.0												Human, Homo sapiens									Positive	Cocci	No	No					HostAssociated		Genome sequence of streptococcus pyogenes strain STAB1102 (emm83), a human pathogen associated with skin tissue infection in Brittany.	
1440772.3	Streptococcus pyogenes STAB901		1440772	Complete	STAB901	serovar M44			MLST.Streptococcus_pyogenes.178				2014-07-22T00:00:00Z	-	PRJNA232121	SAMN03081523	GCA_000732385.1	CP007024.1	-	Bacteriology Service, CHU Pontchaillou Rennes, France	Complete	454	30x	CLC Genomics workbench v. 6.5.1	1.0		1		1795609	38.5	2029		1358.0												Human, Homo sapiens									Positive	Cocci									Invasive and epidemic strain of serotype M44 group A streptococcus;many frameshifted proteins	
1437007.3	Streptococcus pyogenes STAB902		1437007	Complete	STAB902				MLST.Streptococcus_pyogenes.406				2014-07-22T00:00:00Z	-	PRJNA231895	SAMN03081524	GCA_000732425.1	CP007041.1	NZ_CP007041.1	nicolas.soriano@univ-rennes1.fr	Complete	Illumina; PCR+Sanger	130	CLC Genomics workbench v. 6.5.1	1.0		1		1892124	38.5	1925		1809.0												Human, Homo sapiens																			S. pyogenes non-invasive M3 strain	
1314.3198	Streptococcus pyogenes TSPY1026		1314	Duplicate	TSPY1026								2021-11-10T00:00:00Z		PRJNA657283	SAMN15824163	GCA_020827075.1	CP060646			Complete	Illumina MiSeq; Oxford Nanopore GridION	270x	Unicycler v. 0.4.6	1.0	0.0	1		1890384	38.44023	1868		1757.0		skin		2016	USA	USA:Houston						Homo sapiens			Cellulitis																	collected_by:UTHSC/BCM
1314.3203	Streptococcus pyogenes TSPY125		1314	Duplicate	TSPY125								2021-10-13T00:00:00Z		PRJNA657283	SAMN15824173	GCA_020483275.1	JACSDO000000000			WGS	Illumina MiSeq	140x	Unicycler v. 0.4.6	0.0	0.0	14		1726049	38.22962	1698		1626.0		wound		2013	USA	USA: Houston						Homo sapiens			Cellulitis																	collected_by:UTHSC, BCM
1314.3196	Streptococcus pyogenes TSPY1309		1314	Duplicate	TSPY1309								2021-11-10T00:00:00Z		PRJNA657283	SAMN15824165	GCA_020827035.1	CP060644			Complete	Illumina MiSeq; Oxford Nanopore GridION	290x	Unicycler v. 0.4.6	1.0	0.0	1		1781254	38.614986	1732		1634.0		skin		2017	USA	USA:Houston						Homo sapiens			Abscess																	collected_by:UTHSC/BCM
1314.3194	Streptococcus pyogenes TSPY1312		1314	Duplicate	TSPY1312				MLST.Streptococcus_pyogenes.378				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824167	GCA_020826995.1	CP060642			Complete	Illumina MiSeq; Oxford Nanopore GridION	147x	Unicycler v. 0.4.6	1.0	0.0	1		1845647	38.508987	1828		1728.0		throat		2017	USA	USA:Houston						Homo sapiens			Abscess																	collected_by:UTHSC/BCM
1314.3197	Streptococcus pyogenes TSPY1349		1314	Duplicate	TSPY1349				MLST.Streptococcus_pyogenes.161				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824164	GCA_020827055.1	CP060645			Complete	Illumina MiSeq; Oxford Nanopore GridION	260x	Unicycler v. 0.4.6	1.0	0.0	1		1902845	38.422836	1901		1793.0		throat		2017	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1314.3199	Streptococcus pyogenes TSPY136		1314	Duplicate	TSPY136				MLST.Streptococcus_pyogenes.46				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824162	GCA_020827095.1	CP060647			Complete	Illumina MiSeq; Oxford Nanopore GridION	420x	Unicycler v. 0.4.6	1.0	0.0	1		1780403	38.63597	1753		1666.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1314.3190	Streptococcus pyogenes TSPY141		1314	Duplicate	TSPY141				MLST.Streptococcus_pyogenes.184				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824172	GCA_020826915.1	CP060638			Complete	Illumina MiSeq; Oxford Nanopore GridION	102x	Unicycler v. 0.4.6	1.0	0.0	1		1878218	38.412262	1872		1768.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1314.3191	Streptococcus pyogenes TSPY153		1314	Duplicate	TSPY153				MLST.Streptococcus_pyogenes.75				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824171	GCA_020826935.1	CP060639			Complete	Illumina MiSeq; Oxford Nanopore GridION	186x	Unicycler v. 0.4.6	1.0	0.0	1		1970284	38.53424	1989		1866.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1314.3193	Streptococcus pyogenes TSPY210		1314	Duplicate	TSPY210								2021-11-10T00:00:00Z		PRJNA657283	SAMN15824169	GCA_020826975.1	CP060641			Complete	Illumina MiSeq; Oxford Nanopore GridION	158x	Unicycler v. 0.4.6	1.0	0.0	1		1841971	38.520206	1844		1725.0		blood		2014	USA	USA:Houston						Homo sapiens			Invasive																	collected_by:UTHSC/BCM
1314.3201	Streptococcus pyogenes TSPY270		1314	Duplicate	TSPY270				MLST.Streptococcus_pyogenes.167				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824160	GCA_020827135.1	CP060649			Complete	Illumina MiSeq; Oxford Nanopore GridION	330x	Unicycler v. 0.4.6	1.0	0.0	1		1852565	38.427963	1834		1738.0		skin		2014	USA	USA:Houston						Homo sapiens			SSTI																	collected_by:UTHSC/BCM
1314.3200	Streptococcus pyogenes TSPY383		1314	Duplicate	TSPY383				MLST.Streptococcus_pyogenes.28				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824161	GCA_020827115.1	CP060648			Complete	Illumina MiSeq; Oxford Nanopore GridION	130x	Unicycler v. 0.4.6	1.0	0.0	1		1827693	38.463352	1838		1744.0		throat		2014	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1314.3195	Streptococcus pyogenes TSPY416		1314	Duplicate	TSPY416								2021-11-10T00:00:00Z		PRJNA657283	SAMN15824166	GCA_020827015.1	CP060643			Complete	Illumina MiSeq; Oxford Nanopore GridION	1090x	Unicycler v. 0.4.6	1.0	0.0	1		1791351	38.482742	1749		1651.0		skin		2014	USA	USA:Houston						Homo sapiens			Cellulitis																	collected_by:UTHSC/BCM
1314.3192	Streptococcus pyogenes TSPY764		1314	Duplicate	TSPY764								2021-11-10T00:00:00Z		PRJNA657283	SAMN15824170	GCA_020826955.1	CP060640			Complete	Illumina MiSeq; Oxford Nanopore GridION	111x	Unicycler v. 0.4.6	1.0	0.0	1		1758170	38.558956	1705		1604.0		throat		2015	USA	USA:Houston						Homo sapiens			Pharyngitis																	collected_by:UTHSC/BCM
1115811.3	Streptococcus pyogenes UTMEM-1	Streptococcus pyogenes UTMEM-1	1115811	WGS	UTMEM-1				MLST.Streptococcus_pyogenes.52				2013-08-22T00:00:00Z		PRJNA78605	SAMN00828757	GCA_000454105.1	AVCF00000000	-	J. Craig Venter Institute	WGS	454	22x	Newbler v. 2.6	0.0	0.0	54		1869665	38.2	1882		1881.0																															-	
1115810.3	Streptococcus pyogenes UTSW-2	Streptococcus pyogenes UTSW-2	1115810	WGS	UTSW-2				MLST.Streptococcus_pyogenes.52				2013-08-22T00:00:00Z		PRJNA78603	SAMN00828755	GCA_000454085.1	AVCG00000000	-	J. Craig Venter Institute	WGS	454	17x	Newbler v. 2.6	0.0	0.0	77		1869259	38.2	1918		1925.0																															-;many frameshifted proteins	
342023.3	Streptococcus pyogenes serotype M12 strain V31		342023	WGS	V31	M12			MLST.Streptococcus_pyogenes.36				2020-08-03T00:00:00Z		PRJNA641926	SAMN15373655	GCA_014050235.1	JACGAH000000000		Federal State Budgetary Scientific Institution Institute of Experimental Medicine	WGS	Illumina MiSeq	290.0x	SPAdes v. 3.6.2	0.0	0.0	52		1856099	38.328667	1904		1795.0		throat swab		2012-10	Viet Nam	Viet Nam: Quang Tri						Human, Homo sapiens			Scarlet fever																Genome analysis following an increase in scarlet fever in Asia 2011	collected_by:Dmitriev A.
301451.12	Streptococcus pyogenes serotype M18		301451	WGS	18				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734422	GCA_001369275.1	CDGO00000000		IZLSLER	WGS						182		1829916	38.37	1989				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.5	Streptococcus pyogenes serotype M18		301451	WGS	M				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734416	GCA_001369155.1	CDGN00000000		IZLSLER	WGS						158		1888279	38.4	2061				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected									Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.11	Streptococcus pyogenes serotype M18		301451	WGS	RO				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734421	GCA_001369255.1	CDGY00000000		IZLSLER	WGS						207		1837109	38.44	2020				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.13	Streptococcus pyogenes serotype M18 strain 18bis		301451	WGS	18bis				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734423	GCA_001369295.1	CDGV00000000		IZLSLER	WGS						182		1866078	38.4	2025				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.6	Streptococcus pyogenes serotype M18 strain B		301451	WGS	B				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734415	GCA_001369135.1	CDGS00000000		IZLSLER	WGS						294		1810475	38.62	1986				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected									Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.4	Streptococcus pyogenes serotype M18 strain CPost		301451	WGS	CPost				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734414	GCA_001369115.1	CDHA00000000		IZLSLER	WGS						222		1862672	38.44	2035				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected									Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.3	Streptococcus pyogenes serotype M18 strain CPre		301451	WGS	CPre				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734413	GCA_001369095.1	CDHB00000000		IZLSLER	WGS						235		1862736	38.42	2057				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected									Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.7	Streptococcus pyogenes serotype M18 strain DI		301451	WGS	DI				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734417	GCA_001369175.1	CDGQ00000000		IZLSLER	WGS						96		1918093	38.4	2077				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected									Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.8	Streptococcus pyogenes serotype M18 strain DO		301451	WGS	DO				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734418	GCA_001369195.1	CDGM00000000		IZLSLER	WGS						81		1829909	38.35	1930				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.10	Streptococcus pyogenes serotype M18 strain ME		301451	WGS	ME				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734419	GCA_001369215.1	CDGX00000000		IZLSLER	WGS						199		1886005	38.37	2085				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
301451.9	Streptococcus pyogenes serotype M18 strain PA		301451	WGS	PA				MLST.Streptococcus_pyogenes.42				2015-03-31T00:00:00Z		PRJEB7108	SAMEA2734420	GCA_001369235.1	CDGW00000000		IZLSLER	WGS						183		1868738	38.38	2043				school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected	isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected		Italy	Italy:Bologna						Human, Homo sapiens																			n February 2013, first notification of an acute rheumatic fever (ARF) case caused by Streptococcus Pyogenes, group A (GAS) following hospital admission occurred in a 11-year-old otherwise healthy boy resident in the Bologna province, Emilia-Romagna region. At the same time, GAS strains isolated from school-age children suffering with faringo-tonsillitis from Bologna metropolitan area were collected. Two months later, a second diagnosis of ARF were notified in a boy resident in the same province. Subsequently, another group of GAS positive samples obtained from children who frequented the class of second ARF case and from the symptomatic children residents in the same area were collected. Whole-genome sequencing was conducted on GAS strains isolated from ARF cases and on a few GAS isolates presenting the same emm-type using an Illumina MiSeq sequencer with a 2x250 pair-end run. Library preparation was performed using an Illumina Nextera XT kit.	isolate:M18BO
160491.19	Streptococcus pyogenes str. Manfredo	Streptococcus pyogenes str. Manfredo	160491	Complete	Manfredo	serovar M5			MLST.Streptococcus_pyogenes.99				2007-03-29T00:00:00Z	17012393	PRJNA270	SAMEA1705956	GCA_000009385.1	AM295007	NC_009332	Wellcome Trust Sanger Institute	Complete				1.0	0.0	1		1841271	38.6	1935		1745.0		patient	isolated from a patient in the 1950's in Chicago	1950s	USA	USA: Chicago						Human, Homo sapiens									+	Coccus	No	No	Mesophilic	30-35	Non-halophilic	Facultative	Host-associated		 Streptococcus pyogenes strain Manfredo. This strain is a serotype M5 strain associated with acute rheumatic fever isolated from a patient in the 1950's in Chicago.	
1314.2410	Streptococcus pyogenes strain 10-85		1314	Complete	10-85				MLST.Streptococcus_pyogenes.28			Yes	2019-06-13T00:00:00Z	26861052	PRJDB4033	SAMD00034931	GCA_006740645.2	AP019548		Nagoya City University	Complete	PacBio RSII	456x	SMRT Analysis v. 2.3.0	1.0		1		1778005	38.581554	1745		1666.0			isolated after 2010, but not before 2010	2010																											"Streptococcus pyogenes, is a Gram-positive bacterium that infects the upper respiratory tract, including the tonsils and pharynx, and is responsible for post-infection diseases such as rheumatic fever and glomerulonephritis. S. pyogenes also causes severe invasive diseases including necrotizing fasciitis and streptococcal toxic shock syndrome (STSS).Recently, we reported that a region encoding the SalR-SalK two component regulatory system and the adjacent type I restriction modification system was deleted in some emm 1 type isolates (APMIS, Volume 122, Issue 10, pages 914-921, DOI: 10.1111/apm.12230). The isolates with the deletion were detected only in the emm 1 strains that were isolated after 2010, but not before 2010. we named the emm 1 strains with the deletion as a ""novel-type"" emm 1 strain. In a experiment using mouse invasive infection model, both of two novel emm 1 type strains (10-85 and 11-171) isolated from ""STSS"" patients were more virulent than a novel emm 1 type strain (11O-2) isolated from a ""non-STSS"" patient. In the present project, we performed whole genome sequences of strains 10-85, 11-171, and 11O-2, and searched them for some specific mutations or single nucleotide polymorphisms (SNPs) existing in only low-virulent strain 11O-2, but not strains 10-85 and 11-171."	
1314.2710	Streptococcus pyogenes strain 1040		1314	Complete	1040								2020-03-15T00:00:00Z		PRJNA609838	SAMN14260617	GCA_011290565.1	CP049799		Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Complete	Illumina GAIIx; Oxford Nanopore GridION	150.0x	MaSuRCA v. 3.2.2	1.0	0.0	1		1832686	38.32697	1771		1679.0		throat		2008	India	India:Chandigarh						Homosapiens																			Gram Positive cocci, non motile, non spore forming, Group A Streptococi	sample_type:pure culture
1314.2711	Streptococcus pyogenes strain 1043		1314	Complete	1043				MLST.Streptococcus_pyogenes.530				2020-03-15T00:00:00Z		PRJNA609843	SAMN14260634	GCA_011290585.1	CP049800		Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Complete	Illumina GAIIx; Oxford Nanopore GridION	150.0x	MaSuRCA v. 3.2.2	1.0	0.0	1		1821897	38.271538	1822		1693.0		skin	isolated from human skin	2008	India	India:Chandigarh						Homosapiens																			This strain of Streptococcus pyogenes is a Gram Positive cocci,(occurs in chains) isolated from human skin. It is non motile , non spore forming.	sample_type:Pure Culture
1314.2589	Streptococcus pyogenes strain 1085		1314	Complete	1085				MLST.Streptococcus_pyogenes.530	genotype:emm1-2			2020-01-07T00:00:00Z		PRJNA596618	SAMN13632409	GCA_009832845.1	CP047120		Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh	Complete	Illumina GAIIx; Oxford Nanopore GridION	150.0x	MaSuRCA v. 3.3	1.0	0.0	1		2010300	38.39606	2050		1937.0		blood		2008	India	India: Chandigarh						Human, Homo sapiens			Invasive																Isolate is emm type 1-2 isolated from blood sample	collected_by:PGIMER
1314.1216	Streptococcus pyogenes strain 14GA0286		1314	WGS	14GA0286	EMM103.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918946	GCA_900984365.1	CAAHNG000000000		SC	WGS						28		1757669	38.361225	1736		1631.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1208	Streptococcus pyogenes strain 14GA0287		1314	WGS	14GA0287	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918954	GCA_900984285.1	CAAHMW000000000		SC	WGS						14		1833381	38.314342	1861		1773.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1200	Streptococcus pyogenes strain 14GA0305		1314	WGS	14GA0305	EMM103.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918962	GCA_900984205.1	CAAHMP000000000		SC	WGS						19		1759302	38.370102	1724		1632.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1305	Streptococcus pyogenes strain 14GA0788		1314	WGS	14GA0788	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919018	GCA_900985255.1	CAAHQQ000000000		SC	WGS						29		1781800	38.32512	1757		1658.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1299	Streptococcus pyogenes strain 14GA0793		1314	WGS	14GA0793	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919025	GCA_900985195.1	CAAHQK000000000		SC	WGS						20		1765271	38.333122	1759		1663.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1223	Streptococcus pyogenes strain 14GA0794		1314	WGS	14GA0794	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918939	GCA_900984435.1	CAAHNM000000000		SC	WGS						19		1797889	38.310562	1810		1719.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1215	Streptococcus pyogenes strain 14GA0809		1314	WGS	14GA0809	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918947	GCA_900984355.1	CAAHNE000000000		SC	WGS						25		1770797	38.343502	1760		1664.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1206	Streptococcus pyogenes strain 14GA0826		1314	WGS	14GA0826	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918955	GCA_900984265.1	CAAHMV000000000		SC	WGS						21		1830391	38.19284	1820		1721.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1195	Streptococcus pyogenes strain 14GA0828		1314	WGS	14GA0828	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918963	GCA_900984155.1	CAAHMI000000000		SC	WGS						22		1830817	38.191494	1822		1723.0		Foot wound		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1188	Streptococcus pyogenes strain 14GA0829		1314	WGS	14GA0829	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918971	GCA_900984085.1	CAAHME000000000		SC	WGS						23		1830348	38.19477	1823		1720.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1181	Streptococcus pyogenes strain 14GA0830		1314	WGS	14GA0830	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918979	GCA_900984015.1	CAAHLW000000000		SC	WGS						20		1830957	38.19212	1828		1723.0		Leg		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1175	Streptococcus pyogenes strain 14GA0832		1314	WGS	14GA0832	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918987	GCA_900983955.1	CAAHLQ000000000		SC	WGS						20		1827869	38.184193	1824		1721.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2403	Streptococcus pyogenes strain 14GA0832 strain DMG1800716		1314	Complete	DMG1800716				MLST.Streptococcus_pyogenes.330	genotype:emm81;genotype:emm81			2019-08-08T00:00:00Z		PRJNA438376	SAMN08714459	GCA_003352145.1	CP027771		University of Melbourne	Complete	PacBio	105.0x	SMRTpipe v. 2.1.0	1.0		1		1869673	38.37008	1876		1795.0		Blood		2014	New Zealand	New Zealand: Christchurch						Human, Homo sapiens			Invasive disease			host_description:Aged care facility resident													This study examined genetic drivers of a Streptococcus pyogenes invasive disease outbreak	collected_by:Institute of Environmental Science and Research, New Zealand
1314.1166	Streptococcus pyogenes strain 14GA0838		1314	WGS	14GA0838	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918995	GCA_900983865.1	CAAHLH000000000		SC	WGS						21		1831207	38.193333	1828		1724.0		Foot ulcer		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2126	Streptococcus pyogenes strain 14GA0839		1314	WGS	14GA0839	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919003	GCA_900993545.1	CAAIWH000000000		SC	WGS						29		1781400	38.324	1764		1655.0				2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1313	Streptococcus pyogenes strain 14GA0844		1314	WGS	14GA0844	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919011	GCA_900985335.1	CAAHQY000000000		SC	WGS						20		1750813	38.392593	1757		1668.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1306	Streptococcus pyogenes strain 14GA0857		1314	WGS	14GA0857	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919019	GCA_900985265.1	CAAHQR000000000		SC	WGS						20		1829831	38.18884	1827		1724.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1298	Streptococcus pyogenes strain 14GA0862		1314	WGS	14GA0862	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919026	GCA_900985185.1	CAAHQJ000000000		SC	WGS						27		1771265	38.38016	1750		1649.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1222	Streptococcus pyogenes strain 14GA0958		1314	WGS	14GA0958	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918940	GCA_900984425.1	CAAHNL000000000		SC	WGS						11		1736831	38.383606	1702		1605.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1315	Streptococcus pyogenes strain 14GA1005		1314	WGS	14GA1005	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919008	GCA_900985355.1	CAAHQX000000000		SC	WGS						19		1802323	38.37523	1834		1738.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1213	Streptococcus pyogenes strain 14GA1005		1314	WGS	14GA1005	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918948	GCA_900984335.1	CAAHNB000000000		SC	WGS						22		1759200	38.3949	1777		1686.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1217	Streptococcus pyogenes strain 14GA1044		1314	WGS	14GA1044	EMM86.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918945	GCA_900984375.1	CAAHNF000000000		SC	WGS						14		1725524	38.42715	1715		1626.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1205	Streptococcus pyogenes strain 14GA1044		1314	WGS	14GA1044	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918956	GCA_900984255.1	CAAHMU000000000		SC	WGS						23		1748778	38.38492	1762		1664.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1201	Streptococcus pyogenes strain 14GA1101		1314	WGS	14GA1101	EMM118.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918961	GCA_900984215.1	CAAHMN000000000		SC	WGS						9		1756880	38.382645	1731		1643.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1193	Streptococcus pyogenes strain 14GA1101		1314	WGS	14GA1101	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918964	GCA_900984135.1	CAAHMM000000000		SC	WGS						18		1761037	38.338295	1746		1659.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1189	Streptococcus pyogenes strain 14GA1136		1314	WGS	14GA1136	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918972	GCA_900984095.1	CAAHMD000000000		SC	WGS						11		1719184	38.38236	1681		1589.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1192	Streptococcus pyogenes strain 14GA1136		1314	WGS	14GA1136	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918969	GCA_900984125.1	CAAHMG000000000		SC	WGS						27		1758540	38.397	1770		1676.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1180	Streptococcus pyogenes strain 14GA1137		1314	WGS	14GA1137	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918980	GCA_900984005.1	CAAHLV000000000		SC	WGS						23		1790572	38.372635	1828		1728.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1183	Streptococcus pyogenes strain 14GA1137		1314	WGS	14GA1137	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918977	GCA_900984035.1	CAAHLY000000000		SC	WGS						24		1758184	38.39407	1775		1679.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.301	Streptococcus pyogenes strain 153		1314	WGS	153	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04456660	GCF_001642145.1	LVYM00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			15		1709332	38.39	1685		1591.0		throat swab		2012	Italy	Italy: Perugia						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.300	Streptococcus pyogenes strain 154		1314	WGS	154	M89							2016-05-11T00:00:00Z		PRJNA310856	SAMN04457490	GCF_001642135.1	LVYN00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			188		1947094	38.27	2134		1947.0		throat swab		2012	Italy	Italy: Perugia						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:not collected
1314.304	Streptococcus pyogenes strain 155		1314	WGS	155	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457491	GCF_001642215.1	LVYO00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			19		1727701	38.38	1713		1622.0		throat swab		2012	Italy	Italy: Perugia						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.303	Streptococcus pyogenes strain 156		1314	WGS	156	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457846	GCF_001642205.1	LVYP00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			16		1822905	38.34	1804		1699.0		throat swab		2012	Italy	Italy: Perugia						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.299	Streptococcus pyogenes strain 157		1314	WGS	157	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457850	GCF_001642125.1	LVYQ00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			19		1812033	38.35	1857		1745.0		throat swab		2012	Italy	Italy: Roma						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.302	Streptococcus pyogenes strain 158		1314	WGS	158	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457851	GCF_001642165.1	LVYR00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			29		1706686	38.41	1682		1589.0		throat swab		2012	Italy	Italy: Perugia						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.305	Streptococcus pyogenes strain 159		1314	WGS	159	M89			MLST.Streptococcus_pyogenes.101				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457853	GCF_001642225.1	LVYS00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			23		1734362	38.37	1734		1630.0		throat swab		2012	Italy	Italy: Roma						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.1172	Streptococcus pyogenes strain 15GA0011		1314	WGS	15GA0011	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918988	GCA_900983925.1	CAAHLN000000000		SC	WGS						19		1711921	38.381935	1697		1615.0		sterile site		2015	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1165	Streptococcus pyogenes strain 15GA0017		1314	WGS	15GA0017	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918996	GCA_900983855.1	CAAHLG000000000		SC	WGS						24		1759622	38.395176	1777		1683.0		throat		2015	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2124	Streptococcus pyogenes strain 15GAS0096		1314	WGS	15GAS0096	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919004	GCA_900993525.1	CAAIWF000000000		SC	WGS						12		1736941	38.3863	1702		1604.0				2015	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1314	Streptococcus pyogenes strain 15GAS0097		1314	WGS	15GAS0097	EMM95.0			MLST.Streptococcus_pyogenes.604				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919012	GCA_900985345.1	CAAHRA000000000		SC	WGS						22		1743847	38.39221	1755		1662.0				2015	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.306	Streptococcus pyogenes strain 160		1314	WGS	160	M89			MLST.Streptococcus_pyogenes.39				2016-05-11T00:00:00Z		PRJNA310856	SAMN04457860	GCF_001642265.1	LVYT00000000		University of Camerino	WGS	Illumina HiSeq	110.0x	CLC NGS Cell v. 7.0.4			33		1839872	38.3	1895		1770.0		throat swab		2012	Italy	Italy: Roma						Human, Homo sapiens			Pharyngotonsillitis											C					Study of emm89 isolates from pharyngotonsillitis	collected_by:Microbiology Unit, School of Pharmacy, University of Camerino
1314.168	Streptococcus pyogenes strain 19615		1314	Complete	ATCC 19615				MLST.Streptococcus_pyogenes.8		ATCC:19615		2014-10-22T00:00:00Z	25258274	PRJNA244349	SAMN02905033	GCF_000743015.1	CP008926	NZ_CP008926.1	Los Alamos National Laboratory	Complete	Illumina; 454	1062x	Newbler v. 2.6; Velvet v. 1.2.08; Allpaths	1.0		1		1844804	38.48	1875		1775.0																					Positive	Cocci									Streptococcus pyogenes 19615 Genome Assembly	biomaterial_provider:USAMRIID
1314.2040	Streptococcus pyogenes strain 20004V1S1		1314	WGS	20004V1S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523505	GCA_900992695.1	CAAITA000000000		SC	WGS						29		1766260	38.294643	1757		1650.0		swab		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2051	Streptococcus pyogenes strain 20006V1I1		1314	WGS	20006V1I1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523533	GCA_900992795.1	CAAITL000000000		SC	WGS						19		1737845	38.416603	1718		1628.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2071	Streptococcus pyogenes strain 20008V1I1		1314	WGS	20008V1I1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523461	GCA_900992995.1	CAAIUD000000000		SC	WGS						12		1753991	38.41835	1764		1674.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2063	Streptococcus pyogenes strain 20011V1S1		1314	WGS	20011V1S1	EMM68.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523528	GCA_900992915.1	CAAITX000000000		SC	WGS						20		1802253	38.32181	1822		1730.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2082	Streptococcus pyogenes strain 20012V1I1		1314	WGS	20012V1I1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523472	GCA_900993105.1	CAAIUP000000000		SC	WGS						19		1706307	38.47268	1670		1582.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2092	Streptococcus pyogenes strain 20018V1I1		1314	WGS	20018V1I1	EMM87.0			MLST.Streptococcus_pyogenes.541				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523479	GCA_900993205.1	CAAIUZ000000000		SC	WGS						31		1718577	38.31932	1687		1589.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2099	Streptococcus pyogenes strain 20019V1I1		1314	WGS	20019V1I1	EMM60.7			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523494	GCA_900993275.1	CAAIVG000000000		SC	WGS						20		1799772	38.295795	1788		1699.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2104	Streptococcus pyogenes strain 20025V1I1		1314	WGS	20025V1I1	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523554	GCA_900993325.1	CAAIVL000000000		SC	WGS						15		1763851	38.453247	1767		1682.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2113	Streptococcus pyogenes strain 20027V1I1		1314	WGS	20027V1I1	EMM110.0			MLST.Streptococcus_pyogenes.515				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523431	GCA_900993415.1	CAAIVU000000000		SC	WGS						25		1780090	38.283928	1776		1684.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2042	Streptococcus pyogenes strain 20028V1I1		1314	WGS	20028V1I1	EMM81.3							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523419	GCA_900992705.1	CAAITB000000000		SC	WGS						24		1751271	38.25972	1723		1639.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2043	Streptococcus pyogenes strain 20033V1I1		1314	WGS	20033V1I1	EMM81.3							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523564	GCA_900992715.1	CAAITC000000000		SC	WGS						19		1751195	38.26016	1726		1640.0		Gynaecological		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2045	Streptococcus pyogenes strain 20034V1I1		1314	WGS	20034V1I1	EMM76.4			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523588	GCA_900992735.1	CAAITE000000000		SC	WGS						12		1727607	38.386738	1692		1609.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2044	Streptococcus pyogenes strain 20051V1I1		1314	WGS	20051V1I1	EMM76.4			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523576	GCA_900992725.1	CAAITD000000000		SC	WGS						16		1727992	38.3827	1704		1609.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2046	Streptococcus pyogenes strain 20057V1I1		1314	WGS	20057V1I1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523492	GCA_900992745.1	CAAITF000000000		SC	WGS						20		1763707	38.31143	1742		1654.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2049	Streptococcus pyogenes strain 20058V1I1		1314	WGS	20058V1I1	EMM18.22			MLST.Streptococcus_pyogenes.535				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523553	GCA_900992775.1	CAAITH000000000		SC	WGS						12		1719086	38.343597	1709		1622.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2047	Streptococcus pyogenes strain 20059V1I1		1314	WGS	20059V1I1	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523539	GCA_900992755.1	CAAITG000000000		SC	WGS						22		1819181	38.241055	1837		1737.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2048	Streptococcus pyogenes strain 20061V1I1		1314	WGS	20061V1I1	EMM76.4			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523434	GCA_900992765.1	CAAITI000000000		SC	WGS						10		1725891	38.38284	1700		1609.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2050	Streptococcus pyogenes strain 20064V1I1		1314	WGS	20064V1I1	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523511	GCA_900992785.1	CAAITJ000000000		SC	WGS						29		1765820	38.352776	1777		1672.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2052	Streptococcus pyogenes strain 20065V1I1		1314	WGS	20065V1I1	EMM113.0			MLST.Streptococcus_pyogenes.148				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523540	GCA_900992805.1	CAAITK000000000		SC	WGS						18		1725789	38.31882	1681		1592.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2053	Streptococcus pyogenes strain 20066V1I1		1314	WGS	20066V1I1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523443	GCA_900992815.1	CAAITM000000000		SC	WGS						16		1753589	38.418465	1762		1672.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2054	Streptococcus pyogenes strain 20068V1I1		1314	WGS	20068V1I1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523510	GCA_900992825.1	CAAITN000000000		SC	WGS						14		1732610	38.303425	1681		1598.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2055	Streptococcus pyogenes strain 20071V1I1		1314	WGS	20071V1I1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523471	GCA_900992835.1	CAAITO000000000		SC	WGS						17		1765214	38.39999	1770		1670.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2056	Streptococcus pyogenes strain 20077V1I1		1314	WGS	20077V1I1	EMM60.7			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523474	GCA_900992845.1	CAAITQ000000000		SC	WGS						16		1799523	38.29698	1787		1697.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2057	Streptococcus pyogenes strain 20079V1I1		1314	WGS	20079V1I1	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523457	GCA_900992855.1	CAAITP000000000		SC	WGS						18		1724544	38.339294	1691		1597.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2059	Streptococcus pyogenes strain 20081V1I1		1314	WGS	20081V1I1	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523459	GCA_900992875.1	CAAITS000000000		SC	WGS						36		1769143	38.408485	1805		1691.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2060	Streptococcus pyogenes strain 20085V1I1		1314	WGS	20085V1I1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523417	GCA_900992885.1	CAAITR000000000		SC	WGS						19		1700341	38.396122	1659		1574.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2058	Streptococcus pyogenes strain 20086V1I1		1314	WGS	20086V1I1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523438	GCA_900992865.1	CAAITT000000000		SC	WGS						18		1753361	38.418865	1762		1674.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2061	Streptococcus pyogenes strain 20095V1I1		1314	WGS	20095V1I1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523483	GCA_900992895.1	CAAITU000000000		SC	WGS						17		1723231	38.376747	1702		1599.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2062	Streptococcus pyogenes strain 20097V1I1		1314	WGS	20097V1I1	EMM106.0			MLST.Streptococcus_pyogenes.140				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523450	GCA_900992905.1	CAAITW000000000		SC	WGS						17		1685525	38.43396	1648		1559.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2064	Streptococcus pyogenes strain 20098V1I1		1314	WGS	20098V1I1	EMM106.0			MLST.Streptococcus_pyogenes.140				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523439	GCA_900992925.1	CAAITV000000000		SC	WGS						17		1685494	38.434727	1648		1559.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2066	Streptococcus pyogenes strain 20099V1I1		1314	WGS	20099V1I1	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523497	GCA_900992945.1	CAAITZ000000000		SC	WGS						11		1718003	38.355347	1694		1613.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2065	Streptococcus pyogenes strain 20109V1I1		1314	WGS	20109V1I1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523416	GCA_900992935.1	CAAITY000000000		SC	WGS						25		1765276	38.38516	1768		1686.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2067	Streptococcus pyogenes strain 20110V1I1		1314	WGS	20110V1I1	EMM76.4			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523489	GCA_900992955.1	CAAIUA000000000		SC	WGS						9		1726004	38.383827	1698		1610.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2068	Streptococcus pyogenes strain 20111V1I1		1314	WGS	20111V1I1	EMM15.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523446	GCA_900992965.1	CAAIUB000000000		SC	WGS						23		1712144	38.444313	1700		1611.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2069	Streptococcus pyogenes strain 20113V1I1		1314	WGS	20113V1I1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523478	GCA_900992975.1	CAAIUC000000000		SC	WGS						29		1760228	38.407978	1776		1678.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2070	Streptococcus pyogenes strain 20116V1I1		1314	WGS	20116V1I1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523466	GCA_900992985.1	CAAIUE000000000		SC	WGS						24		1720721	38.40059	1711		1623.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2072	Streptococcus pyogenes strain 20123V1I1		1314	WGS	20123V1I1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523558	GCA_900993005.1	CAAIUF000000000		SC	WGS						33		1800996	38.36677	1843		1744.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2073	Streptococcus pyogenes strain 20139V1I1		1314	WGS	20139V1I1	EMM77.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523516	GCA_900993015.1	CAAIUG000000000		SC	WGS						17		1748473	38.356747	1705		1619.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2074	Streptococcus pyogenes strain 20148V1I1		1314	WGS	20148V1I1	EMM106.0			MLST.Streptococcus_pyogenes.140				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523480	GCA_900993025.1	CAAIUH000000000		SC	WGS						17		1713540	38.431026	1675		1590.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2075	Streptococcus pyogenes strain 20170V1I1		1314	WGS	20170V1I1	EMM22.0			MLST.Streptococcus_pyogenes.202				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523572	GCA_900993035.1	CAAIUI000000000		SC	WGS						22		1761753	38.323555	1727		1633.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2076	Streptococcus pyogenes strain 20174V1I1		1314	WGS	20174V1I1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523583	GCA_900993045.1	CAAIUJ000000000		SC	WGS						22		1778014	38.33811	1789		1681.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2078	Streptococcus pyogenes strain 20178V1I1		1314	WGS	20178V1I1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523570	GCA_900993065.1	CAAIUK000000000		SC	WGS						18		1787181	38.419724	1773		1688.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2077	Streptococcus pyogenes strain 20183V1I1		1314	WGS	20183V1I1	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523567	GCA_900993055.1	CAAIUL000000000		SC	WGS						20		1725939	38.36526	1709		1613.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2080	Streptococcus pyogenes strain 20184V1I1		1314	WGS	20184V1I1	EMM75.1			MLST.Streptococcus_pyogenes.468				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523425	GCA_900993085.1	CAAIUN000000000		SC	WGS						17		1830423	38.46051	1793		1701.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2079	Streptococcus pyogenes strain 20232V1I1		1314	WGS	20232V1I1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523582	GCA_900993075.1	CAAIUM000000000		SC	WGS						20		1720670	38.363953	1718		1637.0		Soft tissue		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2081	Streptococcus pyogenes strain 20237V1I1		1314	WGS	20237V1I1	EMM63.3			MLST.Streptococcus_pyogenes.297				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523418	GCA_900993095.1	CAAIUO000000000		SC	WGS						22		1896804	38.306824	1924		1823.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2083	Streptococcus pyogenes strain 20242V1I1		1314	WGS	20242V1I1	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523458	GCA_900993115.1	CAAIUQ000000000		SC	WGS						35		1753890	38.452812	1774		1672.0		sterile site		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2084	Streptococcus pyogenes strain 30083V1T1		1314	WGS	30083V1T1	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523469	GCA_900993125.1	CAAIUR000000000		SC	WGS						15		1719185	38.424145	1708		1618.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2085	Streptococcus pyogenes strain 30085V1T1		1314	WGS	30085V1T1	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523481	GCA_900993135.1	CAAIUS000000000		SC	WGS						25		1712097	38.374542	1680		1584.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2086	Streptococcus pyogenes strain 30108V1T1		1314	WGS	30108V1T1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523506	GCA_900993145.1	CAAIUT000000000		SC	WGS						16		1738988	38.415905	1715		1630.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2087	Streptococcus pyogenes strain 30109V1T1		1314	WGS	30109V1T1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523500	GCA_900993155.1	CAAIUU000000000		SC	WGS						9		1740158	38.33922	1720		1640.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2089	Streptococcus pyogenes strain 30124V1T1		1314	WGS	30124V1T1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523515	GCA_900993175.1	CAAIUX000000000		SC	WGS						9		1741274	38.343845	1720		1639.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2090	Streptococcus pyogenes strain 30164V1T1		1314	WGS	30164V1T1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523519	GCA_900993185.1	CAAIUW000000000		SC	WGS						19		1762458	38.309906	1750		1648.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2088	Streptococcus pyogenes strain 30178V1T1		1314	WGS	30178V1T1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523538	GCA_900993165.1	CAAIUV000000000		SC	WGS						18		1733040	38.301888	1687		1601.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2093	Streptococcus pyogenes strain 30227V1T1		1314	WGS	30227V1T1	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523543	GCA_900993215.1	CAAIVA000000000		SC	WGS						26		1711902	38.378014	1673		1586.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2091	Streptococcus pyogenes strain 30237V1T1		1314	WGS	30237V1T1	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523498	GCA_900993195.1	CAAIUY000000000		SC	WGS						20		1759173	38.438686	1771		1673.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2095	Streptococcus pyogenes strain 30239V1T1		1314	WGS	30239V1T1	EMM238.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523473	GCA_900993235.1	CAAIVC000000000		SC	WGS						23		1690216	38.361923	1646		1567.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1456	Streptococcus pyogenes strain 31001V1S1		1314	WGS	31001V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876691	GCA_900986765.1	CAAHWL000000000		SC	WGS						8		1806212	38.325203	1827		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2107	Streptococcus pyogenes strain 31001V5S1		1314	WGS	31001V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523562	GCA_900993355.1	CAAIVP000000000		SC	WGS						24		1734782	38.38661	1708		1628.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2094	Streptococcus pyogenes strain 31002V1T1		1314	WGS	31002V1T1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523541	GCA_900993225.1	CAAIVB000000000		SC	WGS						18		1702309	38.41218	1692		1592.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2110	Streptococcus pyogenes strain 31002V5S1		1314	WGS	31002V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523565	GCA_900993375.1	CAAIVQ000000000		SC	WGS						24		1738936	38.4197	1714		1626.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1641	Streptococcus pyogenes strain 31004V2S1		1314	WGS	31004V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523467	GCA_900988685.1	CAAIDQ000000000		SC	WGS						35		1796080	38.307648	1813		1701.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1538	Streptococcus pyogenes strain 31004V4S1		1314	WGS	31004V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876535	GCA_900987585.1	CAAHZQ000000000		SC	WGS						9		1672206	38.422188	1633		1544.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2109	Streptococcus pyogenes strain 31004V6S1		1314	WGS	31004V6S1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523444	GCA_900993385.1	CAAIVR000000000		SC	WGS						26		1817360	38.34612	1845		1744.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2111	Streptococcus pyogenes strain 31005V6S1		1314	WGS	31005V6S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523424	GCA_900993395.1	CAAIVS000000000		SC	WGS						30		1811704	38.385464	1857		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1643	Streptococcus pyogenes strain 31006V2S1		1314	WGS	31006V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523441	GCA_900988705.1	CAAIDO000000000		SC	WGS						25		1795956	38.307842	1809		1706.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2112	Streptococcus pyogenes strain 31006V5S1		1314	WGS	31006V5S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523575	GCA_900993405.1	CAAIVT000000000		SC	WGS						23		1782702	38.283985	1796		1695.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1541	Streptococcus pyogenes strain 31009V4S1		1314	WGS	31009V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876513	GCA_900987615.1	CAAHZT000000000		SC	WGS						14		1677729	38.456627	1633		1543.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2114	Streptococcus pyogenes strain 31009V5S1		1314	WGS	31009V5S1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523470	GCA_900993425.1	CAAIVV000000000		SC	WGS						27		1817722	38.34508	1842		1748.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1465	Streptococcus pyogenes strain 31010V1S1		1314	WGS	31010V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876646	GCA_900986855.1	CAAHWU000000000		SC	WGS						10		1810563	38.35934	1825		1733.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1514	Streptococcus pyogenes strain 31010V3S1		1314	WGS	31010V3S1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876552	GCA_900987345.1	CAAHYQ000000000		SC	WGS						14		1731977	38.296467	1681		1596.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1404	Streptococcus pyogenes strain 31011V3T1		1314	WGS	31011V3T1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876539	GCA_900986245.1	CAAHUL000000000		SC	WGS						17		1758731	38.46529	1769		1673.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1476	Streptococcus pyogenes strain 31012V1S1		1314	WGS	31012V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876639	GCA_900986965.1	CAAHXE000000000		SC	WGS						17		1781924	38.38626	1800		1693.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1644	Streptococcus pyogenes strain 31012V2S1		1314	WGS	31012V2S1	EMM73.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523436	GCA_900988715.1	CAAIDS000000000		SC	WGS						13		1672252	38.420883	1636		1545.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1415	Streptococcus pyogenes strain 31013V2T1		1314	WGS	31013V2T1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876559	GCA_900986355.1	CAAHUW000000000		SC	WGS						20		1811633	38.38476	1855		1754.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1516	Streptococcus pyogenes strain 31013V3S1		1314	WGS	31013V3S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876530	GCA_900987365.1	CAAHYV000000000		SC	WGS						16		1777442	38.332783	1783		1684.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2115	Streptococcus pyogenes strain 31022V5S1		1314	WGS	31022V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523464	GCA_900993435.1	CAAIVW000000000		SC	WGS						18		1738584	38.416264	1715		1629.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1423	Streptococcus pyogenes strain 31023V2T1		1314	WGS	31023V2T1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876557	GCA_900986435.1	CAAHVE000000000		SC	WGS						15		1703670	38.41325	1689		1594.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1645	Streptococcus pyogenes strain 31026V2S1		1314	WGS	31026V2S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523426	GCA_900988725.1	CAAIDU000000000		SC	WGS						18		1763492	38.309185	1749		1652.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1651	Streptococcus pyogenes strain 31027V2S1		1314	WGS	31027V2S1	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523517	GCA_900988785.1	CAAIDX000000000		SC	WGS						18		1717165	38.362904	1691		1608.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1583	Streptococcus pyogenes strain 31027V4S1		1314	WGS	31027V4S1	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876775	GCA_900988035.1	CAAIBI000000000		SC	WGS						14		1725825	38.366116	1704		1616.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1648	Streptococcus pyogenes strain 31028V2S1		1314	WGS	31028V2S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523420	GCA_900988755.1	CAAIDY000000000		SC	WGS						24		1782120	38.386826	1805		1684.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1517	Streptococcus pyogenes strain 31029V3S1		1314	WGS	31029V3S1	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876538	GCA_900987385.1	CAAHYU000000000		SC	WGS						14		1726368	38.359665	1703		1617.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1489	Streptococcus pyogenes strain 31032V1S2		1314	WGS	31032V1S2	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876626	GCA_900987085.1	CAAHXQ000000000		SC	WGS						11		1805903	38.328693	1825		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1542	Streptococcus pyogenes strain 31032V4S1		1314	WGS	31032V4S1	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876520	GCA_900987625.1	CAAHZS000000000		SC	WGS						15		1723435	38.33761	1685		1598.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1406	Streptococcus pyogenes strain 31034V1S1		1314	WGS	31034V1S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876615	GCA_900986265.1	CAAHUO000000000		SC	WGS						12		1763552	38.307972	1739		1651.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1540	Streptococcus pyogenes strain 31034V4S1		1314	WGS	31034V4S1	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876637	GCA_900987605.1	CAAHZR000000000		SC	WGS						15		1726094	38.366043	1710		1614.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1405	Streptococcus pyogenes strain 31036V1S1		1314	WGS	31036V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876603	GCA_900986255.1	CAAHUM000000000		SC	WGS						11		1807735	38.32276	1827		1738.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1544	Streptococcus pyogenes strain 31037V4S1		1314	WGS	31037V4S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876644	GCA_900987645.1	CAAHZV000000000		SC	WGS						35		1807247	38.32796	1820		1711.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2116	Streptococcus pyogenes strain 31038V6S1		1314	WGS	31038V6S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523587	GCA_900993445.1	CAAIVX000000000		SC	WGS						28		1782899	38.283855	1787		1692.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1407	Streptococcus pyogenes strain 31039V1S1		1314	WGS	31039V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876606	GCA_900986275.1	CAAHUN000000000		SC	WGS						10		1813355	38.366165	1831		1736.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2117	Streptococcus pyogenes strain 31039V5S1		1314	WGS	31039V5S1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523495	GCA_900993455.1	CAAIVY000000000		SC	WGS						28		1816448	38.345825	1847		1746.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1435	Streptococcus pyogenes strain 31039V5T1		1314	WGS	31039V5T1	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876524	GCA_900986555.1	CAAHVP000000000		SC	WGS						15		1758479	38.339725	1752		1663.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2119	Streptococcus pyogenes strain 31039V6S1		1314	WGS	31039V6S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523514	GCA_900993475.1	CAAIVZ000000000		SC	WGS						13		1671407	38.41871	1635		1544.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1650	Streptococcus pyogenes strain 31041V2S1		1314	WGS	31041V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523447	GCA_900988775.1	CAAIDW000000000		SC	WGS						31		1794772	38.30492	1810		1707.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2118	Streptococcus pyogenes strain 31042V5S1		1314	WGS	31042V5S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523428	GCA_900993465.1	CAAIWA000000000		SC	WGS						15		1704335	38.416355	1697		1595.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1409	Streptococcus pyogenes strain 31043V1S1		1314	WGS	31043V1S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876595	GCA_900986295.1	CAAHUP000000000		SC	WGS						18		1795881	38.303707	1804		1708.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2120	Streptococcus pyogenes strain 31043V6S1		1314	WGS	31043V6S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523530	GCA_900993485.1	CAAIWB000000000		SC	WGS						19		1703439	38.408714	1693		1594.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1543	Streptococcus pyogenes strain 31044V4S1		1314	WGS	31044V4S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876612	GCA_900987635.1	CAAHZU000000000		SC	WGS						19		1811332	38.383907	1853		1754.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1586	Streptococcus pyogenes strain 31046V5S1		1314	WGS	31046V5S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523546	GCA_900988125.1	CAAIBM000000000		SC	WGS						22		1777682	38.333122	1787		1683.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1518	Streptococcus pyogenes strain 31048V3S1		1314	WGS	31048V3S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876628	GCA_900987375.1	CAAHYT000000000		SC	WGS						7		1810501	38.358887	1825		1734.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1597	Streptococcus pyogenes strain 31049V5S1		1314	WGS	31049V5S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523544	GCA_900988235.1	CAAIBX000000000		SC	WGS						22		1760139	38.460712	1770		1671.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1605	Streptococcus pyogenes strain 31049V5S2		1314	WGS	31049V5S2	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523569	GCA_900988315.1	CAAICD000000000		SC	WGS						33		1796182	38.306847	1815		1704.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1519	Streptococcus pyogenes strain 31050V3S1		1314	WGS	31050V3S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876692	GCA_900987395.1	CAAHZA000000000		SC	WGS						22		1783589	38.279243	1796		1693.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1617	Streptococcus pyogenes strain 31050V6S1		1314	WGS	31050V6S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523577	GCA_900988435.1	CAAICS000000000		SC	WGS						21		1765769	38.401512	1772		1667.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1545	Streptococcus pyogenes strain 31053V4S1		1314	WGS	31053V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876624	GCA_900987655.1	CAAHZW000000000		SC	WGS						11		1672852	38.420494	1634		1546.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1647	Streptococcus pyogenes strain 31056V2S1		1314	WGS	31056V2S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523452	GCA_900988745.1	CAAIDZ000000000		SC	WGS						22		1760180	38.463226	1771		1670.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1627	Streptococcus pyogenes strain 31056V5S1		1314	WGS	31056V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523529	GCA_900988535.1	CAAIDA000000000		SC	WGS						19		1734602	38.386444	1716		1626.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1637	Streptococcus pyogenes strain 31056V6S1		1314	WGS	31056V6S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523414	GCA_900988635.1	CAAIDK000000000		SC	WGS						21		1734851	38.38912	1714		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1547	Streptococcus pyogenes strain 31058V4S1		1314	WGS	31058V4S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876620	GCA_900987675.1	CAAHZY000000000		SC	WGS						19		1782267	38.284016	1789		1697.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1546	Streptococcus pyogenes strain 31059V4S1		1314	WGS	31059V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876610	GCA_900987665.1	CAAHZX000000000		SC	WGS						11		1683536	38.449192	1649		1556.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1646	Streptococcus pyogenes strain 31059V6S1		1314	WGS	31059V6S1	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523448	GCA_900988735.1	CAAIDT000000000		SC	WGS						37		1751217	38.403408	1780		1679.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1654	Streptococcus pyogenes strain 31062V6S1		1314	WGS	31062V6S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523585	GCA_900988815.1	CAAIED000000000		SC	WGS						24		1783617	38.284843	1794		1693.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1411	Streptococcus pyogenes strain 31063V1S1		1314	WGS	31063V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876567	GCA_900986305.1	CAAHUQ000000000		SC	WGS						22		1740319	38.36075	1730		1624.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1549	Streptococcus pyogenes strain 31063V4S1		1314	WGS	31063V4S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876593	GCA_900987705.1	CAAIAA000000000		SC	WGS						22		1794897	38.300583	1808		1707.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1408	Streptococcus pyogenes strain 31065V1S1		1314	WGS	31065V1S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876704	GCA_900986285.1	CAAHUR000000000		SC	WGS						12		1702698	38.41057	1688		1593.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1649	Streptococcus pyogenes strain 31067V2S1		1314	WGS	31067V2S1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523421	GCA_900988765.1	CAAIDV000000000		SC	WGS						22		1827064	38.42396	1868		1766.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1412	Streptococcus pyogenes strain 31068V1S1		1314	WGS	31068V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876701	GCA_900986325.1	CAAHUT000000000		SC	WGS						19		1740326	38.35994	1737		1626.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1652	Streptococcus pyogenes strain 31069V2S1		1314	WGS	31069V2S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523475	GCA_900988795.1	CAAIEA000000000		SC	WGS						25		1777798	38.33388	1794		1684.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1522	Streptococcus pyogenes strain 31069V3S1		1314	WGS	31069V3S1	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876673	GCA_900987425.1	CAAHYX000000000		SC	WGS						20		1867555	38.308342	1878		1786.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1657	Streptococcus pyogenes strain 31072V6S1		1314	WGS	31072V6S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523465	GCA_900988845.1	CAAIEE000000000		SC	WGS						18		1738724	38.41739	1714		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1587	Streptococcus pyogenes strain 31072V6S2		1314	WGS	31072V6S2	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523460	GCA_900988135.1	CAAIBL000000000		SC	WGS						16		1753519	38.41692	1764		1673.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1588	Streptococcus pyogenes strain 31073V5S1		1314	WGS	31073V5S1	EMM76.4			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523496	GCA_900988145.1	CAAIBN000000000		SC	WGS						16		1726456	38.382675	1698		1607.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1551	Streptococcus pyogenes strain 31075V4S1		1314	WGS	31075V4S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876582	GCA_900987715.1	CAAIAB000000000		SC	WGS						13		1738621	38.416134	1716		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1589	Streptococcus pyogenes strain 31075V5S1		1314	WGS	31075V5S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523485	GCA_900988155.1	CAAIBO000000000		SC	WGS						16		1702968	38.414757	1689		1591.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1653	Streptococcus pyogenes strain 31076V2S1		1314	WGS	31076V2S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523513	GCA_900988805.1	CAAIEB000000000		SC	WGS						24		1705552	38.40739	1702		1594.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1550	Streptococcus pyogenes strain 31077V4S1		1314	WGS	31077V4S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876580	GCA_900987695.1	CAAHZZ000000000		SC	WGS						18		1760266	38.46129	1764		1674.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1410	Streptococcus pyogenes strain 31078V1S1		1314	WGS	31078V1S1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876709	GCA_900986315.1	CAAHUS000000000		SC	WGS						26		1889428	38.325428	1955		1859.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1414	Streptococcus pyogenes strain 31080V1S1		1314	WGS	31080V1S1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876679	GCA_900986345.1	CAAHUV000000000		SC	WGS						20		1890982	38.32307	1955		1858.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1413	Streptococcus pyogenes strain 31081V1S1		1314	WGS	31081V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876697	GCA_900986335.1	CAAHUU000000000		SC	WGS						18		1741203	38.359974	1743		1629.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1552	Streptococcus pyogenes strain 31081V4S1		1314	WGS	31081V4S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876566	GCA_900987725.1	CAAIAE000000000		SC	WGS						18		1763955	38.455063	1775		1681.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1418	Streptococcus pyogenes strain 31082V1S1		1314	WGS	31082V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876659	GCA_900986385.1	CAAHUY000000000		SC	WGS						20		1741020	38.36058	1733		1628.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1655	Streptococcus pyogenes strain 31082V2S1		1314	WGS	31082V2S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523451	GCA_900988825.1	CAAIEC000000000		SC	WGS						20		1738563	38.418797	1715		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1656	Streptococcus pyogenes strain 31084V2S1		1314	WGS	31084V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523548	GCA_900988835.1	CAAIEF000000000		SC	WGS						31		1794662	38.30248	1808		1704.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1416	Streptococcus pyogenes strain 31086V1S1		1314	WGS	31086V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876674	GCA_900986365.1	CAAHUX000000000		SC	WGS						19		1743486	38.35762	1741		1631.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1504	Streptococcus pyogenes strain 31086V2S2		1314	WGS	31086V2S2	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876757	GCA_900987245.1	CAAHYH000000000		SC	WGS						25		1795140	38.304535	1807		1706.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1523	Streptococcus pyogenes strain 31086V3S1		1314	WGS	31086V3S1	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876651	GCA_900987435.1	CAAHYY000000000		SC	WGS						22		1725108	38.33834	1690		1598.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1591	Streptococcus pyogenes strain 31086V5S1		1314	WGS	31086V5S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523578	GCA_900988175.1	CAAIBQ000000000		SC	WGS						19		1760384	38.46178	1770		1670.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1553	Streptococcus pyogenes strain 31088V4S1		1314	WGS	31088V4S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876564	GCA_900987735.1	CAAIAD000000000		SC	WGS						20		1814561	38.37854	1859		1757.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1521	Streptococcus pyogenes strain 31089V2S1		1314	WGS	31089V2S1	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876714	GCA_900987415.1	CAAHYZ000000000		SC	WGS						17		1870181	38.30598	1883		1795.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1520	Streptococcus pyogenes strain 31089V3S1		1314	WGS	31089V3S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876731	GCA_900987405.1	CAAHYW000000000		SC	WGS						21		1794186	38.298035	1805		1705.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1590	Streptococcus pyogenes strain 31090V5S1		1314	WGS	31090V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523537	GCA_900988165.1	CAAIBP000000000		SC	WGS						17		1734690	38.38824	1712		1629.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1558	Streptococcus pyogenes strain 31091V4S1		1314	WGS	31091V4S1	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876553	GCA_900987785.1	CAAIAI000000000		SC	WGS						17		1839426	38.400425	1870		1773.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1524	Streptococcus pyogenes strain 31094V3S1		1314	WGS	31094V3S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876720	GCA_900987445.1	CAAHZB000000000		SC	WGS						16		1777485	38.333546	1787		1687.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1441	Streptococcus pyogenes strain 31097V2T1		1314	WGS	31097V2T1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876516	GCA_900986615.1	CAAHVY000000000		SC	WGS						16		1777407	38.33348	1789		1686.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1592	Streptococcus pyogenes strain 31097V5S1		1314	WGS	31097V5S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523561	GCA_900988185.1	CAAIBR000000000		SC	WGS						17		1703196	38.41513	1690		1590.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1525	Streptococcus pyogenes strain 31099V3S1		1314	WGS	31099V3S1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876716	GCA_900987455.1	CAAHZC000000000		SC	WGS						12		1732051	38.298664	1686		1601.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1554	Streptococcus pyogenes strain 31101V4S1		1314	WGS	31101V4S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876549	GCA_900987745.1	CAAIAF000000000		SC	WGS						21		1810784	38.36434	1855		1745.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1532	Streptococcus pyogenes strain 31104V2S1		1314	WGS	31104V2S1	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876710	GCA_900987525.1	CAAHZI000000000		SC	WGS						18		1870098	38.307144	1885		1791.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1417	Streptococcus pyogenes strain 31106V1S1		1314	WGS	31106V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876578	GCA_900986375.1	CAAHUZ000000000		SC	WGS						12		1812061	38.35721	1831		1737.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1548	Streptococcus pyogenes strain 31107V2S1		1314	WGS	31107V2S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876515	GCA_900987685.1	CAAIAC000000000		SC	WGS						26		1761434	38.301975	1753		1644.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1593	Streptococcus pyogenes strain 31107V5S1		1314	WGS	31107V5S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523552	GCA_900988195.1	CAAIBU000000000		SC	WGS						20		1703398	38.484665	1667		1578.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1596	Streptococcus pyogenes strain 31108V5S1		1314	WGS	31108V5S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523556	GCA_900988225.1	CAAIBV000000000		SC	WGS						14		1672165	38.42109	1632		1544.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1556	Streptococcus pyogenes strain 31109V4S1		1314	WGS	31109V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876542	GCA_900987765.1	CAAIAG000000000		SC	WGS						10		1672566	38.420906	1632		1546.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1419	Streptococcus pyogenes strain 31111V1S1		1314	WGS	31111V1S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876570	GCA_900986395.1	CAAHVA000000000		SC	WGS						9		1714508	38.398598	1693		1609.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1594	Streptococcus pyogenes strain 31113V5S1		1314	WGS	31113V5S1	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523527	GCA_900988205.1	CAAIBS000000000		SC	WGS						24		1748083	38.348717	1729		1645.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1420	Streptococcus pyogenes strain 31114V1S1		1314	WGS	31114V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876765	GCA_900986405.1	CAAHVB000000000		SC	WGS						8		1812457	38.370422	1827		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1555	Streptococcus pyogenes strain 31114V4S1		1314	WGS	31114V4S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876655	GCA_900987755.1	CAAIAH000000000		SC	WGS						11		1672229	38.42213	1635		1546.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1595	Streptococcus pyogenes strain 31114V5S1		1314	WGS	31114V5S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523518	GCA_900988215.1	CAAIBT000000000		SC	WGS						25		1812665	38.385693	1856		1753.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1598	Streptococcus pyogenes strain 31114V6S1		1314	WGS	31114V6S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523512	GCA_900988245.1	CAAIBW000000000		SC	WGS						21		1782135	38.283237	1788		1694.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1557	Streptococcus pyogenes strain 31117V4S1		1314	WGS	31117V4S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876672	GCA_900987775.1	CAAIAJ000000000		SC	WGS						21		1811787	38.368305	1851		1748.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1560	Streptococcus pyogenes strain 31118V2S1		1314	WGS	31118V2S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876523	GCA_900987805.1	CAAIAM000000000		SC	WGS						16		1760026	38.464092	1766		1674.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1526	Streptococcus pyogenes strain 31118V3S1		1314	WGS	31118V3S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876707	GCA_900987465.1	CAAHZD000000000		SC	WGS						21		1777855	38.33372	1791		1684.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1528	Streptococcus pyogenes strain 31118V3S2		1314	WGS	31118V3S2	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876587	GCA_900987485.1	CAAHZE000000000		SC	WGS						21		1762001	38.33176	1754		1665.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1559	Streptococcus pyogenes strain 31119V4S1		1314	WGS	31119V4S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876627	GCA_900987795.1	CAAIAK000000000		SC	WGS						17		1777859	38.363842	1794		1695.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1561	Streptococcus pyogenes strain 31121V4S1		1314	WGS	31121V4S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876617	GCA_900987815.1	CAAIAL000000000		SC	WGS						25		1811524	38.38613	1855		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1421	Streptococcus pyogenes strain 31122V1S1		1314	WGS	31122V1S1	EMM207.1			MLST.Streptococcus_pyogenes.332				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876772	GCA_900986415.1	CAAHVC000000000		SC	WGS						13		1797597	38.31712	1812		1719.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1582	Streptococcus pyogenes strain 31124V2S1		1314	WGS	31124V2S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876528	GCA_900988025.1	CAAIBH000000000		SC	WGS						22		1729501	38.271732	1716		1611.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1563	Streptococcus pyogenes strain 31124V4S1		1314	WGS	31124V4S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876643	GCA_900987835.1	CAAIAN000000000		SC	WGS						15		1759685	38.461998	1768		1672.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1562	Streptococcus pyogenes strain 31125V4S1		1314	WGS	31125V4S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876632	GCA_900987825.1	CAAIAP000000000		SC	WGS						20		1761725	38.461414	1773		1674.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1599	Streptococcus pyogenes strain 31126V5S1		1314	WGS	31126V5S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523486	GCA_900988255.1	CAAICB000000000		SC	WGS						21		1760278	38.462673	1765		1671.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1527	Streptococcus pyogenes strain 31128V3S1		1314	WGS	31128V3S1	EMM42.0			MLST.Streptococcus_pyogenes.80				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876608	GCA_900987475.1	CAAHZF000000000		SC	WGS						12		1734791	38.370155	1711		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1564	Streptococcus pyogenes strain 31128V4S1		1314	WGS	31128V4S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876583	GCA_900987845.1	CAAIAO000000000		SC	WGS						16		1738959	38.41695	1725		1628.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1600	Streptococcus pyogenes strain 31128V6S1		1314	WGS	31128V6S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523493	GCA_900988265.1	CAAICA000000000		SC	WGS						25		1795090	38.3056	1807		1708.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1422	Streptococcus pyogenes strain 31129V1S2		1314	WGS	31129V1S2	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876776	GCA_900986425.1	CAAHVD000000000		SC	WGS						15		1782205	38.383858	1811		1696.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1565	Streptococcus pyogenes strain 31129V4S1		1314	WGS	31129V4S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876575	GCA_900987855.1	CAAIAQ000000000		SC	WGS						26		1811765	38.38555	1859		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1426	Streptococcus pyogenes strain 31132V1S1		1314	WGS	31132V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876785	GCA_900986465.1	CAAHVH000000000		SC	WGS						11		1811033	38.35938	1827		1734.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1529	Streptococcus pyogenes strain 31132V3S1		1314	WGS	31132V3S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876613	GCA_900987495.1	CAAHZG000000000		SC	WGS						18		1760287	38.464012	1771		1674.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1566	Streptococcus pyogenes strain 31134V4S1		1314	WGS	31134V4S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876756	GCA_900987865.1	CAAIAR000000000		SC	WGS						21		1811583	38.385876	1852		1753.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1602	Streptococcus pyogenes strain 31134V5S1		1314	WGS	31134V5S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523521	GCA_900988285.1	CAAIBZ000000000		SC	WGS						18		1738999	38.416813	1718		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1568	Streptococcus pyogenes strain 31136V4S1		1314	WGS	31136V4S1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876706	GCA_900987885.1	CAAIAT000000000		SC	WGS						20		1817379	38.34836	1844		1747.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1601	Streptococcus pyogenes strain 31136V5S1		1314	WGS	31136V5S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523525	GCA_900988275.1	CAAIBY000000000		SC	WGS						12		1735524	38.415565	1739		1639.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1606	Streptococcus pyogenes strain 31136V6S1		1314	WGS	31136V6S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523430	GCA_900988325.1	CAAICG000000000		SC	WGS						28		1811923	38.385075	1860		1750.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2096	Streptococcus pyogenes strain 31138V1T1		1314	WGS	31138V1T1	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523487	GCA_900993245.1	CAAIVD000000000		SC	WGS						23		1866939	38.307594	1883		1788.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1603	Streptococcus pyogenes strain 31138V6S1		1314	WGS	31138V6S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523550	GCA_900988295.1	CAAICC000000000		SC	WGS						27		1812261	38.385654	1857		1752.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1424	Streptococcus pyogenes strain 31140V1S1		1314	WGS	31140V1S1	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876652	GCA_900986445.1	CAAHVF000000000		SC	WGS						13		1819907	38.420666	1843		1756.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1505	Streptococcus pyogenes strain 31142V2S1		1314	WGS	31142V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876778	GCA_900987255.1	CAAHYI000000000		SC	WGS						19		1794712	38.30258	1809		1707.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1607	Streptococcus pyogenes strain 31142V6S1		1314	WGS	31142V6S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523557	GCA_900988335.1	CAAICF000000000		SC	WGS						11		1671591	38.419445	1632		1546.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1425	Streptococcus pyogenes strain 31143V1S1		1314	WGS	31143V1S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876668	GCA_900986455.1	CAAHVG000000000		SC	WGS						21		1729448	38.27441	1717		1607.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1530	Streptococcus pyogenes strain 31143V3S1		1314	WGS	31143V3S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876623	GCA_900987505.1	CAAHZH000000000		SC	WGS						16		1777529	38.363876	1794		1695.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1507	Streptococcus pyogenes strain 31144V2S1		1314	WGS	31144V2S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876770	GCA_900987265.1	CAAHYJ000000000		SC	WGS						20		1777900	38.333145	1786		1685.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1604	Streptococcus pyogenes strain 31144V6S1		1314	WGS	31144V6S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523484	GCA_900988305.1	CAAICE000000000		SC	WGS						28		1763364	38.304287	1756		1649.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1608	Streptococcus pyogenes strain 31145V5S1		1314	WGS	31145V5S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523574	GCA_900988345.1	CAAICH000000000		SC	WGS						12		1671384	38.417263	1628		1544.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1427	Streptococcus pyogenes strain 31147V1S1		1314	WGS	31147V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876680	GCA_900986475.1	CAAHVJ000000000		SC	WGS						11		1805997	38.32581	1832		1736.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1531	Streptococcus pyogenes strain 31147V3S1		1314	WGS	31147V3S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876634	GCA_900987515.1	CAAHZJ000000000		SC	WGS						13		1739122	38.399895	1742		1645.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1570	Streptococcus pyogenes strain 31148V4S1		1314	WGS	31148V4S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876712	GCA_900987905.1	CAAIAS000000000		SC	WGS						19		1794349	38.30409	1814		1718.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1428	Streptococcus pyogenes strain 31150V1S1		1314	WGS	31150V1S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876683	GCA_900986485.1	CAAHVI000000000		SC	WGS						9		1702461	38.41251	1690		1593.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2097	Streptococcus pyogenes strain 31150V1T1		1314	WGS	31150V1T1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523455	GCA_900993255.1	CAAIVE000000000		SC	WGS						15		1702208	38.414223	1686		1590.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1506	Streptococcus pyogenes strain 31152V2S1		1314	WGS	31152V2S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876763	GCA_900987275.1	CAAHYK000000000		SC	WGS						13		1714863	38.44523	1702		1610.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1508	Streptococcus pyogenes strain 31154V2S1		1314	WGS	31154V2S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876611	GCA_900987285.1	CAAHYL000000000		SC	WGS						14		1808219	38.32213	1835		1738.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1609	Streptococcus pyogenes strain 31154V5S1		1314	WGS	31154V5S1	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523584	GCA_900988355.1	CAAICI000000000		SC	WGS						23		1867078	38.30697	1876		1786.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1610	Streptococcus pyogenes strain 31155V6S1		1314	WGS	31155V6S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523422	GCA_900988365.1	CAAICK000000000		SC	WGS						17		1736427	38.414307	1737		1641.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1429	Streptococcus pyogenes strain 31158V1S1		1314	WGS	31158V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876698	GCA_900986495.1	CAAHVK000000000		SC	WGS						11		1805827	38.32953	1826		1734.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1495	Streptococcus pyogenes strain 31158V1S1_01		1314	WGS	31158V1S1_01	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876517	GCA_900987155.1	CAAHXX000000000		SC	WGS						12		1811488	38.35753	1831		1733.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1494	Streptococcus pyogenes strain 31158V1S2		1314	WGS	31158V1S2	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876773	GCA_900987145.1	CAAHXY000000000		SC	WGS						13		1806442	38.327	1833		1734.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1493	Streptococcus pyogenes strain 31158V3S1		1314	WGS	31158V3S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876671	GCA_900987135.1	CAAHXW000000000		SC	WGS						10		1672975	38.421494	1631		1545.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1533	Streptococcus pyogenes strain 31158V3S1a		1314	WGS	31158V3S1a	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876636	GCA_900987535.1	CAAHZK000000000		SC	WGS						11		1678139	38.455215	1634		1543.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1534	Streptococcus pyogenes strain 31158V3S1b		1314	WGS	31158V3S1b	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876648	GCA_900987545.1	CAAHZL000000000		SC	WGS						22		1811518	38.363186	1854		1748.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1498	Streptococcus pyogenes strain 31158V3S2_01		1314	WGS	31158V3S2_01	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876600	GCA_900987185.1	CAAHYB000000000		SC	WGS						19		1811793	38.367188	1856		1753.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1497	Streptococcus pyogenes strain 31158V4S1		1314	WGS	31158V4S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876705	GCA_900987175.1	CAAHYA000000000		SC	WGS						16		1811500	38.36925	1848		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1611	Streptococcus pyogenes strain 31158V5S1		1314	WGS	31158V5S1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523427	GCA_900988375.1	CAAICJ000000000		SC	WGS						28		1817135	38.34641	1848		1746.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1500	Streptococcus pyogenes strain 31158V5S1_01		1314	WGS	31158V5S1_01	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876625	GCA_900987205.1	CAAHYC000000000		SC	WGS						22		1819863	38.345325	1851		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1535	Streptococcus pyogenes strain 31163V3S1		1314	WGS	31163V3S1	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876666	GCA_900987555.1	CAAHZN000000000		SC	WGS						16		1839841	38.400566	1867		1774.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1613	Streptococcus pyogenes strain 31163V5S1		1314	WGS	31163V5S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523412	GCA_900988395.1	CAAICM000000000		SC	WGS						32		1796085	38.306538	1804		1702.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1430	Streptococcus pyogenes strain 31165V1S1		1314	WGS	31165V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876547	GCA_900986505.1	CAAHVL000000000		SC	WGS						9		1805964	38.324795	1828		1736.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1511	Streptococcus pyogenes strain 31165V2S1		1314	WGS	31165V2S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876569	GCA_900987315.1	CAAHYM000000000		SC	WGS						12		1672752	38.41968	1637		1545.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1567	Streptococcus pyogenes strain 31165V4S1		1314	WGS	31165V4S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876725	GCA_900987875.1	CAAIAV000000000		SC	WGS						13		1736361	38.406185	1739		1641.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1612	Streptococcus pyogenes strain 31165V6S1		1314	WGS	31165V6S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523563	GCA_900988385.1	CAAICL000000000		SC	WGS						27		1811917	38.384594	1852		1751.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1509	Streptococcus pyogenes strain 31166V2S1		1314	WGS	31166V2S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876577	GCA_900987295.1	CAAHYO000000000		SC	WGS						18		1777961	38.333855	1792		1687.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1431	Streptococcus pyogenes strain 31167V1S1		1314	WGS	31167V1S1	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876543	GCA_900986515.1	CAAHVM000000000		SC	WGS						9		1737222	38.40275	1746		1651.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1569	Streptococcus pyogenes strain 31167V4S1		1314	WGS	31167V4S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876728	GCA_900987895.1	CAAIAU000000000		SC	WGS						15		1738702	38.41613	1715		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2098	Streptococcus pyogenes strain 31168V1T1		1314	WGS	31168V1T1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523491	GCA_900993265.1	CAAIVF000000000		SC	WGS						20		1761706	38.381546	1771		1685.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1510	Streptococcus pyogenes strain 31168V2S1		1314	WGS	31168V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876558	GCA_900987305.1	CAAHYN000000000		SC	WGS						23		1794049	38.297447	1808		1706.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1615	Streptococcus pyogenes strain 31168V5S1		1314	WGS	31168V5S1	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523477	GCA_900988415.1	CAAICO000000000		SC	WGS						28		1811881	38.386517	1856		1750.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1515	Streptococcus pyogenes strain 31170V2S1		1314	WGS	31170V2S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876555	GCA_900987355.1	CAAHYR000000000		SC	WGS						20		1777870	38.33447	1790		1686.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1536	Streptococcus pyogenes strain 31170V3S1		1314	WGS	31170V3S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876661	GCA_900987565.1	CAAHZM000000000		SC	WGS						20		1781947	38.387337	1800		1688.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1614	Streptococcus pyogenes strain 31170V5S1		1314	WGS	31170V5S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523468	GCA_900988405.1	CAAICN000000000		SC	WGS						11		1671674	38.421066	1630		1545.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1539	Streptococcus pyogenes strain 31171V3S1		1314	WGS	31171V3S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876526	GCA_900987595.1	CAAHZP000000000		SC	WGS						12		1677874	38.456284	1633		1546.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1432	Streptococcus pyogenes strain 31175V1S1		1314	WGS	31175V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876751	GCA_900986525.1	CAAHVN000000000		SC	WGS						15		1805984	38.323486	1832		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1512	Streptococcus pyogenes strain 31175V2S1		1314	WGS	31175V2S1	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876561	GCA_900987325.1	CAAHYP000000000		SC	WGS						25		1800001	38.308064	1817		1713.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1434	Streptococcus pyogenes strain 31176V1S1		1314	WGS	31176V1S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876755	GCA_900986545.1	CAAHVO000000000		SC	WGS						19		1810660	38.36402	1850		1749.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1513	Streptococcus pyogenes strain 31176V2S2		1314	WGS	31176V2S2	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876540	GCA_900987335.1	CAAHYS000000000		SC	WGS						27		1788062	38.274734	1798		1702.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1571	Streptococcus pyogenes strain 31176V4S1		1314	WGS	31176V4S1	EMM76.4							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876656	GCA_900987915.1	CAAIAW000000000		SC	WGS						10		1728726	38.37734	1695		1612.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1537	Streptococcus pyogenes strain 31177V3S1		1314	WGS	31177V3S1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876531	GCA_900987575.1	CAAHZO000000000		SC	WGS						14		1732633	38.30234	1687		1596.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1478	Streptococcus pyogenes strain 33011V3S1		1314	WGS	33011V3S1	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876667	GCA_900986985.1	CAAHXI000000000		SC	WGS						12		1752000	38.297146	1742		1650.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1436	Streptococcus pyogenes strain 33014V1S1		1314	WGS	33014V1S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876737	GCA_900986565.1	CAAHVR000000000		SC	WGS						11		1762483	38.301476	1744		1651.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1481	Streptococcus pyogenes strain 33016V3S1		1314	WGS	33016V3S1	EMM53.0			MLST.Streptococcus_pyogenes.363				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876654	GCA_900987015.1	CAAHXL000000000		SC	WGS						10		1750862	38.40211	1754		1668.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1433	Streptococcus pyogenes strain 33017V1S1		1314	WGS	33017V1S1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876746	GCA_900986535.1	CAAHVQ000000000		SC	WGS						7		1740574	38.34103	1720		1638.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1437	Streptococcus pyogenes strain 33022V1S1		1314	WGS	33022V1S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876780	GCA_900986575.1	CAAHVT000000000		SC	WGS						16		1774748	38.327583	1784		1681.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2022	Streptococcus pyogenes strain 33022V1T1		1314	WGS	33022V1T1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324170	GCA_900992505.1	CAAISI000000000		SC	WGS						28		1772837	38.316326	1811		1697.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1438	Streptococcus pyogenes strain 33041V1S1		1314	WGS	33041V1S1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876784	GCA_900986585.1	CAAHVS000000000		SC	WGS						13		1754424	38.421898	1759		1671.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2023	Streptococcus pyogenes strain 33042V1T1		1314	WGS	33042V1T1	EMM14.4			MLST.Streptococcus_pyogenes.118				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324151	GCA_900992515.1	CAAISG000000000		SC	WGS						21		1725857	38.44322	1748		1657.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1482	Streptococcus pyogenes strain 33045V3S1		1314	WGS	33045V3S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876664	GCA_900987025.1	CAAHXK000000000		SC	WGS						14		1764689	38.305355	1745		1652.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1439	Streptococcus pyogenes strain 33048V1S1		1314	WGS	33048V1S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876711	GCA_900986595.1	CAAHVU000000000		SC	WGS						9		1805395	38.326847	1826		1734.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1440	Streptococcus pyogenes strain 33050V1S1		1314	WGS	33050V1S1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876721	GCA_900986605.1	CAAHVV000000000		SC	WGS						16		1850149	38.301964	1882		1797.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1442	Streptococcus pyogenes strain 33052V1S1		1314	WGS	33052V1S1	EMM75.1			MLST.Streptococcus_pyogenes.468				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876735	GCA_900986625.1	CAAHVZ000000000		SC	WGS						13		1809242	38.447205	1770		1675.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1464	Streptococcus pyogenes strain 33052V2S1		1314	WGS	33052V2S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876736	GCA_900986845.1	CAAHWT000000000		SC	WGS						10		1806760	38.327003	1830		1736.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1444	Streptococcus pyogenes strain 33061V1S1		1314	WGS	33061V1S1	EMM105.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876579	GCA_900986645.1	CAAHVW000000000		SC	WGS						13		1763085	38.30405	1748		1649.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2024	Streptococcus pyogenes strain 33076V1T1		1314	WGS	33076V1T1	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324145	GCA_900992525.1	CAAISJ000000000		SC	WGS						32		1712538	38.355537	1742		1634.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1443	Streptococcus pyogenes strain 33080V1S1		1314	WGS	33080V1S1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876571	GCA_900986635.1	CAAHVX000000000		SC	WGS						8		1740771	38.34186	1720		1639.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1483	Streptococcus pyogenes strain 33080V3S1		1314	WGS	33080V3S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876541	GCA_900987035.1	CAAHXM000000000		SC	WGS						17		1744762	38.339096	1734		1637.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1445	Streptococcus pyogenes strain 33082V1S1		1314	WGS	33082V1S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876602	GCA_900986655.1	CAAHWA000000000		SC	WGS						19		1728932	38.275654	1715		1604.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2025	Streptococcus pyogenes strain 33087V1T1		1314	WGS	33087V1T1	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324177	GCA_900992535.1	CAAISK000000000		SC	WGS						21		1805667	38.262413	1870		1762.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1446	Streptococcus pyogenes strain 33089V1S1		1314	WGS	33089V1S1	EMM54.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876607	GCA_900986665.1	CAAHWB000000000		SC	WGS						11		1739743	38.40711	1741		1660.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1578	Streptococcus pyogenes strain 33092V2T1		1314	WGS	33092V2T1	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876747	GCA_900987985.1	CAAIBD000000000		SC	WGS						17		1820088	38.31683	1856		1759.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1484	Streptococcus pyogenes strain 33093V3S1		1314	WGS	33093V3S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876548	GCA_900987045.1	CAAHXN000000000		SC	WGS						20		1728844	38.273552	1716		1604.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1466	Streptococcus pyogenes strain 33094V2S1		1314	WGS	33094V2S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876748	GCA_900986865.1	CAAHWV000000000		SC	WGS						8		1806078	38.32603	1827		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1575	Streptococcus pyogenes strain 33098V2T1		1314	WGS	33098V2T1	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876688	GCA_900987955.1	CAAIBA000000000		SC	WGS						11		1752155	38.297867	1740		1651.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1448	Streptococcus pyogenes strain 33100V1S1		1314	WGS	33100V1S1	EMM54.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876629	GCA_900986685.1	CAAHWD000000000		SC	WGS						13		1742022	38.421925	1743		1657.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1447	Streptococcus pyogenes strain 33100V1S1		1314	WGS	33100V1S1	EMM54.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876597	GCA_900986675.1	CAAHWC000000000		SC	WGS						15		1745589	38.441067	1752		1659.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2026	Streptococcus pyogenes strain 33100V1T1		1314	WGS	33100V1T1	EMM54.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324161	GCA_900992545.1	CAAISL000000000		SC	WGS						26		1736090	38.39849	1784		1686.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2029	Streptococcus pyogenes strain 33101V1T1		1314	WGS	33101V1T1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324176	GCA_900992575.1	CAAISP000000000		SC	WGS						18		1750932	38.406975	1818		1717.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1485	Streptococcus pyogenes strain 33101V3S1		1314	WGS	33101V3S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876594	GCA_900987055.1	CAAHXO000000000		SC	WGS						12		1706123	38.475067	1666		1584.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1449	Streptococcus pyogenes strain 33107V1S1		1314	WGS	33107V1S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876616	GCA_900986695.1	CAAHWE000000000		SC	WGS						19		1740882	38.356693	1729		1623.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1486	Streptococcus pyogenes strain 33107V3S1		1314	WGS	33107V3S1	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876591	GCA_900987065.1	CAAHXP000000000		SC	WGS						16		1776764	38.36094	1791		1696.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2027	Streptococcus pyogenes strain 33112V1T1		1314	WGS	33112V1T1	EMM42.0			MLST.Streptococcus_pyogenes.80				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324139	GCA_900992555.1	CAAISN000000000		SC	WGS						17		1734058	38.360195	1768		1667.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1487	Streptococcus pyogenes strain 33115V3S1		1314	WGS	33115V3S1	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876604	GCA_900987075.1	CAAHXR000000000		SC	WGS						10		1672693	38.422592	1632		1548.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1450	Streptococcus pyogenes strain 33117V1S1		1314	WGS	33117V1S1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876741	GCA_900986705.1	CAAHWF000000000		SC	WGS						11		1716838	38.438107	1705		1615.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1488	Streptococcus pyogenes strain 33119V3S1		1314	WGS	33119V3S1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876568	GCA_900987095.1	CAAHXS000000000		SC	WGS						13		1732631	38.301636	1683		1598.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1467	Streptococcus pyogenes strain 33120V2S1		1314	WGS	33120V2S1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876753	GCA_900986875.1	CAAHWW000000000		SC	WGS						14		1753554	38.41735	1759		1673.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1453	Streptococcus pyogenes strain 33122V1S1		1314	WGS	33122V1S1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876727	GCA_900986735.1	CAAHWI000000000		SC	WGS						16		1766380	38.369205	1775		1689.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1451	Streptococcus pyogenes strain 33122V1S2		1314	WGS	33122V1S2	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876734	GCA_900986715.1	CAAHWG000000000		SC	WGS						17		1760760	38.37013	1749		1657.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1468	Streptococcus pyogenes strain 33123V2S1		1314	WGS	33123V2S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876758	GCA_900986885.1	CAAHWX000000000		SC	WGS						22		1729930	38.27993	1713		1608.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1452	Streptococcus pyogenes strain 33124V1S1		1314	WGS	33124V1S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876700	GCA_900986725.1	CAAHWH000000000		SC	WGS						17		1740227	38.475212	1719		1631.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2030	Streptococcus pyogenes strain 33124V1T1		1314	WGS	33124V1T1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324183	GCA_900992585.1	CAAISM000000000		SC	WGS						23		1741695	38.46399	1743		1649.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1581	Streptococcus pyogenes strain 33124V2T1		1314	WGS	33124V2T1	EMM54.1							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876771	GCA_900988015.1	CAAIBG000000000		SC	WGS						16		1741848	38.40536	1750		1664.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1490	Streptococcus pyogenes strain 33126V3S1		1314	WGS	33126V3S1	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876589	GCA_900987105.1	CAAHXT000000000		SC	WGS						15		1765789	38.400284	1772		1672.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2028	Streptococcus pyogenes strain 33129V1T1		1314	WGS	33129V1T1	EMM75.1			MLST.Streptococcus_pyogenes.468				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324153	GCA_900992565.1	CAAISO000000000		SC	WGS						21		1821949	38.426598	1817		1716.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2031	Streptococcus pyogenes strain 33131V1T1		1314	WGS	33131V1T1	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324173	GCA_900992595.1	CAAISQ000000000		SC	WGS						31		1709449	38.356335	1714		1611.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1491	Streptococcus pyogenes strain 33132V3S1		1314	WGS	33132V3S1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876638	GCA_900987115.1	CAAHXU000000000		SC	WGS						13		1719716	38.362206	1715		1635.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2032	Streptococcus pyogenes strain 33133V1T1		1314	WGS	33133V1T1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324152	GCA_900992605.1	CAAISR000000000		SC	WGS						32		1722533	38.272415	1750		1630.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1577	Streptococcus pyogenes strain 33133V3T1		1314	WGS	33133V3T1	EMM238.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876740	GCA_900987975.1	CAAIBC000000000		SC	WGS						15		1690665	38.36088	1649		1565.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1454	Streptococcus pyogenes strain 33134V1S1		1314	WGS	33134V1S1	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876713	GCA_900986745.1	CAAHWK000000000		SC	WGS						13		1818199	38.242348	1834		1737.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1580	Streptococcus pyogenes strain 33138V3T1		1314	WGS	33138V3T1	EMM122.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876787	GCA_900988005.1	CAAIBF000000000		SC	WGS						13		1732448	38.41951	1735		1649.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1469	Streptococcus pyogenes strain 33139V2S1		1314	WGS	33139V2S1	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876702	GCA_900986895.1	CAAHWY000000000		SC	WGS						20		1774746	38.304916	1750		1659.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1492	Streptococcus pyogenes strain 33139V3S1		1314	WGS	33139V3S1	EMM60.7			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876649	GCA_900987125.1	CAAHXV000000000		SC	WGS						18		1799521	38.296745	1794		1702.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1496	Streptococcus pyogenes strain 33139V3S2		1314	WGS	33139V3S2	EMM60.7			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876622	GCA_900987165.1	CAAHXZ000000000		SC	WGS						21		1799870	38.295933	1793		1701.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2033	Streptococcus pyogenes strain 33140V1T1		1314	WGS	33140V1T1	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324157	GCA_900992615.1	CAAISS000000000		SC	WGS						27		1758997	38.361996	1788		1690.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1574	Streptococcus pyogenes strain 33141V2T1		1314	WGS	33141V2T1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876687	GCA_900987945.1	CAAIAY000000000		SC	WGS						26		1890073	38.327927	1953		1859.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1579	Streptococcus pyogenes strain 33141V4T1		1314	WGS	33141V4T1	EMM238.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876779	GCA_900987995.1	CAAIBE000000000		SC	WGS						15		1690497	38.36061	1649		1564.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2035	Streptococcus pyogenes strain 33149V1T1		1314	WGS	33149V1T1	EMM77.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324142	GCA_900992635.1	CAAISU000000000		SC	WGS						25		1733532	38.37232	1732		1631.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1455	Streptococcus pyogenes strain 33153V1S1		1314	WGS	33153V1S1	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876681	GCA_900986755.1	CAAHWJ000000000		SC	WGS						17		1740355	38.474335	1717		1632.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1458	Streptococcus pyogenes strain 33156V1S1		1314	WGS	33156V1S1	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876690	GCA_900986785.1	CAAHWM000000000		SC	WGS						17		1756482	38.336403	1746		1656.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1457	Streptococcus pyogenes strain 33156V1S2		1314	WGS	33156V1S2	EMM86.2							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876694	GCA_900986775.1	CAAHWN000000000		SC	WGS						15		1755747	38.338917	1744		1653.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1573	Streptococcus pyogenes strain 33157V2T1		1314	WGS	33157V2T1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876676	GCA_900987935.1	CAAIAZ000000000		SC	WGS						17		1720509	38.36458	1717		1636.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1470	Streptococcus pyogenes strain 33158V2S1		1314	WGS	33158V2S1	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876703	GCA_900986905.1	CAAHWZ000000000		SC	WGS						21		1767619	38.482727	1780		1679.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1572	Streptococcus pyogenes strain 33160V2T1		1314	WGS	33160V2T1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876658	GCA_900987925.1	CAAIAX000000000		SC	WGS						10		1743460	38.374783	1720		1641.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2034	Streptococcus pyogenes strain 33167V1T1		1314	WGS	33167V1T1	EMM230.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324185	GCA_900992625.1	CAAIST000000000		SC	WGS						15		1759834	38.48113	1751		1659.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1471	Streptococcus pyogenes strain 33169V2S1		1314	WGS	33169V2S1	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876717	GCA_900986915.1	CAAHXA000000000		SC	WGS						19		1767554	38.48867	1776		1678.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1472	Streptococcus pyogenes strain 33169V2S2		1314	WGS	33169V2S2	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876521	GCA_900986925.1	CAAHXC000000000		SC	WGS						20		1767833	38.485367	1777		1679.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2036	Streptococcus pyogenes strain 33173V1T1		1314	WGS	33173V1T1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324179	GCA_900992645.1	CAAISV000000000		SC	WGS						34		1764064	38.251354	1821		1694.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2038	Streptococcus pyogenes strain 33181V1T1		1314	WGS	33181V1T1	EMM137.0			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324143	GCA_900992665.1	CAAISW000000000		SC	WGS						24		1805772	38.33345	1869		1767.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1499	Streptococcus pyogenes strain 33181V1T1_01		1314	WGS	33181V1T1_01	EMM137.0			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876551	GCA_900987195.1	CAAHYD000000000		SC	WGS						18		1806893	38.345547	1844		1749.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1501	Streptococcus pyogenes strain 33181V3S1		1314	WGS	33181V3S1	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876718	GCA_900987215.1	CAAHYE000000000		SC	WGS						14		1747209	38.23745	1739		1652.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1576	Streptococcus pyogenes strain 33181V3T1		1314	WGS	33181V3T1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876759	GCA_900987965.1	CAAIBB000000000		SC	WGS						12		1719947	38.363506	1717		1636.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1502	Streptococcus pyogenes strain 33181V3T1		1314	WGS	33181V3T1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876768	GCA_900987225.1	CAAHYF000000000		SC	WGS						14		1720237	38.363434	1711		1637.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1503	Streptococcus pyogenes strain 33181V4T1		1314	WGS	33181V4T1	EMM205.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876760	GCA_900987235.1	CAAHYG000000000		SC	WGS						17		1719258	38.36062	1724		1634.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1585	Streptococcus pyogenes strain 33181V5T1		1314	WGS	33181V5T1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB3201	SAMEA1903439	GCA_900988115.1	CAAIBK000000000		SC	WGS						34		1737949	38.343243	1749		1645.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/staphylococcus-aureus.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1584	Streptococcus pyogenes strain 33181V6T1		1314	WGS	33181V6T1	EMM92.0							2019-04-09T00:00:00Z		PRJEB3201	SAMEA1903448	GCA_900988105.1	CAAIBJ000000000		SC	WGS						13		1741247	38.344246	1717		1638.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/staphylococcus-aureus.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2037	Streptococcus pyogenes strain 33185V1T1		1314	WGS	33185V1T1	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324172	GCA_900992655.1	CAAISY000000000		SC	WGS						22		1741829	38.332798	1742		1651.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1459	Streptococcus pyogenes strain 33187V1S1		1314	WGS	33187V1S1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876663	GCA_900986795.1	CAAHWO000000000		SC	WGS						22		1890407	38.328857	1956		1860.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1473	Streptococcus pyogenes strain 33188V2S2		1314	WGS	33188V2S2	EMM73.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876510	GCA_900986935.1	CAAHXB000000000		SC	WGS						21		1741586	38.35914	1741		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1474	Streptococcus pyogenes strain 33189V2S2		1314	WGS	33189V2S2	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876514	GCA_900986945.1	CAAHXF000000000		SC	WGS						17		1765552	38.36766	1777		1687.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1475	Streptococcus pyogenes strain 33190V2S1		1314	WGS	33190V2S1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876537	GCA_900986955.1	CAAHXD000000000		SC	WGS						9		1753696	38.419716	1761		1674.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1477	Streptococcus pyogenes strain 33191V2S1		1314	WGS	33191V2S1	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876529	GCA_900986975.1	CAAHXG000000000		SC	WGS						11		1732484	38.341652	1723		1634.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1460	Streptococcus pyogenes strain 33192V1S1		1314	WGS	33192V1S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876675	GCA_900986805.1	CAAHWP000000000		SC	WGS						20		1787064	38.278133	1795		1702.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1479	Streptococcus pyogenes strain 33192V2S1		1314	WGS	33192V2S1	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876693	GCA_900986995.1	CAAHXH000000000		SC	WGS						8		1805450	38.328117	1824		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1463	Streptococcus pyogenes strain 33193V1S1		1314	WGS	33193V1S1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876783	GCA_900986835.1	CAAHWR000000000		SC	WGS						19		1890041	38.32704	1952		1860.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2039	Streptococcus pyogenes strain 33193V1T1		1314	WGS	33193V1T1	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324147	GCA_900992675.1	CAAISX000000000		SC	WGS						35		1890678	38.323997	1965		1859.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1461	Streptococcus pyogenes strain 33194V1S1		1314	WGS	33194V1S1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876777	GCA_900986815.1	CAAHWQ000000000		SC	WGS						16		1763662	38.3764	1777		1687.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1480	Streptococcus pyogenes strain 33194V2S1		1314	WGS	33194V2S1	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876678	GCA_900987005.1	CAAHXJ000000000		SC	WGS						16		1721872	38.357403	1722		1638.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1462	Streptococcus pyogenes strain 33201V1S1		1314	WGS	33201V1S1	EMM92.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1876786	GCA_900986825.1	CAAHWS000000000		SC	WGS						7		1743183	38.374397	1724		1641.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2041	Streptococcus pyogenes strain 33202V1T1		1314	WGS	33202V1T1	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1324169	GCA_900992685.1	CAAISZ000000000		SC	WGS						18		1751362	38.40596	1783		1688.0		throat		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2827	Streptococcus pyogenes strain 37-97		1314	Complete	37-97				MLST.Streptococcus_pyogenes.62	genotype:ST62			2020-08-17T00:00:00Z		PRJNA553828	SAMN12251806	GCA_014218015.1	CP041408		Federal University of Rio de Janeiro	Complete	Illumina HiSeq	275.0x	Newbler v. 3.0	1.0	0.0	1		1918725	38.509377	1987		1909.0		oropharynx		1997	Brazil	Brazil						Human, Homo sapiens			not reported																Streptococcus pyogenes ST62 emm62	collected_by:Bernadete Carvalho
1314.2775	Streptococcus pyogenes strain 4063-05		1314	Complete	4063-05				MLST.Streptococcus_pyogenes.39				2020-06-09T00:00:00Z		PRJNA623467	SAMN14547667	GCA_013306985.1	CP051138		College of Medicine, National Taiwan University	Complete	PacBio Sequel	4333.0x	Flye v. v2.7	1.0	0.0	1		1890399	38.487694	1913						2005	USA	USA						Human, Homo sapiens																			draft genome of GAS strain 4063-05	sample_type:clinical isolate
1314.1616	Streptococcus pyogenes strain 41095V1S1		1314	WGS	41095V1S1	EMM63.3			MLST.Streptococcus_pyogenes.297				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523442	GCA_900988425.1	CAAICP000000000		SC	WGS						35		1936394	38.299076	1995		1884.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1619	Streptococcus pyogenes strain 41126V1S1		1314	WGS	41126V1S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523453	GCA_900988455.1	CAAICR000000000		SC	WGS						20		1738684	38.41572	1717		1627.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1618	Streptococcus pyogenes strain 42003V1S1		1314	WGS	42003V1S1	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523535	GCA_900988445.1	CAAICQ000000000		SC	WGS						29		1729659	38.27321	1721		1605.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1620	Streptococcus pyogenes strain 42023V1S1		1314	WGS	42023V1S1	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523433	GCA_900988465.1	CAAICT000000000		SC	WGS						37		1865407	38.299202	1915		1815.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1621	Streptococcus pyogenes strain 42024V1S1		1314	WGS	42024V1S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523499	GCA_900988475.1	CAAICU000000000		SC	WGS						23		1739927	38.416348	1715		1625.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1624	Streptococcus pyogenes strain 42028V1S1		1314	WGS	42028V1S1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523524	GCA_900988505.1	CAAICW000000000		SC	WGS						29		1764466	38.37416	1787		1685.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1622	Streptococcus pyogenes strain 42043V1S1		1314	WGS	42043V1S1	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523536	GCA_900988485.1	CAAICX000000000		SC	WGS						21		1748151	38.34869	1730		1645.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1623	Streptococcus pyogenes strain 42048V1S1		1314	WGS	42048V1S1	EMM81.3							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523522	GCA_900988495.1	CAAICV000000000		SC	WGS						23		1750627	38.25875	1734		1636.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1625	Streptococcus pyogenes strain 42056V1S1a		1314	WGS	42056V1S1a	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523542	GCA_900988515.1	CAAICY000000000		SC	WGS						14		1805874	38.325375	1831		1735.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1626	Streptococcus pyogenes strain 42058V1S1		1314	WGS	42058V1S1	EMM74.1			MLST.Streptococcus_pyogenes.468				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523490	GCA_900988525.1	CAAICZ000000000		SC	WGS						14		1823883	38.42752	1785		1698.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1628	Streptococcus pyogenes strain 42063V1S1		1314	WGS	42063V1S1	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523526	GCA_900988545.1	CAAIDB000000000		SC	WGS						25		1839490	38.41081	1868		1770.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1631	Streptococcus pyogenes strain 42070V1S1		1314	WGS	42070V1S1	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523476	GCA_900988575.1	CAAIDE000000000		SC	WGS						22		1755795	38.28528	1743		1653.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1629	Streptococcus pyogenes strain 43078V1S1		1314	WGS	43078V1S1	EMM122.X							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523415	GCA_900988555.1	CAAIDC000000000		SC	WGS						21		1733393	38.426083	1734		1652.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1630	Streptococcus pyogenes strain 43086V1S1		1314	WGS	43086V1S1	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523586	GCA_900988565.1	CAAIDD000000000		SC	WGS						20		1773944	38.380917	1767		1684.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1633	Streptococcus pyogenes strain 43110V1S1		1314	WGS	43110V1S1	EMM57.0							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523581	GCA_900988595.1	CAAIDG000000000		SC	WGS						21		1726885	38.3648	1712		1615.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1632	Streptococcus pyogenes strain 44001V1S1		1314	WGS	44001V1S1	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523508	GCA_900988585.1	CAAIDF000000000		SC	WGS						16		1732812	38.30283	1688		1598.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1634	Streptococcus pyogenes strain 44002V1S1		1314	WGS	44002V1S1	EMM103.0			MLST.Streptococcus_pyogenes.327				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523560	GCA_900988605.1	CAAIDH000000000		SC	WGS						25		1782537	38.283997	1783		1693.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1635	Streptococcus pyogenes strain 44004V1S1		1314	WGS	44004V1S1	EMM82.1			MLST.Streptococcus_pyogenes.591				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523555	GCA_900988615.1	CAAIDI000000000		SC	WGS						20		1777717	38.350143	1790		1688.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1636	Streptococcus pyogenes strain 44015V1S1		1314	WGS	44015V1S1	EMM81.3							2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523580	GCA_900988625.1	CAAIDJ000000000		SC	WGS						25		1755563	38.253597	1736		1644.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1638	Streptococcus pyogenes strain 44031V1S1		1314	WGS	44031V1S1	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523534	GCA_900988655.1	CAAIDL000000000		SC	WGS						27		1778296	38.338104	1792		1681.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1639	Streptococcus pyogenes strain 44037V1S1		1314	WGS	44037V1S1	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523523	GCA_900988665.1	CAAIDM000000000		SC	WGS						18		1738802	38.447678	1733		1640.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1640	Streptococcus pyogenes strain 44052V1S1		1314	WGS	44052V1S1	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523502	GCA_900988675.1	CAAIDR000000000		SC	WGS						15		1751681	38.297554	1729		1649.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1642	Streptococcus pyogenes strain 44079V1S1		1314	WGS	44079V1S1	EMM87.0			MLST.Streptococcus_pyogenes.541				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523488	GCA_900988695.1	CAAIDP000000000		SC	WGS						34		1721926	38.30933	1698		1596.0		skin		2006	Fiji	Fiji						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1045	Streptococcus pyogenes strain 5448		1314	Complete	5448	M1T1			MLST.Streptococcus_pyogenes.28		102.100.100.25705		2019-01-10T00:00:00Z		PRJEB29800	SAMEA5096233	GCA_900619585.1	LR130236		Bioplatforms Australia	Complete				1.0		1		1829838	38.50084	1826				blood		1994	Canada	Canada						Human, Homo sapiens						host_health_state:diseased													The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.The pathogens included in this initiative are: Escherichia coli, Klebsiella pneumoniae complex, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. The following project contains the complete genomes and sequence data for Streptococcus pyogenes.	
1314.194	Streptococcus pyogenes strain 5448		1314	Complete	5448	emm 1			MLST.Streptococcus_pyogenes.28				2015-06-08T00:00:00Z		PRJNA252999	SAMN02866032	GCF_001021955.1	CP008776	NZ_CP008776.1	Helmholtz Centre for Infection Research	Complete	Illumina HiSeq 2000	872x	Velvet v. 1.0.20	1.0		1		1829516	38.5	1834		1723.0				1994	Canada	Canada:Ontario						Human, Homo sapiens			necrotizing fasciitis						Positive	Cocci	No							Necrotizing fasciitis	Genome sequencing of mouse-virulent S. pyogenes strain 5448	
1314.542	Streptococcus pyogenes strain 71-698		1314	Plasmid	71-698								2016-07-26T00:00:00Z					AY995189			Plasmid					1.0	1		3041	34.86	7		3.0																																
1314.541	Streptococcus pyogenes strain 71-724		1314	Plasmid	71-724								2016-07-26T00:00:00Z	15518879				AY648561			Plasmid					1.0	1		3351	33.96	7		3.0																																
1314.543	Streptococcus pyogenes strain 9116-03		1314	Plasmid	9116-03								2016-07-26T00:00:00Z	18180360				EU192194			Plasmid					1.0	1		4968	37.34	8		4.0																																
1314.1134	Streptococcus pyogenes strain A1013		1314	WGS	A1013	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919130	GCA_900983545.1	CAAHKA000000000		SC	WGS						17		1784417	38.33488	1789		1693.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1129	Streptococcus pyogenes strain A1138		1314	WGS	A1138	EMM12.40			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919131	GCA_900983495.1	CAAHJW000000000		SC	WGS						21		1761972	38.366047	1749		1651.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1130	Streptococcus pyogenes strain A1144		1314	WGS	A1144	EMM12.40			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919132	GCA_900983505.1	CAAHJX000000000		SC	WGS						21		1763368	38.37304	1747		1652.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1128	Streptococcus pyogenes strain A1151		1314	WGS	A1151	EMM104.0			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919133	GCA_900983485.1	CAAHJV000000000		SC	WGS						13		1762196	38.319347	1727		1639.0		invasive		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1127	Streptococcus pyogenes strain A1152		1314	WGS	A1152	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919134	GCA_900983475.1	CAAHJU000000000			WGS						19		1733185	38.41927	1718		1619.0		invasive		2007-2010	India	India						Human, Homo sapiens																				
1314.1125	Streptococcus pyogenes strain A1267		1314	WGS	A1267	EMM43.3			MLST.Streptococcus_pyogenes.475				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919135	GCA_900983455.1	CAAHJS000000000		SC	WGS						17		1791665	38.39966	1822		1739.0		invasive		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1124	Streptococcus pyogenes strain A1268		1314	WGS	A1268	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919137	GCA_900983445.1	CAAHJQ000000000		SC	WGS						18		1803967	38.372833	1844		1743.0		invasive		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1126	Streptococcus pyogenes strain A1287		1314	WGS	A1287	EMM49.0			MLST.Streptococcus_pyogenes.371				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919136	GCA_900983465.1	CAAHJT000000000		SC	WGS						21		1801515	38.327515	1810		1720.0		invasive		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1297	Streptococcus pyogenes strain A829		1314	WGS	A829	EMM28.5			MLST.Streptococcus_pyogenes.473				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919092	GCA_900985175.1	CAAHQH000000000		SC	WGS						8		1713394	38.409225	1658		1581.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1288	Streptococcus pyogenes strain A837		1314	WGS	A837	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919093	GCA_900985085.1	CAAHPZ000000000		SC	WGS						15		1783560	38.3334	1792		1695.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1275	Streptococcus pyogenes strain A838		1314	WGS	A838	EMM49.4			MLST.Streptococcus_pyogenes.534				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919094	GCA_900984955.1	CAAHPM000000000		SC	WGS						12		1788426	38.342415	1780		1688.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1269	Streptococcus pyogenes strain A839		1314	WGS	A839	EMM75.1			MLST.Streptococcus_pyogenes.357				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919095	GCA_900984895.1	CAAHPG000000000		SC	WGS						16		1889841	38.43814	1881		1781.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1259	Streptococcus pyogenes strain A840		1314	WGS	A840	EMM77.0			MLST.Streptococcus_pyogenes.482				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919096	GCA_900984795.1	CAAHOV000000000		SC	WGS						11		1758570	38.34877	1711		1631.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1250	Streptococcus pyogenes strain A841		1314	WGS	A841	EMM77.0			MLST.Streptococcus_pyogenes.482				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919097	GCA_900984705.1	CAAHOM000000000		SC	WGS						12		1759695	38.355644	1713		1631.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1163	Streptococcus pyogenes strain A842		1314	WGS	A842	EMM3.22			MLST.Streptococcus_pyogenes.335				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919098	GCA_900983835.1	CAAHLD000000000		SC	WGS						20		1804814	38.29786	1816		1727.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1159	Streptococcus pyogenes strain A843		1314	WGS	A843	EMM3.22			MLST.Streptococcus_pyogenes.335				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919099	GCA_900983795.1	CAAHLA000000000		SC	WGS						22		1804559	38.29971	1820		1726.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1160	Streptococcus pyogenes strain A846		1314	WGS	A846	EMM28.5			MLST.Streptococcus_pyogenes.473				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919100	GCA_900983805.1	CAAHKZ000000000		SC	WGS						8		1754624	38.39244	1723		1642.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1161	Streptococcus pyogenes strain A848		1314	WGS	A848	EMM63.3			MLST.Streptococcus_pyogenes.297				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919101	GCA_900983815.1	CAAHKY000000000		SC	WGS						24		1918504	38.208797	1956		1856.0		Pharygitis		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.546	Streptococcus pyogenes strain A852		1314	Plasmid	A852								2016-07-26T00:00:00Z					KC895878			Plasmid					1.0	1		2644	34.46	6		3.0																																
1314.1158	Streptococcus pyogenes strain A855		1314	WGS	A855	EMM108.0			MLST.Streptococcus_pyogenes.304				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919102	GCA_900983785.1	CAAHLC000000000		SC	WGS						12		1759857	38.410698	1739		1660.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1155	Streptococcus pyogenes strain A856		1314	WGS	A856	EMM3.23			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919103	GCA_900983755.1	CAAHKW000000000		SC	WGS						14		1796040	38.39382	1851		1765.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1157	Streptococcus pyogenes strain A868		1314	WGS	A868	EMM108.0			MLST.Streptococcus_pyogenes.304				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919104	GCA_900983775.1	CAAHKX000000000		SC	WGS						15		1754601	38.38052	1744		1659.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1156	Streptococcus pyogenes strain A870		1314	WGS	A870	EMM168.1			MLST.Streptococcus_pyogenes.358				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919105	GCA_900983765.1	CAAHLB000000000		SC	WGS						24		1755837	38.29828	1726		1631.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1154	Streptococcus pyogenes strain A873		1314	WGS	A873	EMM3.23			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919106	GCA_900983745.1	CAAHKV000000000		SC	WGS						11		1795940	38.394455	1850		1767.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1153	Streptococcus pyogenes strain A876		1314	WGS	A876	EMM18.12			MLST.Streptococcus_pyogenes.535				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919107	GCA_900983735.1	CAAHKU000000000		SC	WGS						16		1741411	38.34358	1714		1634.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1152	Streptococcus pyogenes strain A879		1314	WGS	A879	EMM12.21							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919108	GCA_900983725.1	CAAHKT000000000		SC	WGS						26		1824251	38.36435	1848		1745.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1151	Streptococcus pyogenes strain A895		1314	WGS	A895	EMM100.6			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919109	GCA_900983715.1	CAAHKR000000000		SC	WGS						23		1805662	38.3747	1837		1743.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1150	Streptococcus pyogenes strain A896		1314	WGS	A896	EMM18.12			MLST.Streptococcus_pyogenes.535				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919110	GCA_900983705.1	CAAHKS000000000		SC	WGS						17		1701085	38.342785	1652		1571.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1147	Streptococcus pyogenes strain A900		1314	WGS	A900	EMM110.0			MLST.Streptococcus_pyogenes.495				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919111	GCA_900983685.1	CAAHKP000000000		SC	WGS						19		1787089	38.31594	1779		1690.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1149	Streptococcus pyogenes strain A904		1314	WGS	A904	EMM113.0			MLST.Streptococcus_pyogenes.499				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919112	GCA_900983695.1	CAAHKQ000000000		SC	WGS						28		1804081	38.36322	1833		1713.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1148	Streptococcus pyogenes strain A905		1314	WGS	A905	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919113	GCA_900983675.1	CAAHKO000000000		SC	WGS						15		1826342	38.340294	1859		1761.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1146	Streptococcus pyogenes strain A906		1314	WGS	A906	EMM104.0			MLST.Streptococcus_pyogenes.353				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919114	GCA_900983665.1	CAAHKN000000000		SC	WGS						14		1762441	38.327263	1727		1636.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1144	Streptococcus pyogenes strain A914		1314	WGS	A914	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919115	GCA_900983645.1	CAAHKM000000000		SC	WGS						15		1776437	38.362183	1763		1676.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1145	Streptococcus pyogenes strain A915		1314	WGS	A915	EMM49.4			MLST.Streptococcus_pyogenes.534				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919116	GCA_900983655.1	CAAHKL000000000		SC	WGS						10		1743002	38.36347	1706		1622.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1143	Streptococcus pyogenes strain A920		1314	WGS	A920	EMM112.2			MLST.Streptococcus_pyogenes.497				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919117	GCA_900983635.1	CAAHKK000000000		SC	WGS						24		1763715	38.307007	1733		1639.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1142	Streptococcus pyogenes strain A960		1314	WGS	A960	EMM168.1			MLST.Streptococcus_pyogenes.358				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919119	GCA_900983625.1	CAAHKJ000000000		SC	WGS						24		1754692	38.295803	1730		1628.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1141	Streptococcus pyogenes strain A967		1314	WGS	A967	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919120	GCA_900983615.1	CAAHKH000000000		SC	WGS						13		1775451	38.320087	1760		1673.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1139	Streptococcus pyogenes strain A969		1314	WGS	A969	EMM100.6			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919121	GCA_900983595.1	CAAHKI000000000		SC	WGS						26		1807301	38.381805	1837		1740.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1137	Streptococcus pyogenes strain A980		1314	WGS	A980	EMM82.1			MLST.Streptococcus_pyogenes.320				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919122	GCA_900983575.1	CAAHKF000000000		SC	WGS						15		1783918	38.333435	1793		1694.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1138	Streptococcus pyogenes strain A981		1314	WGS	A981	EMM102.2			MLST.Streptococcus_pyogenes.349				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919123	GCA_900983585.1	CAAHKE000000000		SC	WGS						18		1786889	38.425945	1774		1679.0				2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1140	Streptococcus pyogenes strain A982		1314	WGS	A982	EMM80.0			MLST.Streptococcus_pyogenes.701				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919124	GCA_900983605.1	CAAHKG000000000		SC	WGS						12		1793215	38.27591	1796		1702.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1136	Streptococcus pyogenes strain A993		1314	WGS	A993	EMM80.0			MLST.Streptococcus_pyogenes.715				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919125	GCA_900983555.1	CAAHJY000000000		SC	WGS						9		1755603	38.34472	1754		1655.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1133	Streptococcus pyogenes strain A995		1314	WGS	A995	EMM22.8			MLST.Streptococcus_pyogenes.360				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919126	GCA_900983535.1	CAAHKB000000000		SC	WGS						36		1913595	38.15201	1967		1836.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1132	Streptococcus pyogenes strain A996		1314	WGS	A996	EMM44.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919127	GCA_900983515.1	CAAHJZ000000000		SC	WGS						17		1839645	38.25392	1823		1729.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.545	Streptococcus pyogenes strain A996		1314	Plasmid	A996								2016-07-26T00:00:00Z					KC895877			Plasmid					1.0	1		3620	31.88	6		5.0																																
1314.1131	Streptococcus pyogenes strain A997		1314	WGS	A997	EMM75.3			MLST.Streptococcus_pyogenes.230				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919128	GCA_900983525.1	CAAHKC000000000		SC	WGS						29		1879683	38.222942	1914		1800.0		skin		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1135	Streptococcus pyogenes strain A998		1314	WGS	A998	EMM80.0			MLST.Streptococcus_pyogenes.701				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919129	GCA_900983565.1	CAAHKD000000000		SC	WGS						14		1745509	38.325634	1712		1619.0		throat		2007-2010	India	India						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.847	Streptococcus pyogenes strain ABC020055975		1314	Complete	ABC020055975	serovar M3			MLST.Streptococcus_pyogenes.15				2018-10-30T00:00:00Z		PRJNA473837	SAMN09284928	GCA_003698205.1	CP029694		UTHSC/McGovern Medical School	Complete	Illumina HiSeq; PacBio	1000.0x	SPAdes v. 3.11.1	1.0		1		1866513	38.593086	1956		1858.0				2011								Human, Homo sapiens			STSS																Complete genome sequence of serotype M3 group A Streptococcus	collected_by:Centers for Disease Control
1314.3078	Streptococcus pyogenes strain ABC122		1314	Complete	ABC122				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234519	GCA_019343025.1	CP049694		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	243x	Unicycler v. 0.4.6	1.0	0.0	1		1866269	38.553497	1879		1772.0		Not collected		2003	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3077	Streptococcus pyogenes strain ABC155		1314	Complete	ABC155				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234551	GCA_019343005.1	CP049693		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	191x	Unicycler v. 0.4.6	1.0	0.0	1		1887828	38.491856	1928		1816.0		Not collected		2004	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3073	Streptococcus pyogenes strain ABC157		1314	Complete	ABC157				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234553	GCA_019342985.1	CP049692		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	182x	Unicycler v. 0.4.6	1.0	0.0	1		1890316	38.48711	1939		1821.0		Not collected		2004	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3074	Streptococcus pyogenes strain ABC199		1314	Complete	ABC199				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234593	GCA_019342965.1	CP049691		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	621x	Unicycler v. 0.4.6	1.0	0.0	1		1823813	38.5409	1817		1715.0		Not collected		2005	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3072	Streptococcus pyogenes strain ABC208		1314	Complete	ABC208				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234602	GCA_019342945.1	CP049690		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	195x	Unicycler v. 0.4.6	1.0	0.0	1		1866583	38.556496	1879		1772.0		Not collected		2005	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3071	Streptococcus pyogenes strain ABC221		1314	Complete	ABC221				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234614	GCA_019342925.1	CP049689		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	787x	Unicycler v. 0.4.6	1.0	0.0	1		1931322	38.48778	1999		1881.0		Not collected		2006	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3069	Streptococcus pyogenes strain ABC245		1314	Complete	ABC245				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234637	GCA_019342905.1	CP049688		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	491x	Unicycler v. 0.4.6	1.0	0.0	1		1885850	38.498928	1931		1814.0		Not collected		2006	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3075	Streptococcus pyogenes strain ABC25		1314	Complete	ABC25				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234425	GCA_019343065.1	CP049696		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	186x	Unicycler v. 0.4.6	1.0	0.0	1		1890992	38.492073	1937		1820.0		Not collected		1998	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3079	Streptococcus pyogenes strain ABC3		1314	Complete	ABC3				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234404	GCA_019343085.1	CP049697		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	166x	Unicycler v. 0.4.6	1.0	0.0	1		1890273	38.48735	1940		1819.0		Not collected		1997	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.3076	Streptococcus pyogenes strain ABC76		1314	Complete	ABC76				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14234475	GCA_019343045.1	CP049695		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	98x	Unicycler v. 0.4.6	1.0	0.0	1		1887256	38.499016	1933		1813.0		Not collected		2000	USA	USA						Homo sapiens			Invasive																Emergence of a novel emm4 GAS clone in the human population	collected_by:CDC/ABCs
1314.200	Streptococcus pyogenes strain AP1		1314	Complete	AP1				MLST.Streptococcus_pyogenes.28				2015-05-07T00:00:00Z		PRJNA242701	SAMN02716635	GCF_000993765.1	CP007537	NZ_CP007537.1	Helmholtz Centre for Infection Research	Complete	Illumina MiSeq	238x	Velvet v. 1.0.20	1.0		1		1908294	38.47	1973		1836.0		blood			Czech Republic	Czech Republic:Prague						Human, Homo sapiens			bacteremia						Positive	Cocci	No								whole genome sequence of the mouse-virulent S. pyogenes strain AP1, belonging to the frequent emm1 serotype. Sequenced within the Combacte project.	
1314.239	Streptococcus pyogenes strain AP53		1314	Complete	AP53				MLST.Streptococcus_pyogenes.11				2016-04-18T00:00:00Z	27044623	PRJNA305806	SAMN04334485	GCF_001620285.1	CP013672	NZ_CP013672.1	University of Notre Dame	Complete	Illumina	200	Velvet v. 1.2	1.0		1		1860554	38.56	1891		1840.0		skin		1967	USA	United States						Human, Homo sapiens			Necrotizing fasciitis											C			HostAssociated		Streptococcus pyogenes is a human pathogenic bacterium with wide range of infectious niches and broad variation in severity. It has caused 700 million disease cases worldwide per year. More compelete genome information will help to further understand its virulence mechanism and establish the association between the genotypes and disease phenotypes.	
1314.2411	Streptococcus pyogenes strain ATCC 11434		1314	WGS	ATCC 11434				MLST.Streptococcus_pyogenes.36		ATCC 11434		2019-08-02T00:00:00Z		PRJDB8157	SAMD00166980	GCA_007990695.1	BJOY00000000		Kyushu university	WGS	Illumina	65x	platanus v. 1.2.2			89		1739442	38.397877	1747		1685.0												Human, Homo sapiens																			We determined the draft genome sequence of Streptococcus pyogenes strain ATCC11434 to identify genes encoding DNase.	biomaterial_provider:ATCC
1314.2457	Streptococcus pyogenes strain ATCC 19615		1314	WGS	ATCC 19615				MLST.Streptococcus_pyogenes.8	genotype:not applicable	ATCC:19615		2019-10-07T00:00:00Z		PRJNA573690	SAMN12822028	GCA_008868255.1	WBMD00000000		Signature Science, LLC	WGS	Illumina MiSeq	160.0x	SPAdes v. 3.13.0			34		1806601	38.31704	1904		1821.0				2019-03																											Sequencing isolates and mixtures of ESKAPE pathogens and C. difficile	collected_by:Weber, K.L. and LeSassier, D.S.
1314.2534	Streptococcus pyogenes strain AUSMDU00010539		1314	Complete	AUSMDU00010539	EMM89.0			MLST.Streptococcus_pyogenes.101	mlst:ST101			2019-11-17T00:00:00Z	33180013	PRJNA556438	SAMN13191653	GCA_009664495.1	CP045930		Microbiological Diagnostic Unit	Complete	llumina NextSeq500/550 or MiSeq	202x	de novo	1.0	0.0	1		1746807	38.55864	1709		1628.0				2013	Australia	Australia						Human, Homo sapiens							Susceptible	AMR Panel											Complete genomes of microbial pathogens are essential for the phylogenomic analyses that increasingly underpin core public health lab activities. Here, we present complete genomes of pathogen strains of regional importance to the Southwest Pacific and Australia. These enrich the catalogue of globally available complete genomes for public health while providing valuable strains to regional public health labs.	
1314.844	Streptococcus pyogenes strain B18039976		1314	WGS	B18039976				MLST.Streptococcus_pyogenes.52				2018-09-24T00:00:00Z		PRJNA489401	SAMN09977091	GCA_003597545.1	QYUF00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	41x	SPAdes v. 3.11.1			106		1944103	38.73113	2087		1981.0		blood		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.843	Streptococcus pyogenes strain B18040580		1314	WGS	B18040580				MLST.Streptococcus_pyogenes.52				2018-09-25T00:00:00Z		PRJNA489401	SAMN09977090	GCA_003594825.1	QZEU00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	63x	SPAdes v. 3.11.1			106		1933174	38.62389	2063		1962.0		Vagina		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.798	Streptococcus pyogenes strain B18040582		1314	WGS	B18040582				MLST.Streptococcus_pyogenes.52				2018-09-24T00:00:00Z		PRJNA489401	SAMN09977094	GCA_003591645.1	QYUD00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	60x	SPAdes v. 3.11.1			105		1892362	38.73857	2002		1905.0		Vagina		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.797	Streptococcus pyogenes strain B18040583		1314	WGS	B18040583				MLST.Streptococcus_pyogenes.52				2018-09-24T00:00:00Z		PRJNA489401	SAMN09977092	GCA_003591635.1	QYUE00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	40x	SPAdes v. 3.11.1			151		1868923	38.64461	1992		1893.0		Vagina		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.799	Streptococcus pyogenes strain B18040967		1314	WGS	B18040967				MLST.Streptococcus_pyogenes.52				2018-09-24T00:00:00Z		PRJNA489401	SAMN09976801	GCA_003591865.1	QYUH00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	65x	SPAdes v. 3.11.1			266		1952159	38.338577	2240		2140.0		blood		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.796	Streptococcus pyogenes strain B18041210		1314	WGS	B18041210				MLST.Streptococcus_pyogenes.52				2018-09-24T00:00:00Z		PRJNA489401	SAMN09977083	GCA_003591155.1	QYUG00000000		Austrian Agency for Health and Food Safety	WGS	Illumina MiSeq	101x	SPAdes v. 3.11.1			44		1902285	38.292053	1993		1896.0		Infected nail well		2018-07-26	Austria	Austria: Salzburg						Human, Homo sapiens			GAS infection																This study aims at the genomic characterization of S. pyogenes isolates obtained from female patients after delivery.	collected_by:Markus Hell
1314.2839	Streptococcus pyogenes strain BSAC_bs1388		1314	WGS	BSAC_bs1388				MLST.Streptococcus_pyogenes.39	genotype:emm4			2020-09-09T00:00:00Z		PRJNA660931	SAMN15964727	GCA_014495945.1	CP061132		University of Sheffield	WGS	Oxford Nanopore; Illumina	34x	Unicycler v. v0.4.7	0.0	0.0	1		1932413	38.496223	1986		1866.0		blood		2006	United Kingdom	United Kingdom: England						Human, Homo sapiens																			Long read sequencing of emm4 genotype S. pyogenes isolates to identify prophage content	sample_type:Culture;biomaterial_provider:British Society of Antimicrobial Chemotherapy
1314.2840	Streptococcus pyogenes strain BSAC_bs1802		1314	WGS	BSAC_bs1802				MLST.Streptococcus_pyogenes.39	genotype:emm4			2020-09-09T00:00:00Z		PRJNA660931	SAMN15964728	GCA_014495965.1	CP061131		University of Sheffield	WGS	Oxford Nanopore; Illumina	34x	Unicycler v. v0.4.7	0.0	0.0	1		1909430	38.526524	1947		1828.0		blood		2008	United Kingdom	United Kingdom: England						Human, Homo sapiens																			Long read sequencing of emm4 genotype S. pyogenes isolates to identify prophage content	sample_type:Culture;biomaterial_provider:British Society of Antimicrobial Chemotherapy
1314.2838	Streptococcus pyogenes strain BSAC_bs192		1314	WGS	BSAC_bs192				MLST.Streptococcus_pyogenes.39	genotype:emm4			2020-09-09T00:00:00Z		PRJNA660931	SAMN15964725	GCA_014495925.1	CP061134		University of Sheffield	WGS	Oxford Nanopore; Illumina	51x	Unicycler v. v0.4.7	0.0	0.0	1		1865571	38.53705	1873		1762.0		blood		2001	United Kingdom	United Kingdom: England						Human, Homo sapiens																			Long read sequencing of emm4 genotype S. pyogenes isolates to identify prophage content	sample_type:Culture;biomaterial_provider:British Society of Antimicrobial Chemotherapy
1314.2841	Streptococcus pyogenes strain BSAC_bs472		1314	WGS	BSAC_bs472				MLST.Streptococcus_pyogenes.39	genotype:emm4			2020-09-09T00:00:00Z		PRJNA660931	SAMN15964726	GCA_014495985.1	CP061133		University of Sheffield	WGS	Oxford Nanopore; Illumina	75x	Unicycler v. v0.4.7	0.0	0.0	1		1859391	38.517986	1873		1763.0		blood		2002	United Kingdom	United Kingdom: England						Human, Homo sapiens																			Long read sequencing of emm4 genotype S. pyogenes isolates to identify prophage content	sample_type:Culture;biomaterial_provider:British Society of Antimicrobial Chemotherapy
1314.1296	Streptococcus pyogenes strain Bel001		1314	WGS	Bel001	EMM75.0			MLST.Streptococcus_pyogenes.150				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919027	GCA_900985165.1	CAAHQI000000000		SC	WGS						17		1821364	38.437786	1853		1753.0		Pharygitis		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1293	Streptococcus pyogenes strain Bel002		1314	WGS	Bel002	EMM186.2			MLST.Streptococcus_pyogenes.147				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919035	GCA_900985135.1	CAAHQE000000000		SC	WGS						22		1746044	38.375004	1749		1653.0		skin infection		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1285	Streptococcus pyogenes strain Bel003		1314	WGS	Bel003	EMM209.0			MLST.Streptococcus_pyogenes.573				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919043	GCA_900985055.1	CAAHPW000000000		SC	WGS						30		1843505	38.314835	1853		1750.0		skin infection		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1282	Streptococcus pyogenes strain Bel004		1314	WGS	Bel004	EMM232.0			MLST.Streptococcus_pyogenes.187				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919049	GCA_900985025.1	CAAHPT000000000		SC	WGS						25		1917646	38.19756	1952		1841.0		Pharygitis		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1273	Streptococcus pyogenes strain Bel005		1314	WGS	Bel005	EMM8.0			MLST.Streptococcus_pyogenes.59				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919054	GCA_900984935.1	CAAHPP000000000		SC	WGS						16		1853080	38.380634	1890		1793.0		Pharygitis		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1271	Streptococcus pyogenes strain Bel006		1314	WGS	Bel006	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919059	GCA_900984915.1	CAAHPI000000000		SC	WGS						9		1725133	38.49914	1723		1639.0		Pharygitis		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1264	Streptococcus pyogenes strain Bel007		1314	WGS	Bel007	EMM184.0			MLST.Streptococcus_pyogenes.174				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919064	GCA_900984845.1	CAAHPB000000000		SC	WGS						17		1809585	38.421295	1845		1750.0		skin infection		2004	Belgium	Belgium						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1255	Streptococcus pyogenes strain Bra001		1314	WGS	Bra001	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919069	GCA_900984755.1	CAAHOW000000000		SC	WGS						37		1873612	38.327732	1941		1824.0		Scarlet fever		2005	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1253	Streptococcus pyogenes strain Bra002		1314	WGS	Bra002	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919074	GCA_900984735.1	CAAHOP000000000		SC	WGS						33		1850312	38.334507	1896		1793.0		Scarlet fever		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1247	Streptococcus pyogenes strain Bra003		1314	WGS	Bra003	EMM28.0			MLST.Streptococcus_pyogenes.626				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919079	GCA_900984675.1	CAAHON000000000		SC	WGS						13		1744451	38.355274	1712		1626.0		Scarlet fever		2009	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1214	Streptococcus pyogenes strain Bra004		1314	WGS	Bra004	EMM56.X			MLST.Streptococcus_pyogenes.174				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919084	GCA_900984345.1	CAAHND000000000		SC	WGS						14		1716588	38.362167	1698		1618.0		Pharygitis		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1174	Streptococcus pyogenes strain Bra005		1314	WGS	Bra005	EMM88.2			MLST.Streptococcus_pyogenes.397				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919088	GCA_900983945.1	CAAHLP000000000		SC	WGS						27		1871747	38.320827	1934		1828.0		skin infection		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1295	Streptococcus pyogenes strain Bra006		1314	WGS	Bra006	EMM68.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919028	GCA_900985155.1	CAAHQF000000000		SC	WGS						32		1720086	38.340504	1702		1596.0		Pharygitis		2004	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1284	Streptococcus pyogenes strain Bra007		1314	WGS	Bra007	EMM101.1			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919044	GCA_900985045.1	CAAHPV000000000		SC	WGS						13		1757812	38.394287	1768		1682.0		Scarlet fever		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1290	Streptococcus pyogenes strain Bra008		1314	WGS	Bra008	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919036	GCA_900985105.1	CAAHQB000000000		SC	WGS						27		1812489	38.45796	1877		1763.0		Throat carriage		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1280	Streptococcus pyogenes strain Bra009		1314	WGS	Bra009	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919050	GCA_900985005.1	CAAHPO000000000		SC	WGS						16		1803736	38.37822	1831		1741.0		Scarlet fever		2004	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1278	Streptococcus pyogenes strain Bra010		1314	WGS	Bra010	EMM64.3							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919055	GCA_900984975.1	CAAHPR000000000		SC	WGS						10		1752563	38.402523	1753		1674.0		Pharygitis		2003	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1268	Streptococcus pyogenes strain Bra011		1314	WGS	Bra011	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919060	GCA_900984885.1	CAAHPE000000000		SC	WGS						29		1798980	38.364918	1818		1708.0		Scarlet fever		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1263	Streptococcus pyogenes strain Bra012		1314	WGS	Bra012	EMM43.5			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919065	GCA_900984835.1	CAAHPA000000000		SC	WGS						20		1815604	38.384018	1861		1767.0		skin infection		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1256	Streptococcus pyogenes strain Bra013		1314	WGS	Bra013	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919070	GCA_900984765.1	CAAHOR000000000		SC	WGS						32		1780104	38.439163	1817		1713.0				2000	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1252	Streptococcus pyogenes strain Bra014		1314	WGS	Bra014	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919075	GCA_900984725.1	CAAHOQ000000000		SC	WGS						17		1776236	38.442337	1780		1687.0		sterile site		2003	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1246	Streptococcus pyogenes strain Bra015		1314	WGS	Bra015	EMM4.0			MLST.Streptococcus_pyogenes.38				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919080	GCA_900984665.1	CAAHOJ000000000		SC	WGS						26		1883551	38.334568	1947		1846.0		sterile site		2007	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1202	Streptococcus pyogenes strain Bra016		1314	WGS	Bra016	EMM80.0			MLST.Streptococcus_pyogenes.538				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919085	GCA_900984225.1	CAAHMR000000000		SC	WGS						13		1759905	38.381958	1770		1689.0		Pharygitis		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1162	Streptococcus pyogenes strain Bra017		1314	WGS	Bra017	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919089	GCA_900983825.1	CAAHLE000000000		SC	WGS						22		1777561	38.435413	1812		1714.0		Scarlet fever		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1294	Streptococcus pyogenes strain Bra018		1314	WGS	Bra018	EMM185.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919029	GCA_900985145.1	CAAHQG000000000		SC	WGS						25		1776071	38.43098	1776		1681.0		Pharygitis		2002	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1289	Streptococcus pyogenes strain Bra019		1314	WGS	Bra019	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919037	GCA_900985095.1	CAAHQA000000000		SC	WGS						17		1804050	38.371796	1825		1743.0		Scarlet fever		2007	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1274	Streptococcus pyogenes strain Bra021		1314	WGS	Bra021	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919051	GCA_900984945.1	CAAHPK000000000		SC	WGS						22		1772917	38.436203	1807		1707.0		Scarlet fever		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1279	Streptococcus pyogenes strain Bra022		1314	WGS	Bra022	EMM59.0			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919056	GCA_900984995.1	CAAHPN000000000		SC	WGS						12		1751839	38.359177	1743		1654.0		Pharygitis		2002	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1266	Streptococcus pyogenes strain Bra023		1314	WGS	Bra023	EMM86.1			MLST.Streptococcus_pyogenes.4				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919061	GCA_900984865.1	CAAHPD000000000		SC	WGS						21		1813661	38.349945	1863		1763.0		Pharygitis		2000	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1262	Streptococcus pyogenes strain Bra024		1314	WGS	Bra024	EMM81.0			MLST.Streptococcus_pyogenes.624				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919066	GCA_900984825.1	CAAHOZ000000000		SC	WGS						28		1874056	38.35456	1952		1841.0		Pharygitis		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1258	Streptococcus pyogenes strain Bra025		1314	WGS	Bra025	EMM48.1			MLST.Streptococcus_pyogenes.161				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919071	GCA_900984785.1	CAAHOU000000000		SC	WGS						16		1923116	38.30513	1967		1861.0		Scarlet fever		2003	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1249	Streptococcus pyogenes strain Bra026		1314	WGS	Bra026	EMM15.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919076	GCA_900984695.1	CAAHOO000000000		SC	WGS						35		1717547	38.394176	1733		1619.0		skin infection		2005	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1245	Streptococcus pyogenes strain Bra027		1314	WGS	Bra027	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919081	GCA_900984655.1	CAAHOI000000000		SC	WGS						30		1811936	38.45252	1878		1761.0		Scarlet fever		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1190	Streptococcus pyogenes strain Bra028		1314	WGS	Bra028	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919086	GCA_900984105.1	CAAHMF000000000		SC	WGS						27		1817427	38.41851	1882		1784.0		Scarlet fever		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1317	Streptococcus pyogenes strain Bra029		1314	WGS	Bra029	EMM34.0			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919090	GCA_900985375.1	CAAHRC000000000		SC	WGS						19		1785896	38.39983	1793		1708.0		sterile site		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1291	Streptococcus pyogenes strain Bra030		1314	WGS	Bra030	EMM2.0			MLST.Streptococcus_pyogenes.55				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919030	GCA_900985115.1	CAAHQD000000000		SC	WGS						20		1882577	38.269245	1937		1829.0		Pharygitis		2005	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1286	Streptococcus pyogenes strain Bra031		1314	WGS	Bra031	EMM8.0			MLST.Streptococcus_pyogenes.59				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919038	GCA_900985065.1	CAAHPY000000000		SC	WGS						17		1848824	38.348614	1874		1779.0		sterile site		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1283	Streptococcus pyogenes strain Bra032		1314	WGS	Bra032	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919046	GCA_900985035.1	CAAHPU000000000		SC	WGS						14		1835984	38.38754	1866		1772.0		Pharygitis		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1276	Streptococcus pyogenes strain Bra033		1314	WGS	Bra033	EMM4.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919052	GCA_900984965.1	CAAHPQ000000000		SC	WGS						26		1889997	38.31753	1953		1853.0		Scarlet fever		2007	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1272	Streptococcus pyogenes strain Bra034		1314	WGS	Bra034	EMM118.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919057	GCA_900984925.1	CAAHPH000000000		SC	WGS						11		1786844	38.274544	1762		1671.0		sterile site		2009	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1267	Streptococcus pyogenes strain Bra035		1314	WGS	Bra035	EMM66.0			MLST.Streptococcus_pyogenes.44				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919062	GCA_900984875.1	CAAHPF000000000		SC	WGS						25		1798546	38.39029	1816		1722.0		sterile site		2008	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1261	Streptococcus pyogenes strain Bra036		1314	WGS	Bra036	EMM169.X			MLST.Streptococcus_pyogenes.53				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919067	GCA_900984815.1	CAAHOY000000000		SC	WGS						13		1848939	38.09942	1816		1734.0		Pharygitis		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1254	Streptococcus pyogenes strain Bra037		1314	WGS	Bra037	EMM63.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919072	GCA_900984745.1	CAAHOT000000000		SC	WGS						14		1903517	38.243965	1895		1795.0		skin infection		2013	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1251	Streptococcus pyogenes strain Bra038		1314	WGS	Bra038	EMM119.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919077	GCA_900984715.1	CAAHOK000000000		SC	WGS						26		1812551	38.40157	1863		1763.0		skin infection		2014	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1236	Streptococcus pyogenes strain Bra039		1314	WGS	Bra039	EMM6.4			MLST.Streptococcus_pyogenes.37				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919082	GCA_900984565.1	CAAHNY000000000		SC	WGS						36		1872546	38.404076	1966		1855.0		sterile site		2007	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1182	Streptococcus pyogenes strain Bra040		1314	WGS	Bra040	EMM9.0			MLST.Streptococcus_pyogenes.75				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919087	GCA_900984025.1	CAAHLX000000000		SC	WGS						22		1877323	38.3777	1884		1790.0		sterile site		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1307	Streptococcus pyogenes strain Bra041		1314	WGS	Bra041	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919091	GCA_900985275.1	CAAHQS000000000		SC	WGS						38		1851378	38.423977	1932		1808.0		skin infection		2014	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1292	Streptococcus pyogenes strain Bra042		1314	WGS	Bra042	EMM75.0			MLST.Streptococcus_pyogenes.150				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919031	GCA_900985125.1	CAAHQC000000000		SC	WGS						16		1815079	38.435516	1849		1742.0				2007	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1287	Streptococcus pyogenes strain Bra043		1314	WGS	Bra043	EMM117.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919039	GCA_900985075.1	CAAHPX000000000		SC	WGS						11		1756455	38.315094	1748		1656.0		skin infection		2003	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1281	Streptococcus pyogenes strain Bra044		1314	WGS	Bra044	EMM27.0			MLST.Streptococcus_pyogenes.308				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919047	GCA_900985015.1	CAAHPS000000000		SC	WGS						26		1841632	38.32288	1900		1785.0		Pharygitis		2011	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1277	Streptococcus pyogenes strain Bra045		1314	WGS	Bra045	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919053	GCA_900984985.1	CAAHPL000000000		SC	WGS						39		1873607	38.335667	1935		1829.0				2000	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1270	Streptococcus pyogenes strain Bra046		1314	WGS	Bra046	EMM94.1			MLST.Streptococcus_pyogenes.89				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919058	GCA_900984905.1	CAAHPJ000000000		SC	WGS						44		1972739	38.102234	2079		1922.0		APSGN		2004	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1265	Streptococcus pyogenes strain Bra047		1314	WGS	Bra047	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919063	GCA_900984855.1	CAAHPC000000000		SC	WGS						27		1839197	38.3444	1873		1773.0		Scarlet fever		2003	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1257	Streptococcus pyogenes strain Bra048		1314	WGS	Bra048	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919068	GCA_900984775.1	CAAHOS000000000		SC	WGS						15		1764417	38.349876	1783		1686.0		Scarlet fever		2006	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1260	Streptococcus pyogenes strain Bra049		1314	WGS	Bra049	EMM83.1			MLST.Streptococcus_pyogenes.5				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919073	GCA_900984805.1	CAAHOX000000000		SC	WGS						20		1842974	38.40553	1877		1777.0		sterile site		2004	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1248	Streptococcus pyogenes strain Bra050		1314	WGS	Bra050	EMM75.0			MLST.Streptococcus_pyogenes.150				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919078	GCA_900984685.1	CAAHOL000000000		SC	WGS						30		1866157	38.43686	1925		1818.0		Scarlet fever		2012	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1225	Streptococcus pyogenes strain Bra051		1314	WGS	Bra051	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919083	GCA_900984455.1	CAAHNN000000000		SC	WGS						22		1802141	38.377575	1822		1715.0		Scarlet fever		2005	Brazil	Brazil						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.435	Streptococcus pyogenes strain CCUG 25570		1314	WGS	CCUG 25570						CCUG:25570		2017-03-03T00:00:00Z		PRJNA301788	SAMN04278900	GCF_002016575.1	LNPL00000000		University of Gothenburg - CCUG	WGS	Illumina HiSeq	200.0x	CLC NGS Cell v. 8.0.1			31		1777498	38.37	1773		1650.0		Human body		1985	Sweden	Sweden: Halland, Halmstad						Human, Homo sapiens														C					The project goal is the identification of proteins biomarkers for identifying pathogenic microorganisms and their metabolic functions.	sample_type:Cell culture;collected_by:Halland Hospital of Halmstad;biomaterial_provider:CCUG
1314.432	Streptococcus pyogenes strain CCUG 33061		1314	WGS	CCUG 33061				MLST.Streptococcus_pyogenes.8				2017-02-01T00:00:00Z		PRJNA302716	SAMN05912983	GCF_001982765.1	MLGB00000000		University of Gothenburg - CCUG	WGS	Illumina MiSeq	80.0x	CLC Genomic Workbench v. 9.5.1			22		1807388	38.3	1864		1743.0		Human pharynx			USA	United States						Human, Homo sapiens			Sore throat			host_description:Child													Identification of protein biomarkers for proteotyping pathogenic bacteria and their metabolic functions.	collected_by:E.Mortimer
1314.951	Streptococcus pyogenes strain CCUG 4207		1314	Complete	CCUG 4207	Lancefield group A, Griffith serotype 1			MLST.Streptococcus_pyogenes.28		CCUG:4207		2019-01-17T00:00:00Z		PRJNA302716	SAMN08915690	GCA_004028355.1	CP028841		University of Gothenburg - CCUG	Complete	Illumina HiSeq; Oxford Nanopore MinION	185.6; 576.4	SPAdes v. 3.11	1.0		1		1914862	38.503246	2017		1921.0		throat swab			United Kingdom	United Kingdom:Manchester						Human, Homo sapiens			Scarlet fever																Identification of protein biomarkers for proteotyping pathogenic bacteria and their metabolic functions.	collected_by:Frederick Griffith
1314.433	Streptococcus pyogenes strain CCUG 4207		1314	WGS	CCUG 4207	1			MLST.Streptococcus_pyogenes.28				2017-02-01T00:00:00Z		PRJNA302716	SAMN05912995	GCF_001982785.1	MLGC00000000		University of Gothenburg - CCUG	WGS	Illumina MiSeq	647.0x	CLC Genomic Workbench v. 9.5.1			45		1863165	38.35	1957		1822.0				1950	United Kingdom	United Kingdom						Human, Homo sapiens			Scarlet fever																Identification of protein biomarkers for proteotyping pathogenic bacteria and their metabolic functions.	collected_by:R. E. O. Williams
1314.434	Streptococcus pyogenes strain CCUG 47803		1314	WGS	CCUG 47803	M1			MLST.Streptococcus_pyogenes.28		CCUG:47803		2017-03-03T00:00:00Z		PRJNA302716	SAMN06286562	GCF_002014815.1	MUYP00000000		University of Gothenburg - CCUG	WGS	Illumina MiSeq	89.0x	CLC Genomic Workbench v. 9.5.1			29		1812632	38.35	1881		1810.0		Human infected wound			USA	USA: Atlanta						Human, Homo sapiens			Wound infection																Identification of protein biomarkers for proteotyping pathogenic bacteria and their metabolic functions.	collected_by:R. R. Facklam, CDC
1314.199	Streptococcus pyogenes strain D471		1314	Complete	D471	serovar emm6			MLST.Streptococcus_pyogenes.37				2015-06-02T00:00:00Z		PRJNA283214	SAMN03610015	GCF_001014305.1	CP011415	NZ_CP011415.1	Washington University School of Medicine	Complete	Illumina	119	DNASTAR SeqMan NGen v. 4.0.0	1.0		1		1811968	38.63	1810		1671.0				1971								Human, Homo sapiens			Rheumatic fever-associated											C					We report the complete genome assemblies of the group A Streptococcus pyogenes serotype emm6 strains D471 and its streptomycin-resistant derivative JRS4. Both of these well studied laboratory strains have been extensively characterized over the past three decades and have been instrumental in the discovery of multiple aspects of streptococcal pathogenesis.	collected_by:Rockefeller University Lancefield Collection
1314.1109	Streptococcus pyogenes strain Dog48		1314	WGS	Dog48	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238018	GCA_900983295.1	CAAHJC000000000		SC	WGS						19		1747790	38.39336	1758		1668.0				1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.850	Streptococcus pyogenes strain Duke-Large		1314	Complete	Duke-Large				MLST.Streptococcus_pyogenes.39				2018-11-23T00:00:00Z		PRJNA505351	SAMN10416086	GCA_003814365.1	CP033907		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; PacBio	51.0x	SPAdes v. 3.10.0	1.0		1		1903852	38.540863	1975		1874.0		blood			USA	USA: North Carolina						Human, Homo sapiens	female	48	Bacteremia																Whole genome sequencing of type emm4 GAS clinical strains	collected_by:Duke University Medical Center
1314.214	Streptococcus pyogenes strain FDAARGOS_149		1314	Complete	FDAARGOS_149				MLST.Streptococcus_pyogenes.28		FDA:FDAARGOS_149		2016-02-11T00:00:00Z		PRJNA231221	SAMN03996295	GCF_001559175.1	CP014027	NZ_CP014027.1	US Food and Drug Administration	Complete	Pacbio	25.567x	HGAP3 v. Nov 2014	1.0		1		1839641	38.54	1848		1745.0		Peripheral blood		2014-04-09	USA	USA:DC						Human, Homo sapiens	male	3Y	Epidural Abscess																FDA, in collaboration with the National Center for Biotechnology Information (NCBI), the Department of Defense (DoD) and the Institute for Genome Sciences at the University of Maryland, established a publicly available, well-curated reference database (FDA-ARGOS: dAtabase for Regulatory Grade micrObial Sequences\; BioProject 231221) of regulatory-grade-quality sequences from diverse infectious microorganisms. This database, which is still growing, comprises data collected from multiple collaborators. Diagnostic test manufacturers develop sequence-based tests to identify infectious agents and/or to detect resistance or virulence markers\; will use this database to advance their development programs and to support the regulatory science review of such tests. This work will facilitate the development of these tests, which are aimed at improving patient outcomes. Continued success of the database and adoption by the community is contingent on populating and curating the database, which in turn will support development of guidance and standards for clinical use of this technology. Discussions held at a relating public workshop on advancing regulatory science for high throughput sequencing devices for microbial identification and detection of antimicrobial resistance markers were essential to establish the safety and effectiveness of these devices.	collected_by:Children's National Hospital
1314.471	Streptococcus pyogenes strain FDAARGOS_190		1314	WGS	FDAARGOS_190				MLST.Streptococcus_pyogenes.101		FDA:FDAARGOS_190		2017-04-10T00:00:00Z		PRJNA231221	SAMN04875527	GCA_002083085.2	NBTO00000000			WGS						1		1763874	38.55	1756		1678.0		wound		2013-10-29	USA	USA: DC						Human, Homo sapiens																				
1314.849	Streptococcus pyogenes strain FDAARGOS_514 strain Not applicable		1314	Complete	Not applicable				MLST.Streptococcus_pyogenes.315		FDA:FDAARGOS_514		2018-11-21T00:00:00Z		PRJNA231221	SAMN10163208	GCA_003812725.1	CP033815,CP033816		US Food and Drug Administration	Complete	Pacbio; Illumina	34.05x	Canu v. 1.4, SPAdes v. 3.6.0	1.0	1.0	2		1902112	38.566917	2016		1908.0		Not specified		2016-01-21								Human, Homo sapiens	male	6Y				host_description:Not applicable													In May 2014, the FDA and collaborators established a publicly available dAtabase for Reference Grade micrObial Sequences called FDA-ARGOS. With funding support from FDAs Office of Counterterrorism and Emerging Threats (OCET) and DoD, the FDA-ARGOS team are initially collecting and sequencing 2000 microbes that include biothreat microorganisms, common clinical pathogens and closely related species. Currently, FDA-ARGOS microbial genomes are generated in 3 phases. Generally:  Phase 1 entails collection of a previously identified microbe and nucleic acid extraction. Phase 2, the microbial nucleic acids are sequenced and de novo assembled using Illumina and PacBio sequencing platforms at the Institute for Genome Sciences at the University of Maryland (UMD-IGS). Phase 3, the assembled genomes are vetted by an ID-NGS subject matter expert working group consisting of FDA personnel and collaborators and the data are deposited in NCBI databases.   The FDA-ARGOS genomes meet the quality metrics for reference-grade genomes for regulatory use. FDA-ARGOS reference genomes have been de novo assembled with high depth of base coverage and placed within a pre-established phylogenetic tree. Each microbial isolate in the database is covered at a minimum of 20X over 95 percent of the assembled core genome. Furthermore, sample specific metadata, raw reads, assemblies, annotation and details of the bioinformatics pipeline are available.	collected_by:Children's National Hospital
1314.848	Streptococcus pyogenes strain FDAARGOS_534 strain Not applicable		1314	Complete	Not applicable				MLST.Streptococcus_pyogenes.36		FDA:FDAARGOS_534		2018-11-21T00:00:00Z		PRJNA231221	SAMN10163229	GCA_003812645.1	CP033767		US Food and Drug Administration	Complete	Pacbio; Illumina	25.63x	CA v. 8.2	1.0		1		1837737	38.537395	1863		1787.0		Endotracheal aspirate		2016-04-19								Human, Homo sapiens	female	14Y				host_description:Not applicable													In May 2014, the FDA and collaborators established a publicly available dAtabase for Reference Grade micrObial Sequences called FDA-ARGOS. With funding support from FDAs Office of Counterterrorism and Emerging Threats (OCET) and DoD, the FDA-ARGOS team are initially collecting and sequencing 2000 microbes that include biothreat microorganisms, common clinical pathogens and closely related species. Currently, FDA-ARGOS microbial genomes are generated in 3 phases. Generally:  Phase 1 entails collection of a previously identified microbe and nucleic acid extraction. Phase 2, the microbial nucleic acids are sequenced and de novo assembled using Illumina and PacBio sequencing platforms at the Institute for Genome Sciences at the University of Maryland (UMD-IGS). Phase 3, the assembled genomes are vetted by an ID-NGS subject matter expert working group consisting of FDA personnel and collaborators and the data are deposited in NCBI databases.   The FDA-ARGOS genomes meet the quality metrics for reference-grade genomes for regulatory use. FDA-ARGOS reference genomes have been de novo assembled with high depth of base coverage and placed within a pre-established phylogenetic tree. Each microbial isolate in the database is covered at a minimum of 20X over 95 percent of the assembled core genome. Furthermore, sample specific metadata, raw reads, assemblies, annotation and details of the bioinformatics pipeline are available.	collected_by:Children's National Hospital
1314.2439	Streptococcus pyogenes strain FDAARGOS_668 strain Not applicable		1314	Complete	Not applicable				MLST.Streptococcus_pyogenes.36		FDA:FDAARGOS_668		2019-09-25T00:00:00Z		PRJNA231221	SAMN11056383	GCA_008694005.1	CP044093,CP044094,CP044095,CP044096		US Food and Drug Administration	Complete	Pacbio; Illumina	4272.79x	SMRT v. 2.3.0, HGAP v. 3, SPAdes v. 3.6.0	1.0	3.0	4		1841346	38.521713	1867		1792.0		clinical isolate			USA	USA: DC						Human, Homo sapiens						host_description:Not applicable													In May 2014, the FDA and collaborators established a publicly available dAtabase for Reference Grade micrObial Sequences called FDA-ARGOS. With funding support from FDAs Office of Counterterrorism and Emerging Threats (OCET) and DoD, the FDA-ARGOS team are initially collecting and sequencing 2000 microbes that include biothreat microorganisms, common clinical pathogens and closely related species. Currently, FDA-ARGOS microbial genomes are generated in 3 phases. Generally:  Phase 1 entails collection of a previously identified microbe and nucleic acid extraction. Phase 2, the microbial nucleic acids are sequenced and de novo assembled using Illumina and PacBio sequencing platforms at the Institute for Genome Sciences at the University of Maryland (UMD-IGS). Phase 3, the assembled genomes are vetted by an ID-NGS subject matter expert working group consisting of FDA personnel and collaborators and the data are deposited in NCBI databases.   The FDA-ARGOS genomes meet the quality metrics for reference-grade genomes for regulatory use. FDA-ARGOS reference genomes have been de novo assembled with high depth of base coverage and placed within a pre-established phylogenetic tree. Each microbial isolate in the database is covered at a minimum of 20X over 95 percent of the assembled core genome. Furthermore, sample specific metadata, raw reads, assemblies, annotation and details of the bioinformatics pipeline are available.	collected_by:Children's National Hospital
1314.2404	Streptococcus pyogenes strain FDAARGOS_774 strain Not applicable		1314	Complete	Not applicable				MLST.Streptococcus_pyogenes.28		ATCC:12344		2019-06-19T00:00:00Z		PRJNA231221	SAMN11056489	GCA_006364235.1	CP040997		US Food and Drug Administration	Complete	Pacbio; Illumina	2852.05x	canu v. 1.7	1.0		1		1914862	38.503193	2017		1919.0					USA	USA:VA												host_description:Not applicable													In May 2014, the FDA and collaborators established a publicly available dAtabase for Reference Grade micrObial Sequences called FDA-ARGOS. With funding support from FDAs Office of Counterterrorism and Emerging Threats (OCET) and DoD, the FDA-ARGOS team are initially collecting and sequencing 2000 microbes that include biothreat microorganisms, common clinical pathogens and closely related species. Currently, FDA-ARGOS microbial genomes are generated in 3 phases. Generally:  Phase 1 entails collection of a previously identified microbe and nucleic acid extraction. Phase 2, the microbial nucleic acids are sequenced and de novo assembled using Illumina and PacBio sequencing platforms at the Institute for Genome Sciences at the University of Maryland (UMD-IGS). Phase 3, the assembled genomes are vetted by an ID-NGS subject matter expert working group consisting of FDA personnel and collaborators and the data are deposited in NCBI databases.   The FDA-ARGOS genomes meet the quality metrics for reference-grade genomes for regulatory use. FDA-ARGOS reference genomes have been de novo assembled with high depth of base coverage and placed within a pre-established phylogenetic tree. Each microbial isolate in the database is covered at a minimum of 20X over 95 percent of the assembled core genome. Furthermore, sample specific metadata, raw reads, assemblies, annotation and details of the bioinformatics pipeline are available.	collected_by:NIST<ATCC
1314.544	Streptococcus pyogenes strain GA2000		1314	Plasmid	GA2000								2016-07-25T00:00:00Z	21899978				JF308631			Plasmid					1.0	1		4967	37.33	9		4.0																																
1314.2214	Streptococcus pyogenes strain GAS02198		1314	WGS	GAS02198	EMM78.3							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918742	GCA_900994425.1	CAAIZR000000000		SC	WGS						18		1776882	38.281586	1751		1664.0		throat		2002	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2299	Streptococcus pyogenes strain GAS03101		1314	WGS	GAS03101	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918887	GCA_900995275.1	CAAJCX000000000		SC	WGS						13		1760014	38.36892	1778		1690.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2215	Streptococcus pyogenes strain GAS03109		1314	WGS	GAS03109	EMM81.3							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918746	GCA_900994435.1	CAAIZT000000000		SC	WGS						23		1780403	38.27993	1776		1678.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2208	Streptococcus pyogenes strain GAS0317		1314	WGS	GAS0317	EMM3.1			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918758	GCA_900994365.1	CAAIZL000000000		SC	WGS						26		1822521	38.424797	1891		1790.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2201	Streptococcus pyogenes strain GAS03188		1314	WGS	GAS03188	EMM89.0			MLST.Streptococcus_pyogenes.142				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918771	GCA_900994295.1	CAAIZE000000000		SC	WGS						22		1737876	38.374325	1721		1641.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2199	Streptococcus pyogenes strain GAS0320		1314	WGS	GAS0320	EMM3.1			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918770	GCA_900994275.1	CAAIZC000000000		SC	WGS						24		1823032	38.428528	1890		1792.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2190	Streptococcus pyogenes strain GAS03202		1314	WGS	GAS03202	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918779	GCA_900994185.1	CAAIYT000000000		SC	WGS						41		1724287	38.39664	1746		1633.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2191	Streptococcus pyogenes strain GAS0327		1314	WGS	GAS0327	EMM3.1			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918778	GCA_900994195.1	CAAIYU000000000		SC	WGS						27		1823061	38.42918	1891		1790.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2183	Streptococcus pyogenes strain GAS0354		1314	WGS	GAS0354	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918791	GCA_900994105.1	CAAIYM000000000		SC	WGS						16		1721744	38.37565	1714		1628.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2176	Streptococcus pyogenes strain GAS0359		1314	WGS	GAS0359	EMM82.0			MLST.Streptococcus_pyogenes.334				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918805	GCA_900994045.1	CAAIYE000000000		SC	WGS						15		1794605	38.360786	1810		1715.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2166	Streptococcus pyogenes strain GAS0361		1314	WGS	GAS0361	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918817	GCA_900993945.1	CAAIXV000000000		SC	WGS						29		1787852	38.421734	1839		1735.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2156	Streptococcus pyogenes strain GAS0370		1314	WGS	GAS0370	EMM82.0			MLST.Streptococcus_pyogenes.334				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918832	GCA_900993845.1	CAAIXK000000000		SC	WGS						17		1794354	38.361	1815		1713.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2148	Streptococcus pyogenes strain GAS0371		1314	WGS	GAS0371	EMM82.0			MLST.Streptococcus_pyogenes.334				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918846	GCA_900993765.1	CAAIXD000000000		SC	WGS						17		1793755	38.3529	1808		1716.0		throat		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2138	Streptococcus pyogenes strain GAS0387		1314	WGS	GAS0387	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918860	GCA_900993665.1	CAAIWT000000000		SC	WGS						16		1773735	38.461384	1778		1688.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2324	Streptococcus pyogenes strain GAS0391		1314	WGS	GAS0391	EMM78.3							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918873	GCA_900995525.1	CAAJDX000000000		SC	WGS						18		1741655	38.271347	1700		1612.0		sterile site		2003	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2172	Streptococcus pyogenes strain GAS05134		1314	WGS	GAS05134	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918807	GCA_900994005.1	CAAIYB000000000		SC	WGS						15		1805367	38.381443	1834		1744.0		throat		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2165	Streptococcus pyogenes strain GAS05150		1314	WGS	GAS05150	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918819	GCA_900993935.1	CAAIXU000000000		SC	WGS						30		1749710	38.414413	1782		1677.0		throat		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2157	Streptococcus pyogenes strain GAS05151		1314	WGS	GAS05151	EMM89.0			MLST.Streptococcus_pyogenes.142				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918834	GCA_900993855.1	CAAIXL000000000		SC	WGS						20		1780797	38.397152	1778		1698.0		throat		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2147	Streptococcus pyogenes strain GAS05154		1314	WGS	GAS05154	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918848	GCA_900993755.1	CAAIXC000000000		SC	WGS						30		1786734	38.414078	1832		1734.0		sterile site		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2139	Streptococcus pyogenes strain GAS05161		1314	WGS	GAS05161	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918862	GCA_900993675.1	CAAIWU000000000		SC	WGS						13		1744340	38.422977	1734		1653.0		throat		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2307	Streptococcus pyogenes strain GAS05207		1314	WGS	GAS05207	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918874	GCA_900995355.1	CAAJDF000000000		SC	WGS						10		1716672	38.403297	1693		1609.0		throat		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2180	Streptococcus pyogenes strain GAS0592		1314	WGS	GAS0592	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918793	GCA_900994085.1	CAAIYK000000000		SC	WGS						12		1755138	38.29994	1732		1652.0		sterile site		2005	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2216	Streptococcus pyogenes strain GAS0615		1314	WGS	GAS0615	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918748	GCA_900994445.1	CAAIZS000000000		SC	WGS						30		1787300	38.41008	1836		1738.0		throat		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2189	Streptococcus pyogenes strain GAS06166		1314	WGS	GAS06166	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918781	GCA_900994175.1	CAAIYS000000000		SC	WGS						25		1762389	38.381763	1759		1652.0		throat		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2205	Streptococcus pyogenes strain GAS0617		1314	WGS	GAS0617	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918762	GCA_900994335.1	CAAIZJ000000000		SC	WGS						23		1803872	38.386425	1824		1720.0		sterile site		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2181	Streptococcus pyogenes strain GAS06216		1314	WGS	GAS06216	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918794	GCA_900994095.1	CAAIYJ000000000		SC	WGS						15		1804749	38.381298	1830		1743.0		throat		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2171	Streptococcus pyogenes strain GAS06220		1314	WGS	GAS06220	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918808	GCA_900993995.1	CAAIYA000000000		SC	WGS						16		1803812	38.379993	1827		1740.0		sterile site		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2164	Streptococcus pyogenes strain GAS06262		1314	WGS	GAS06262	EMM54.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918820	GCA_900993925.1	CAAIXR000000000		SC	WGS						14		1750409	38.43487	1744		1653.0		sterile site		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2155	Streptococcus pyogenes strain GAS06308		1314	WGS	GAS06308	EMM54.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918836	GCA_900993835.1	CAAIXM000000000		SC	WGS						12		1743228	38.42173	1745		1665.0		throat		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2198	Streptococcus pyogenes strain GAS0656		1314	WGS	GAS0656	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918772	GCA_900994265.1	CAAIZB000000000		SC	WGS						22		1722485	38.447994	1709		1620.0		sterile site		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2300	Streptococcus pyogenes strain GAS066		1314	WGS	GAS066	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918889	GCA_900995285.1	CAAJDA000000000		SC	WGS						24		1723809	38.451042	1718		1624.0		throat		2006	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2146	Streptococcus pyogenes strain GAS07147		1314	WGS	GAS07147	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918850	GCA_900993745.1	CAAIXB000000000		SC	WGS						12		1799658	38.280106	1810		1731.0		throat		2007	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2134	Streptococcus pyogenes strain GAS07167		1314	WGS	GAS07167	EMM6.0			MLST.Streptococcus_pyogenes.411				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918864	GCA_900993625.1	CAAIWR000000000		SC	WGS						31		1822582	38.39838	1896		1797.0		throat		2007	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2323	Streptococcus pyogenes strain GAS07174		1314	WGS	GAS07174	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918876	GCA_900995515.1	CAAJDW000000000		SC	WGS						23		1754226	38.358818	1749		1649.0		throat		2007	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2211	Streptococcus pyogenes strain GAS08119		1314	WGS	GAS08119	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918749	GCA_900994395.1	CAAIZQ000000000		SC	WGS						28		1707108	38.410706	1723		1609.0		throat		2008	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2294	Streptococcus pyogenes strain GAS0830		1314	WGS	GAS0830	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918890	GCA_900995225.1	CAAJCU000000000		SC	WGS						10		1754455	38.42101	1760		1674.0		throat		2008	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2207	Streptococcus pyogenes strain GAS08308		1314	WGS	GAS08308	EMM6.0			MLST.Streptococcus_pyogenes.382				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918763	GCA_900994355.1	CAAIZK000000000		SC	WGS						28		1822786	38.397266	1897		1796.0		throat		2008	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2145	Streptococcus pyogenes strain GAS09155		1314	WGS	GAS09155	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918852	GCA_900993735.1	CAAIWZ000000000		SC	WGS						18		1707717	38.473877	1669		1586.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2197	Streptococcus pyogenes strain GAS0917		1314	WGS	GAS0917	EMM6.0			MLST.Streptococcus_pyogenes.382				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918773	GCA_900994255.1	CAAIZA000000000		SC	WGS						30		1822860	38.39763	1904		1800.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2188	Streptococcus pyogenes strain GAS0919		1314	WGS	GAS0919	EMM6.X			MLST.Streptococcus_pyogenes.382				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918783	GCA_900994165.1	CAAIYR000000000		SC	WGS						28		1822892	38.39882	1896		1797.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2135	Streptococcus pyogenes strain GAS09190		1314	WGS	GAS09190	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918865	GCA_900993635.1	CAAIWQ000000000		SC	WGS						44		1873017	38.327595	1942		1823.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2303	Streptococcus pyogenes strain GAS09194		1314	WGS	GAS09194	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918879	GCA_900995315.1	CAAJDC000000000		SC	WGS						23		1724216	38.448895	1718		1624.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2295	Streptococcus pyogenes strain GAS09204		1314	WGS	GAS09204	EMM93.4			MLST.Streptococcus_pyogenes.814				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918891	GCA_900995235.1	CAAJCT000000000		SC	WGS						12		1716157	38.402996	1697		1609.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2213	Streptococcus pyogenes strain GAS09205		1314	WGS	GAS09205	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918751	GCA_900994405.1	CAAIZO000000000		SC	WGS						14		1755928	38.46342	1755		1672.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2203	Streptococcus pyogenes strain GAS09219		1314	WGS	GAS09219	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918765	GCA_900994315.1	CAAIZH000000000		SC	WGS						18		1766600	38.333183	1757		1668.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2195	Streptococcus pyogenes strain GAS09226		1314	WGS	GAS09226	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918774	GCA_900994235.1	CAAIYZ000000000		SC	WGS						15		1767623	38.340294	1755		1667.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2184	Streptococcus pyogenes strain GAS09227		1314	WGS	GAS09227	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918785	GCA_900994125.1	CAAIYQ000000000		SC	WGS						17		1738132	38.43416	1722		1631.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2177	Streptococcus pyogenes strain GAS0925		1314	WGS	GAS0925	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918796	GCA_900994055.1	CAAIYG000000000		SC	WGS						16		1799815	38.337086	1816		1728.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2179	Streptococcus pyogenes strain GAS09257		1314	WGS	GAS09257	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918798	GCA_900994075.1	CAAIYI000000000		SC	WGS						18		1816951	38.35103	1855		1760.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2170	Streptococcus pyogenes strain GAS09267		1314	WGS	GAS09267	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918811	GCA_900993985.1	CAAIXZ000000000		SC	WGS						16		1737488	38.42766	1720		1633.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2161	Streptococcus pyogenes strain GAS09330		1314	WGS	GAS09330	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918825	GCA_900993895.1	CAAIXQ000000000		SC	WGS						19		1744657	38.34003	1735		1644.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2153	Streptococcus pyogenes strain GAS09344		1314	WGS	GAS09344	EMM106.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918839	GCA_900993815.1	CAAIXJ000000000		SC	WGS						15		1758730	38.41331	1754		1671.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2144	Streptococcus pyogenes strain GAS09379		1314	WGS	GAS09379	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918853	GCA_900993725.1	CAAIXA000000000		SC	WGS						21		1703644	38.43922	1673		1593.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2136	Streptococcus pyogenes strain GAS09398		1314	WGS	GAS09398	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918866	GCA_900993645.1	CAAIWP000000000		SC	WGS						26		1868300	38.40124	1890		1776.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2301	Streptococcus pyogenes strain GAS09418		1314	WGS	GAS09418	EMM105.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918881	GCA_900995305.1	CAAJDB000000000		SC	WGS						18		1767110	38.323257	1750		1654.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2291	Streptococcus pyogenes strain GAS09422		1314	WGS	GAS09422	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918892	GCA_900995195.1	CAAJCL000000000		SC	WGS						24		1800096	38.37406	1809		1710.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2210	Streptococcus pyogenes strain GAS09426		1314	WGS	GAS09426	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918753	GCA_900994385.1	CAAIZN000000000		SC	WGS						11		1719949	38.38535	1713		1620.0		tonsils		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2204	Streptococcus pyogenes strain GAS09437		1314	WGS	GAS09437	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918767	GCA_900994325.1	CAAIZG000000000		SC	WGS						25		1800784	38.37814	1818		1711.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2194	Streptococcus pyogenes strain GAS09438		1314	WGS	GAS09438	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918775	GCA_900994225.1	CAAIYX000000000		SC	WGS						19		1735680	38.43507	1720		1639.0		sterile site		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2163	Streptococcus pyogenes strain GAS0944		1314	WGS	GAS0944	EMM6.X			MLST.Streptococcus_pyogenes.382				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918822	GCA_900993915.1	CAAIXT000000000		SC	WGS						28		1821337	38.403843	1897		1792.0		mastoid,swab,wound		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2185	Streptococcus pyogenes strain GAS09441		1314	WGS	GAS09441	EMM113.0			MLST.Streptococcus_pyogenes.148				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918786	GCA_900994135.1	CAAIYN000000000		SC	WGS						20		1713310	38.340115	1654		1571.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2152	Streptococcus pyogenes strain GAS0945		1314	WGS	GAS0945	EMM6.0			MLST.Streptococcus_pyogenes.382				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918838	GCA_900993805.1	CAAIXI000000000		SC	WGS						28		1823052	38.399673	1898		1797.0		throat		2009	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2212	Streptococcus pyogenes strain GAS10104		1314	WGS	GAS10104	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918755	GCA_900994415.1	CAAIZP000000000		SC	WGS						11		1736797	38.385544	1702		1604.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2202	Streptococcus pyogenes strain GAS10112		1314	WGS	GAS10112	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918768	GCA_900994305.1	CAAIZF000000000		SC	WGS						30		1732903	38.287106	1724		1608.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2193	Streptococcus pyogenes strain GAS10113		1314	WGS	GAS10113	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918776	GCA_900994215.1	CAAIYW000000000		SC	WGS						17		1800990	38.34277	1817		1731.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2186	Streptococcus pyogenes strain GAS10141		1314	WGS	GAS10141	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918788	GCA_900994145.1	CAAIYO000000000		SC	WGS						13		1760361	38.405342	1736		1651.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2175	Streptococcus pyogenes strain GAS10144		1314	WGS	GAS10144	EMM6.0			MLST.Streptococcus_pyogenes.411				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918802	GCA_900994035.1	CAAIYC000000000		SC	WGS						30		1861272	38.41803	1956		1849.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2167	Streptococcus pyogenes strain GAS10157		1314	WGS	GAS10157	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918814	GCA_900993955.1	CAAIXX000000000		SC	WGS						13		1764631	38.411537	1744		1656.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2160	Streptococcus pyogenes strain GAS10179		1314	WGS	GAS10179	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918828	GCA_900993885.1	CAAIXP000000000		SC	WGS						19		1751099	38.390312	1761		1666.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2178	Streptococcus pyogenes strain GAS1019		1314	WGS	GAS1019	EMM22.0			MLST.Streptococcus_pyogenes.202				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918799	GCA_900994065.1	CAAIYH000000000		SC	WGS						25		1764265	38.3197	1742		1637.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2150	Streptococcus pyogenes strain GAS10197		1314	WGS	GAS10197	EMM113.0			MLST.Streptococcus_pyogenes.148				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918843	GCA_900993785.1	CAAIXF000000000		SC	WGS						19		1714935	38.345848	1650		1571.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2141	Streptococcus pyogenes strain GAS10210		1314	WGS	GAS10210	EMM87.0			MLST.Streptococcus_pyogenes.62				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918857	GCA_900993695.1	CAAIWW000000000		SC	WGS						45		1871027	38.333347	1946		1818.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2132	Streptococcus pyogenes strain GAS10213		1314	WGS	GAS10213	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918870	GCA_900993605.1	CAAIWN000000000		SC	WGS						20		1737154	38.443466	1721		1638.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2297	Streptococcus pyogenes strain GAS10219		1314	WGS	GAS10219	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918884	GCA_900995255.1	CAAJCV000000000		SC	WGS						14		1764111	38.407078	1738		1655.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2169	Streptococcus pyogenes strain GAS1023		1314	WGS	GAS1023	EMM113.0			MLST.Streptococcus_pyogenes.148				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918813	GCA_900993975.1	CAAIXY000000000		SC	WGS						20		1715621	38.33967	1656		1575.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2293	Streptococcus pyogenes strain GAS10243		1314	WGS	GAS10243	EMM105.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918895	GCA_900995215.1	CAAJCJ000000000		SC	WGS						18		1766472	38.312107	1748		1653.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2209	Streptococcus pyogenes strain GAS10245		1314	WGS	GAS10245	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918757	GCA_900994375.1	CAAIZM000000000		SC	WGS						12		1737006	38.386475	1703		1604.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2200	Streptococcus pyogenes strain GAS10250		1314	WGS	GAS10250	EMM87.0			MLST.Streptococcus_pyogenes.541				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918769	GCA_900994285.1	CAAIZD000000000		SC	WGS						27		1736051	38.27798	1705		1616.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2192	Streptococcus pyogenes strain GAS10262		1314	WGS	GAS10262	EMM22.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918777	GCA_900994205.1	CAAIYV000000000		SC	WGS						21		1753277	38.325397	1759		1642.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2182	Streptococcus pyogenes strain GAS10275		1314	WGS	GAS10275	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918790	GCA_900994115.1	CAAIYL000000000		SC	WGS						20		1762340	38.346706	1753		1664.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2174	Streptococcus pyogenes strain GAS10325		1314	WGS	GAS10325	EMM105.0			MLST.Streptococcus_pyogenes.151				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918803	GCA_900994015.1	CAAIYF000000000		SC	WGS						15		1769881	38.31228	1739		1646.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2168	Streptococcus pyogenes strain GAS10339		1314	WGS	GAS10339	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918816	GCA_900993965.1	CAAIXW000000000		SC	WGS						37		1828144	38.40886	1898		1796.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2158	Streptococcus pyogenes strain GAS10346		1314	WGS	GAS10346	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918830	GCA_900993865.1	CAAIXN000000000		SC	WGS						33		1733104	38.283646	1721		1608.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2149	Streptococcus pyogenes strain GAS10358		1314	WGS	GAS10358	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918845	GCA_900993775.1	CAAIXE000000000		SC	WGS						27		1709965	38.418526	1715		1614.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2140	Streptococcus pyogenes strain GAS10367		1314	WGS	GAS10367	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918859	GCA_900993685.1	CAAIWV000000000		SC	WGS						27		1777864	38.44709	1812		1714.0		tonsils		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2159	Streptococcus pyogenes strain GAS1041		1314	WGS	GAS1041	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918827	GCA_900993875.1	CAAIXO000000000		SC	WGS						20		1748972	38.395767	1754		1663.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2137	Streptococcus pyogenes strain GAS10411		1314	WGS	GAS10411	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918871	GCA_900993655.1	CAAIWS000000000		SC	WGS						21		1749986	38.393986	1759		1665.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2298	Streptococcus pyogenes strain GAS10417		1314	WGS	GAS10417	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918885	GCA_900995265.1	CAAJCY000000000		SC	WGS						11		1763302	38.41545	1742		1653.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2289	Streptococcus pyogenes strain GAS10458		1314	WGS	GAS10458	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918898	GCA_900995175.1	CAAJCS000000000		SC	WGS						18		1737230	38.440483	1719		1637.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2287	Streptococcus pyogenes strain GAS10463		1314	WGS	GAS10463	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918741	GCA_900995155.1	CAAJCK000000000		SC	WGS						15		1763336	38.407894	1740		1654.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2151	Streptococcus pyogenes strain GAS1047		1314	WGS	GAS1047	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918841	GCA_900993795.1	CAAIXG000000000		SC	WGS						19		1736960	38.441105	1719		1638.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2277	Streptococcus pyogenes strain GAS10470		1314	WGS	GAS10470	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918756	GCA_900995055.1	CAAJCC000000000		SC	WGS						14		1763388	38.351707	1753		1664.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2273	Streptococcus pyogenes strain GAS10476		1314	WGS	GAS10476	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918787	GCA_900995015.1	CAAJBT000000000		SC	WGS						8		1791660	38.41382	1822		1733.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2259	Streptococcus pyogenes strain GAS10481		1314	WGS	GAS10481	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918806	GCA_900994875.1	CAAJBL000000000		SC	WGS						13		1795464	38.341537	1807		1720.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2253	Streptococcus pyogenes strain GAS10495		1314	WGS	GAS10495	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918826	GCA_900994815.1	CAAJBF000000000		SC	WGS						17		1796135	38.446888	1830		1743.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2143	Streptococcus pyogenes strain GAS1050		1314	WGS	GAS1050	EMM68.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918855	GCA_900993715.1	CAAIWY000000000		SC	WGS						21		1772251	38.32436	1775		1679.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2133	Streptococcus pyogenes strain GAS1073		1314	WGS	GAS1073	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918868	GCA_900993615.1	CAAIWO000000000		SC	WGS						20		1736302	38.436214	1722		1639.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2302	Streptococcus pyogenes strain GAS1074		1314	WGS	GAS1074	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918882	GCA_900995295.1	CAAJCZ000000000		SC	WGS						25		1733337	38.287556	1723		1613.0		sterile site		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2290	Streptococcus pyogenes strain GAS1084		1314	WGS	GAS1084	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918893	GCA_900995185.1	CAAJCR000000000		SC	WGS						14		1764632	38.412563	1742		1654.0		throat		2010	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1241	Streptococcus pyogenes strain GAS11117		1314	WGS	GAS11117	EMM68.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918925	GCA_900984615.1	CAAHOE000000000		SC	WGS						21		1764230	38.31371	1774		1673.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2285	Streptococcus pyogenes strain GAS11129		1314	WGS	GAS11129	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918743	GCA_900995135.1	CAAJCM000000000		SC	WGS						27		1793049	38.39719	1818		1729.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2280	Streptococcus pyogenes strain GAS11141		1314	WGS	GAS11141	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918759	GCA_900995085.1	CAAJCG000000000		SC	WGS						14		1768190	38.337948	1759		1666.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2267	Streptococcus pyogenes strain GAS11146		1314	WGS	GAS11146	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918789	GCA_900994955.1	CAAJBQ000000000		SC	WGS						12		1755412	38.301003	1731		1650.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2258	Streptococcus pyogenes strain GAS11154		1314	WGS	GAS11154	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918809	GCA_900994865.1	CAAJBJ000000000		SC	WGS						25		1759737	38.396008	1775		1683.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.3035	Streptococcus pyogenes strain GAS1117		1314	WGS	GAS1117				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031112	GCA_019335545.1	JAHWSH000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	31		1933127	38.28807	2009		1894.0		throat swab		2017-03-19	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.2254	Streptococcus pyogenes strain GAS11186		1314	WGS	GAS11186	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918829	GCA_900994825.1	CAAJBE000000000		SC	WGS						20		1796791	38.455635	1834		1741.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2244	Streptococcus pyogenes strain GAS11195		1314	WGS	GAS11195	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918847	GCA_900994725.1	CAAJAV000000000		SC	WGS						26		1781581	38.329308	1787		1690.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2245	Streptococcus pyogenes strain GAS1121		1314	WGS	GAS1121	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918844	GCA_900994735.1	CAAJAW000000000		SC	WGS						25		1792578	38.400055	1813		1726.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2235	Streptococcus pyogenes strain GAS11212		1314	WGS	GAS11212	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918867	GCA_900994635.1	CAAJAM000000000		SC	WGS						15		1761854	38.341106	1749		1669.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2226	Streptococcus pyogenes strain GAS11237		1314	WGS	GAS11237	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918886	GCA_900994545.1	CAAJAD000000000		SC	WGS						14		1796878	38.341022	1794		1711.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2218	Streptococcus pyogenes strain GAS11262		1314	WGS	GAS11262	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918902	GCA_900994465.1	CAAIZX000000000		SC	WGS						16		1761072	38.33898	1752		1667.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2131	Streptococcus pyogenes strain GAS11282		1314	WGS	GAS11282	EMM100.5			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918910	GCA_900993595.1	CAAIWL000000000		SC	WGS						24		1765323	38.37983	1782		1688.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2220	Streptococcus pyogenes strain GAS11290		1314	WGS	GAS11290	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918918	GCA_900994485.1	CAAIZW000000000		SC	WGS						19		1795786	38.450073	1837		1746.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1238	Streptococcus pyogenes strain GAS11291		1314	WGS	GAS11291	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918926	GCA_900984585.1	CAAHOC000000000		SC	WGS						16		1788363	38.448845	1777		1690.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2288	Streptococcus pyogenes strain GAS11334		1314	WGS	GAS11334	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918744	GCA_900995165.1	CAAJCQ000000000		SC	WGS						17		1737664	38.433224	1714		1632.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2278	Streptococcus pyogenes strain GAS11340		1314	WGS	GAS11340	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918761	GCA_900995065.1	CAAJCD000000000		SC	WGS						20		1795726	38.448517	1830		1741.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2266	Streptococcus pyogenes strain GAS11353		1314	WGS	GAS11353	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918792	GCA_900994945.1	CAAJBS000000000		SC	WGS						18		1737055	38.433407	1719		1631.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2263	Streptococcus pyogenes strain GAS11364		1314	WGS	GAS11364	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918812	GCA_900994915.1	CAAJBK000000000		SC	WGS						13		1795269	38.344776	1804		1716.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2251	Streptococcus pyogenes strain GAS11371		1314	WGS	GAS11371	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918831	GCA_900994795.1	CAAJBC000000000		SC	WGS						16		1782817	38.418716	1784		1692.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2236	Streptococcus pyogenes strain GAS1142		1314	WGS	GAS1142	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918863	GCA_900994645.1	CAAJAO000000000		SC	WGS						16		1709219	38.48417	1670		1588.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2243	Streptococcus pyogenes strain GAS11423		1314	WGS	GAS11423	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918849	GCA_900994715.1	CAAJAU000000000		SC	WGS						32		1788499	38.411507	1845		1739.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2233	Streptococcus pyogenes strain GAS11426		1314	WGS	GAS11426	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918869	GCA_900994615.1	CAAJAL000000000		SC	WGS						30		1787653	38.404716	1832		1738.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2225	Streptococcus pyogenes strain GAS11441		1314	WGS	GAS11441	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918888	GCA_900994535.1	CAAJAC000000000		SC	WGS						19		1769064	38.48342	1774		1688.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2206	Streptococcus pyogenes strain GAS11453		1314	WGS	GAS11453	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918903	GCA_900994345.1	CAAIZI000000000		SC	WGS						20		1737039	38.438976	1719		1637.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2296	Streptococcus pyogenes strain GAS11456		1314	WGS	GAS11456	EMM36.2			MLST.Streptococcus_pyogenes.748				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918911	GCA_900995245.1	CAAJCW000000000		SC	WGS						19		1737492	38.43753	1718		1638.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2130	Streptococcus pyogenes strain GAS11493		1314	WGS	GAS11493	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918919	GCA_900993585.1	CAAIWM000000000		SC	WGS						16		1796507	38.454144	1832		1743.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1237	Streptococcus pyogenes strain GAS11549		1314	WGS	GAS11549	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918927	GCA_900984575.1	CAAHOB000000000		SC	WGS						31		1733495	38.27731	1728		1611.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2292	Streptococcus pyogenes strain GAS11551		1314	WGS	GAS11551	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918745	GCA_900995205.1	CAAJCP000000000		SC	WGS						32		1733063	38.28424	1732		1608.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2227	Streptococcus pyogenes strain GAS1156		1314	WGS	GAS1156	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918883	GCA_900994555.1	CAAJAE000000000		SC	WGS						19		1727182	38.456944	1718		1629.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2217	Streptococcus pyogenes strain GAS1161		1314	WGS	GAS1161	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918901	GCA_900994455.1	CAAIZV000000000		SC	WGS						28		1732891	38.285618	1721		1609.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2142	Streptococcus pyogenes strain GAS1186		1314	WGS	GAS1186	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918909	GCA_900993705.1	CAAIWX000000000		SC	WGS						16		1705917	38.49155	1662		1582.0		sterile site		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2230	Streptococcus pyogenes strain GAS1187		1314	WGS	GAS1187	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918917	GCA_900994585.1	CAAJAG000000000		SC	WGS						32		1732946	38.276516	1730		1610.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.3057	Streptococcus pyogenes strain GAS1208		1314	WGS	GAS1208				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031094	GCA_019335965.1	JAHWSZ000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	46		1850669	38.266113	1877		1773.0		throat swab		2017-04-26	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.2286	Streptococcus pyogenes strain GAS12106		1314	WGS	GAS12106	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918912	GCA_900995145.1	CAAJCN000000000		SC	WGS						22		1784165	38.377983	1781		1681.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1244	Streptococcus pyogenes strain GAS12107		1314	WGS	GAS12107	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918920	GCA_900984645.1	CAAHOH000000000		SC	WGS						9		1746380	38.247253	1736		1652.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1235	Streptococcus pyogenes strain GAS12118		1314	WGS	GAS12118	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918928	GCA_900984555.1	CAAHNZ000000000		SC	WGS						14		1715020	38.395294	1679		1601.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2282	Streptococcus pyogenes strain GAS1213		1314	WGS	GAS1213	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918764	GCA_900995105.1	CAAJCH000000000		SC	WGS						16		1764006	38.406372	1744		1653.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2284	Streptococcus pyogenes strain GAS12139		1314	WGS	GAS12139	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918747	GCA_900995125.1	CAAJCO000000000		SC	WGS						15		1727207	38.344994	1691		1602.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2276	Streptococcus pyogenes strain GAS12140		1314	WGS	GAS12140	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918766	GCA_900995045.1	CAAJCA000000000		SC	WGS						13		1764254	38.41301	1742		1655.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2265	Streptococcus pyogenes strain GAS12144		1314	WGS	GAS12144	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918797	GCA_900994935.1	CAAJBX000000000		SC	WGS						19		1755528	38.462105	1757		1671.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2262	Streptococcus pyogenes strain GAS12150		1314	WGS	GAS12150	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918818	GCA_900994905.1	CAAJBO000000000		SC	WGS						13		1765629	38.413155	1743		1654.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2250	Streptococcus pyogenes strain GAS12163		1314	WGS	GAS12163	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918835	GCA_900994775.1	CAAJAY000000000		SC	WGS						15		1753027	38.466263	1748		1667.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2242	Streptococcus pyogenes strain GAS12171		1314	WGS	GAS12171	EMM3.33			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918854	GCA_900994705.1	CAAJAS000000000		SC	WGS						30		1863474	38.418365	1968		1860.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2232	Streptococcus pyogenes strain GAS12172		1314	WGS	GAS12172	EMM3.1			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918875	GCA_900994605.1	CAAJAJ000000000		SC	WGS						30		1864158	38.42157	1965		1862.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2269	Streptococcus pyogenes strain GAS1218		1314	WGS	GAS1218	EMM3.1			MLST.Streptococcus_pyogenes.15				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918795	GCA_900994975.1	CAAJBY000000000		SC	WGS						28		1862401	38.41529	1967		1860.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2222	Streptococcus pyogenes strain GAS12180		1314	WGS	GAS12180	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918896	GCA_900994505.1	CAAIZZ000000000		SC	WGS						22		1824624	38.366104	1844		1746.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2187	Streptococcus pyogenes strain GAS12183		1314	WGS	GAS12183	EMM89.14			MLST.Streptococcus_pyogenes.380				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918905	GCA_900994155.1	CAAIYP000000000		SC	WGS						18		1851407	38.388725	1907		1804.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2260	Streptococcus pyogenes strain GAS1219		1314	WGS	GAS1219	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918815	GCA_900994885.1	CAAJBM000000000		SC	WGS						16		1756513	38.460518	1760		1675.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2249	Streptococcus pyogenes strain GAS1222		1314	WGS	GAS1222	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918833	GCA_900994785.1	CAAJBB000000000		SC	WGS						30		1734384	38.274734	1727		1612.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2274	Streptococcus pyogenes strain GAS12229		1314	WGS	GAS12229	EMM238.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918913	GCA_900995025.1	CAAJBZ000000000		SC	WGS						19		1680936	38.352165	1628		1552.0		tissue,wound		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1243	Streptococcus pyogenes strain GAS12233		1314	WGS	GAS12233	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918921	GCA_900984635.1	CAAHOG000000000		SC	WGS						19		1803450	38.37733	1831		1738.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1230	Streptococcus pyogenes strain GAS12235		1314	WGS	GAS12235	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918929	GCA_900984505.1	CAAHNW000000000		SC	WGS						16		1727740	38.35811	1707		1629.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2238	Streptococcus pyogenes strain GAS1224		1314	WGS	GAS1224	EMM238.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918851	GCA_900994675.1	CAAJAT000000000		SC	WGS						14		1725453	38.342686	1680		1602.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2283	Streptococcus pyogenes strain GAS12243		1314	WGS	GAS12243	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918750	GCA_900995115.1	CAAJCI000000000		SC	WGS						17		1802913	38.3793	1832		1741.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2268	Streptococcus pyogenes strain GAS12244		1314	WGS	GAS12244	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918800	GCA_900994965.1	CAAJBU000000000		SC	WGS						28		1732164	38.278824	1720		1609.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2275	Streptococcus pyogenes strain GAS12252		1314	WGS	GAS12252	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918780	GCA_900995035.1	CAAJCB000000000		SC	WGS						15		1804847	38.379494	1829		1744.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2257	Streptococcus pyogenes strain GAS12260		1314	WGS	GAS12260	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918821	GCA_900994855.1	CAAJBH000000000		SC	WGS						18		1726408	38.338287	1693		1600.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2248	Streptococcus pyogenes strain GAS12271		1314	WGS	GAS12271	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918837	GCA_900994765.1	CAAJBA000000000		SC	WGS						16		1804527	38.3794	1833		1741.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2239	Streptococcus pyogenes strain GAS12274		1314	WGS	GAS12274	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918856	GCA_900994665.1	CAAJAP000000000		SC	WGS						9		1746449	38.250324	1736		1651.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2231	Streptococcus pyogenes strain GAS12314		1314	WGS	GAS12314	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918877	GCA_900994595.1	CAAJAI000000000		SC	WGS						28		1706653	38.39721	1724		1609.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2224	Streptococcus pyogenes strain GAS12316		1314	WGS	GAS12316	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918897	GCA_900994525.1	CAAJAB000000000		SC	WGS						17		1761936	38.34525	1746		1661.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2173	Streptococcus pyogenes strain GAS12332		1314	WGS	GAS12332	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918906	GCA_900994025.1	CAAIYD000000000		SC	WGS						8		1754710	38.42056	1761		1676.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2264	Streptococcus pyogenes strain GAS12357		1314	WGS	GAS12357	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918914	GCA_900994925.1	CAAJBN000000000		SC	WGS						25		1757830	38.3898	1780		1682.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1239	Streptococcus pyogenes strain GAS12392		1314	WGS	GAS12392	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918922	GCA_900984595.1	CAAHOA000000000		SC	WGS						20		1765480	38.341095	1764		1663.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1231	Streptococcus pyogenes strain GAS12394		1314	WGS	GAS12394	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918930	GCA_900984515.1	CAAHNR000000000		SC	WGS						25		1759084	38.395428	1770		1680.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2281	Streptococcus pyogenes strain GAS12411		1314	WGS	GAS12411	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918752	GCA_900995095.1	CAAJCF000000000		SC	WGS						9		1746572	38.248833	1739		1651.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2272	Streptococcus pyogenes strain GAS12446		1314	WGS	GAS12446	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918782	GCA_900995005.1	CAAJBV000000000		SC	WGS						18		1762012	38.34305	1746		1660.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2271	Streptococcus pyogenes strain GAS12463		1314	WGS	GAS12463	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918801	GCA_900994995.1	CAAJBW000000000		SC	WGS						25		1759049	38.39694	1769		1680.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2256	Streptococcus pyogenes strain GAS12484		1314	WGS	GAS12484	EMM77.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918823	GCA_900994845.1	CAAJBI000000000		SC	WGS						6		1733717	38.389908	1692		1611.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2234	Streptococcus pyogenes strain GAS1262		1314	WGS	GAS1262	EMM104.0			MLST.Streptococcus_pyogenes.789				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918872	GCA_900994625.1	CAAJAK000000000		SC	WGS						14		1727062	38.342163	1685		1600.0		sterile site		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2223	Streptococcus pyogenes strain GAS1282		1314	WGS	GAS1282	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918894	GCA_900994515.1	CAAJAA000000000		SC	WGS						20		1784730	38.37828	1787		1685.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2196	Streptococcus pyogenes strain GAS1291		1314	WGS	GAS1291	EMM77.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918904	GCA_900994245.1	CAAIYY000000000		SC	WGS						9		1779463	38.379353	1766		1680.0		throat		2012	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.3027	Streptococcus pyogenes strain GAS1299		1314	WGS	GAS1299								2021-07-25T00:00:00Z		PRJNA743366	SAMN20031123	GCA_019335345.1	JAHWRW000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	32		1899607	38.298122	1968		1856.0		throat swab		2017-06-04	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.1234	Streptococcus pyogenes strain GAS131015		1314	WGS	GAS131015	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918934	GCA_900984545.1	CAAHNS000000000		SC	WGS						23		1729703	38.465298	1720		1629.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1221	Streptococcus pyogenes strain GAS131103		1314	WGS	GAS131103	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918942	GCA_900984415.1	CAAHNK000000000		SC	WGS						19		1727776	38.452778	1715		1629.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1211	Streptococcus pyogenes strain GAS131111		1314	WGS	GAS131111	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918950	GCA_900984315.1	CAAHNA000000000		SC	WGS						14		1829683	38.308445	1864		1774.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1203	Streptococcus pyogenes strain GAS131138		1314	WGS	GAS131138	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918958	GCA_900984235.1	CAAHMS000000000		SC	WGS						19		1762508	38.32567	1754		1665.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1196	Streptococcus pyogenes strain GAS131141		1314	WGS	GAS131141	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918966	GCA_900984165.1	CAAHMK000000000		SC	WGS						10		1844185	38.290806	1879		1792.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1187	Streptococcus pyogenes strain GAS131142		1314	WGS	GAS131142	EMM76.0			MLST.Streptococcus_pyogenes.378				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918974	GCA_900984075.1	CAAHMB000000000		SC	WGS						12		1778563	38.394875	1757		1670.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1179	Streptococcus pyogenes strain GAS131153		1314	WGS	GAS131153	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918982	GCA_900983995.1	CAAHLT000000000		SC	WGS						17		1737505	38.43243	1718		1631.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1171	Streptococcus pyogenes strain GAS131159		1314	WGS	GAS131159	EMM70.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918990	GCA_900983915.1	CAAHLL000000000		SC	WGS						26		1798704	38.310978	1817		1715.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2129	Streptococcus pyogenes strain GAS131166		1314	WGS	GAS131166	EMM58.2			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918998	GCA_900993575.1	CAAIWK000000000		SC	WGS						29		1895382	38.31794	1956		1833.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2121	Streptococcus pyogenes strain GAS131172		1314	WGS	GAS131172	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919006	GCA_900993495.1	CAAIWC000000000		SC	WGS						17		1762146	38.341805	1751		1668.0		aspirate		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1312	Streptococcus pyogenes strain GAS131175		1314	WGS	GAS131175	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919014	GCA_900985325.1	CAAHRB000000000		SC	WGS						15		1831535	38.312492	1863		1775.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1233	Streptococcus pyogenes strain GAS13118		1314	WGS	GAS13118	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918931	GCA_900984535.1	CAAHNU000000000		SC	WGS						18		1762332	38.34611	1751		1663.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1302	Streptococcus pyogenes strain GAS131202		1314	WGS	GAS131202	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919021	GCA_900985225.1	CAAHQO000000000		SC	WGS						15		1765308	38.424477	1745		1654.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1232	Streptococcus pyogenes strain GAS131204		1314	WGS	GAS131204	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918935	GCA_900984525.1	CAAHNX000000000		SC	WGS						28		1862405	38.406994	1905		1788.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1219	Streptococcus pyogenes strain GAS131222		1314	WGS	GAS131222	EMM81.0			MLST.Streptococcus_pyogenes.330				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918943	GCA_900984395.1	CAAHNH000000000		SC	WGS						24		1819664	38.383335	1836		1733.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1210	Streptococcus pyogenes strain GAS131223		1314	WGS	GAS131223	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918951	GCA_900984305.1	CAAHMZ000000000		SC	WGS						12		1831781	38.316193	1867		1776.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1199	Streptococcus pyogenes strain GAS131241		1314	WGS	GAS131241	EMM58.2			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918959	GCA_900984195.1	CAAHMO000000000		SC	WGS						27		1856458	38.291325	1899		1781.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1197	Streptococcus pyogenes strain GAS131245		1314	WGS	GAS131245	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918967	GCA_900984175.1	CAAHML000000000		SC	WGS						17		1753805	38.42856	1734		1655.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1184	Streptococcus pyogenes strain GAS131252		1314	WGS	GAS131252	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918975	GCA_900984055.1	CAAHMA000000000		SC	WGS						18		1830148	38.30777	1864		1775.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1178	Streptococcus pyogenes strain GAS131255		1314	WGS	GAS131255	EMM58.2			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918983	GCA_900983985.1	CAAHLU000000000		SC	WGS						24		1854100	38.28483	1890		1777.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1169	Streptococcus pyogenes strain GAS131267		1314	WGS	GAS131267	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918991	GCA_900983895.1	CAAHLK000000000		SC	WGS						17		1830459	38.308434	1864		1776.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2127	Streptococcus pyogenes strain GAS131275		1314	WGS	GAS131275	EMM77.0			MLST.Streptococcus_pyogenes.63				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918999	GCA_900993555.1	CAAIWI000000000		SC	WGS						19		1927340	38.292206	1949		1841.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2122	Streptococcus pyogenes strain GAS131282		1314	WGS	GAS131282	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919007	GCA_900993505.1	CAAIWD000000000		SC	WGS						14		1692975	38.385647	1654		1572.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1310	Streptococcus pyogenes strain GAS131286		1314	WGS	GAS131286	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919015	GCA_900985305.1	CAAHQV000000000		SC	WGS						28		1802190	38.372093	1830		1736.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1303	Streptococcus pyogenes strain GAS131318		1314	WGS	GAS131318	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919022	GCA_900985235.1	CAAHQN000000000		SC	WGS						15		1757176	38.46509	1756		1673.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2279	Streptococcus pyogenes strain GAS13132		1314	WGS	GAS13132	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918754	GCA_900995075.1	CAAJCE000000000		SC	WGS						14		1757917	38.46989	1749		1674.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1227	Streptococcus pyogenes strain GAS131322		1314	WGS	GAS131322	EMM108.1			MLST.Streptococcus_pyogenes.14				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918936	GCA_900984475.1	CAAHNQ000000000		SC	WGS						14		1711323	38.469616	1681		1598.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1218	Streptococcus pyogenes strain GAS131348		1314	WGS	GAS131348	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918944	GCA_900984385.1	CAAHNI000000000		SC	WGS						29		1779528	38.415874	1819		1715.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2270	Streptococcus pyogenes strain GAS13137		1314	WGS	GAS13137	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918784	GCA_900994985.1	CAAJBR000000000		SC	WGS						20		1792331	38.41073	1807		1724.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1209	Streptococcus pyogenes strain GAS131413		1314	WGS	GAS131413	EMM76.0			MLST.Streptococcus_pyogenes.378				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918952	GCA_900984295.1	CAAHMY000000000		SC	WGS						14		1779560	38.397884	1766		1667.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1198	Streptococcus pyogenes strain GAS131421		1314	WGS	GAS131421	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918960	GCA_900984185.1	CAAHMQ000000000		SC	WGS						20		1752039	38.361004	1732		1650.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1191	Streptococcus pyogenes strain GAS131460		1314	WGS	GAS131460	EMM76.0			MLST.Streptococcus_pyogenes.378				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918968	GCA_900984115.1	CAAHMH000000000		SC	WGS						18		1773117	38.36216	1761		1666.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1185	Streptococcus pyogenes strain GAS131465		1314	WGS	GAS131465	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918976	GCA_900984045.1	CAAHLZ000000000		SC	WGS						35		1828457	38.41211	1902		1796.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1177	Streptococcus pyogenes strain GAS131472		1314	WGS	GAS131472	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918984	GCA_900983975.1	CAAHLR000000000		SC	WGS						24		1806527	38.3843	1852		1757.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1168	Streptococcus pyogenes strain GAS131474		1314	WGS	GAS131474	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918992	GCA_900983885.1	CAAHLI000000000		SC	WGS						31		1787452	38.413227	1848		1737.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2128	Streptococcus pyogenes strain GAS131487		1314	WGS	GAS131487	EMM74.0			MLST.Streptococcus_pyogenes.375				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919000	GCA_900993565.1	CAAIWJ000000000		SC	WGS						13		1795488	38.28384	1793		1703.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2247	Streptococcus pyogenes strain GAS1315		1314	WGS	GAS1315	EMM76.0			MLST.Streptococcus_pyogenes.378				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918840	GCA_900994755.1	CAAJAZ000000000		SC	WGS						14		1779367	38.394722	1762		1669.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2261	Streptococcus pyogenes strain GAS13169		1314	WGS	GAS13169	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918804	GCA_900994895.1	CAAJBP000000000		SC	WGS						15		1765209	38.413208	1745		1654.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2240	Streptococcus pyogenes strain GAS1318		1314	WGS	GAS1318	EMM232.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918858	GCA_900994695.1	CAAJAQ000000000		SC	WGS						15		1760951	38.403904	1735		1649.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2255	Streptococcus pyogenes strain GAS13208		1314	WGS	GAS13208	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918824	GCA_900994835.1	CAAJBG000000000		SC	WGS						17		1761547	38.340908	1749		1662.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2246	Streptococcus pyogenes strain GAS13257		1314	WGS	GAS13257	EMM95.0			MLST.Streptococcus_pyogenes.604				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918842	GCA_900994745.1	CAAJAX000000000		SC	WGS						22		1744901	38.393524	1761		1662.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2229	Streptococcus pyogenes strain GAS1328		1314	WGS	GAS1328	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918878	GCA_900994575.1	CAAJAH000000000		SC	WGS						19		1761956	38.341644	1749		1662.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2237	Streptococcus pyogenes strain GAS13350		1314	WGS	GAS13350	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918861	GCA_900994655.1	CAAJAN000000000		SC	WGS						21		1769504	38.47894	1779		1691.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2228	Streptococcus pyogenes strain GAS13358		1314	WGS	GAS13358	EMM197.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918880	GCA_900994565.1	CAAJAF000000000		SC	WGS						22		1773524	38.478138	1802		1700.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2219	Streptococcus pyogenes strain GAS13362		1314	WGS	GAS13362	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918900	GCA_900994475.1	CAAIZU000000000		SC	WGS						18		1796605	38.454884	1833		1741.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2154	Streptococcus pyogenes strain GAS13376		1314	WGS	GAS13376	EMM49.0			MLST.Streptococcus_pyogenes.433				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918908	GCA_900993825.1	CAAIXH000000000		SC	WGS						17		1790384	38.31247	1806		1716.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2241	Streptococcus pyogenes strain GAS13399		1314	WGS	GAS13399	EMM100.5			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918916	GCA_900994685.1	CAAJAR000000000		SC	WGS						22		1817949	38.397026	1844		1757.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1240	Streptococcus pyogenes strain GAS13409		1314	WGS	GAS13409	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918924	GCA_900984605.1	CAAHOD000000000		SC	WGS						16		1796056	38.454613	1832		1741.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2221	Streptococcus pyogenes strain GAS1341		1314	WGS	GAS1341	EMM197.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918899	GCA_900994495.1	CAAIZY000000000		SC	WGS						20		1769868	38.452698	1799		1703.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1228	Streptococcus pyogenes strain GAS13426		1314	WGS	GAS13426	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918932	GCA_900984495.1	CAAHNT000000000		SC	WGS						16		1744583	38.466866	1743		1651.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1229	Streptococcus pyogenes strain GAS13432		1314	WGS	GAS13432	EMM19.X			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918933	GCA_900984485.1	CAAHNV000000000		SC	WGS						16		1795853	38.45378	1829		1743.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1220	Streptococcus pyogenes strain GAS13450		1314	WGS	GAS13450	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918941	GCA_900984405.1	CAAHNJ000000000		SC	WGS						20		1797618	38.456642	1834		1741.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1212	Streptococcus pyogenes strain GAS13472		1314	WGS	GAS13472	EMM70.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918949	GCA_900984325.1	CAAHNC000000000		SC	WGS						24		1798280	38.322807	1808		1712.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1204	Streptococcus pyogenes strain GAS13474		1314	WGS	GAS13474	EMM95.0			MLST.Streptococcus_pyogenes.604				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918957	GCA_900984245.1	CAAHMT000000000		SC	WGS						24		1743691	38.38469	1753		1662.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1194	Streptococcus pyogenes strain GAS13475		1314	WGS	GAS13475	EMM197.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918965	GCA_900984145.1	CAAHMJ000000000		SC	WGS						19		1769895	38.45088	1804		1702.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1186	Streptococcus pyogenes strain GAS13476		1314	WGS	GAS13476	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918973	GCA_900984065.1	CAAHMC000000000		SC	WGS						14		1795295	38.445045	1831		1743.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1176	Streptococcus pyogenes strain GAS13480		1314	WGS	GAS13480	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918981	GCA_900983965.1	CAAHLS000000000		SC	WGS						17		1787201	38.435486	1805		1714.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1170	Streptococcus pyogenes strain GAS13502		1314	WGS	GAS13502	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918989	GCA_900983905.1	CAAHLM000000000		SC	WGS						16		1778926	38.41005	1790		1697.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1164	Streptococcus pyogenes strain GAS13507		1314	WGS	GAS13507	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918997	GCA_900983845.1	CAAHLF000000000		SC	WGS						10		1808494	38.333332	1830		1738.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2123	Streptococcus pyogenes strain GAS13589		1314	WGS	GAS13589	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919005	GCA_900993515.1	CAAIWE000000000		SC	WGS						27		1796170	38.38432	1835		1740.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1316	Streptococcus pyogenes strain GAS13599		1314	WGS	GAS13599	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919013	GCA_900985365.1	CAAHQZ000000000		SC	WGS						19		1715521	38.403286	1710		1620.0		sterile site		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1304	Streptococcus pyogenes strain GAS13637		1314	WGS	GAS13637	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919020	GCA_900985245.1	CAAHQP000000000		SC	WGS						19		1705089	38.4881	1667		1582.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2162	Streptococcus pyogenes strain GAS1376		1314	WGS	GAS1376	EMM70.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918907	GCA_900993905.1	CAAIXS000000000		SC	WGS						16		1765442	38.310596	1761		1670.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2252	Streptococcus pyogenes strain GAS1377		1314	WGS	GAS1377	EMM59.1			MLST.Streptococcus_pyogenes.172				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918915	GCA_900994805.1	CAAJBD000000000		SC	WGS						18		1766963	38.33682	1752		1665.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1242	Streptococcus pyogenes strain GAS1396		1314	WGS	GAS1396	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918923	GCA_900984625.1	CAAHOF000000000		SC	WGS						16		1749335	38.4061	1741		1653.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1300	Streptococcus pyogenes strain GAS1414		1314	WGS	GAS1414	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919023	GCA_900985205.1	CAAHQM000000000		SC	WGS						11		1736934	38.38634	1702		1605.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1173	Streptococcus pyogenes strain GAS14211		1314	WGS	GAS14211	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918985	GCA_900983935.1	CAAHLO000000000		SC	WGS						17		1743225	38.408123	1739		1643.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1167	Streptococcus pyogenes strain GAS14243		1314	WGS	GAS14243	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918993	GCA_900983875.1	CAAHLJ000000000		SC	WGS						25		1802659	38.378273	1820		1710.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.2125	Streptococcus pyogenes strain GAS14246		1314	WGS	GAS14246	EMM86.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919001	GCA_900993535.1	CAAIWG000000000		SC	WGS						13		1724964	38.42941	1717		1625.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1311	Streptococcus pyogenes strain GAS14265		1314	WGS	GAS14265	EMM86.2							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919009	GCA_900985315.1	CAAHQW000000000		SC	WGS						18		1766320	38.436565	1779		1690.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1308	Streptococcus pyogenes strain GAS14266		1314	WGS	GAS14266	EMM118.0							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919017	GCA_900985285.1	CAAHQT000000000		SC	WGS						9		1757539	38.387733	1731		1644.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1301	Streptococcus pyogenes strain GAS14267		1314	WGS	GAS14267	EMM54.1							2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919024	GCA_900985215.1	CAAHQL000000000		SC	WGS						13		1782393	38.396294	1803		1715.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1224	Streptococcus pyogenes strain GAS14274		1314	WGS	GAS14274	EMM95.0			MLST.Streptococcus_pyogenes.604				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918938	GCA_900984445.1	CAAHNO000000000		SC	WGS						24		1747437	38.39281	1757		1660.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1226	Streptococcus pyogenes strain GAS1441		1314	WGS	GAS1441	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918937	GCA_900984465.1	CAAHNP000000000		SC	WGS						28		1837366	38.311058	1850		1750.0		sterile site		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1309	Streptococcus pyogenes strain GAS146		1314	WGS	GAS146	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3919016	GCA_900985295.1	CAAHQU000000000		SC	WGS						27		1801565	38.37247	1820		1710.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.1207	Streptococcus pyogenes strain GAS1464		1314	WGS	GAS1464	EMM58.7			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB13003	SAMEA3918953	GCA_900984275.1	CAAHMX000000000		SC	WGS						12		1932983	38.176197	1986		1885.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens																			This project consists of a two-phase action plan designed to validate the overall aims of the GAS vaccinology programme as well as generating publishable units from scientifically robust comparisons. Apart from vaccine antigen design, this programme of sequencing will support targeted analyses of specific disease associations and global transmission patterns of prominent sequence types- all ongoing sequencing based research foci that Sanger (Mark Davies) is currently analysing. PHASE 1. Hi-seq (n=750), Pacbio (n=30) and RNA-seq (n=48) Hi-seq (750) We currently have a collection of 750 genomes extracted and ready for Hi-seq (objective 1) - 90 South China and North China (15 emm types, 10 years) - 50 South America (40 emm types, 14 years) - 210 Southern Europe and Northern Europe (30 emm types, 10 years) - 50 South and North India (29 emm types, 5 years) - 350 New Zealand (53 emm types, 13 years) The sampling strategy is based on epidemiological (emm) patterns, temporal and clinical relevance in order to provide significant representation from all continents and all GAS clinical manifestations. Two things to reiterate: 1. The geographical and spatial epidemiology of GAS varies. Deep sampling is required for informed global vaccine design. page 1 [A5] Please state all collaborating PIs (and name of Institution) [A7] Is this a joint project with another Sanger PI, if so state name(s) [A9] Does this project use samples? [A10] Please choose which types of sample you will be using 2. The geographical locations being sampled are also being targeted as sites for future vaccine trials. A baseline understanding of genetic stability is required for genomic epidemiological surveillance. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute please see http://www.sanger.ac.uk/datasharing/	
1314.3029	Streptococcus pyogenes strain GAS1483		1314	WGS	GAS1483				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031119	GCA_019335395.1	JAHWSA000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1899737	38.29214	1973		1860.0		throat swab		2017-10-29	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3041	Streptococcus pyogenes strain GAS1693		1314	WGS	GAS1693				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031113	GCA_019335565.1	JAHWSG000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	27		1861039	38.267456	1906		1807.0		throat swab		2017-12-13	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3053	Streptococcus pyogenes strain GAS1843		1314	WGS	GAS1843				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031095	GCA_019335885.1	JAHWSY000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	43		1846486	38.266205	1870		1767.0		throat swab		2017-12-30	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3044	Streptococcus pyogenes strain GAS1854		1314	WGS	GAS1854				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031100	GCA_019335785.1	JAHWST000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	35		1820246	38.289722	1829		1730.0		throat swab		2017-12-31	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3056	Streptococcus pyogenes strain GAS1858		1314	WGS	GAS1858				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031096	GCA_019335895.1	JAHWSX000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	48		1851465	38.266613	1882		1776.0		throat swab		2018-01-01	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3031	Streptococcus pyogenes strain GAS1869		1314	WGS	GAS1869				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031114	GCA_019335445.1	JAHWSF000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	30		1899861	38.293644	1969		1858.0		throat swab		2018-01-01	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3028	Streptococcus pyogenes strain GAS1907		1314	WGS	GAS1907				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031122	GCA_019335365.1	JAHWRX000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	27		1869430	38.302208	1920		1810.0		throat swab		2018-01-05	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3026	Streptococcus pyogenes strain GAS1909		1314	WGS	GAS1909				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031121	GCA_019335355.1	JAHWRY000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1899794	38.29357	1974		1860.0		throat swab		2018-01-06	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3051	Streptococcus pyogenes strain GAS1914		1314	WGS	GAS1914				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031097	GCA_019335835.1	JAHWSW000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	36		1824430	38.282585	1830		1732.0		throat swab		2018-01-07	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3033	Streptococcus pyogenes strain GAS1916		1314	WGS	GAS1916				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031115	GCA_019335465.1	JAHWSE000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1838978	38.36212	1913		1807.0		throat swab		2018-01-07	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3048	Streptococcus pyogenes strain GAS1966		1314	WGS	GAS1966				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031101	GCA_019335805.1	JAHWSS000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1849449	38.263897	1879		1770.0		throat swab		2018-01-14	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3052	Streptococcus pyogenes strain GAS2000		1314	WGS	GAS2000				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031098	GCA_019335845.1	JAHWSV000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1851932	38.2717	1882		1775.0		throat swab		2018-01-16	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3025	Streptococcus pyogenes strain GAS2001		1314	WGS	GAS2001				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031124	GCA_019335315.1	JAHWRV000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	28		1861420	38.262024	1918		1808.0		throat swab		2018-01-17	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3034	Streptococcus pyogenes strain GAS2015		1314	WGS	GAS2015				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031116	GCA_019335505.1	JAHWSD000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	25		1797975	38.340153	1839		1740.0		throat swab		2018-01-18	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.1105	Streptococcus pyogenes strain GAS253		1314	WGS	GAS253	EMM19.7			MLST.Streptococcus_pyogenes.370				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238009	GCA_900983255.1	CAAHIV000000000		SC	WGS						27		1810865	38.369358	1860		1754.0				1800-2018	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.3049	Streptococcus pyogenes strain GAS270		1314	WGS	GAS270				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031104	GCA_019335705.1	JAHWSP000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1899795	38.292923	1975		1860.0		throat swab		2017-01-15	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3055	Streptococcus pyogenes strain GAS303		1314	WGS	GAS303				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031092	GCA_019335945.1	JAHWTB000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	46		1851035	38.26746	1882		1773.0		throat swab		2017-07-19	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3063	Streptococcus pyogenes strain GAS306		1314	WGS	GAS306				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031083	GCA_019336135.1	JAHWTK000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	35		1819444	38.290615	1827		1726.0		throat swab		2017-07-27	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3062	Streptococcus pyogenes strain GAS315		1314	WGS	GAS315				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031084	GCA_019336125.1	JAHWTJ000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	46		1851100	38.2666	1883		1776.0		throat swab		2017-09-01	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3059	Streptococcus pyogenes strain GAS318		1314	WGS	GAS318				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031089	GCA_019335995.1	JAHWTE000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	48		1851183	38.265644	1880		1775.0		throat swab		2017-09-07	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3058	Streptococcus pyogenes strain GAS335		1314	WGS	GAS335				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031091	GCA_019335985.1	JAHWTC000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1851338	38.267776	1878		1775.0		throat swab		2017-11-15	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3065	Streptococcus pyogenes strain GAS337		1314	WGS	GAS337				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031090	GCA_019336025.1	JAHWTD000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	36		1820458	38.29179	1833		1732.0		throat swab		2017-11-21	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3046	Streptococcus pyogenes strain GAS343		1314	WGS	GAS343				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031105	GCA_019335725.1	JAHWSO000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	27		1861040	38.267273	1905		1802.0		throat swab		2017-11-29	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3043	Streptococcus pyogenes strain GAS350		1314	WGS	GAS350				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031106	GCA_019335675.1	JAHWSN000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	23		1859337	38.265038	1909		1799.0		throat swab		2017-12-06	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3061	Streptococcus pyogenes strain GAS367		1314	WGS	GAS367				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031085	GCA_019336105.1	JAHWTI000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	42		1793992	38.265896	1805		1706.0		throat swab		2017-12-22	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3064	Streptococcus pyogenes strain GAS373		1314	WGS	GAS373				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031086	GCA_019336085.1	JAHWTH000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1851892	38.271244	1881		1775.0		throat swab		2018-01-01	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3042	Streptococcus pyogenes strain GAS377		1314	WGS	GAS377				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031107	GCA_019335665.1	JAHWSM000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1862022	38.300583	1904		1800.0		throat swab		2018-01-05	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3060	Streptococcus pyogenes strain GAS390		1314	WGS	GAS390				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031087	GCA_019336045.1	JAHWTG000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	34		1824729	38.270573	1836		1734.0		throat swab		2018-01-15	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3066	Streptococcus pyogenes strain GAS424		1314	WGS	GAS424				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031088	GCA_019336065.1	JAHWTF000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	46		1850828	38.266876	1881		1775.0		throat swab		2018-10-17	China	China: Shenzhen						Homo sapiens			OSAS																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3047	Streptococcus pyogenes strain GAS552		1314	WGS	GAS552				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031102	GCA_019335745.1	JAHWSR000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1851617	38.267323	1877		1775.0		throat swab		2016-01-26	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3040	Streptococcus pyogenes strain GAS561		1314	WGS	GAS561				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031109	GCA_019335615.1	JAHWSK000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	31		1899811	38.296406	1961		1856.0		throat swab		2016-01-22	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3050	Streptococcus pyogenes strain GAS669		1314	WGS	GAS669				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031099	GCA_019335825.1	JAHWSU000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	35		1819538	38.292583	1824		1726.0		throat swab		2016-05-30	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3036	Streptococcus pyogenes strain GAS688		1314	WGS	GAS688				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031118	GCA_019335525.1	JAHWSB000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	29		1899960	38.29291	1974		1861.0		throat swab		2016-06-14	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3045	Streptococcus pyogenes strain GAS738		1314	WGS	GAS738				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031103	GCA_019335765.1	JAHWSQ000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	45		1850944	38.266804	1877		1775.0		throat swab		2016-07-23	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3039	Streptococcus pyogenes strain GAS744		1314	WGS	GAS744				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031108	GCA_019335645.1	JAHWSL000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	46		1851318	38.2661	1877		1776.0		throat swab		2016-08-01	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3038	Streptococcus pyogenes strain GAS772		1314	WGS	GAS772				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031110	GCA_019335605.1	JAHWSJ000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	26		1861809	38.2652	1919		1806.0		throat swab		2016-10-07	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3037	Streptococcus pyogenes strain GAS865		1314	WGS	GAS865				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031111	GCA_019335555.1	JAHWSI000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	32		1900159	38.290745	1975		1860.0		throat swab		2016-12-21	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3030	Streptococcus pyogenes strain GAS874		1314	WGS	GAS874				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031120	GCA_019335425.1	JAHWRZ000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	30		1899574	38.29306	1974		1860.0		throat swab		2016-12-20	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3054	Streptococcus pyogenes strain GAS875		1314	WGS	GAS875				MLST.Streptococcus_pyogenes.36				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031093	GCA_019335925.1	JAHWTA000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	37		1828873	38.376156	1830		1731.0		throat swab		2016-12-29	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.3032	Streptococcus pyogenes strain GAS961		1314	WGS	GAS961				MLST.Streptococcus_pyogenes.28				2021-07-25T00:00:00Z		PRJNA743366	SAMN20031117	GCA_019335455.1	JAHWSC000000000		BGI-Shenzhen	WGS	Illumina HiSeq	100x	SOAPdenovo v. 2.04	0.0	0.0	32		1906957	38.36236	1975		1861.0		throat swab		2017-01-15	China	China: Shenzhen						Homo sapiens			Scarlet fever																Characteristics of S. pyogenes isolated from Chinese children with different diseases	collected_by:Shenzhen Children's Hospital
1314.2019	Streptococcus pyogenes strain GAS_dog		1314	WGS	GAS_dog	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407056	GCA_900992475.1	CAAISF000000000		SC	WGS						24		1796435	38.30403	1837		1738.0				1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2021	Streptococcus pyogenes strain GAS_dog48		1314	WGS	GAS_dog48	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407044	GCA_900992495.1	CAAISH000000000		SC	WGS						20		1753537	38.423428	1762		1667.0				1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2020	Streptococcus pyogenes strain GAS_dogM3		1314	WGS	GAS_dogM3	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407054	GCA_900992485.1	CAAISE000000000		SC	WGS						23		1797953	38.30764	1833		1733.0				1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2675	Streptococcus pyogenes strain GCH100		1314	WGS	GCH100				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599509	SAMN13754795	GCA_009905975.1	JAAANE000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	618.76x	SPAdes v. 3.10.1	0.0	0.0	22		1847751	38.312305	1915		1808.0		throat		2017-04-18	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH100	sample_type:Throat swab culture
1314.2678	Streptococcus pyogenes strain GCH101		1314	WGS	GCH101				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599510	SAMN13754796	GCA_009906025.1	JAAANF000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	694.48x	SPAdes v. 3.10.1	0.0	0.0	22		1846794	38.310986	1908		1803.0		throat		2017-04-18	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH101	sample_type:Throat swab culture
1314.2677	Streptococcus pyogenes strain GCH102		1314	WGS	GCH102				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599512	SAMN13754797	GCA_009906015.1	JAAANG000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	681.29x	SPAdes v. 3.10.1	0.0	0.0	21		1846178	38.310555	1909		1802.0		throat		2017-05-26	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH102	sample_type:Throat swab culture
1314.2681	Streptococcus pyogenes strain GCH103		1314	WGS	GCH103				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA599513	SAMN13754798	GCA_009906095.1	JAAANH000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	510.62x	SPAdes v. 3.10.1	0.0	0.0	28		1758522	38.369495	1779		1696.0		throat		2017-06-01	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH103	sample_type:Throat swab culture
1314.2679	Streptococcus pyogenes strain GCH104		1314	WGS	GCH104				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA599514	SAMN13754799	GCA_009906035.1	JAAANI000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	592.12x	SPAdes v. 3.10.1	0.0	0.0	28		1758610	38.369564	1788		1695.0		throat		2017-06-13	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH104	sample_type:Throat swab culture
1314.2682	Streptococcus pyogenes strain GCH105		1314	WGS	GCH105				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA599515	SAMN13754800	GCA_009906135.1	JAAANJ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	734.98x	SPAdes v. 3.10.1	0.0	0.0	30		1758936	38.369106	1784		1696.0		throat		2017-07-24	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH105	sample_type:Throat swab culture
1314.2680	Streptococcus pyogenes strain GCH106		1314	WGS	GCH106				MLST.Streptococcus_pyogenes.52				2020-01-19T00:00:00Z		PRJNA599520	SAMN13754823	GCA_009906075.1	JAAANK000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	534.98x	SPAdes v. 3.10.1	0.0	0.0	13		1820353	38.171936	1849		1752.0		throat		2017-07-24	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH106	sample_type:Throat swab culture
1314.2684	Streptococcus pyogenes strain GCH107		1314	WGS	GCH107				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599523	SAMN13755462	GCA_009906295.1	JAAANL000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	445.01x	SPAdes v. 3.10.1	0.0	0.0	21		1847447	38.31	1912		1804.0		throat		2017-05-24	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH107	sample_type:Throat swab culture
1314.2683	Streptococcus pyogenes strain GCH108		1314	WGS	GCH108				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA599524	SAMN13755469	GCA_009906255.1	JAAANM000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	717.32x	SPAdes v. 3.10.1	0.0	0.0	28		1759031	38.372776	1779		1695.0		throat		2017-06-23	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH108	sample_type:Throat swab culture
1314.2694	Streptococcus pyogenes strain GCH109		1314	WGS	GCH109				MLST.Streptococcus_pyogenes.399				2020-01-19T00:00:00Z		PRJNA599527	SAMN13756122	GCA_009906805.1	JAAANN000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	492.36x	SPAdes v. 3.10.1	0.0	0.0	24		1745089	38.32601	1736		1647.0		blood		1997-02-16	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH109	sample_type:Blood culture
1314.2693	Streptococcus pyogenes strain GCH110		1314	WGS	GCH110								2020-01-19T00:00:00Z		PRJNA599528	SAMN13756201	GCA_009906775.1	JAAANO000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	544.2x	SPAdes v. 3.10.1	0.0	0.0	28		1780334	38.258327	1801		1720.0		blood		1997-10-22	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH110	sample_type:Blood culture
1314.2685	Streptococcus pyogenes strain GCH111		1314	WGS	GCH111				MLST.Streptococcus_pyogenes.15				2020-01-19T00:00:00Z		PRJNA600046	SAMN13781252	GCA_009906615.1	JAAANP000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	623.67x	SPAdes v. 3.10.1	0.0	0.0	16		1746020	38.382206	1786		1692.0		blood		2002-01-26	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH111	sample_type:Blood culture
1314.2687	Streptococcus pyogenes strain GCH112		1314	WGS	GCH112				MLST.Streptococcus_pyogenes.15				2020-01-19T00:00:00Z		PRJNA600091	SAMN13781734	GCA_009906655.1	JAAANQ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	602.25x	SPAdes v. 3.10.1	0.0	0.0	30		1851236	38.39813	1959		1849.0		blood		2004-06-04	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH112	sample_type:Blood culture
1314.2690	Streptococcus pyogenes strain GCH113		1314	WGS	GCH113				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA600093	SAMN13781741	GCA_009906695.1	JAAANR000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	461.79x	SPAdes v. 3.10.1	0.0	0.0	38		1793682	38.369957	1833		1749.0		Joint fluid		2010-10-15	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH113	sample_type:Joint fluid culture
1314.2686	Streptococcus pyogenes strain GCH114		1314	WGS	GCH114				MLST.Streptococcus_pyogenes.28				2020-01-19T00:00:00Z		PRJNA600095	SAMN13781751	GCA_009906625.1	JAAANS000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	467.09x	SPAdes v. 3.10.1	0.0	0.0	20		1796997	38.363003	1841		1751.0		blood		2011-05-08	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH114	sample_type:Blood culture
1314.2692	Streptococcus pyogenes strain GCH115		1314	WGS	GCH115				MLST.Streptococcus_pyogenes.15				2020-01-19T00:00:00Z		PRJNA600096	SAMN13781754	GCA_009906735.1	JAAANT000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	638.04x	SPAdes v. 3.10.1	0.0	0.0	30		1851366	38.399754	1959		1849.0		Joint fluid		2011-07-16	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH115	sample_type:Joint fluid culture
1314.2688	Streptococcus pyogenes strain GCH116		1314	WGS	GCH116				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA600097	SAMN13781757	GCA_009906675.1	JAAANU000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	636.92x	SPAdes v. 3.10.1	0.0	0.0	30		1844568	38.30783	1907		1805.0		blood		2014-12-09	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH116	sample_type:Blood culture
1314.2691	Streptococcus pyogenes strain GCH117		1314	WGS	GCH117				MLST.Streptococcus_pyogenes.28				2020-01-19T00:00:00Z		PRJNA600098	SAMN13781758	GCA_009906745.1	JAAANV000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	535.97x	SPAdes v. 3.10.1	0.0	0.0	22		1798556	38.37006	1843		1752.0		blood		2016-02-19	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH117	sample_type:Blood culture
1314.2689	Streptococcus pyogenes strain GCH118		1314	WGS	GCH118				MLST.Streptococcus_pyogenes.36				2020-01-19T00:00:00Z		PRJNA600099	SAMN13781760	GCA_009906685.1	JAAANW000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	540.82x	SPAdes v. 3.10.1	0.0	0.0	32		1753632	38.367855	1763		1685.0		Joint fluid		2017-10-30	South Korea	South Korea:Seoul						Human, Homo sapiens																			Genome sequence of GCH118	sample_type:Joint fluid culture
1314.2666	Streptococcus pyogenes strain GCH119		1314	WGS	GCH119				MLST.Streptococcus_pyogenes.36				2020-01-17T00:00:00Z		PRJNA600340	SAMN13814078	GCA_009901545.1	WXZD00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	404.76x	SPAdes v. 3.10.1	0.0	0.0	29		1920934	38.26373	1973		1872.0		throat		2002-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH119	sample_type:Throat swab culture
1314.2667	Streptococcus pyogenes strain GCH120		1314	WGS	GCH120				MLST.Streptococcus_pyogenes.36				2020-01-17T00:00:00Z		PRJNA600341	SAMN13814079	GCA_009901605.1	WXZE00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	491.79x	SPAdes v. 3.10.1	0.0	0.0	29		1920944	38.263477	1974		1872.0		throat		2002-01-01	South Korea	South Korea:Jinju						Gomo sapiens																			Genome sequence of GCH120	sample_type:Throat swab culture
1314.2661	Streptococcus pyogenes strain GCH121		1314	WGS	GCH121				MLST.Streptococcus_pyogenes.36				2020-01-16T00:00:00Z		PRJNA600343	SAMN13814080	GCA_009887425.1	WXZF00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	523.44x	SPAdes v. 3.10.1	0.0	0.0	25		1874469	38.34222	1930		1829.0		throat		2004-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH121	sample_type:Throat swab culture
1314.2662	Streptococcus pyogenes strain GCH122		1314	WGS	GCH122				MLST.Streptococcus_pyogenes.36				2020-01-16T00:00:00Z		PRJNA600344	SAMN13814087	GCA_009887445.1	WXZG00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	412.57x	SPAdes v. 3.10.1	0.0	0.0	26		1874929	38.343426	1930		1830.0		throat		2004-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH122	sample_type:Throat swab culture
1314.2660	Streptococcus pyogenes strain GCH123		1314	WGS	GCH123								2020-01-16T00:00:00Z		PRJNA600348	SAMN13814127	GCA_009887435.1	WXZH00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	402.7x	SPAdes v. 3.10.1	0.0	0.0	39		1783713	38.46353	1825		1728.0		throat		2002-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH123	sample_type:Throat swab culture
1314.2766	Streptococcus pyogenes strain GCH124		1314	WGS	GCH124				MLST.Streptococcus_pyogenes.49				2020-01-28T00:00:00Z		PRJNA602571	SAMN13899304	GCA_009938925.1	JAACJI000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	422.8x	SPAdes v. 3.10.1	0.0	0.0	11		1772917	38.535534	1789		1690.0		throat swab		2002-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH124	sample_type:pure culture
1314.2665	Streptococcus pyogenes strain GCH125		1314	WGS	GCH125				MLST.Streptococcus_pyogenes.49				2020-01-16T00:00:00Z		PRJNA600351	SAMN13814165	GCA_009887545.1	WXZI00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	525.79x	SPAdes v. 3.10.1	0.0	0.0	11		1784369	38.505432	1807		1700.0		throat		2002-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH125	sample_type:Throat swab culture
1314.2664	Streptococcus pyogenes strain GCH126		1314	WGS	GCH126				MLST.Streptococcus_pyogenes.75				2020-01-16T00:00:00Z		PRJNA600352	SAMN13814166	GCA_009887515.1	WXZJ00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	517.11x	SPAdes v. 3.10.1	0.0	0.0	23		1817412	38.45391	1831		1723.0		throat		2004-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH126	sample_type:Throat swab culture
1314.2663	Streptococcus pyogenes strain GCH127		1314	WGS	GCH127				MLST.Streptococcus_pyogenes.75				2020-01-16T00:00:00Z		PRJNA600355	SAMN13814168	GCA_009887505.1	WXZK00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	407.22x	SPAdes v. 3.10.1	0.0	0.0	22		1839046	38.437267	1864		1754.0		throat		2004-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH127	sample_type:Throat swab culture
1314.2821	Streptococcus pyogenes strain GCH128		1314	WGS	GCH128				MLST.Streptococcus_pyogenes.36				2020-06-13T00:00:00Z		PRJNA635520	SAMN15042487	GCA_013341175.1	JABUOL000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	470.81x	SPAdes v. 3.10.1	0.0	0.0	28		1759168	38.37388	1770		1675.0		throat		2011-01-11	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH128	sample_type:Throat swab culture
1314.2774	Streptococcus pyogenes strain GCH129		1314	WGS	GCH129				MLST.Streptococcus_pyogenes.36				2020-05-25T00:00:00Z		PRJNA633942	SAMN14977657	GCA_013166495.1	JABLSL000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	553.04x	SPAdes v. 3.10.1	0.0	0.0	28		1758890	38.373123	1786		1695.0		throat		2012-02-22	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH129	sample_type:Throat swab culture
1314.2818	Streptococcus pyogenes strain GCH130		1314	WGS	GCH130				MLST.Streptococcus_pyogenes.28				2020-06-13T00:00:00Z		PRJNA635521	SAMN15042488	GCA_013341125.1	JABUOM000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	523.95x	SPAdes v. 3.10.1	0.0	0.0	23		1803600	38.377743	1839		1739.0		throat		2012-10-04	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH130	sample_type:Throat swab culture
1314.2817	Streptococcus pyogenes strain GCH131		1314	WGS	GCH131				MLST.Streptococcus_pyogenes.28				2020-06-13T00:00:00Z		PRJNA635522	SAMN15042579	GCA_013341135.1	JABUON000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	517.5x	SPAdes v. 3.10.1	0.0	0.0	23		1803349	38.37704	1840		1739.0		throat		2012-10-13	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH131	sample_type:Throat swab culture
1314.2820	Streptococcus pyogenes strain GCH132		1314	WGS	GCH132				MLST.Streptococcus_pyogenes.49				2020-06-13T00:00:00Z		PRJNA635526	SAMN15042584	GCA_013341145.1	JABUOO000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	533.37x	SPAdes v. 3.10.1	0.0	0.0	15		1747048	38.48681	1757		1644.0		throat		2013-02-19	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH132	sample_type:Throat swab culture
1314.2819	Streptococcus pyogenes strain GCH133		1314	WGS	GCH133				MLST.Streptococcus_pyogenes.785				2020-06-13T00:00:00Z		PRJNA635528	SAMN15042585	GCA_013341115.1	JABUOP000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	431.99x	SPAdes v. 3.10.1	0.0	0.0	17		1800489	38.36702	1835		1736.0		throat		2015-04-14	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH133	sample_type:Throat swab culture
1314.2822	Streptococcus pyogenes strain GCH134		1314	WGS	GCH134				MLST.Streptococcus_pyogenes.28				2020-06-13T00:00:00Z		PRJNA635529	SAMN15042586	GCA_013341215.1	JABUOQ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	472.14x	SPAdes v. 3.10.1	0.0	0.0	22		1803342	38.38074	1837		1738.0		throat		2015-03-27	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH134	sample_type:Throat swab culture
1314.2796	Streptococcus pyogenes strain GCH135		1314	WGS	GCH135				MLST.Streptococcus_pyogenes.52				2020-06-10T00:00:00Z		PRJNA636236	SAMN15069581	GCA_013327875.1	JABUJB000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	426.83x	SPAdes v. 3.10.1	0.0	0.0	20		1861038	38.1759	1914		1816.0		throat swab		2016-05-02	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH135	sample_type:Throat swab culture
1314.2802	Streptococcus pyogenes strain GCH136		1314	WGS	GCH136				MLST.Streptococcus_pyogenes.28				2020-06-10T00:00:00Z		PRJNA636237	SAMN15069582	GCA_013327895.1	JABUJC000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	772.31x	SPAdes v. 3.10.1	0.0	0.0	22		1803065	38.37904	1838		1740.0		throat swab		2016-02-17	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH136	sample_type:Throat swab culture
1314.2801	Streptococcus pyogenes strain GCH137		1314	WGS	GCH137				MLST.Streptococcus_pyogenes.15				2020-06-10T00:00:00Z		PRJNA636238	SAMN15069583	GCA_013327935.1	JABUJD000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	383.92x	SPAdes v. 3.10.1	0.0	0.0	33		1860923	38.41755	1965		1857.0		throat swab		2017-05-24	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH137	sample_type:Throat swab culture
1314.2799	Streptococcus pyogenes strain GCH138		1314	WGS	GCH138				MLST.Streptococcus_pyogenes.39				2020-06-10T00:00:00Z		PRJNA636240	SAMN15069585	GCA_013327945.1	JABUJE000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	412.17x	SPAdes v. 3.10.1	0.0	0.0	30		1851417	38.318054	1914		1795.0		throat swab		2017-10-24	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH138	sample_type:Throat swab culture
1314.2809	Streptococcus pyogenes strain GCH139		1314	WGS	GCH139				MLST.Streptococcus_pyogenes.52				2020-06-10T00:00:00Z		PRJNA636242	SAMN15069588	GCA_013328025.1	JABUJF000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	516.45x	SPAdes v. 3.10.1	0.0	0.0	18		1860223	38.174725	1913		1813.0		throat swab		2017-12-02	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH139	sample_type:Throat swab culture
1314.2797	Streptococcus pyogenes strain GCH140		1314	WGS	GCH140				MLST.Streptococcus_pyogenes.28				2020-06-10T00:00:00Z		PRJNA636246	SAMN15069606	GCA_013327975.1	JABUJG000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	1033.27x	SPAdes v. 3.10.1	0.0	0.0	22		1803071	38.381184	1837		1738.0		throat swab		2018-04-14	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH140	sample_type:Throat swab culture
1314.2798	Streptococcus pyogenes strain GCH141		1314	WGS	GCH141				MLST.Streptococcus_pyogenes.52				2020-06-10T00:00:00Z		PRJNA636248	SAMN15069608	GCA_013327985.1	JABUJH000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	963.12x	SPAdes v. 3.10.1	0.0	0.0	16		1820780	38.174133	1844		1753.0		throat swab		2018-07-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH141	sample_type:Throat swab culture
1314.2805	Streptococcus pyogenes strain GCH142		1314	WGS	GCH142				MLST.Streptococcus_pyogenes.36				2020-06-10T00:00:00Z		PRJNA636253	SAMN15069674	GCA_013328035.1	JABUJI000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	220.6x	SPAdes v. 3.10.1	0.0	0.0	29		1757985	38.36927	1767		1677.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH142	sample_type:Throat swab culture
1314.2800	Streptococcus pyogenes strain GCH143		1314	WGS	GCH143				MLST.Streptococcus_pyogenes.253				2020-06-10T00:00:00Z		PRJNA636254	SAMN15069685	GCA_013328015.1	JABUJJ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	297.19x	SPAdes v. 3.10.1	0.0	0.0	14		1709462	38.44502	1694		1608.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH143	sample_type:Throat swab culture
1314.2804	Streptococcus pyogenes strain GCH144		1314	WGS	GCH144				MLST.Streptococcus_pyogenes.37				2020-06-10T00:00:00Z		PRJNA636256	SAMN15069686	GCA_013328075.1	JABUJK000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	291.51x	SPAdes v. 3.10.1	0.0	0.0	21		1790498	38.403057	1851		1752.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH144	sample_type:Throat swab culture
1314.2803	Streptococcus pyogenes strain GCH145		1314	WGS	GCH145				MLST.Streptococcus_pyogenes.62				2020-06-10T00:00:00Z		PRJNA636257	SAMN15069693	GCA_013328095.1	JABUJL000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	274.31x	SPAdes v. 3.10.1	0.0	0.0	26		1797841	38.341267	1824		1714.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH145	sample_type:Throat swab culture
1314.2808	Streptococcus pyogenes strain GCH146		1314	WGS	GCH146								2020-06-10T00:00:00Z		PRJNA636259	SAMN15069694	GCA_013328105.1	JABUJM000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	243.61x	SPAdes v. 3.10.1	0.0	0.0	13		1801157	38.197224	1789		1681.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH146	sample_type:Throat swab culture
1314.2810	Streptococcus pyogenes strain GCH147		1314	WGS	GCH147				MLST.Streptococcus_pyogenes.46				2020-06-10T00:00:00Z		PRJNA636531	SAMN15079192	GCA_013328135.1	JABUJN000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	258.05x	SPAdes v. 3.10.1	0.0	0.0	28		1774722	38.44202	1819		1721.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH147	sample_type:Throat swab culture
1314.2807	Streptococcus pyogenes strain GCH148		1314	WGS	GCH148				MLST.Streptococcus_pyogenes.99				2020-06-10T00:00:00Z		PRJNA636532	SAMN15079193	GCA_013328175.1	JABUJO000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	259.59x	SPAdes v. 3.10.1	0.0	0.0	18		1863011	38.398056	1932		1833.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH148	sample_type:Throat swab culture
1314.2811	Streptococcus pyogenes strain GCH149		1314	WGS	GCH149								2020-06-10T00:00:00Z		PRJNA636577	SAMN15079306	GCA_013328215.1	JABUJP000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	289.78x	SPAdes v. 3.10.1	0.0	0.0	31		1811796	38.35371	1853		1754.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH149	sample_type:Throat swab culture
1314.2806	Streptococcus pyogenes strain GCH150		1314	WGS	GCH150				MLST.Streptococcus_pyogenes.46				2020-06-10T00:00:00Z		PRJNA636579	SAMN15079310	GCA_013328195.1	JABUJQ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	241.3x	SPAdes v. 3.10.1	0.0	0.0	29		1774948	38.44676	1821		1719.0		throat swab		2006-06-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH150	sample_type:Throat swab culture
1314.2812	Streptococcus pyogenes strain GCH151		1314	WGS	GCH151				MLST.Streptococcus_pyogenes.253				2020-06-10T00:00:00Z		PRJNA636605	SAMN15080633	GCA_013328225.1	JABUJR000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	395.27x	SPAdes v. 3.10.1	0.0	0.0	14		1749462	38.44073	1763		1665.0		throat swab		2005-12-16	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH151	sample_type:Throat swab culture
1314.2815	Streptococcus pyogenes strain GCH152		1314	WGS	GCH152				MLST.Streptococcus_pyogenes.46				2020-06-10T00:00:00Z		PRJNA636607	SAMN15080641	GCA_013328275.1	JABUJS000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	540.07x	SPAdes v. 3.10.1	0.0	0.0	45		1867950	38.416393	1981		1870.0		throat swab		2005-12-16	South Korea	South Korea: Jinju						Human, Homo sapiens																			GNUCH_SPyo_GCH152	sample_type:Throat swab culture
1314.2813	Streptococcus pyogenes strain GCH153		1314	WGS	GCH153				MLST.Streptococcus_pyogenes.253				2020-06-10T00:00:00Z		PRJNA636638	SAMN15080645	GCA_013328315.1	JABUJT000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	491.12x	SPAdes v. 3.10.1	0.0	0.0	14		1749740	38.442455	1763		1664.0		throat swab		2005-12-16	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH153	sample_type:Throat swab culture
1314.2816	Streptococcus pyogenes strain GCH154		1314	WGS	GCH154				MLST.Streptococcus_pyogenes.253				2020-06-10T00:00:00Z		PRJNA636636	SAMN15080646	GCA_013328325.1	JABUJU000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	262.93x	SPAdes v. 3.10.1	0.0	0.0	15		1749939	38.444027	1766		1664.0		throat swab		2005-12-16	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH154	sample_type:Throat swab culture
1314.2814	Streptococcus pyogenes strain GCH155		1314	WGS	GCH155				MLST.Streptococcus_pyogenes.89				2020-06-10T00:00:00Z		PRJNA636632	SAMN15080647	GCA_013328295.1	JABUJV000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	292.37x	SPAdes v. 3.10.1	0.0	0.0	25		1811737	38.230824	1841		1721.0		throat swab		2005-12-16	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH155	sample_type:Throat swab culture
1314.2789	Streptococcus pyogenes strain GCH156		1314	WGS	GCH156				MLST.Streptococcus_pyogenes.89				2020-06-09T00:00:00Z		PRJNA636883	SAMN15087647	GCA_013315575.1	JABUAZ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	375.77x	SPAdes v. 3.10.1	0.0	0.0	29		1811967	38.230278	1843		1720.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH156	sample_type:Throat swab culture
1314.2792	Streptococcus pyogenes strain GCH157		1314	WGS	GCH157				MLST.Streptococcus_pyogenes.99				2020-06-09T00:00:00Z		PRJNA636882	SAMN15087646	GCA_013315605.1	JABUBA000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	452.57x	SPAdes v. 3.10.1	0.0	0.0	21		1864414	38.40016	1936		1841.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH157	sample_type:Throat swab culture
1314.2793	Streptococcus pyogenes strain GCH158		1314	WGS	GCH158				MLST.Streptococcus_pyogenes.99				2020-06-09T00:00:00Z		PRJNA636884	SAMN15087648	GCA_013315635.1	JABUBB000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	372.3x	SPAdes v. 3.10.1	0.0	0.0	21		1864338	38.401566	1936		1843.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH158	sample_type:Throat swab culture
1314.2782	Streptococcus pyogenes strain GCH159		1314	WGS	GCH159				MLST.Streptococcus_pyogenes.253				2020-06-09T00:00:00Z		PRJNA636880	SAMN15087629	GCA_013315485.1	JABUAT000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	333.15x	SPAdes v. 3.10.1	0.0	0.0	14		1749749	38.44243	1763		1666.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH159	sample_type:Throat swab culture
1314.2778	Streptococcus pyogenes strain GCH160		1314	WGS	GCH160				MLST.Streptococcus_pyogenes.46				2020-06-09T00:00:00Z		PRJNA636873	SAMN15087496	GCA_013315335.1	JABUAP000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	335.75x	SPAdes v. 3.10.1	0.0	0.0	28		1774786	38.443	1819		1720.0		throat		2006-06-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH160	sample_type:Throat swab culture
1314.2788	Streptococcus pyogenes strain GCH161		1314	WGS	GCH161				MLST.Streptococcus_pyogenes.46				2020-06-09T00:00:00Z		PRJNA636872	SAMN15087495	GCA_013315415.1	JABUAQ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	357.61x	SPAdes v. 3.10.1	0.0	0.0	27		1774607	38.441357	1817		1718.0		throat		2006-06-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH161	sample_type:Throat swab culture
1314.2794	Streptococcus pyogenes strain GCH163		1314	WGS	GCH163				MLST.Streptococcus_pyogenes.25				2020-06-09T00:00:00Z		PRJNA636881	SAMN15087645	GCA_013315645.1	JABUBC000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	281.34x	SPAdes v. 3.10.1	0.0	0.0	24		1789253	38.31856	1833		1717.0		throat		2006-06-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH163	sample_type:Throat swab culture
1314.2785	Streptococcus pyogenes strain GCH164		1314	WGS	GCH164				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636878	SAMN15087508	GCA_013315475.1	JABUAU000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	281.98x	SPAdes v. 3.10.1	0.0	0.0	26		1803091	38.3695	1831		1736.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH164	sample_type:Throat swab culture
1314.2791	Streptococcus pyogenes strain GCH165		1314	WGS	GCH165				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636877	SAMN15087500	GCA_013315535.1	JABUAV000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	306.67x	SPAdes v. 3.10.1	0.0	0.0	23		1802169	38.363163	1833		1737.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH165	sample_type:Throat swab culture
1314.2784	Streptococcus pyogenes strain GCH166		1314	WGS	GCH166				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636876	SAMN15087499	GCA_013315505.1	JABUAW000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	295.99x	SPAdes v. 3.10.1	0.0	0.0	24		1854850	38.384773	1897		1792.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH166	sample_type:Throat swab culture
1314.2790	Streptococcus pyogenes strain GCH167		1314	WGS	GCH167				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636874	SAMN15087498	GCA_013315545.1	JABUAX000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	273.77x	SPAdes v. 3.10.1	0.0	0.0	26		1802426	38.36718	1832		1734.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH167	sample_type:Throat swab culture
1314.2795	Streptococcus pyogenes strain GCH168		1314	WGS	GCH168				MLST.Streptococcus_pyogenes.38				2020-06-09T00:00:00Z		PRJNA636875	SAMN15087497	GCA_013315595.1	JABUAY000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	237.99x	SPAdes v. 3.10.1	0.0	0.0	255		2111007	38.31598	2353		2195.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH168	sample_type:Throat swab culture
1314.2787	Streptococcus pyogenes strain GCH169		1314	WGS	GCH169				MLST.Streptococcus_pyogenes.28				2020-06-09T00:00:00Z		PRJNA636871	SAMN15087494	GCA_013315455.1	JABUAR000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	347.93x	SPAdes v. 3.10.1	0.0	0.0	20		1764213	38.347466	1786		1689.0		throat		1995-12-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH169	sample_type:Throat swab culture
1314.2786	Streptococcus pyogenes strain GCH170		1314	WGS	GCH170				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636869	SAMN15087490	GCA_013315435.1	JABUAS000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	307.52x	SPAdes v. 3.10.1	0.0	0.0	30		1759651	38.377327	1771		1678.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH170	sample_type:Throat swab culture
1314.2777	Streptococcus pyogenes strain GCH171		1314	WGS	GCH171				MLST.Streptococcus_pyogenes.36				2020-06-09T00:00:00Z		PRJNA636868	SAMN15087489	GCA_013315225.1	JABUAJ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	293.45x	SPAdes v. 3.10.1	0.0	0.0	28		1758039	38.370365	1771		1676.0		throat		2005-12-16	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH171	sample_type:Throat swab culture
1314.2776	Streptococcus pyogenes strain GCH172		1314	WGS	GCH172				MLST.Streptococcus_pyogenes.458				2020-06-09T00:00:00Z		PRJNA636867	SAMN15087482	GCA_013315275.1	JABUAK000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	292.08x	SPAdes v. 3.10.1	0.0	0.0	12		1819849	38.169594	1839		1739.0		throat		2017-07-11	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH172	sample_type:Throat swab culture
1314.2779	Streptococcus pyogenes strain GCH173		1314	WGS	GCH173				MLST.Streptococcus_pyogenes.52				2020-06-09T00:00:00Z		PRJNA636864	SAMN15087441	GCA_013315375.1	JABUAL000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	521.12x	SPAdes v. 3.10.1	0.0	0.0	12		1820471	38.172043	1838		1740.0		throat		2017-08-25	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH173	sample_type:Throat swab culture
1314.2783	Streptococcus pyogenes strain GCH174		1314	WGS	GCH174				MLST.Streptococcus_pyogenes.28				2020-06-09T00:00:00Z		PRJNA636843	SAMN15087382	GCA_013315315.1	JABUAM000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	615.88x	SPAdes v. 3.10.1	0.0	0.0	19		1800960	38.361984	1839		1739.0		throat		2017-04-14	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH174	sample_type:Throat swab culture
1314.2781	Streptococcus pyogenes strain GCH175		1314	WGS	GCH175				MLST.Streptococcus_pyogenes.52				2020-06-09T00:00:00Z		PRJNA636845	SAMN15087383	GCA_013315385.1	JABUAN000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	499.9x	SPAdes v. 3.10.1	0.0	0.0	13		1865566	38.086296	1880		1780.0		throat		2017-06-16	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH175	sample_type:Throat swab culture
1314.2780	Streptococcus pyogenes strain GCH178		1314	WGS	GCH178				MLST.Streptococcus_pyogenes.39				2020-06-09T00:00:00Z		PRJNA636863	SAMN15087440	GCA_013315345.1	JABUAO000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	576.13x	SPAdes v. 3.10.1	0.0	0.0	22		1847562	38.309406	1906		1792.0		throat		2017-06-17	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH178	sample_type:Throat swab culture
1314.2586	Streptococcus pyogenes strain GCH79		1314	WGS	GCH79				MLST.Streptococcus_pyogenes.28				1900-01-01T00:00:00Z		PRJNA595796	SAMN13567474	GCA_009789515.1	WSTD00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	414.35x	SPAdes v. 3.10.1	0.0	0.0	17		1801349	38.37291	1856		1761.0		throat swab		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH79	sample_type:Throat swab culture
1314.2585	Streptococcus pyogenes strain GCH80		1314	WGS	GCH80				MLST.Streptococcus_pyogenes.28				1900-01-01T00:00:00Z		PRJNA595799	SAMN13567712	GCA_009789495.1	WSTE00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	747.03x	SPAdes v. 3.10.1	0.0	0.0	20		1836761	38.352295	1911		1815.0		throat swab		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GNUCH_SPyo_80	sample_type:Throat swab culture
1314.2587	Streptococcus pyogenes strain GCH82		1314	WGS	GCH82				MLST.Streptococcus_pyogenes.39				2019-12-23T00:00:00Z		PRJNA596340	SAMN13618832	GCA_009795965.1	WTFQ00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	540.97x	SPAdes v. 3.10.1	0.0	0.0	25		1848077	38.30663	1918		1814.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GNUCH_SPyo_GCH82	sample_type:Throat swab culture
1314.2659	Streptococcus pyogenes strain GCH83		1314	WGS	GCH83				MLST.Streptococcus_pyogenes.38				1900-01-01T00:00:00Z		PRJNA599257	SAMN13742135	GCA_009857415.1	WWFH00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	646.88x	SPAdes v. 3.10.1	0.0	0.0	25		1894288	38.312073	1945		1844.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GNUCH_SPyo_GCH83	sample_type:Throat swab culture
1314.2652	Streptococcus pyogenes strain GCH84		1314	WGS	GCH84				MLST.Streptococcus_pyogenes.36				1900-01-01T00:00:00Z		PRJNA599260	SAMN13742191	GCA_009857195.1	WWFI00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	523.65x	SPAdes v. 3.10.1	0.0	0.0	23		1800679	38.36214	1844		1750.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH84	sample_type:Throat swab culture
1314.2653	Streptococcus pyogenes strain GCH85		1314	WGS	GCH85				MLST.Streptococcus_pyogenes.36				1900-01-01T00:00:00Z		PRJNA599264	SAMN13742193	GCA_009857215.1	WWFJ00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	557.17x	SPAdes v. 3.10.1	0.0	0.0	24		1798005	38.364132	1836		1746.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH85	sample_type:Throat swab culture
1314.2658	Streptococcus pyogenes strain GCH86		1314	WGS	GCH86				MLST.Streptococcus_pyogenes.36				1900-01-01T00:00:00Z		PRJNA599266	SAMN13742195	GCA_009857345.1	WWFK00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	507.78x	SPAdes v. 3.10.1	0.0	0.0	24		1801410	38.367832	1850		1751.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH86	sample_type:Throat swab culture
1314.2654	Streptococcus pyogenes strain GCH87		1314	WGS	GCH87				MLST.Streptococcus_pyogenes.28				1900-01-01T00:00:00Z		PRJNA599272	SAMN13742256	GCA_009857295.1	WWFL00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	529.58x	SPAdes v. 3.10.1	0.0	0.0	18		1799658	38.36679	1850		1757.0		throat		2004-01-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH87	sample_type:Throat swab culture
1314.2657	Streptococcus pyogenes strain GCH88		1314	WGS	GCH88				MLST.Streptococcus_pyogenes.28				1900-01-01T00:00:00Z		PRJNA599276	SAMN13742269	GCA_009857325.1	WWFM00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	602.47x	SPAdes v. 3.10.1	0.0	0.0	19		1800948	38.36296	1849		1759.0		throat		2004-01-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH88	sample_type:Throat swab culture
1314.2655	Streptococcus pyogenes strain GCH89		1314	WGS	GCH89				MLST.Streptococcus_pyogenes.15				1900-01-01T00:00:00Z		PRJNA599278	SAMN13742319	GCA_009857305.1	WWFN00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	559.07x	SPAdes v. 3.10.1	0.0	0.0	32		1857697	38.410194	1975		1864.0		throat		2006-01-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH89	sample_type:Throat swab culutre
1314.2656	Streptococcus pyogenes strain GCH90		1314	WGS	GCH90				MLST.Streptococcus_pyogenes.15				1900-01-01T00:00:00Z		PRJNA599279	SAMN13742320	GCA_009857315.1	WWFO00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	625.18x	SPAdes v. 3.10.1	0.0	0.0	14		1743960	38.456673	1779		1685.0		throat		2006-01-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GCH90	sample_type:Throat swab culture
1314.2669	Streptococcus pyogenes strain GCH91		1314	WGS	GCH91				MLST.Streptococcus_pyogenes.15				2020-01-19T00:00:00Z		PRJNA599492	SAMN13753689	GCA_009905825.1	JAAAMW000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	471.66x	SPAdes v. 3.10.1	0.0	0.0	30		1856420	38.40467	1975		1865.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH91	sample_type:Throat swab culture
1314.2671	Streptococcus pyogenes strain GCH92		1314	WGS	GCH92				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599493	SAMN13753692	GCA_009905885.1	JAAAMX000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	640.86x	SPAdes v. 3.10.1	0.0	0.0	23		1846863	38.31172	1914		1801.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH92	sample_type:Throat swab culture
1314.2668	Streptococcus pyogenes strain GCH93		1314	WGS	GCH93				MLST.Streptococcus_pyogenes.39				2020-01-19T00:00:00Z		PRJNA599496	SAMN13753694	GCA_009905815.1	JAAAMY000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	718.82x	SPAdes v. 3.10.1	0.0	0.0	27		1850710	38.316216	1922		1808.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH93	sample_type:Throat swab culture
1314.2674	Streptococcus pyogenes strain GCH94		1314	WGS	GCH94				MLST.Streptococcus_pyogenes.28				2020-01-19T00:00:00Z		PRJNA599497	SAMN13753774	GCA_009905935.1	JAAAMZ000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	724.25x	SPAdes v. 3.10.1	0.0	0.0	17		1800213	38.364403	1845		1757.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH94	sample_type:Throat swab culture
1314.2670	Streptococcus pyogenes strain GCH95		1314	WGS	GCH95								2020-01-19T00:00:00Z		PRJNA599498	SAMN13753856	GCA_009905855.1	JAAANA000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	608.4x	SPAdes v. 3.10.1	0.0	0.0	19		1831716	38.422333	1882		1777.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH95	sample_type:Throat swab culture
1314.2672	Streptococcus pyogenes strain GCH96		1314	WGS	GCH96				MLST.Streptococcus_pyogenes.52				2020-01-19T00:00:00Z		PRJNA599499	SAMN13753988	GCA_009905915.1	JAAANB000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	446.91x	SPAdes v. 3.10.1	0.0	0.0	21		1896521	38.09755	1950		1848.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH96	sample_type:Throat swab culture
1314.2673	Streptococcus pyogenes strain GCH97		1314	WGS	GCH97				MLST.Streptococcus_pyogenes.28				2020-01-19T00:00:00Z		PRJNA599500	SAMN13754156	GCA_009905945.1	JAAANC000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	817.8x	SPAdes v. 3.10.1	0.0	0.0	20		1723666	38.34722	1736		1650.0		throat		2006-01-01	South Korea	South Korea:Jinju						Human, Homo sapiens																			Genome sequence of GCH97	sample_type:Throat swab culture
1314.2676	Streptococcus pyogenes strain GCH98		1314	WGS	GCH98				MLST.Streptococcus_pyogenes.28				2020-01-19T00:00:00Z		PRJNA599501	SAMN13754371	GCA_009905985.1	JAAAND000000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	747.03x	SPAdes v. 3.10.1	0.0	0.0	22		1802965	38.377728	1851		1759.0		throat		2017-08-08	South Korea	South Korea:Changwon						Human, Homo sapiens																			Genome sequence of GCH98	sample_type:Throat swab culture
1314.2588	Streptococcus pyogenes strain GNUCH_SPyo_81		1314	WGS	GNUCH_SPyo_81								2019-12-23T00:00:00Z		PRJNA596308	SAMN13618339	GCA_009795975.1	WTFP00000000		Gyeongsang National University Changwon Hospital	WGS	Illumina MiSeq	478.32x	SPAdes v. 3.10.1	0.0	0.0	28		1859976	38.412914	1988		1874.0		throat		1995-12-01	South Korea	South Korea: Jinju						Human, Homo sapiens																			Genome sequence of GNUCH_SPyo_81	sample_type:Throat swab culture
1314.497	Streptococcus pyogenes strain GUR		1314	Complete	GUR	emm111			MLST.Streptococcus_pyogenes.1065				2017-07-28T00:00:00Z		PRJNA376567	SAMN06434935	GCA_002236875.1	CP022354		University of Copenhagen	Complete	Illumina MiSeq	208.0x	SPAdes v. 3.10.0	1.0		1		1890204	38.54	1959		1871.0		throat	isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients	1938	Russia	Russia						Human, Homo sapiens																			This study was designed to investigate Streptococcus pyogenes serotype emm111 strain GUR, isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients.	sample_type:monoclonal culture;biomaterial_provider:Valery A. Chereshnev, Institute of Ecology and Genetics of Microorganisms, Ural Branch of the Russian Academy of Sciences, 13 Goleva, Perm 614081, Russia
1314.517	Streptococcus pyogenes strain GUR		1314	Duplicate	GUR	emm111			MLST.Streptococcus_pyogenes.1065				2017-07-28T00:00:00Z		PRJNA376567	SAMN06434935	GCA_002236875.1	CP022354		University of Copenhagen	Complete	Illumina MiSeq	208.0x	SPAdes v. 3.10.0	1.0		1		1890204	38.54	1959		1871.0		throat	isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients	1938	Russia	Russia						Human, Homo sapiens																			This study was designed to investigate Streptococcus pyogenes serotype emm111 strain GUR, isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients.	sample_type:monoclonal culture;biomaterial_provider:Valery A. Chereshnev, Institute of Ecology and Genetics of Microorganisms, Ural Branch of the Russian Academy of Sciences, 13 Goleva, Perm 614081, Russia
1314.496	Streptococcus pyogenes strain GURSA1		1314	Complete	GURSA1	emm111			MLST.Streptococcus_pyogenes.1065	genotype:emm mutant			2017-07-28T00:00:00Z		PRJNA376567	SAMN06435541	GCA_002236855.1	CP022206		University of Copenhagen	Complete	Illumina MiSeq	105.0x	SPAdes v. 3.10.0	1.0		1		1893171	38.54	1966		1875.0		the throat swab of a scarlet fever patient	isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients	2011	Russia	Russia						Human, Homo sapiens																			This study was designed to investigate Streptococcus pyogenes serotype emm111 strain GUR, isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients.	sample_type:monoclonal culture;biomaterial_provider:Alexander Suvorov, FSBSI Institute of Experimental Medicine, St. Petersburg, Russian Federation
1314.518	Streptococcus pyogenes strain GURSA1		1314	Duplicate	GURSA1	emm111			MLST.Streptococcus_pyogenes.1065	genotype:emm mutant			2017-07-28T00:00:00Z		PRJNA376567	SAMN06435541	GCA_002236855.1	CP022206		University of Copenhagen	Complete	Illumina MiSeq	105.0x	SPAdes v. 3.10.0	1.0		1		1893171	38.54	1966		1875.0		the throat swab of a scarlet fever patient	isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients	2011	Russia	Russia						Human, Homo sapiens																			This study was designed to investigate Streptococcus pyogenes serotype emm111 strain GUR, isolated from the throat swab of a scarlet fever patient in Russia in 1938, which has been used to treat cancer patients.	sample_type:monoclonal culture;biomaterial_provider:Alexander Suvorov, FSBSI Institute of Experimental Medicine, St. Petersburg, Russian Federation
1314.307	Streptococcus pyogenes strain H091220183-sc-2011-03-02-1091939		1314	WGS	H091220183-sc-2011-03-02-1091939				MLST.Streptococcus_pyogenes.15				2016-05-19T00:00:00Z		PRJEB13322	SAMEA1027094	GCA_900087555.1	FLKQ00000000		PHE	WGS						29		1826913	38.4	1904																																	A sudden increase in invasive Group A Streptococcus (iGAS) infections associated with emm/M3 isolates during the winter of 2008/09 prompted the initiation of enhanced surveillance in England. In order to characterise the population of emm/M3 GAS within the UK and determine bacterial factors that might be responsible for this upsurge, 442 emm/M3 isolates from cases of invasive and non-invasive infections during the period 2001 to 2013 were subjected to whole genome sequencing. MLST analysis differentiated emm/M3 isolates into three sequence types (STs): ST15, ST315 and ST406. Analysis of the whole genome SNP-based phylogeny showed that the majority of isolates from the 2008-2009 upsurge period belonged to a distinct lineage characterised by the presence of a prophage carrying the speC exotoxin and spd1 DNAase genes but loss of two other prophages considered typical of the emm/M3 lineage. This lineage was significantly associated with the upsurge in iGAS cases and we postulate that the upsurge could be attributed in part to expansion of this novel prophage-containing lineage within the population. The study underlines the importance of prompt genomic analysis of changes in the GAS population, providing an advanced public health warning systems for newly emergent, pathogenic strains.	
1314.190	Streptococcus pyogenes strain H293		1314	Complete	H293				MLST.Streptococcus_pyogenes.101				2015-07-21T00:00:00Z	26173696	PRJEB1935		GCF_001039695.1	HG316453		ICL-CFB	Complete				1.0		1		1726248	38.55	1674		1601.0																															The complete genome of the clinical M89 Streptococcus pyogenes strain H293 from a patient with necrotizing fasciitis and sepsis syndrome in the UK.	
1314.1871	Streptococcus pyogenes strain HKU165		1314	WGS	HKU165	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034094	GCA_900990995.1	CAAIMM000000000		SC	WGS						20		1897702	38.246037	1916		1819.0		sputum	isolated in Hong Kong between 2005 and 2011	2005	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1870	Streptococcus pyogenes strain HKU22		1314	WGS	HKU22	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034114	GCA_900990985.1	CAAIML000000000		SC	WGS						21		1755736	38.378147	1744		1648.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1869	Streptococcus pyogenes strain HKU30		1314	WGS	HKU30	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2589	SAMEA1031413	GCA_900990975.1	CAAIMK000000000		SC	WGS						25		1887637	38.335026	1901		1809.0		throat swab		2011	Hong Kong	Hong Kong						Human, Homo sapiens																			"""Streptococcus agalactiae clones infecting humans were selected and fixed through the extensive use of tetracycline."" Pubmed ID: 25088811. Streptococcus agalactiae (Group B Streptococcus, GBS) is a commensal of the digestive and genitourinary tracts of humans that emerged as the leading cause of bacterial neonatal infections in Europe and North America during the 1960s. Due to the lack of epidemiological and genomic data, the reasons for this emergence are unknown. Here we show by comparative genome analysis and phylogenetic reconstruction of 229 isolates that the rise of human GBS infections corresponds to the selection and worldwide dissemination of only a few clones. The parallel expansion of the clones is preceded by the insertion of integrative and conjugative elements conferring tetracycline resistance (TcR). Thus, we propose that the use of tetracycline from 1948 onwards led in humans to the complete replacement of a diverse GBS population by only few TcR clones particularly well adapted to their host, causing the observed emergence of GBS diseases in neonates."	
1314.1872	Streptococcus pyogenes strain HKU306		1314	WGS	HKU306	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034137	GCA_900991005.1	CAAIMN000000000		SC	WGS						25		1844013	38.28645	1843		1748.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1873	Streptococcus pyogenes strain HKU360		1314	WGS	HKU360	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034066	GCA_900991015.1	CAAIMO000000000		SC	WGS						32		1881847	38.276276	1917		1804.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1876	Streptococcus pyogenes strain HKU364		1314	WGS	HKU364	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034119	GCA_900991045.1	CAAIMS000000000		SC	WGS						27		1797244	38.372356	1816		1706.0		Vaginal swab	isolated in Hong Kong between 2005 and 2011	2008	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1874	Streptococcus pyogenes strain HKU383		1314	WGS	HKU383	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034012	GCA_900991025.1	CAAIMP000000000		SC	WGS						21		1822029	38.29804	1822		1713.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1875	Streptococcus pyogenes strain HKU388		1314	WGS	HKU388	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034045	GCA_900991035.1	CAAIMR000000000		SC	WGS						22		1836417	38.370647	1872		1763.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1877	Streptococcus pyogenes strain HKU397		1314	WGS	HKU397	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2657	SAMEA1034043	GCA_900991055.1	CAAIMQ000000000		SC	WGS						24		1897374	38.3457	1908		1798.0		throat swab	isolated in Hong Kong between 2005 and 2011	2011	Hong Kong	Hong Kong						Human, Homo sapiens																			A scarlet fever outbreak began in mainland China and Hong Kong in 2011. Macrolide- and tetracycline-resistant Streptococcus pyogenes emm12 isolates represent the majority of clinical cases. Recently, we identified two mobile genetic elements that were closely associated with emm12 outbreak isolates: the integrative and conjugative element ICE-emm12, encoding genes for tetracycline and macrolide resistance, and prophage ?HKU.vir, encoding the superantigens SSA and SpeC, as well as the DNase Spd1. Here we sequenced the genomes of 141 emm12 isolates, including 132 isolated in Hong Kong between 2005 and 2011. We found that the introduction of several ICE-emm12 variants, ?HKU.vir and a new prophage, ?HKU.ssa, occurred in three distinct emm12 lineages late in the twentieth century. Acquisition of ssa and transposable elements encoding multidrug resistance genes triggered the expansion of scarlet fever-associated emm12 lineages in Hong Kong. The occurrence of multidrug-resistant ssa-harboring scarlet fever strains should prompt heightened surveillance within China and abroad for the dissemination of these mobile genetic elements. http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1047	Streptococcus pyogenes strain HKU419		1314	Complete	HKU419	M1T1			MLST.Streptococcus_pyogenes.28		102.100.100.25707		2019-01-10T00:00:00Z		PRJEB29800	SAMEA5096235	GCA_900619605.1	LR130238		Bioplatforms Australia	Complete				1.0		1		1943295	38.452267	1963				throat		2012-02-23	China	China						Human, Homo sapiens						host_health_state:diseased													The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.The pathogens included in this initiative are: Escherichia coli, Klebsiella pneumoniae complex, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. The following project contains the complete genomes and sequence data for Streptococcus pyogenes.	
1314.2100	Streptococcus pyogenes strain HKU434		1314	WGS	HKU434	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523463	GCA_900993285.1	CAAIVH000000000		SC	WGS						23		1800997	38.373024	1835		1736.0		throat swab		2011	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2101	Streptococcus pyogenes strain HKU464		1314	WGS	HKU464	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523440	GCA_900993295.1	CAAIVI000000000		SC	WGS						31		1864796	38.30258	1900		1789.0		sterile site		2012	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2102	Streptococcus pyogenes strain HKU474		1314	WGS	HKU474	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523545	GCA_900993305.1	CAAIVJ000000000		SC	WGS						22		1801057	38.3743	1839		1738.0		throat swab		2012	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2103	Streptococcus pyogenes strain HKU484		1314	WGS	HKU484	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523462	GCA_900993315.1	CAAIVK000000000		SC	WGS						26		1832957	38.36364	1877		1779.0		throat swab		2012	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2105	Streptococcus pyogenes strain HKU486		1314	WGS	HKU486	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523423	GCA_900993335.1	CAAIVM000000000		SC	WGS						23		1904454	38.301792	1957		1853.0		throat swab		2011	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2106	Streptococcus pyogenes strain HKU487		1314	WGS	HKU487	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523571	GCA_900993345.1	CAAIVN000000000		SC	WGS						29		1902896	38.297153	1961		1850.0		throat swab		2011	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2108	Streptococcus pyogenes strain HKU488		1314	WGS	HKU488	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2839	SAMEA1523579	GCA_900993365.1	CAAIVO000000000		SC	WGS						25		1902158	38.296345	1958		1850.0		throat swab		2012	Hong Kong	Hong Kong						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.191	Streptococcus pyogenes strain HKU488		1314	Complete	HKU488	serovar M1			MLST.Streptococcus_pyogenes.28				2015-07-09T00:00:00Z		PRJNA289181	SAMN03846812	GCF_001051095.1	CP012045	NZ_CP012045.1	University of Queensland	Complete	PacBio	114	SMRT Portal - HGAP v. 2.2.0	1.0		1		1943415	38.45	1959		1882.0				2012-01-08	Hong Kong	Hong Kong						Human, Homo sapiens			Scarlet Fever											C					Complete genome of Scarlet Fever-associated serotype M1 Streptococcus pyogenes strain HKU488	
1314.536	Streptococcus pyogenes strain HarveyGAS		1314	Complete	HarveyGAS	M28			MLST.Streptococcus_pyogenes.52	genotype:M28			2017-10-16T00:00:00Z		PRJNA413555	SAMN07757765	GCA_002557755.1	CP023769		Houston Methodist Hospital	Complete	Illumina MiSeq; Oxford Nanopore MinION	501.0x	Unicycler v. 0.4.1	1.0		1		1852980	38.34	1869		1788.0		wound		2017-08-30	USA	USA: Houston, Texas						Human, Homo sapiens			necrotizing fasciitis																Whole genome sequencing of a Group A Streptococcus causing necrotizing fasciitis acquired contemporaneously with Hurricane Harvey.	collected_by:Houston Methodist Hospital
1314.2618	Streptococcus pyogenes strain INFECT2001_SPY		1314	WGS	INFECT2001_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634197	GCA_009847515.1	WVGP00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	31		1800059	38.33669	1853				Blood		2013	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2649	Streptococcus pyogenes strain INFECT2002_SPY		1314	WGS	INFECT2002_SPY				MLST.Streptococcus_pyogenes.36	genotype:M12			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634198	GCA_009848225.1	WVGO00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	39		1795329	38.364555	1799				Blood		2013	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2717	Streptococcus pyogenes strain INFECT2056_SPY		1314	WGS	INFECT2056_SPY				MLST.Streptococcus_pyogenes.46	genotype:M22			2020-03-16T00:00:00Z		PRJNA524111	SAMN13671699	GCA_011317345.1	WUCJ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	35		1837216	38.33757	1847				Blood		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2648	Streptococcus pyogenes strain INFECT2058_SPY		1314	WGS	INFECT2058_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634200	GCA_009848195.1	WVGM00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	17		1818124	38.18018	1822				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2615	Streptococcus pyogenes strain INFECT2060_SPY		1314	WGS	INFECT2060_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634201	GCA_009847455.1	WVGL00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	27		1798294	38.372368	1828				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2617	Streptococcus pyogenes strain INFECT2068_SPY		1314	WGS	INFECT2068_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634202	GCA_009847475.1	WVGK00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	33		1842510	38.37374	1896				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2613	Streptococcus pyogenes strain INFECT2072_SPY		1314	WGS	INFECT2072_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3.23			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634203	GCA_009847445.1	WVGJ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1796038	38.396515	1841				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2629	Streptococcus pyogenes strain INFECT2073_SPY		1314	WGS	INFECT2073_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634204	GCA_009847785.1	WVGI00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	29		1802969	38.361725	1831				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2612	Streptococcus pyogenes strain INFECT2075_SPY		1314	WGS	INFECT2075_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634205	GCA_009847385.1	WVGH00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	26		1802174	38.364277	1828				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2632	Streptococcus pyogenes strain INFECT2076_SPY		1314	WGS	INFECT2076_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634206	GCA_009847855.1	WVGG00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	43		1854165	38.41298	1949				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2635	Streptococcus pyogenes strain INFECT2077_SPY		1314	WGS	INFECT2077_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634207	GCA_009847875.1	WVGF00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	32		1804478	38.361565	1840				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2624	Streptococcus pyogenes strain INFECT2080_SPY		1314	WGS	INFECT2080_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634208	GCA_009847675.1	WVGE00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	41		1852861	38.410435	1948				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2597	Streptococcus pyogenes strain INFECT2084_SPY		1314	WGS	INFECT2084_SPY				MLST.Streptococcus_pyogenes.28	genotype:M196.1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634209	GCA_009847085.1	WVGD00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798772	38.37418	1824				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2623	Streptococcus pyogenes strain INFECT2085_SPY		1314	WGS	INFECT2085_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634210	GCA_009847665.1	WVGC00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798223	38.370213	1825				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2611	Streptococcus pyogenes strain INFECT2092_SPY		1314	WGS	INFECT2092_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634212	GCA_009847375.1	WVGA00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	29		1838352	38.38128	1889				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2647	Streptococcus pyogenes strain INFECT2094_SPY		1314	WGS	INFECT2094_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634213	GCA_009848175.1	WVFZ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	29		1797104	38.370068	1832				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2646	Streptococcus pyogenes strain INFECT2096_SPY		1314	WGS	INFECT2096_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634214	GCA_009848135.1	WVFY00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	52		1854732	38.41795	1961				Tissue		2014	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2645	Streptococcus pyogenes strain INFECT2106_SPY		1314	WGS	INFECT2106_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634215	GCA_009848105.1	WVFX00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798533	38.36894	1825				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2644	Streptococcus pyogenes strain INFECT2118_SPY		1314	WGS	INFECT2118_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1.25			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634216	GCA_009848085.1	WVFW00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	24		1799160	38.367016	1824				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2614	Streptococcus pyogenes strain INFECT2131_SPY		1314	WGS	INFECT2131_SPY				MLST.Streptococcus_pyogenes.382	genotype:M6			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634217	GCA_009847425.1	WVFV00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	46		1880917	38.4001	1999				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2608	Streptococcus pyogenes strain INFECT2132_SPY		1314	WGS	INFECT2132_SPY				MLST.Streptococcus_pyogenes.62	genotype:M87			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634218	GCA_009847345.1	WVFU00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	53		1861601	38.319115	1906				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2610	Streptococcus pyogenes strain INFECT2134_SPY		1314	WGS	INFECT2134_SPY				MLST.Streptococcus_pyogenes.46	genotype:M22			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634219	GCA_009847355.1	WVFT00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	22		1807742	38.355694	1807				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2604	Streptococcus pyogenes strain INFECT2146_SPY		1314	WGS	INFECT2146_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634220	GCA_009847225.1	WVFS00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	43		1793765	38.388138	1836				Tissue		2015	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2606	Streptococcus pyogenes strain INFECT2154_SPY		1314	WGS	INFECT2154_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634221	GCA_009847285.1	WVFR00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	42		1854530	38.418358	1953				Tissue		2016	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2605	Streptococcus pyogenes strain INFECT2174_SPY		1314	WGS	INFECT2174_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634222	GCA_009847245.1	WVFQ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	43		1855039	38.412994	1951				Tissue		2016	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2609	Streptococcus pyogenes strain INFECT2175_SPY		1314	WGS	INFECT2175_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634223	GCA_009847315.1	WVFP00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	41		1820331	38.410378	1892				Tissue		2016	Denmark	Denmark: Copenhagen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2607	Streptococcus pyogenes strain INFECT3008_SPY		1314	WGS	INFECT3008_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634224	GCA_009847295.1	WVFO00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	17		1849432	38.194103	1860				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2601	Streptococcus pyogenes strain INFECT3009_SPY		1314	WGS	INFECT3009_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634225	GCA_009847215.1	WVFN00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	24		1798674	38.368877	1821				Blood		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2636	Streptococcus pyogenes strain INFECT3010_SPY		1314	WGS	INFECT3010_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634226	GCA_009847925.1	WVFM00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	44		1855165	38.41238	1959				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2630	Streptococcus pyogenes strain INFECT3016_SPY		1314	WGS	INFECT3016_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634227	GCA_009847805.1	WVFL00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	47		1852323	38.409336	1955				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2633	Streptococcus pyogenes strain INFECT3017_SPY		1314	WGS	INFECT3017_SPY				MLST.Streptococcus_pyogenes.101	genotype:M89			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634228	GCA_009847865.1	WVFK00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	26		1787541	38.41288	1795				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2631	Streptococcus pyogenes strain INFECT3019_SPY		1314	WGS	INFECT3019_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634229	GCA_009847815.1	WVFJ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	24		1758023	38.335163	1765				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2599	Streptococcus pyogenes strain INFECT3021_SPY		1314	WGS	INFECT3021_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1.25			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634230	GCA_009847115.1	WVFI00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	26		1799264	38.37047	1827				Tissue		2014	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2603	Streptococcus pyogenes strain INFECT3032_SPY		1314	WGS	INFECT3032_SPY				MLST.Streptococcus_pyogenes.44	genotype:M66.0			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634231	GCA_009847195.1	WVFH00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	52		1785238	38.364017	1822				Blood		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2602	Streptococcus pyogenes strain INFECT3033_SPY		1314	WGS	INFECT3033_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634232	GCA_009847185.1	WVFG00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	46		1819887	38.424694	1896				Tissue		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2716	Streptococcus pyogenes strain INFECT3037_SPY		1314	WGS	INFECT3037_SPY				MLST.Streptococcus_pyogenes.39	genotype:M4			2020-03-16T00:00:00Z		PRJNA524111	SAMN13671700	GCA_011317275.1	WUCI00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	76		1846887	38.311657	1927				Blood		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2600	Streptococcus pyogenes strain INFECT3041_SPY		1314	WGS	INFECT3041_SPY				MLST.Streptococcus_pyogenes.36	genotype:M12			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634233	GCA_009847125.1	WVFF00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	38		1795115	38.36239	1798				Tissue		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2598	Streptococcus pyogenes strain INFECT3043_SPY		1314	WGS	INFECT3043_SPY				MLST.Streptococcus_pyogenes.660	genotype:M25			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634234	GCA_009847095.1	WVFE00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	28		1901881	38.23846	1927				Tissue		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2596	Streptococcus pyogenes strain INFECT3046_SPY		1314	WGS	INFECT3046_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634235	GCA_009847055.1	WVFD00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1756851	38.339508	1768				Blood		2016	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2628	Streptococcus pyogenes strain INFECT3054_SPY		1314	WGS	INFECT3054_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634236	GCA_009847775.1	WVFC00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1798751	38.368458	1825				Tissue		2016	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2627	Streptococcus pyogenes strain INFECT3057_SPY		1314	WGS	INFECT3057_SPY				MLST.Streptococcus_pyogenes.101	genotype:M89			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634237	GCA_009847715.1	WVFB00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	18		1713445	38.391193	1676				Blood		2017	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2626	Streptococcus pyogenes strain INFECT3061_SPY		1314	WGS	INFECT3061_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634238	GCA_009847735.1	WVFA00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798620	38.371197	1825				Tissue		2017	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2625	Streptococcus pyogenes strain INFECT4008_SPY		1314	WGS	INFECT4008_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634239	GCA_009847685.1	WVEZ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	24		1839688	38.378464	1882				Tissue		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2622	Streptococcus pyogenes strain INFECT4009_SPY		1314	WGS	INFECT4009_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634240	GCA_009847645.1	WVEY00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1818860	38.17798	1815				Tissue		2015	Sweden	Sweden: Stockholm						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2714	Streptococcus pyogenes strain INFECT5010_SPY		1314	WGS	INFECT5010_SPY				MLST.Streptococcus_pyogenes.46	genotype:M22			2020-03-16T00:00:00Z		PRJNA524111	SAMN13671701	GCA_011317265.1	WUCH00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	34		1755195	38.443024	1789				Tissue		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2643	Streptococcus pyogenes strain INFECT5011_SPY		1314	WGS	INFECT5011_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634241	GCA_009848045.1	WVEX00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	25		1798330	38.375828	1826				Blood		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2712	Streptococcus pyogenes strain INFECT5012_SPY		1314	WGS	INFECT5012_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-03-16T00:00:00Z		PRJNA524111	SAMN13671702	GCA_011317245.1	WUCG00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	24		1854209	38.19731	1876				Blood		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2642	Streptococcus pyogenes strain INFECT5013_SPY		1314	WGS	INFECT5013_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634242	GCA_009848075.1	WVEW00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	41		1853583	38.408047	1940				Tissue		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2641	Streptococcus pyogenes strain INFECT5014_SPY		1314	WGS	INFECT5014_SPY				MLST.Streptococcus_pyogenes.315	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634243	GCA_009848035.1	WVEV00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	44		1854518	38.409496	1955				Blood		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2640	Streptococcus pyogenes strain INFECT5020_SPY		1314	WGS	INFECT5020_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634244	GCA_009848015.1	WVEU00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	40		1823287	38.42286	1889				Tissue		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2639	Streptococcus pyogenes strain INFECT5022_SPY		1314	WGS	INFECT5022_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634245	GCA_009847995.1	WVET00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1799305	38.36809	1828				Blood		2014	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:cell culture
1314.2595	Streptococcus pyogenes strain INFECT5024_SPY		1314	WGS	INFECT5024_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634593	GCA_009847025.1	WVHJ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	42		1851758	38.40815	1946				Blood		2015	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2591	Streptococcus pyogenes strain INFECT5031_SPY		1314	WGS	INFECT5031_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634595	GCA_009846925.1	WVHH00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1765458	38.378483	1772				Blood		2015	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2634	Streptococcus pyogenes strain INFECT5032_SPY		1314	WGS	INFECT5032_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634596	GCA_009847905.1	WVHG00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	41		1854291	38.411823	1947				Tissue		2015	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2638	Streptococcus pyogenes strain INFECT5033_SPY		1314	WGS	INFECT5033_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634597	GCA_009847955.1	WVHF00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798570	38.37104	1825				Blood		2015	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2637	Streptococcus pyogenes strain INFECT5034_SPY		1314	WGS	INFECT5034_SPY				MLST.Streptococcus_pyogenes.62	genotype:M87			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634598	GCA_009847935.1	WVHE00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	40		1822735	38.34046	1845				Blood		2015	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2592	Streptococcus pyogenes strain INFECT5042_SPY		1314	WGS	INFECT5042_SPY					genotype:M180.1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634600	GCA_009846945.1	WVHC00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	26		1763026	38.288033	1748				Tissue		2016	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2593	Streptococcus pyogenes strain INFECT5045_SPY		1314	WGS	INFECT5045_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634601	GCA_009846965.1	WVHB00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	26		1838115	38.380352	1885				Blood		2017	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2594	Streptococcus pyogenes strain INFECT5048_SPY		1314	WGS	INFECT5048_SPY				MLST.Streptococcus_pyogenes.15	genotype:M3			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634602	GCA_009846955.1	WVHA00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	40		1820093	38.408806	1892				Blood		2017	Sweden	Sweden: Gothenborg						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2620	Streptococcus pyogenes strain INFECT6029_SPY		1314	WGS	INFECT6029_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634603	GCA_009847565.1	WVGZ00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1798257	38.36971	1824				Tissue		2014	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2621	Streptococcus pyogenes strain INFECT6034_SPY		1314	WGS	INFECT6034_SPY				MLST.Streptococcus_pyogenes.176	genotype:M58.5			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634604	GCA_009847615.1	WVGY00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1891263	38.16053	1904				Blood		2014	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2619	Streptococcus pyogenes strain INFECT6039_SPY		1314	WGS	INFECT6039_SPY				MLST.Streptococcus_pyogenes.28	genotype:M1			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634606	GCA_009847555.1	WVGW00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	22		1757527	38.337162	1769				Blood		2015	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2616	Streptococcus pyogenes strain INFECT6045_SPY		1314	WGS	INFECT6045_SPY				MLST.Streptococcus_pyogenes.242	genotype:M12			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634607	GCA_009847505.1	WVGV00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	39		1795398	38.36425	1807				Blood		2015	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2650	Streptococcus pyogenes strain INFECT6046_SPY		1314	WGS	INFECT6046_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634608	GCA_009848235.1	WVGU00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1818690	38.18353	1817				Tissue		2015	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2713	Streptococcus pyogenes strain INFECT6057_SPY		1314	WGS	INFECT6057_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-03-16T00:00:00Z		PRJNA524111	SAMN13671703	GCA_011317225.1	WUCF00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1846882	38.200546	1860				Blood		2016	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.2651	Streptococcus pyogenes strain INFECT6058_SPY		1314	WGS	INFECT6058_SPY				MLST.Streptococcus_pyogenes.52	genotype:M28			2020-01-10T00:00:00Z		PRJNA524111	SAMN13634611	GCA_009848245.1	WVGR00000000		Rostock University Medical Center	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	23		1859379	38.18377	1881				Blood		2016	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	sample_type:Cell culture
1314.436	Streptococcus pyogenes strain ISR		1314	WGS	ISR				MLST.Streptococcus_pyogenes.46				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520969	GCF_900106395.1	FNMM00000000		CHUV-UNIL	WGS						33		1868156	38.33	1935		1875.0		Blood culture		2016-02-25								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.441	Streptococcus pyogenes strain ISR1		1314	WGS	ISR1				MLST.Streptococcus_pyogenes.15				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520962	GCF_900106445.1	FNMH00000000		CHUV-UNIL	WGS						29		1823729	38.42	1911		1856.0		Blood culture		2015-12-15								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.438	Streptococcus pyogenes strain ISR10		1314	WGS	ISR10				MLST.Streptococcus_pyogenes.101				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520971	GCF_900106415.1	FNMG00000000		CHUV-UNIL	WGS						16		1689494	38.4	1655		1630.0		Blood culture		2016-01-21								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.437	Streptococcus pyogenes strain ISR11		1314	WGS	ISR11				MLST.Streptococcus_pyogenes.52				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520972	GCF_900106405.1	FNMI00000000		CHUV-UNIL	WGS						21		1847894	38.21	1878		1844.0		Blood culture		2015-12-18								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.446	Streptococcus pyogenes strain ISR2		1314	WGS	ISR2				MLST.Streptococcus_pyogenes.880				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520963	GCF_900106495.1	FNMQ00000000		CHUV-UNIL	WGS						18		1860675	38.46	1929		1893.0		Blood culture		2016-01-04								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.440	Streptococcus pyogenes strain ISR3		1314	WGS	ISR3				MLST.Streptococcus_pyogenes.28				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520964	GCF_900106435.1	FNMJ00000000		CHUV-UNIL	WGS						20		1800238	38.38	1836		1808.0		Blood culture		2016-01-27								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.445	Streptococcus pyogenes strain ISR4		1314	WGS	ISR4				MLST.Streptococcus_pyogenes.28				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520965	GCF_900106485.1	FNMO00000000		CHUV-UNIL	WGS						16		1800964	38.37	1835		1811.0		Blood culture		2016-02-29								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.439	Streptococcus pyogenes strain ISR5		1314	WGS	ISR5				MLST.Streptococcus_pyogenes.331				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520966	GCF_900106425.1	FNML00000000		CHUV-UNIL	WGS						30		1844829	38.38	1907		1866.0		Blood culture		2016-01-01								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.442	Streptococcus pyogenes strain ISR6		1314	WGS	ISR6				MLST.Streptococcus_pyogenes.99				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520967	GCF_900106455.1	FNMK00000000		CHUV-UNIL	WGS						26		1852149	38.42	1915		1867.0		Blood culture		2015-12-18								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.444	Streptococcus pyogenes strain ISR7		1314	WGS	ISR7				MLST.Streptococcus_pyogenes.46				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520968	GCF_900106475.1	FNMP00000000		CHUV-UNIL	WGS						26		1844325	38.34	1884		1840.0		Blood culture		2016-02-25								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.443	Streptococcus pyogenes strain ISR9		1314	WGS	ISR9				MLST.Streptococcus_pyogenes.458				2017-01-25T00:00:00Z		PRJEB14938	SAMEA4520970	GCF_900106465.1	FNMF00000000		CHUV-UNIL	WGS						18		1822707	38.19	1847		1814.0		Blood culture		2016-03-08								Human, Homo sapiens						host_health_state:diseased													After noticing an increase of invasive Streptococcus pyogenes infections in Switzerland, we performed a whole genome sequence (WGS) analysis of 11 isolates withdrawn between the 13.12.2015 and the 12.03.2016. Compared with emm-typing, MLST, only WGS allowed a good discrimination between the isolates and could rule out an outbreak of a hypervirulent clone. Characterization of the genes involved in the virulence and antibiotic resistances was also performed. Results were given to the clinicians in less than 10 days after the start of the analysis and had a positive impact on public health.	
1314.535	Streptococcus pyogenes strain JMUB1235		1314	Complete	JMUB1235				MLST.Streptococcus_pyogenes.101				2016-08-27T00:00:00Z		PRJDB5086	SAMD00057778	GCA_002355815.1	AP017629		Division of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University	Complete	MiSeq;ABI 3730	86.9X	Velvet de novo Assembly v. 1.2.10	1.0		1		1741982	38.52	1715		1659.0				2016	Japan	Japan															Positive	Cocci									Acute phlegmonous gastritis is an uncommon endogenous bacterial gastritis presenting with a hich mortality rate. Here, we submit the complete genome sequence of an emm89 Streptococcus pyogenes strain JMUB1235, which is the causetive agent of acute phelgmonous gastritis.	
1314.548	Streptococcus pyogenes strain JS12		1314	Complete	JS12				MLST.Streptococcus_pyogenes.619				2017-12-18T00:00:00Z		PRJNA388295	SAMN07174848	GCA_002844355.1	CP021640		National University of Singapore and Genome Institute of Singapore	Complete	PacBio	200.0x	HGAP3 v. JUL-2016	1.0		1		1810283	38.46	1782		1721.0		CSF	isolate from a meningitis patient in Jerusalem, Israel to gain insights into its pathogenicity	1997	Israel	Israel						Human, Homo sapiens			Meningitis																Sequencing of Group A Streptococcus strain JS12, a sil-positive isolate from a meningitis patient in Jerusalem, Israel to gain insights into its pathogenicity.	collected_by:Ministry of Health Streptococcal Reference Laboratory, Jerusalem, Israel
1314.429	Streptococcus pyogenes strain JS95		1314	WGS	JS95				MLST.Streptococcus_pyogenes.84				2017-01-05T00:00:00Z		PRJNA358871	SAMN06186737	GCF_001937265.1	MSMN00000000		National University of Singapore and Genome Institute of Singapore	WGS	Illumina HiSeq	900.0x	Velvet v. 1.2.10			30		1785289	38.35	1875		1784.0		soft tissue		1997	Israel	Israel						Human, Homo sapiens			necrotizing fasciitis																Whole genome sequencing of emm14 Streptococcus pyogenes strain JS95. This strain is a necrotizing fasciitis strain isolated in Israel	collected_by:Ministry of Health Streptococcal Reference Laboratory, Jerusalem, Israel
1314.1820	Streptococcus pyogenes strain K10016		1314	WGS	K10016	EMM103.0			MLST.Streptococcus_pyogenes.233				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711789	GCA_900990475.1	CAAIKM000000000		SC	WGS						14		1800373	38.228745	1788		1686.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1821	Streptococcus pyogenes strain K10021		1314	WGS	K10021	EMM103.0			MLST.Streptococcus_pyogenes.233				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711811	GCA_900990485.1	CAAIKN000000000		SC	WGS						15		1798053	38.224403	1776		1682.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1822	Streptococcus pyogenes strain K10040		1314	WGS	K10040	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711740	GCA_900990495.1	CAAIKO000000000		SC	WGS						16		1848055	38.295254	1843		1749.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1824	Streptococcus pyogenes strain K10105		1314	WGS	K10105	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711653	GCA_900990515.1	CAAIKS000000000		SC	WGS						16		1846856	38.295082	1840		1747.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1333	Streptococcus pyogenes strain K10167		1314	WGS	K10167	EMM98.3			MLST.Streptococcus_pyogenes.136				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711804	GCA_900985535.1	CAAHRT000000000		SC	WGS						16		1706927	38.389515	1693		1599.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1356	Streptococcus pyogenes strain K10213		1314	WGS	K10213	EMM169.1			MLST.Streptococcus_pyogenes.238				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711641	GCA_900985765.1	CAAHSQ000000000		SC	WGS						22		1896260	38.304157	1965		1856.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1074	Streptococcus pyogenes strain K10234		1314	WGS	K10234	EMM65.5			MLST.Streptococcus_pyogenes.215				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238157	GCA_900982945.1	CAAHHR000000000		SC	WGS						13		1753095	38.371895	1737		1649.0		skin, soft tissue and Pneumonia		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1828	Streptococcus pyogenes strain K10238		1314	WGS	K10238	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711563	GCA_900990555.1	CAAIKU000000000		SC	WGS						10		1799985	38.156727	1809		1713.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1073	Streptococcus pyogenes strain K10246		1314	WGS	K10246	EMM162.1			MLST.Streptococcus_pyogenes.412				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238158	GCA_900982935.1	CAAHHU000000000		SC	WGS						15		1761635	38.342045	1724		1641.0		skin, soft tissue and Pneumonia		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1344	Streptococcus pyogenes strain K10311		1314	WGS	K10311	EMM50.3			MLST.Streptococcus_pyogenes.217				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711694	GCA_900985645.1	CAAHSD000000000		SC	WGS						15		1713972	38.323906	1675		1593.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1772	Streptococcus pyogenes strain K10332		1314	WGS	K10332	EMM183.2			MLST.Streptococcus_pyogenes.761				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711628	GCA_900989995.1	CAAIIQ000000000		SC	WGS						15		1740160	38.347702	1693		1607.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1322	Streptococcus pyogenes strain K10378		1314	WGS	K10378	EMM50.3			MLST.Streptococcus_pyogenes.217				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711617	GCA_900985435.1	CAAHRI000000000		SC	WGS						20		1720786	38.307224	1691		1603.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1771	Streptococcus pyogenes strain K10474		1314	WGS	K10474	EMM118.2			MLST.Streptococcus_pyogenes.752				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711642	GCA_900989985.1	CAAIIP000000000		SC	WGS						16		1770203	38.239952	1719		1630.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1400	Streptococcus pyogenes strain K10514		1314	WGS	K10514	EMM77.0			MLST.Streptococcus_pyogenes.218				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711630	GCA_900986205.1	CAAHUF000000000		SC	WGS						17		1759322	38.332855	1730		1640.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1773	Streptococcus pyogenes strain K10586		1314	WGS	K10586	EMM50.3			MLST.Streptococcus_pyogenes.217				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711621	GCA_900990005.1	CAAIIR000000000		SC	WGS						17		1748628	38.314667	1729		1643.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1331	Streptococcus pyogenes strain K10676		1314	WGS	K10676	EMM103.0			MLST.Streptococcus_pyogenes.233				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711774	GCA_900985515.1	CAAHRQ000000000		SC	WGS						16		1801096	38.22756	1786		1687.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1837	Streptococcus pyogenes strain K10697		1314	WGS	K10697	EMM18.21			MLST.Streptococcus_pyogenes.221				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711681	GCA_900990645.1	CAAILD000000000		SC	WGS						16		1766766	38.337845	1738		1648.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1825	Streptococcus pyogenes strain K10712		1314	WGS	K10712	EMM183.2			MLST.Streptococcus_pyogenes.219				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711640	GCA_900990525.1	CAAIKP000000000		SC	WGS						18		1779854	38.359493	1750		1665.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1774	Streptococcus pyogenes strain K10722		1314	WGS	K10722	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711602	GCA_900990015.1	CAAIIS000000000		SC	WGS						15		1846285	38.301205	1830		1744.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1345	Streptococcus pyogenes strain K10812		1314	WGS	K10812	EMM82.5			MLST.Streptococcus_pyogenes.257				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711715	GCA_900985665.1	CAAHSF000000000		SC	WGS						27		1872723	38.25969	1868		1764.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1827	Streptococcus pyogenes strain K10987		1314	WGS	K10987	EMM230.1			MLST.Streptococcus_pyogenes.755				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711577	GCA_900990545.1	CAAIKT000000000		SC	WGS						19		1757544	38.342583	1756		1658.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1775	Streptococcus pyogenes strain K11116		1314	WGS	K11116	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711579	GCA_900990025.1	CAAIIT000000000		SC	WGS						15		1819169	38.247177	1857		1751.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1776	Streptococcus pyogenes strain K11239		1314	WGS	K11239	EMM169.1			MLST.Streptococcus_pyogenes.238				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711821	GCA_900990035.1	CAAIIU000000000		SC	WGS						17		1852700	38.311985	1888		1784.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1778	Streptococcus pyogenes strain K11243		1314	WGS	K11243	EMM114.5			MLST.Streptococcus_pyogenes.220				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711838	GCA_900990055.1	CAAIIW000000000		SC	WGS						15		1748643	38.41613	1726		1637.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1351	Streptococcus pyogenes strain K11254		1314	WGS	K11254	EMM18.21			MLST.Streptococcus_pyogenes.221				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711756	GCA_900985715.1	CAAHSK000000000		SC	WGS						18		1784072	38.328384	1758		1669.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1352	Streptococcus pyogenes strain K11271		1314	WGS	K11271	EMM25.4			MLST.Streptococcus_pyogenes.222				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711704	GCA_900985725.1	CAAHSJ000000000		SC	WGS						14		1816129	38.317654	1786		1688.0		sterile site		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1779	Streptococcus pyogenes strain K11319		1314	WGS	K11319	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711766	GCA_900990065.1	CAAIIX000000000		SC	WGS						13		1728832	38.32038	1706		1626.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1740	Streptococcus pyogenes strain K11464		1314	WGS	K11464	EMM99.5			MLST.Streptococcus_pyogenes.781				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711629	GCA_900989675.1	CAAIHL000000000		SC	WGS						11		1713563	38.36433	1690		1617.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1738	Streptococcus pyogenes strain K11814		1314	WGS	K11814	EMM169.1			MLST.Streptococcus_pyogenes.226				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711655	GCA_900989655.1	CAAIHK000000000		SC	WGS						20		1852114	38.300797	1888		1785.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1695	Streptococcus pyogenes strain K11898		1314	WGS	K11898	EMM111.2			MLST.Streptococcus_pyogenes.737				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695399	GCA_900989225.1	CAAIFR000000000		SC	WGS						12		1751373	38.35385	1716		1628.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1853	Streptococcus pyogenes strain K12183		1314	WGS	K12183	EMM124.2			MLST.Streptococcus_pyogenes.231				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711688	GCA_900990805.1	CAAILT000000000		SC	WGS						12		1731963	38.358692	1683		1597.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1065	Streptococcus pyogenes strain K12363		1314	WGS	K12363	EMM79.5			MLST.Streptococcus_pyogenes.714				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238159	GCA_900982855.1	CAAHHL000000000		SC	WGS						9		1800045	38.35239	1769		1686.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1691	Streptococcus pyogenes strain K12434		1314	WGS	K12434	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695420	GCA_900989185.1	CAAIFL000000000		SC	WGS						16		1785174	38.270332	1791		1699.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1063	Streptococcus pyogenes strain K12452		1314	WGS	K12452	EMM183.2			MLST.Streptococcus_pyogenes.761				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238160	GCA_900982835.1	CAAHHI000000000		SC	WGS						9		1743128	38.35749	1691		1607.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1723	Streptococcus pyogenes strain K12473		1314	WGS	K12473	EMM55.0			MLST.Streptococcus_pyogenes.232				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695413	GCA_900989505.1	CAAIGT000000000		SC	WGS						26		1767377	38.36852	1758		1664.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1394	Streptococcus pyogenes strain K12537		1314	WGS	K12537	EMM103.0			MLST.Streptococcus_pyogenes.233				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711568	GCA_900986145.1	CAAHUB000000000		SC	WGS						17		1801677	38.2215	1785		1684.0		CSF		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1082	Streptococcus pyogenes strain K12537		1314	WGS	K12537	EMM103.0			MLST.Streptococcus_pyogenes.233				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238161	GCA_900983025.1	CAAHIB000000000		SC	WGS						6		1802752	38.23839	1770		1679.0		Meningitis, Pneumonia		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1341	Streptococcus pyogenes strain K12554		1314	WGS	K12554	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711739	GCA_900985615.1	CAAHSA000000000		SC	WGS						17		1783177	38.272026	1800		1694.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1398	Streptococcus pyogenes strain K12614		1314	WGS	K12614	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711743	GCA_900986185.1	CAAHUG000000000		SC	WGS						11		1777500	38.279064	1754		1656.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1325	Streptococcus pyogenes strain K12669		1314	WGS	K12669	EMM183.2			MLST.Streptococcus_pyogenes.234				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711781	GCA_900985455.1	CAAHRK000000000		SC	WGS						16		1754020	38.32915	1714		1629.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1851	Streptococcus pyogenes strain K13045		1314	WGS	K13045	EMM192.0			MLST.Streptococcus_pyogenes.261				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711672	GCA_900990785.1	CAAILR000000000		SC	WGS						15		1801558	38.383	1823		1721.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1782	Streptococcus pyogenes strain K13065		1314	WGS	K13065	EMM75.1			MLST.Streptococcus_pyogenes.578				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711785	GCA_900990095.1	CAAIIZ000000000		SC	WGS						17		1874826	38.398655	1867		1775.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1781	Streptococcus pyogenes strain K13107		1314	WGS	K13107	EMM183.2			MLST.Streptococcus_pyogenes.219				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711733	GCA_900990085.1	CAAIJA000000000		SC	WGS						18		1780340	38.360897	1749		1663.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1393	Streptococcus pyogenes strain K13179		1314	WGS	K13179	STG7882.3			MLST.Streptococcus_pyogenes.235				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711793	GCA_900986135.1	CAAHUA000000000		SC	WGS						21		1844116	38.1929	1858		1752.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1780	Streptococcus pyogenes strain K13190		1314	WGS	K13190	EMM39.4			MLST.Streptococcus_pyogenes.236				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711752	GCA_900990075.1	CAAIIY000000000		SC	WGS						29		1777453	38.355274	1758		1661.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1080	Streptococcus pyogenes strain K13254		1314	WGS	K13254	EMM63.5			MLST.Streptococcus_pyogenes.764				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238162	GCA_900983005.1	CAAHHZ000000000		SC	WGS						21		1910387	38.27515	1946		1839.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1785	Streptococcus pyogenes strain K13372		1314	WGS	K13372	EMM81.2			MLST.Streptococcus_pyogenes.766				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711701	GCA_900990125.1	CAAIJB000000000		SC	WGS						25		1883576	38.258133	1912		1805.0		skin, soft tissue infection		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1401	Streptococcus pyogenes strain K13389		1314	WGS	K13389	EMM169.1			MLST.Streptococcus_pyogenes.238				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711747	GCA_900986215.1	CAAHUI000000000		SC	WGS						23		1854347	38.295753	1892		1784.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1372	Streptococcus pyogenes strain K13389		1314	WGS	K13389	EMM169.1			MLST.Streptococcus_pyogenes.238				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711668	GCA_900985925.1	CAAHTF000000000		SC	WGS						22		1850879	38.3042	1876		1779.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1342	Streptococcus pyogenes strain K13484		1314	WGS	K13484	EMM119.2			MLST.Streptococcus_pyogenes.239				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711576	GCA_900985625.1	CAAHSB000000000		SC	WGS						9		1790472	38.181942	1778		1685.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1064	Streptococcus pyogenes strain K13569		1314	WGS	K13569	EMM63.5			MLST.Streptococcus_pyogenes.764				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238163	GCA_900982845.1	CAAHHJ000000000		SC	WGS						23		1869881	38.29094	1879		1772.0		sterile site		2004	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1698	Streptococcus pyogenes strain K13994		1314	WGS	K13994	EMM77.0			MLST.Streptococcus_pyogenes.747				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695417	GCA_900989255.1	CAAIFU000000000		SC	WGS						24		1894629	38.263435	1922		1822.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1357	Streptococcus pyogenes strain K14810		1314	WGS	K14810	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711605	GCA_900985775.1	CAAHSP000000000		SC	WGS						13		1811671	38.254223	1832		1731.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1699	Streptococcus pyogenes strain K16544		1314	WGS	K16544	EMM11.0			MLST.Streptococcus_pyogenes.250				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695387	GCA_900989265.1	CAAIFV000000000		SC	WGS						14		1728982	38.386692	1692		1596.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1066	Streptococcus pyogenes strain K16587		1314	WGS	K16587	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238164	GCA_900982865.1	CAAHHK000000000		SC	WGS						13		1751362	38.28151	1732		1631.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1665	Streptococcus pyogenes strain K16727		1314	WGS	K16727	EMM65.0			MLST.Streptococcus_pyogenes.778				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695411	GCA_900988925.1	CAAIEN000000000		SC	WGS						22		1755021	38.35333	1737		1637.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1843	Streptococcus pyogenes strain K16738		1314	WGS	K16738	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711721	GCA_900990705.1	CAAILJ000000000		SC	WGS						16		1728835	38.31935	1711		1631.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1839	Streptococcus pyogenes strain K16772		1314	WGS	K16772	EMM89.8			MLST.Streptococcus_pyogenes.245				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711673	GCA_900990665.1	CAAILE000000000		SC	WGS						20		1759608	38.27483	1716		1613.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1696	Streptococcus pyogenes strain K16781		1314	WGS	K16781	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695468	GCA_900989235.1	CAAIFS000000000		SC	WGS						17		1747114	38.272488	1727		1635.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1697	Streptococcus pyogenes strain K16837		1314	WGS	K16837	EMM83.12			MLST.Streptococcus_pyogenes.393				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695435	GCA_900989245.1	CAAIFT000000000		SC	WGS						14		1754880	38.345757	1729		1634.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1067	Streptococcus pyogenes strain K16849		1314	WGS	K16849	EMM83.12			MLST.Streptococcus_pyogenes.393				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238165	GCA_900982875.1	CAAHHM000000000		SC	WGS						9		1757879	38.358784	1723		1635.0		sepsis (no localising source)		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1725	Streptococcus pyogenes strain K16898		1314	WGS	K16898	EMM112.5			MLST.Streptococcus_pyogenes.246				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695393	GCA_900989525.1	CAAIGV000000000		SC	WGS						9		1738855	38.34305	1703		1621.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1072	Streptococcus pyogenes strain K17011		1314	WGS	K17011	EMM79.5			MLST.Streptococcus_pyogenes.714				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238166	GCA_900982925.1	CAAHHV000000000		SC	WGS						10		1790898	38.347862	1766		1684.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1085	Streptococcus pyogenes strain K17074		1314	WGS	K17074	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238167	GCA_900983055.1	CAAHIF000000000		SC	WGS						12		1738283	38.25234	1742		1646.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1338	Streptococcus pyogenes strain K17097		1314	WGS	K17097	EMM223.0			MLST.Streptococcus_pyogenes.536				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711615	GCA_900985585.1	CAAHRX000000000		SC	WGS						17		1798365	38.14843	1763		1656.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1783	Streptococcus pyogenes strain K17276		1314	WGS	K17276	EMM92.0			MLST.Streptococcus_pyogenes.674				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711723	GCA_900990105.1	CAAIJC000000000		SC	WGS						13		1762294	38.301044	1737		1649.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1742	Streptococcus pyogenes strain K17300		1314	WGS	K17300	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711680	GCA_900989695.1	CAAIHN000000000		SC	WGS						20		1781784	38.23606	1788		1688.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1831	Streptococcus pyogenes strain K17494		1314	WGS	K17494	EMM55.0			MLST.Streptococcus_pyogenes.248				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711606	GCA_900990585.1	CAAIKX000000000		SC	WGS						32		1866568	38.381676	1924		1822.0		sterile site		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1743	Streptococcus pyogenes strain K17716		1314	WGS	K17716	EMM19.10			MLST.Streptococcus_pyogenes.769				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711671	GCA_900989705.1	CAAIHM000000000		SC	WGS						28		1818979	38.29434	1847		1739.0		skin, soft tissue infection		2005	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1321	Streptococcus pyogenes strain K17786		1314	WGS	K17786	EMM11.0			MLST.Streptococcus_pyogenes.251				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711580	GCA_900985415.1	CAAHRG000000000		SC	WGS						13		1729829	38.39035	1708		1607.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1848	Streptococcus pyogenes strain K17786		1314	WGS	K17786	EMM11.0			MLST.Streptococcus_pyogenes.250				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711607	GCA_900990755.1	CAAILP000000000		SC	WGS						16		1728647	38.390198	1691		1595.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1835	Streptococcus pyogenes strain K18724		1314	WGS	K18724	EMM11.0			MLST.Streptococcus_pyogenes.250				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711707	GCA_900990625.1	CAAILB000000000		SC	WGS						12		1728878	38.388134	1697		1598.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1709	Streptococcus pyogenes strain K19083		1314	WGS	K19083	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695459	GCA_900989365.1	CAAIGH000000000		SC	WGS						23		1789959	38.428867	1798		1702.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1084	Streptococcus pyogenes strain K19188		1314	WGS	K19188	EMM8.3			MLST.Streptococcus_pyogenes.505				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238168	GCA_900983045.1	CAAHID000000000		SC	WGS						12		1817558	38.30492	1797		1702.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1747	Streptococcus pyogenes strain K19219		1314	WGS	K19219	EMM124.2			MLST.Streptococcus_pyogenes.231				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711676	GCA_900989745.1	CAAIHR000000000		SC	WGS						16		1730666	38.359394	1674		1593.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1793	Streptococcus pyogenes strain K19347		1314	WGS	K19347	STG1750.0			MLST.Streptococcus_pyogenes.258				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711786	GCA_900990205.1	CAAIJL000000000		SC	WGS						20		1807880	38.326073	1798		1702.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1794	Streptococcus pyogenes strain K19376		1314	WGS	K19376	EMM75.1			MLST.Streptococcus_pyogenes.578				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711696	GCA_900990215.1	CAAIJM000000000		SC	WGS						20		1920333	38.416332	1940		1847.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1811	Streptococcus pyogenes strain K19417		1314	WGS	K19417	EMM122.0			MLST.Streptococcus_pyogenes.200				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711809	GCA_900990385.1	CAAIKD000000000		SC	WGS						17		1829484	38.258984	1867		1758.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1068	Streptococcus pyogenes strain K19464		1314	WGS	K19464	STG653.1			MLST.Streptococcus_pyogenes.254				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238169	GCA_900982885.1	CAAHHN000000000		SC	WGS						12		1768403	38.217567	1743		1658.0		skin, soft tissue and Pneumonia		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1830	Streptococcus pyogenes strain K19639		1314	WGS	K19639	EMM111.1			MLST.Streptococcus_pyogenes.496				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711619	GCA_900990575.1	CAAIKW000000000		SC	WGS						14		1782639	38.25637	1767		1673.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1795	Streptococcus pyogenes strain K19669		1314	WGS	K19669	STG1750.0			MLST.Streptococcus_pyogenes.258				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711748	GCA_900990225.1	CAAIJO000000000		SC	WGS						18		1814230	38.31914	1820		1720.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1847	Streptococcus pyogenes strain K19873		1314	WGS	K19873	EMM78.5			MLST.Streptococcus_pyogenes.255				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711780	GCA_900990745.1	CAAILN000000000		SC	WGS						16		1765223	38.27828	1713		1626.0		CSF		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1798	Streptococcus pyogenes strain K19875		1314	WGS	K19875	EMM111.2			MLST.Streptococcus_pyogenes.256				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711742	GCA_900990255.1	CAAIJQ000000000		SC	WGS						13		1756954	38.32895	1725		1635.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1799	Streptococcus pyogenes strain K19912		1314	WGS	K19912	EMM92.0			MLST.Streptococcus_pyogenes.674				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711648	GCA_900990265.1	CAAIJR000000000		SC	WGS						16		1795890	38.292656	1794		1698.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1800	Streptococcus pyogenes strain K19952		1314	WGS	K19952	EMM92.0			MLST.Streptococcus_pyogenes.674				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711686	GCA_900990275.1	CAAIJU000000000		SC	WGS						10		1797337	38.296627	1796		1701.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1801	Streptococcus pyogenes strain K19952		1314	WGS	K19952	EMM92.0			MLST.Streptococcus_pyogenes.674				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711634	GCA_900990285.1	CAAIJS000000000		SC	WGS						10		1797596	38.29086	1798		1706.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1396	Streptococcus pyogenes strain K19961		1314	WGS	K19961	EMM82.5			MLST.Streptococcus_pyogenes.257				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711597	GCA_900986165.1	CAAHUC000000000		SC	WGS						27		1873603	38.257378	1873		1769.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1360	Streptococcus pyogenes strain K20001		1314	WGS	K20001	EMM77.0			MLST.Streptococcus_pyogenes.747				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711575	GCA_900985805.1	CAAHST000000000		SC	WGS						24		1862817	38.258316	1876		1780.0		sterile site		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1802	Streptococcus pyogenes strain K20201		1314	WGS	K20201	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711674	GCA_900990295.1	CAAIJT000000000		SC	WGS						12		1816426	38.27582	1826		1742.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1763	Streptococcus pyogenes strain K20641		1314	WGS	K20641	EMM80.0			MLST.Streptococcus_pyogenes.701				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711801	GCA_900989905.1	CAAIIH000000000		SC	WGS						24		1816722	38.383915	1854		1742.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1764	Streptococcus pyogenes strain K20653		1314	WGS	K20653	EMM209.0			MLST.Streptococcus_pyogenes.260				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711833	GCA_900989915.1	CAAIII000000000		SC	WGS						12		1721999	38.395027	1678		1590.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1765	Streptococcus pyogenes strain K20746		1314	WGS	K20746	EMM97.1			MLST.Streptococcus_pyogenes.283				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711711	GCA_900989925.1	CAAIIJ000000000		SC	WGS						12		1775485	38.212826	1756		1669.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1766	Streptococcus pyogenes strain K20747		1314	WGS	K20747	EMM84.1			MLST.Streptococcus_pyogenes.259				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711702	GCA_900989935.1	CAAIIK000000000		SC	WGS						12		1764347	38.369267	1748		1663.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1767	Streptococcus pyogenes strain K20882		1314	WGS	K20882	EMM209.0			MLST.Streptococcus_pyogenes.260				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711685	GCA_900989955.1	CAAIIM000000000		SC	WGS						14		1723483	38.40177	1674		1585.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1769	Streptococcus pyogenes strain K20910		1314	WGS	K20910	EMM9.0			MLST.Streptococcus_pyogenes.447				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711664	GCA_900989965.1	CAAIIN000000000		SC	WGS						19		1756438	38.311058	1718		1624.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1770	Streptococcus pyogenes strain K21246		1314	WGS	K21246	EMM77.0			MLST.Streptococcus_pyogenes.747				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711646	GCA_900989975.1	CAAIIO000000000		SC	WGS						25		1858799	38.262363	1870		1768.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1682	Streptococcus pyogenes strain K21345		1314	WGS	K21345	STG866.1			MLST.Streptococcus_pyogenes.265				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695444	GCA_900989095.1	CAAIFF000000000		SC	WGS						18		1747461	38.27052	1732		1636.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1329	Streptococcus pyogenes strain K21633		1314	WGS	K21633	EMM15.1			MLST.Streptococcus_pyogenes.266				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711567	GCA_900985495.1	CAAHRO000000000		SC	WGS						21		1800707	38.28113	1785		1690.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1707	Streptococcus pyogenes strain K21710		1314	WGS	K21710	EMM109.1			MLST.Streptococcus_pyogenes.718				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695432	GCA_900989345.1	CAAIGD000000000		SC	WGS						18		1855750	38.309956	1865		1766.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1083	Streptococcus pyogenes strain K21771		1314	WGS	K21771	EMM60.7			MLST.Streptococcus_pyogenes.700				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238171	GCA_900983035.1	CAAHIC000000000		SC	WGS						13		1807549	38.31764	1802		1704.0		sepsis (no localising source), stss		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1701	Streptococcus pyogenes strain K22338		1314	WGS	K22338	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695398	GCA_900989285.1	CAAIFX000000000		SC	WGS						17		1735138	38.315247	1719		1623.0		skin, soft tissue infection		2006	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1702	Streptococcus pyogenes strain K22633		1314	WGS	K22633	EMM89.8			MLST.Streptococcus_pyogenes.772				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695469	GCA_900989295.1	CAAIFY000000000		SC	WGS						17		1856655	38.267315	1861		1763.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1700	Streptococcus pyogenes strain K22757		1314	WGS	K22757	EMM83.12			MLST.Streptococcus_pyogenes.393				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695450	GCA_900989275.1	CAAIFW000000000		SC	WGS						17		1761970	38.346508	1731		1636.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1706	Streptococcus pyogenes strain K22813		1314	WGS	K22813	EMM121.0			MLST.Streptococcus_pyogenes.262				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695429	GCA_900989335.1	CAAIGC000000000		SC	WGS						14		1745642	38.381203	1749		1655.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1704	Streptococcus pyogenes strain K23180		1314	WGS	K23180	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695401	GCA_900989315.1	CAAIGA000000000		SC	WGS						19		1814064	38.276047	1828		1737.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1395	Streptococcus pyogenes strain K23182		1314	WGS	K23182	EMM63.5			MLST.Streptococcus_pyogenes.274				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711669	GCA_900986155.1	CAAHUD000000000		SC	WGS						18		1848768	38.399742	1826		1729.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1705	Streptococcus pyogenes strain K23323		1314	WGS	K23323	EMM84.1			MLST.Streptococcus_pyogenes.259				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695407	GCA_900989325.1	CAAIGB000000000		SC	WGS						16		1785371	38.38205	1781		1697.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1717	Streptococcus pyogenes strain K23617		1314	WGS	K23617	EMM48.0			MLST.Streptococcus_pyogenes.278				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695396	GCA_900989445.1	CAAIGN000000000		SC	WGS						14		1858468	38.38129	1818		1733.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1673	Streptococcus pyogenes strain K23653		1314	WGS	K23653	EMM8.3			MLST.Streptococcus_pyogenes.241				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695381	GCA_900989005.1	CAAIEU000000000		SC	WGS						12		1825082	38.313587	1813		1717.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1784	Streptococcus pyogenes strain K23685		1314	WGS	K23685	EMM79.5			MLST.Streptococcus_pyogenes.714				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711660	GCA_900990115.1	CAAIJD000000000		SC	WGS						20		1821681	38.305794	1822		1732.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1786	Streptococcus pyogenes strain K23745		1314	WGS	K23745	EMM60.7			MLST.Streptococcus_pyogenes.279				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711639	GCA_900990135.1	CAAIJE000000000		SC	WGS						17		1813588	38.438244	1780		1694.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1703	Streptococcus pyogenes strain K23799		1314	WGS	K23799	EMM124.2			MLST.Streptococcus_pyogenes.280				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695388	GCA_900989305.1	CAAIFZ000000000		SC	WGS						18		1736395	38.351032	1698		1612.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1787	Streptococcus pyogenes strain K23866		1314	WGS	K23866	EMM82.5			MLST.Streptococcus_pyogenes.257				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711625	GCA_900990145.1	CAAIJF000000000		SC	WGS						37		1916018	38.247555	1943		1823.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1789	Streptococcus pyogenes strain K23890		1314	WGS	K23890	EMM97.1			MLST.Streptococcus_pyogenes.283				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711610	GCA_900990165.1	CAAIJH000000000		SC	WGS						15		1776074	38.212822	1756		1669.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1790	Streptococcus pyogenes strain K24146		1314	WGS	K24146	EMM165.0			MLST.Streptococcus_pyogenes.768				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711599	GCA_900990175.1	CAAIJI000000000		SC	WGS						20		1829088	38.283234	1811		1717.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1791	Streptococcus pyogenes strain K24190		1314	WGS	K24190	EMM28.0			MLST.Streptococcus_pyogenes.763				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711582	GCA_900990185.1	CAAIJJ000000000		SC	WGS						13		1816723	38.325768	1801		1702.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1071	Streptococcus pyogenes strain K24357		1314	WGS	K24357	EMM209.0			MLST.Streptococcus_pyogenes.260				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238173	GCA_900982915.1	CAAHHO000000000		SC	WGS						7		1752284	38.451927	1721		1639.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1792	Streptococcus pyogenes strain K24525		1314	WGS	K24525	EMM11.0							2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711765	GCA_900990195.1	CAAIJK000000000		SC	WGS						14		1760540	38.388676	1752		1659.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1746	Streptococcus pyogenes strain K24601		1314	WGS	K24601	EMM89.8			MLST.Streptococcus_pyogenes.772				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711716	GCA_900989735.1	CAAIHQ000000000		SC	WGS						18		1811051	38.28269	1784		1686.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1745	Streptococcus pyogenes strain K24635		1314	WGS	K24635	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711802	GCA_900989725.1	CAAIHO000000000		SC	WGS						17		1821641	38.274097	1842		1751.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1690	Streptococcus pyogenes strain K25147		1314	WGS	K25147	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695439	GCA_900989175.1	CAAIFM000000000		SC	WGS						15		1832534	38.320652	1851		1763.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1715	Streptococcus pyogenes strain K25325		1314	WGS	K25325	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695447	GCA_900989425.1	CAAIGL000000000		SC	WGS						14		1797334	38.324883	1785		1700.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1748	Streptococcus pyogenes strain K25713		1314	WGS	K25713	EMM124.2			MLST.Streptococcus_pyogenes.280				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711829	GCA_900989755.1	CAAIHS000000000		SC	WGS						18		1734496	38.34728	1680		1601.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1749	Streptococcus pyogenes strain K26504		1314	WGS	K26504	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711834	GCA_900989765.1	CAAIHT000000000		SC	WGS						17		1784784	38.275578	1793		1699.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1807	Streptococcus pyogenes strain K27345		1314	WGS	K27345	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711692	GCA_900990365.1	CAAIKB000000000		SC	WGS						21		1745763	38.268066	1728		1631.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1672	Streptococcus pyogenes strain K27345		1314	WGS	K27345	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695425	GCA_900988995.1	CAAIEV000000000		SC	WGS						18		1746024	38.26937	1727		1632.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1810	Streptococcus pyogenes strain K28044		1314	WGS	K28044	EMM25.1			MLST.Streptococcus_pyogenes.323				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711830	GCA_900990375.1	CAAIKC000000000		SC	WGS						24		1830552	38.266293	1798		1701.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1674	Streptococcus pyogenes strain K28044		1314	WGS	K28044	EMM25.1			MLST.Streptococcus_pyogenes.323				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695456	GCA_900989015.1	CAAIEW000000000		SC	WGS						18		1833067	38.27547	1814		1715.0		sterile site		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1750	Streptococcus pyogenes strain K28162		1314	WGS	K28162	EMM83.12			MLST.Streptococcus_pyogenes.393				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711767	GCA_900989775.1	CAAIHU000000000		SC	WGS						17		1759724	38.34556	1731		1632.0		skin, soft tissue infection		2007	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1751	Streptococcus pyogenes strain K29166		1314	WGS	K29166	EMM162.1			MLST.Streptococcus_pyogenes.412				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711794	GCA_900989785.1	CAAIHV000000000		SC	WGS						22		1757570	38.318928	1727		1632.0		sterile site		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1754	Streptococcus pyogenes strain K29527		1314	WGS	K29527	EMM4.5			MLST.Streptococcus_pyogenes.771				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711608	GCA_900989815.1	CAAIHX000000000		SC	WGS						15		1784339	38.2801	1747		1652.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1753	Streptococcus pyogenes strain K29655		1314	WGS	K29655	EMM53.4			MLST.Streptococcus_pyogenes.460				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711624	GCA_900989805.1	CAAIHW000000000		SC	WGS						14		1699089	38.34677	1652		1571.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1752	Streptococcus pyogenes strain K29743		1314	WGS	K29743	EMM114.5			MLST.Streptococcus_pyogenes.220				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711566	GCA_900989795.1	CAAIHY000000000		SC	WGS						14		1717501	38.431595	1672		1588.0		sterile site		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1755	Streptococcus pyogenes strain K30067		1314	WGS	K30067	EMM73.0			MLST.Streptococcus_pyogenes.469				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711586	GCA_900989825.1	CAAIHZ000000000		SC	WGS						17		1769439	38.37318	1762		1662.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1670	Streptococcus pyogenes strain K30465		1314	WGS	K30465	EMM8.3			MLST.Streptococcus_pyogenes.505				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695430	GCA_900988975.1	CAAIET000000000		SC	WGS						12		1816264	38.299774	1795		1705.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1808	Streptococcus pyogenes strain K31028		1314	WGS	K31028	EMM93.6			MLST.Streptococcus_pyogenes.583				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711720	GCA_900990345.1	CAAIJY000000000		SC	WGS						16		1767263	38.21396	1746		1650.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1694	Streptococcus pyogenes strain K31028		1314	WGS	K31028	EMM93.6			MLST.Streptococcus_pyogenes.613				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695452	GCA_900989215.1	CAAIFQ000000000		SC	WGS						11		1765320	38.211258	1744		1650.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1756	Streptococcus pyogenes strain K31063		1314	WGS	K31063	EMM209.0			MLST.Streptococcus_pyogenes.260				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711571	GCA_900989835.1	CAAIIA000000000		SC	WGS						18		1728837	38.41166	1677		1591.0		sterile site		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1757	Streptococcus pyogenes strain K31539		1314	WGS	K31539	EMM238.1			MLST.Streptococcus_pyogenes.713				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711616	GCA_900989845.1	CAAIIB000000000		SC	WGS						9		1759120	38.298183	1730		1653.0		sterile site		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1758	Streptococcus pyogenes strain K31611		1314	WGS	K31611	EMM93.6			MLST.Streptococcus_pyogenes.613				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711598	GCA_900989855.1	CAAIIC000000000		SC	WGS						19		1733046	38.218548	1695		1593.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1760	Streptococcus pyogenes strain K32502		1314	WGS	K32502	EMM165.0			MLST.Streptococcus_pyogenes.768				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711768	GCA_900989875.1	CAAIIE000000000		SC	WGS						23		1843964	38.268433	1853		1737.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1761	Streptococcus pyogenes strain K33560		1314	WGS	K33560	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711764	GCA_900989885.1	CAAIIF000000000		SC	WGS						16		1765502	38.31675	1781		1684.0		CSF		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1762	Streptococcus pyogenes strain K33560		1314	WGS	K33560	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711776	GCA_900989895.1	CAAIIG000000000		SC	WGS						13		1765013	38.307423	1779		1689.0		CSF		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1759	Streptococcus pyogenes strain K33937		1314	WGS	K33937	EMM60.7			MLST.Streptococcus_pyogenes.700				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711819	GCA_900989865.1	CAAIID000000000		SC	WGS						15		1717996	38.368134	1696		1596.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1736	Streptococcus pyogenes strain K33937		1314	WGS	K33937	EMM60.7			MLST.Streptococcus_pyogenes.700				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711590	GCA_900989635.1	CAAIHG000000000		SC	WGS						15		1718744	38.37151	1689		1596.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1768	Streptococcus pyogenes strain K33951		1314	WGS	K33951	EMM80.0			MLST.Streptococcus_pyogenes.701				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711837	GCA_900989945.1	CAAIIL000000000		SC	WGS						17		1817943	38.387398	1848		1749.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1777	Streptococcus pyogenes strain K33983		1314	WGS	K33983	EMM30.15			MLST.Streptococcus_pyogenes.537				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711770	GCA_900990045.1	CAAIIV000000000		SC	WGS						17		1813534	38.355408	1848		1747.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1809	Streptococcus pyogenes strain K35129		1314	WGS	K35129	STG1750.0			MLST.Streptococcus_pyogenes.258				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711719	GCA_900990355.1	CAAIKA000000000		SC	WGS						21		1853432	38.318428	1880		1779.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1803	Streptococcus pyogenes strain K35215		1314	WGS	K35215	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711758	GCA_900990305.1	CAAIJV000000000		SC	WGS						18		1746093	38.269463	1728		1631.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1069	Streptococcus pyogenes strain K35215		1314	WGS	K35215	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238174	GCA_900982895.1	CAAHHP000000000		SC	WGS						14		1751442	38.28062	1723		1633.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1844	Streptococcus pyogenes strain K3525		1314	WGS	K3525	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711751	GCA_900990715.1	CAAILK000000000		SC	WGS						22		1833760	38.34237	1855		1760.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1051	Streptococcus pyogenes strain K3534		1314	WGS	K3534	EMM65.0			MLST.Streptococcus_pyogenes.716				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238130	GCA_900982675.1	CAAHHA000000000		SC	WGS						19		1752906	38.429626	1724		1622.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1842	Streptococcus pyogenes strain K3573		1314	WGS	K3573	EMM116.2			MLST.Streptococcus_pyogenes.702				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711675	GCA_900990695.1	CAAILI000000000		SC	WGS						31		1845266	38.2361	1872		1769.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1788	Streptococcus pyogenes strain K35870		1314	WGS	K35870	EMM229.0			MLST.Streptococcus_pyogenes.703				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711784	GCA_900990155.1	CAAIJG000000000		SC	WGS						28		1753421	38.320766	1743		1641.0		skin, soft tissue infection		2008	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1050	Streptococcus pyogenes strain K3589		1314	WGS	K3589	EMM8.3			MLST.Streptococcus_pyogenes.241				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238131	GCA_900982655.1	CAAHGU000000000		SC	WGS						10		1826942	38.33312	1816		1712.0		Meningitis, Pneumonia		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1347	Streptococcus pyogenes strain K3589		1314	WGS	K3589	EMM8.3			MLST.Streptococcus_pyogenes.241				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711813	GCA_900985675.1	CAAHSG000000000		SC	WGS						14		1824644	38.322327	1812		1714.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1796	Streptococcus pyogenes strain K35909		1314	WGS	K35909	EMM75.1			MLST.Streptococcus_pyogenes.704				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711718	GCA_900990235.1	CAAIJN000000000		SC	WGS						19		1839858	38.40166	1815		1715.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1805	Streptococcus pyogenes strain K36067		1314	WGS	K36067	EMM85.1			MLST.Streptococcus_pyogenes.774				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711697	GCA_900990325.1	CAAIJX000000000		SC	WGS						17		1853365	38.334995	1849		1765.0		aspirate		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1739	Streptococcus pyogenes strain K36294		1314	WGS	K36294	EMM49.9			MLST.Streptococcus_pyogenes.705				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711595	GCA_900989665.1	CAAIHI000000000		SC	WGS						21		1758769	38.332153	1728		1636.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1741	Streptococcus pyogenes strain K36347		1314	WGS	K36347	EMM65.0			MLST.Streptococcus_pyogenes.716				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711612	GCA_900989685.1	CAAIHJ000000000		SC	WGS						20		1801253	38.378616	1799		1695.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1720	Streptococcus pyogenes strain K3637		1314	WGS	K3637	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695453	GCA_900989475.1	CAAIGQ000000000		SC	WGS						14		1829272	38.252342	1832		1735.0		skin, soft tissue infection		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1804	Streptococcus pyogenes strain K36395		1314	WGS	K36395	EMM81.2			MLST.Streptococcus_pyogenes.766				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711581	GCA_900990315.1	CAAIJW000000000		SC	WGS						42		1986343	38.281254	2097		1963.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1675	Streptococcus pyogenes strain K36535		1314	WGS	K36535	EMM100.2			MLST.Streptococcus_pyogenes.773				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695385	GCA_900989025.1	CAAIEX000000000		SC	WGS						14		1771342	38.340614	1752		1665.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1086	Streptococcus pyogenes strain K36563		1314	WGS	K36563	EMM229.0			MLST.Streptococcus_pyogenes.703				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238175	GCA_900983065.1	CAAHIE000000000		SC	WGS						22		1755725	38.33442	1733		1638.0		skin, soft tissue and Pneumonia		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1735	Streptococcus pyogenes strain K37164		1314	WGS	K37164	EMM224.1			MLST.Streptococcus_pyogenes.707				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711592	GCA_900989625.1	CAAIHF000000000		SC	WGS						20		1799236	38.31154	1806		1696.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1731	Streptococcus pyogenes strain K37164		1314	WGS	K37164	EMM224.1			MLST.Streptococcus_pyogenes.707				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711710	GCA_900989585.1	CAAIHB000000000		SC	WGS						22		1801181	38.304367	1796		1692.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1737	Streptococcus pyogenes strain K37287		1314	WGS	K37287	EMM55.0			MLST.Streptococcus_pyogenes.248				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711609	GCA_900989645.1	CAAIHH000000000		SC	WGS						34		1859019	38.38046	1907		1795.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1323	Streptococcus pyogenes strain K3730		1314	WGS	K3730	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711555	GCA_900985425.1	CAAHRH000000000		SC	WGS						15		1788442	38.331463	1775		1687.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1671	Streptococcus pyogenes strain K37698		1314	WGS	K37698	EMM85.1			MLST.Streptococcus_pyogenes.709				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695415	GCA_900988985.1	CAAIER000000000		SC	WGS						19		1854263	38.338272	1859		1768.0		CSF		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1669	Streptococcus pyogenes strain K37698		1314	WGS	K37698	EMM85.1			MLST.Streptococcus_pyogenes.774				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695433	GCA_900988965.1	CAAIES000000000		SC	WGS						16		1855997	38.335182	1862		1771.0		CSF		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1676	Streptococcus pyogenes strain K37741		1314	WGS	K37741	EMM239.1			MLST.Streptococcus_pyogenes.776				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695418	GCA_900989035.1	CAAIEY000000000		SC	WGS						23		1825821	38.225216	1842		1742.0		sterile site		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1318	Streptococcus pyogenes strain K37914		1314	WGS	K37914	EMM119.2			MLST.Streptococcus_pyogenes.239				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711627	GCA_900985385.1	CAAHRD000000000		SC	WGS						10		1792341	38.189774	1770		1688.0		urine		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1726	Streptococcus pyogenes strain K37990		1314	WGS	K37990	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695443	GCA_900989535.1	CAAIGX000000000		SC	WGS						15		1729109	38.317482	1708		1626.0		sterile site		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1659	Streptococcus pyogenes strain K37990		1314	WGS	K37990	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695474	GCA_900988865.1	CAAIEG000000000		SC	WGS						14		1728613	38.316	1708		1627.0		sterile site		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1359	Streptococcus pyogenes strain K3808		1314	WGS	K3808	EMM95.0			MLST.Streptococcus_pyogenes.712				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711626	GCA_900985795.1	CAAHSS000000000		SC	WGS						15		1734184	38.241974	1694		1595.0		skin, soft tissue infection		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1713	Streptococcus pyogenes strain K38181		1314	WGS	K38181	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695383	GCA_900989405.1	CAAIGJ000000000		SC	WGS						17		1808168	38.403347	1835		1742.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1361	Streptococcus pyogenes strain K3828		1314	WGS	K3828	EMM238.1			MLST.Streptococcus_pyogenes.713				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711647	GCA_900985815.1	CAAHSU000000000		SC	WGS						10		1763123	38.303795	1737		1657.0		skin, soft tissue infection		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1087	Streptococcus pyogenes strain K38470		1314	WGS	K38470	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238176	GCA_900983075.1	CAAHIG000000000		SC	WGS						14		1832485	38.253574	1872		1767.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1732	Streptococcus pyogenes strain K38591		1314	WGS	K38591	EMM124.2			MLST.Streptococcus_pyogenes.231				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711730	GCA_900989595.1	CAAIHC000000000		SC	WGS						18		1734123	38.35111	1684		1598.0		skin, soft tissue infection		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1845	Streptococcus pyogenes strain K3879		1314	WGS	K3879	EMM183.2			MLST.Streptococcus_pyogenes.714				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711783	GCA_900990735.1	CAAILM000000000		SC	WGS						15		1791414	38.329666	1779		1689.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1070	Streptococcus pyogenes strain K39244		1314	WGS	K39244	EMM80.0			MLST.Streptococcus_pyogenes.715				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238177	GCA_900982905.1	CAAHHQ000000000		SC	WGS						16		1789688	38.139557	1794		1690.0		skin, soft tissue and Pneumonia		2009	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1343	Streptococcus pyogenes strain K3944		1314	WGS	K3944	EMM122.0			MLST.Streptococcus_pyogenes.200				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711750	GCA_900985635.1	CAAHSC000000000		SC	WGS						18		1831696	38.259754	1871		1760.0		sterile site		1998	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1363	Streptococcus pyogenes strain K3964		1314	WGS	K3964	EMM65.0			MLST.Streptococcus_pyogenes.716				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711662	GCA_900985835.1	CAAHSV000000000		SC	WGS						21		1760453	38.39356	1730		1635.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1362	Streptococcus pyogenes strain K3997		1314	WGS	K3997	EMM65.0			MLST.Streptococcus_pyogenes.716				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711683	GCA_900985825.1	CAAHSW000000000		SC	WGS						23		1758207	38.39772	1725		1624.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1714	Streptococcus pyogenes strain K40810		1314	WGS	K40810	EMM93.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695431	GCA_900989415.1	CAAIGK000000000		SC	WGS						27		1884781	38.339626	1938		1825.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1721	Streptococcus pyogenes strain K40818		1314	WGS	K40818	EMM112.5			MLST.Streptococcus_pyogenes.777				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695426	GCA_900989485.1	CAAIGS000000000		SC	WGS						13		1738272	38.340374	1715		1623.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1364	Streptococcus pyogenes strain K4134		1314	WGS	K4134	EMM209.1			MLST.Streptococcus_pyogenes.717				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711700	GCA_900985845.1	CAAHSX000000000		SC	WGS						18		1841230	38.28783	1832		1731.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1716	Streptococcus pyogenes strain K41947		1314	WGS	K41947	EMM109.1			MLST.Streptococcus_pyogenes.718				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695464	GCA_900989435.1	CAAIGM000000000		SC	WGS						20		1853684	38.30572	1861		1759.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1733	Streptococcus pyogenes strain K41948		1314	WGS	K41948	EMM208.0			MLST.Streptococcus_pyogenes.719				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711775	GCA_900989605.1	CAAIHD000000000		SC	WGS						12		1726839	38.380554	1709		1623.0		aspirate		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1366	Streptococcus pyogenes strain K4240		1314	WGS	K4240	EMM74.0			MLST.Streptococcus_pyogenes.720				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711712	GCA_900985865.1	CAAHSZ000000000		SC	WGS						15		1801647	38.07011	1800		1701.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1719	Streptococcus pyogenes strain K4254		1314	WGS	K4254	EMM85.1			MLST.Streptococcus_pyogenes.774				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695476	GCA_900989465.1	CAAIGO000000000		SC	WGS						22		1891572	38.32627	1919		1816.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1734	Streptococcus pyogenes strain K42600		1314	WGS	K42600	EMM42.3			MLST.Streptococcus_pyogenes.721				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711569	GCA_900989615.1	CAAIHE000000000		SC	WGS						14		1757590	38.400425	1756		1665.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1365	Streptococcus pyogenes strain K4263		1314	WGS	K4263	EMM230.1			MLST.Streptococcus_pyogenes.755				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711726	GCA_900985855.1	CAAHSY000000000		SC	WGS						21		1758101	38.34427	1756		1657.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1658	Streptococcus pyogenes strain K42771		1314	WGS	K42771	EMM124.2			MLST.Streptococcus_pyogenes.231				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695455	GCA_900988855.1	CAAIEH000000000		SC	WGS						17		1733973	38.35454	1686		1600.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1088	Streptococcus pyogenes strain K42952		1314	WGS	K42952	EMM111.2			MLST.Streptococcus_pyogenes.737				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238178	GCA_900983085.1	CAAHIH000000000		SC	WGS						14		1750755	38.36344	1716		1626.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1089	Streptococcus pyogenes strain K43037		1314	WGS	K43037	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238179	GCA_900983095.1	CAAHII000000000		SC	WGS						12		1819941	38.291935	1837		1743.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1686	Streptococcus pyogenes strain K43101		1314	WGS	K43101	EMM55.0			MLST.Streptococcus_pyogenes.248				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695384	GCA_900989135.1	CAAIFI000000000		SC	WGS						33		1858035	38.39147	1894		1789.0		aspirate		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1687	Streptococcus pyogenes strain K43304		1314	WGS	K43304	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695419	GCA_900989145.1	CAAIFK000000000		SC	WGS						18		1810063	38.25872	1838		1735.0		aspirate		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1355	Streptococcus pyogenes strain K4350		1314	WGS	K4350	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711796	GCA_900985745.1	CAAHSM000000000		SC	WGS						15		1848006	38.293262	1837		1747.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1681	Streptococcus pyogenes strain K44098		1314	WGS	K44098	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695416	GCA_900989085.1	CAAIFE000000000		SC	WGS						15		1810772	38.25926	1834		1731.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1685	Streptococcus pyogenes strain K44582		1314	WGS	K44582	EMM57.0			MLST.Streptococcus_pyogenes.723				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695457	GCA_900989125.1	CAAIFH000000000		SC	WGS						10		1725516	38.311092	1678		1593.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1684	Streptococcus pyogenes strain K44869		1314	WGS	K44869	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695441	GCA_900989115.1	CAAIFG000000000		SC	WGS						19		1779207	38.278908	1776		1688.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1683	Streptococcus pyogenes strain K44896		1314	WGS	K44896	EMM99.5			MLST.Streptococcus_pyogenes.781				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695422	GCA_900989105.1	CAAIFD000000000		SC	WGS						11		1712975	38.36661	1695		1618.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1679	Streptococcus pyogenes strain K45527		1314	WGS	K45527	EMM192.0			MLST.Streptococcus_pyogenes.724				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695390	GCA_900989065.1	CAAIFB000000000		SC	WGS						11		1767711	38.32261	1731		1637.0		sterile site		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1680	Streptococcus pyogenes strain K45900		1314	WGS	K45900	EMM118.2			MLST.Streptococcus_pyogenes.725				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695471	GCA_900989075.1	CAAIFC000000000		SC	WGS						17		1769609	38.23983	1722		1625.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1666	Streptococcus pyogenes strain K46187		1314	WGS	K46187	EMM68.8			MLST.Streptococcus_pyogenes.726				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695475	GCA_900988935.1	CAAIEO000000000		SC	WGS						13		1765586	38.347607	1752		1660.0		skin, soft tissue infection		2010	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1367	Streptococcus pyogenes strain K4656		1314	WGS	K4656	EMM92.1			MLST.Streptococcus_pyogenes.727				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711790	GCA_900985875.1	CAAHTA000000000		SC	WGS						10		1853245	38.328663	1846		1759.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1663	Streptococcus pyogenes strain K47020		1314	WGS	K47020	EMM80.0			MLST.Streptococcus_pyogenes.701				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695451	GCA_900988905.1	CAAIEL000000000		SC	WGS						18		1784186	38.36887	1805		1702.0		aspirate		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1664	Streptococcus pyogenes strain K47118		1314	WGS	K47118	EMM217.0			MLST.Streptococcus_pyogenes.728				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695404	GCA_900988915.1	CAAIEM000000000		SC	WGS						16		1760769	38.385468	1752		1656.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1319	Streptococcus pyogenes strain K4728		1314	WGS	K4728	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711687	GCA_900985395.1	CAAHRE000000000		SC	WGS						18		1788373	38.27246	1806		1702.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1075	Streptococcus pyogenes strain K47483		1314	WGS	K47483	EMM225.0			MLST.Streptococcus_pyogenes.262				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238180	GCA_900982955.1	CAAHHS000000000		SC	WGS						11		1734939	38.39772	1710		1623.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1662	Streptococcus pyogenes strain K47581		1314	WGS	K47581	EMM80.0			MLST.Streptococcus_pyogenes.729				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695461	GCA_900988895.1	CAAIEK000000000		SC	WGS						16		1785960	38.37266	1803		1700.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1840	Streptococcus pyogenes strain K4761		1314	WGS	K4761	EMM8.3			MLST.Streptococcus_pyogenes.730				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711657	GCA_900990675.1	CAAILG000000000		SC	WGS						11		1823936	38.320206	1810		1713.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1667	Streptococcus pyogenes strain K48083		1314	WGS	K48083	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695437	GCA_900988945.1	CAAIEP000000000		SC	WGS						13		1822831	38.265446	1815		1722.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1660	Streptococcus pyogenes strain K48186		1314	WGS	K48186	STG1750.0			MLST.Streptococcus_pyogenes.731				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695403	GCA_900988875.1	CAAIEI000000000		SC	WGS						18		1809705	38.329895	1801		1706.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1368	Streptococcus pyogenes strain K4819		1314	WGS	K4819	EMM230.1			MLST.Streptococcus_pyogenes.755				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711759	GCA_900985885.1	CAAHTB000000000		SC	WGS						21		1770377	38.334717	1772		1675.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1389	Streptococcus pyogenes strain K4828		1314	WGS	K4828	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711622	GCA_900986105.1	CAAHTX000000000		SC	WGS						14		1790667	38.26362	1777		1679.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1661	Streptococcus pyogenes strain K48650		1314	WGS	K48650	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695467	GCA_900988885.1	CAAIEJ000000000		SC	WGS						25		1847827	38.280876	1897		1801.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1693	Streptococcus pyogenes strain K48807		1314	WGS	K48807	EMM75.1			MLST.Streptococcus_pyogenes.704				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695466	GCA_900989205.1	CAAIFP000000000		SC	WGS						13		1837084	38.394432	1812		1717.0		sterile site		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1692	Streptococcus pyogenes strain K48817		1314	WGS	K48817	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695392	GCA_900989195.1	CAAIFN000000000		SC	WGS						14		1812024	38.07345	1813		1711.0		sterile site		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1688	Streptococcus pyogenes strain K48877		1314	WGS	K48877	EMM74.0			MLST.Streptococcus_pyogenes.732				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695438	GCA_900989155.1	CAAIFJ000000000		SC	WGS						16		1840634	38.09986	1851		1746.0		aspirate		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1689	Streptococcus pyogenes strain K49285		1314	WGS	K49285	EMM103.0			MLST.Streptococcus_pyogenes.733				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695442	GCA_900989165.1	CAAIFO000000000		SC	WGS						23		1819137	38.28504	1869		1769.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1710	Streptococcus pyogenes strain K49294		1314	WGS	K49294	EMM90.5			MLST.Streptococcus_pyogenes.734				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695460	GCA_900989375.1	CAAIGG000000000		SC	WGS						24		1829870	38.288754	1837		1744.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1712	Streptococcus pyogenes strain K49551		1314	WGS	K49551	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695470	GCA_900989395.1	CAAIGI000000000		SC	WGS						16		1816133	38.277924	1830		1745.0		sterile site		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1832	Streptococcus pyogenes strain K4973		1314	WGS	K4973	EMM25.4			MLST.Streptococcus_pyogenes.735				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711799	GCA_900990595.1	CAAIKY000000000		SC	WGS						15		1770961	38.291153	1728		1622.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1849	Streptococcus pyogenes strain K4973		1314	WGS	K4973	EMM25.4			MLST.Streptococcus_pyogenes.735				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711623	GCA_900990765.1	CAAILO000000000		SC	WGS						15		1772857	38.29025	1729		1624.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1370	Streptococcus pyogenes strain K4982		1314	WGS	K4982	EMM124.2			MLST.Streptococcus_pyogenes.736				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711828	GCA_900985905.1	CAAHTD000000000		SC	WGS						21		1811752	38.350006	1820		1727.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1708	Streptococcus pyogenes strain K49882		1314	WGS	K49882	EMM111.2			MLST.Streptococcus_pyogenes.737				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695405	GCA_900989355.1	CAAIGE000000000		SC	WGS						16		1780929	38.354534	1761		1670.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1806	Streptococcus pyogenes strain K50105		1314	WGS	K50105	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711738	GCA_900990335.1	CAAIJZ000000000		SC	WGS						14		1850552	38.268818	1847		1753.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1668	Streptococcus pyogenes strain K50105		1314	WGS	K50105	EMM22.5			MLST.Streptococcus_pyogenes.213				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695463	GCA_900988955.1	CAAIEQ000000000		SC	WGS						15		1850123	38.273075	1842		1753.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1397	Streptococcus pyogenes strain K5017		1314	WGS	K5017	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711650	GCA_900986175.1	CAAHUE000000000		SC	WGS						14		1784055	38.27236	1799		1705.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1841	Streptococcus pyogenes strain K5017		1314	WGS	K5017	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711659	GCA_900990685.1	CAAILH000000000		SC	WGS						17		1783602	38.272217	1800		1696.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1812	Streptococcus pyogenes strain K50316		1314	WGS	K50316	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711795	GCA_900990395.1	CAAIKE000000000		SC	WGS						16		1761008	38.3243	1757		1680.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1797	Streptococcus pyogenes strain K50593		1314	WGS	K50593	EMM9.0			MLST.Streptococcus_pyogenes.740				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711731	GCA_900990245.1	CAAIJP000000000		SC	WGS						20		1775620	38.319065	1750		1661.0		sterile site		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1744	Streptococcus pyogenes strain K50658		1314	WGS	K50658	EMM9.0			MLST.Streptococcus_pyogenes.740				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711706	GCA_900989715.1	CAAIHP000000000		SC	WGS						18		1778570	38.31614	1751		1668.0		aspirate		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1826	Streptococcus pyogenes strain K5086		1314	WGS	K5086	EMM238.1			MLST.Streptococcus_pyogenes.713				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711682	GCA_900990535.1	CAAIKR000000000		SC	WGS						10		1762018	38.30199	1735		1658.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1090	Streptococcus pyogenes strain K50977		1314	WGS	K50977	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238181	GCA_900983105.1	CAAHIJ000000000		SC	WGS						20		1860436	38.275955	1886		1773.0		sepsis (no localising source)		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1081	Streptococcus pyogenes strain K51725		1314	WGS	K51725	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238182	GCA_900983015.1	CAAHHX000000000		SC	WGS						16		1783037	38.27793	1779		1678.0		skin, soft tissue infection		2011	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1838	Streptococcus pyogenes strain K5192		1314	WGS	K5192	EMM147.0			MLST.Streptococcus_pyogenes.741				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711667	GCA_900990655.1	CAAILF000000000		SC	WGS						14		1786335	38.327076	1779		1683.0		sterile site		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1724	Streptococcus pyogenes strain K5248		1314	WGS	K5248	EMM43.1			MLST.Streptococcus_pyogenes.770				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695465	GCA_900989515.1	CAAIGU000000000		SC	WGS						25		1832476	38.261585	1831		1730.0		skin, soft tissue infection		1999	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1369	Streptococcus pyogenes strain K5460		1314	WGS	K5460	EMM11.0			MLST.Streptococcus_pyogenes.742				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711805	GCA_900985895.1	CAAHTC000000000		SC	WGS						13		1729527	38.37639	1691		1598.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1052	Streptococcus pyogenes strain K5499		1314	WGS	K5499	EMM65.5			MLST.Streptococcus_pyogenes.215				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238132	GCA_900982695.1	CAAHGX000000000		SC	WGS						15		1756728	38.365776	1741		1654.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1373	Streptococcus pyogenes strain K5660		1314	WGS	K5660	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711689	GCA_900985935.1	CAAHTG000000000		SC	WGS						17		1736104	38.317657	1720		1625.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1332	Streptococcus pyogenes strain K5679		1314	WGS	K5679	EMM177.0			MLST.Streptococcus_pyogenes.743				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711574	GCA_900985525.1	CAAHRR000000000		SC	WGS						13		1814151	38.298763	1820		1726.0		sterile site		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1374	Streptococcus pyogenes strain K5690		1314	WGS	K5690	EMM81.11			MLST.Streptococcus_pyogenes.744				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711632	GCA_900985945.1	CAAHTH000000000		SC	WGS						19		1830306	38.139053	1828		1721.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1711	Streptococcus pyogenes strain K5698		1314	WGS	K5698	EMM109.1			MLST.Streptococcus_pyogenes.718				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695423	GCA_900989385.1	CAAIGF000000000		SC	WGS						19		1855316	38.3035	1864		1761.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1054	Streptococcus pyogenes strain K5721		1314	WGS	K5721	EMM26.3			MLST.Streptococcus_pyogenes.745				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238133	GCA_900982735.1	CAAHGV000000000		SC	WGS						18		1790549	38.412968	1811		1721.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1375	Streptococcus pyogenes strain K5727		1314	WGS	K5727	EMM25.1			MLST.Streptococcus_pyogenes.746				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711644	GCA_900985955.1	CAAHTI000000000		SC	WGS						25		1888375	38.206818	1900		1791.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1378	Streptococcus pyogenes strain K5797		1314	WGS	K5797	EMM77.0			MLST.Streptococcus_pyogenes.747				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711572	GCA_900985985.1	CAAHTL000000000		SC	WGS						19		1825030	38.25536	1811		1713.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1677	Streptococcus pyogenes strain K5797		1314	WGS	K5797	EMM77.0			MLST.Streptococcus_pyogenes.747				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695421	GCA_900989045.1	CAAIEZ000000000		SC	WGS						23		1821355	38.249565	1806		1711.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1326	Streptococcus pyogenes strain K5851		1314	WGS	K5851	EMM230.1			MLST.Streptococcus_pyogenes.755				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711763	GCA_900985465.1	CAAHRL000000000		SC	WGS						22		1772151	38.332737	1785		1680.0		sterile site		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1380	Streptococcus pyogenes strain K5898		1314	WGS	K5898	EMM209.1			MLST.Streptococcus_pyogenes.749				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711836	GCA_900986005.1	CAAHTN000000000		SC	WGS						20		1840659	38.285908	1832		1727.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1379	Streptococcus pyogenes strain K5910		1314	WGS	K5910	EMM92.1			MLST.Streptococcus_pyogenes.750				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711817	GCA_900985995.1	CAAHTM000000000		SC	WGS						12		1811453	38.310406	1781		1692.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1055	Streptococcus pyogenes strain K5911		1314	WGS	K5911	EMM217.0			MLST.Streptococcus_pyogenes.728				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238134	GCA_900982745.1	CAAHGY000000000		SC	WGS						13		1761962	38.40884	1744		1652.0		sepsis (no localising source)		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1382	Streptococcus pyogenes strain K5965		1314	WGS	K5965	EMM147.0			MLST.Streptococcus_pyogenes.753				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711792	GCA_900986025.1	CAAHTP000000000		SC	WGS						11		1788402	38.33505	1761		1673.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1381	Streptococcus pyogenes strain K6008		1314	WGS	K6008	EMM75.1			MLST.Streptococcus_pyogenes.751				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711778	GCA_900986015.1	CAAHTO000000000		SC	WGS						12		1866278	38.209473	1858		1767.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1383	Streptococcus pyogenes strain K6038		1314	WGS	K6038	EMM118.2			MLST.Streptococcus_pyogenes.752				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711760	GCA_900986035.1	CAAHTQ000000000		SC	WGS						19		1810074	38.269928	1775		1681.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1384	Streptococcus pyogenes strain K6048		1314	WGS	K6048	EMM147.0			MLST.Streptococcus_pyogenes.753				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711746	GCA_900986045.1	CAAHTR000000000		SC	WGS						14		1785401	38.32906	1766		1668.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1385	Streptococcus pyogenes strain K6085		1314	WGS	K6085	EMM8.3			MLST.Streptococcus_pyogenes.241				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711744	GCA_900986055.1	CAAHTS000000000		SC	WGS						12		1823000	38.31618	1808		1714.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1386	Streptococcus pyogenes strain K6099		1314	WGS	K6099	EMM77.0			MLST.Streptococcus_pyogenes.482				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711729	GCA_900986065.1	CAAHTU000000000		SC	WGS						15		1757554	38.335297	1723		1638.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1678	Streptococcus pyogenes strain K6102		1314	WGS	K6102	EMM109.1			MLST.Streptococcus_pyogenes.718				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695409	GCA_900989055.1	CAAIFA000000000		SC	WGS						20		1854181	38.314114	1855		1763.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1718	Streptococcus pyogenes strain K6108		1314	WGS	K6108	EMM25.1			MLST.Streptococcus_pyogenes.323				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695434	GCA_900989455.1	CAAIGP000000000		SC	WGS						19		1829781	38.300976	1809		1709.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1340	Streptococcus pyogenes strain K6222		1314	WGS	K6222	EMM70.0			MLST.Streptococcus_pyogenes.754				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711600	GCA_900985605.1	CAAHRZ000000000		SC	WGS						13		1723791	38.363758	1706		1613.0		sterile site		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1053	Streptococcus pyogenes strain K6239		1314	WGS	K6239	EMM9.0			MLST.Streptococcus_pyogenes.740				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238137	GCA_900982705.1	CAAHGW000000000		SC	WGS						11		1778305	38.329975	1762		1669.0		sterile site		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1387	Streptococcus pyogenes strain K6363		1314	WGS	K6363	EMM230.1			MLST.Streptococcus_pyogenes.755				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711638	GCA_900986075.1	CAAHTT000000000		SC	WGS						22		1770828	38.332462	1770		1677.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1388	Streptococcus pyogenes strain K6428		1314	WGS	K6428	EMM97.1			MLST.Streptococcus_pyogenes.756				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711684	GCA_900986095.1	CAAHTW000000000		SC	WGS						12		1771455	38.33809	1737		1643.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1058	Streptococcus pyogenes strain K6429		1314	WGS	K6429	EMM38.1			MLST.Streptococcus_pyogenes.757				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238138	GCA_900982785.1	CAAHHC000000000		SC	WGS						28		1744151	38.35614	1713		1626.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1403	Streptococcus pyogenes strain K6613		1314	WGS	K6613	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711769	GCA_900986235.1	CAAHUK000000000		SC	WGS						11		1799819	38.15771	1796		1701.0		sterile site		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1722	Streptococcus pyogenes strain K6635		1314	WGS	K6635	EMM177.0			MLST.Streptococcus_pyogenes.758				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695389	GCA_900989495.1	CAAIGR000000000		SC	WGS						17		1773805	38.36957	1772		1682.0		skin, soft tissue infection		2000	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1062	Streptococcus pyogenes strain K6821		1314	WGS	K6821	EMM177.0			MLST.Streptococcus_pyogenes.758				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238141	GCA_900982825.1	CAAHHE000000000		SC	WGS						13		1773811	38.37608	1762		1677.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1092	Streptococcus pyogenes strain K6847		1314	WGS	K6847	EMM65.5			MLST.Streptococcus_pyogenes.215				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238142	GCA_900983125.1	CAAHIK000000000		SC	WGS						13		1752923	38.37024	1738		1651.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1391	Streptococcus pyogenes strain K6917		1314	WGS	K6917	EMM65.5			MLST.Streptococcus_pyogenes.215				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711573	GCA_900986115.1	CAAHTY000000000		SC	WGS						15		1750581	38.352924	1742		1653.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1093	Streptococcus pyogenes strain K6932		1314	WGS	K6932	EMM217.0			MLST.Streptococcus_pyogenes.728				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238143	GCA_900983135.1	CAAHIM000000000		SC	WGS						15		1761778	38.406883	1747		1652.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1729	Streptococcus pyogenes strain K7024		1314	WGS	K7024	EMM18.21			MLST.Streptococcus_pyogenes.402				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695412	GCA_900989565.1	CAAIGW000000000		SC	WGS						15		1820343	38.245934	1863		1753.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1728	Streptococcus pyogenes strain K7087		1314	WGS	K7087	EMM11.0			MLST.Streptococcus_pyogenes.742				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695386	GCA_900989555.1	CAAIGY000000000		SC	WGS						17		1729710	38.3821	1704		1603.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1727	Streptococcus pyogenes strain K7087		1314	WGS	K7087	EMM11.0			MLST.Streptococcus_pyogenes.742				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695410	GCA_900989545.1	CAAIGZ000000000		SC	WGS						19		1730934	38.387623	1707		1609.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1730	Streptococcus pyogenes strain K7113		1314	WGS	K7113	EMM11.0			MLST.Streptococcus_pyogenes.742				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1695454	GCA_900989575.1	CAAIHA000000000		SC	WGS						15		1730933	38.392612	1695		1599.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1815	Streptococcus pyogenes strain K7114		1314	WGS	K7114	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711661	GCA_900990425.1	CAAIKG000000000		SC	WGS						17		1737125	38.32006	1719		1624.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1814	Streptococcus pyogenes strain K7151		1314	WGS	K7151	EMM183.2			MLST.Streptococcus_pyogenes.761				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711713	GCA_900990415.1	CAAIKF000000000		SC	WGS						18		1739829	38.347836	1696		1608.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1834	Streptococcus pyogenes strain K7175		1314	WGS	K7175	EMM165.0			MLST.Streptococcus_pyogenes.762				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711771	GCA_900990615.1	CAAILA000000000		SC	WGS						20		1882002	38.36422	1851		1747.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1336	Streptococcus pyogenes strain K7219		1314	WGS	K7219	EMM28.0			MLST.Streptococcus_pyogenes.763				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711724	GCA_900985565.1	CAAHRS000000000		SC	WGS						12		1816475	38.330227	1808		1709.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1091	Streptococcus pyogenes strain K7275		1314	WGS	K7275	STG866.1			MLST.Streptococcus_pyogenes.450				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238144	GCA_900983115.1	CAAHIL000000000		SC	WGS						12		1784947	38.2786	1783		1691.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1061	Streptococcus pyogenes strain K7367		1314	WGS	K7367	EMM55.0			MLST.Streptococcus_pyogenes.248				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238145	GCA_900982815.1	CAAHHG000000000		SC	WGS						28		1828975	38.396587	1833		1742.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1337	Streptococcus pyogenes strain K7393		1314	WGS	K7393	EMM63.5			MLST.Streptococcus_pyogenes.764				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711578	GCA_900985575.1	CAAHRW000000000		SC	WGS						25		1958115	38.23335	1998		1903.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1099	Streptococcus pyogenes strain K7478		1314	WGS	K7478	EMM65.5			MLST.Streptococcus_pyogenes.215				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238146	GCA_900983195.1	CAAHIU000000000		SC	WGS						14		1752736	38.370285	1736		1650.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1390	Streptococcus pyogenes strain K7498		1314	WGS	K7498	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711649	GCA_900986085.1	CAAHTV000000000		SC	WGS						15		1784613	38.26804	1797		1698.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1813	Streptococcus pyogenes strain K7541		1314	WGS	K7541	EMM81.2			MLST.Streptococcus_pyogenes.766				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711651	GCA_900990405.1	CAAIKH000000000		SC	WGS						15		1884138	38.293552	1915		1809.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1836	Streptococcus pyogenes strain K7554		1314	WGS	K7554	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711677	GCA_900990635.1	CAAILC000000000		SC	WGS						15		1789536	38.33558	1773		1688.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1846	Streptococcus pyogenes strain K7559		1314	WGS	K7559	EMM110.0			MLST.Streptococcus_pyogenes.767				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711693	GCA_900990725.1	CAAILL000000000		SC	WGS						12		1775777	38.29315	1738		1642.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1358	Streptococcus pyogenes strain K7731		1314	WGS	K7731	EMM100.2			MLST.Streptococcus_pyogenes.773				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711791	GCA_900985785.1	CAAHSR000000000		SC	WGS						15		1771086	38.34587	1754		1660.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1354	Streptococcus pyogenes strain K7736		1314	WGS	K7736	EMM19.10			MLST.Streptococcus_pyogenes.769				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711831	GCA_900985755.1	CAAHSO000000000		SC	WGS						28		1821641	38.295746	1842		1742.0		swab		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1852	Streptococcus pyogenes strain K7736		1314	WGS	K7736	EMM165.0			MLST.Streptococcus_pyogenes.768				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711596	GCA_900990795.1	CAAILS000000000		SC	WGS						24		1828950	38.284645	1821		1720.0		swab		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1327	Streptococcus pyogenes strain K7792		1314	WGS	K7792	EMM43.1			MLST.Streptococcus_pyogenes.770				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711604	GCA_900985475.1	CAAHRM000000000		SC	WGS						21		1845073	38.227257	1860		1751.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1823	Streptococcus pyogenes strain K7829		1314	WGS	K7829	EMM186.1			MLST.Streptococcus_pyogenes.262				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711800	GCA_900990505.1	CAAIKQ000000000		SC	WGS						18		1761301	38.347164	1772		1689.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1346	Streptococcus pyogenes strain K7846		1314	WGS	K7846	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711728	GCA_900985655.1	CAAHSE000000000		SC	WGS						13		1799726	38.068016	1790		1693.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1833	Streptococcus pyogenes strain K7908		1314	WGS	K7908	EMM65.4			MLST.Streptococcus_pyogenes.129				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711589	GCA_900990605.1	CAAIKZ000000000		SC	WGS						17		1714999	38.404533	1713		1621.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1100	Streptococcus pyogenes strain K7928		1314	WGS	K7928	EMM4.5			MLST.Streptococcus_pyogenes.771				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238147	GCA_900983205.1	CAAHIO000000000		SC	WGS						11		1788886	38.287464	1748		1653.0		skin, soft tissue, stss		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1817	Streptococcus pyogenes strain K7928		1314	WGS	K7928	EMM4.5			MLST.Streptococcus_pyogenes.771				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711823	GCA_900990435.1	CAAIKI000000000		SC	WGS						12		1785812	38.27555	1753		1658.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1335	Streptococcus pyogenes strain K8015		1314	WGS	K8015	EMM99.5			MLST.Streptococcus_pyogenes.781				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711564	GCA_900985555.1	CAAHRU000000000		SC	WGS						10		1713162	38.363796	1695		1617.0		skin, soft tissue infection		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1350	Streptococcus pyogenes strain K8057		1314	WGS	K8057	EMM179.0			MLST.Streptococcus_pyogenes.619				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711753	GCA_900985705.1	CAAHSL000000000		SC	WGS						15		1790343	38.260323	1779		1683.0		sterile site		2001	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1371	Streptococcus pyogenes strain K8396		1314	WGS	K8396	EMM89.8			MLST.Streptococcus_pyogenes.772				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711690	GCA_900985915.1	CAAHTE000000000		SC	WGS						16		1803024	38.279545	1780		1685.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1324	Streptococcus pyogenes strain K8460		1314	WGS	K8460	EMM82.5			MLST.Streptococcus_pyogenes.257				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711601	GCA_900985445.1	CAAHRJ000000000		SC	WGS						30		1878155	38.24993	1881		1774.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1376	Streptococcus pyogenes strain K8492		1314	WGS	K8492	EMM100.2			MLST.Streptococcus_pyogenes.773				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711594	GCA_900985965.1	CAAHTJ000000000		SC	WGS						15		1770590	38.34071	1744		1661.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1348	Streptococcus pyogenes strain K8543		1314	WGS	K8543	EMM85.1			MLST.Streptococcus_pyogenes.774				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711839	GCA_900985685.1	CAAHSH000000000		SC	WGS						22		1793370	38.373173	1807		1720.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1392	Streptococcus pyogenes strain K8728		1314	WGS	K8728	EMM64.3			MLST.Streptococcus_pyogenes.223				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711603	GCA_900986125.1	CAAHTZ000000000		SC	WGS						17		1727874	38.318325	1711		1622.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1377	Streptococcus pyogenes strain K8744		1314	WGS	K8744	EMM8.3			MLST.Streptococcus_pyogenes.241				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711585	GCA_900985975.1	CAAHTK000000000		SC	WGS						13		1825614	38.313763	1818		1722.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1850	Streptococcus pyogenes strain K8861		1314	WGS	K8861	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711583	GCA_900990775.1	CAAILQ000000000		SC	WGS						13		1784751	38.268776	1795		1700.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1816	Streptococcus pyogenes strain K8955		1314	WGS	K8955	EMM65.0			MLST.Streptococcus_pyogenes.778				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711782	GCA_900990445.1	CAAIKJ000000000		SC	WGS						22		1755360	38.35635	1736		1635.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1353	Streptococcus pyogenes strain K9037		1314	WGS	K9037	EMM239.1			MLST.Streptococcus_pyogenes.776				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711558	GCA_900985735.1	CAAHSN000000000		SC	WGS						19		1753681	38.23873	1734		1635.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1402	Streptococcus pyogenes strain K9189		1314	WGS	K9189	EMM182.1			MLST.Streptococcus_pyogenes.229				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711699	GCA_900986225.1	CAAHUJ000000000		SC	WGS						10		1773241	38.211296	1729		1648.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1339	Streptococcus pyogenes strain K9215		1314	WGS	K9215	EMM112.5			MLST.Streptococcus_pyogenes.777				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711658	GCA_900985595.1	CAAHRY000000000		SC	WGS						15		1742209	38.34161	1726		1632.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1818	Streptococcus pyogenes strain K9333		1314	WGS	K9333	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711825	GCA_900990455.1	CAAIKK000000000		SC	WGS						14		1837043	38.30976	1856		1766.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1056	Streptococcus pyogenes strain K9340		1314	WGS	K9340	EMM18.21			MLST.Streptococcus_pyogenes.221				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238149	GCA_900982765.1	CAAHHD000000000		SC	WGS						11		1775248	38.37065	1729		1648.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1399	Streptococcus pyogenes strain K9361		1314	WGS	K9361	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711732	GCA_900986195.1	CAAHUH000000000		SC	WGS						26		1859334	38.255867	1907		1800.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1078	Streptococcus pyogenes strain K9374		1314	WGS	K9374	EMM18.21			MLST.Streptococcus_pyogenes.221				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238150	GCA_900982985.1	CAAHIA000000000		SC	WGS						10		1768264	38.34822	1730		1645.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1076	Streptococcus pyogenes strain K9400		1314	WGS	K9400	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238151	GCA_900982965.1	CAAHHW000000000		SC	WGS						15		1798224	38.323242	1778		1691.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1059	Streptococcus pyogenes strain K9404		1314	WGS	K9404	EMM90.5			MLST.Streptococcus_pyogenes.708				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238152	GCA_900982795.1	CAAHHB000000000		SC	WGS						12		1797210	38.3229	1779		1691.0		sepsis (no localising source)		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1819	Streptococcus pyogenes strain K9408		1314	WGS	K9408	EMM65.0			MLST.Streptococcus_pyogenes.778				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711717	GCA_900990465.1	CAAIKL000000000		SC	WGS						20		1753057	38.347927	1732		1638.0		skin, soft tissue infection		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1057	Streptococcus pyogenes strain K9429		1314	WGS	K9429	EMM95.0			MLST.Streptococcus_pyogenes.712				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238153	GCA_900982775.1	CAAHHH000000000		SC	WGS						15		1739767	38.24418	1695		1604.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1829	Streptococcus pyogenes strain K9440		1314	WGS	K9440	EMM99.5			MLST.Streptococcus_pyogenes.779				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711565	GCA_900990565.1	CAAIKV000000000		SC	WGS						12		1713395	38.366108	1698		1620.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1328	Streptococcus pyogenes strain K9454		1314	WGS	K9454	EMM50.3			MLST.Streptococcus_pyogenes.217				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711714	GCA_900985485.1	CAAHRN000000000		SC	WGS						15		1713374	38.324112	1682		1592.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1060	Streptococcus pyogenes strain K9466		1314	WGS	K9466	EMM78.5			MLST.Streptococcus_pyogenes.255				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238154	GCA_900982805.1	CAAHHF000000000		SC	WGS						10		1767886	38.28745	1710		1624.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1334	Streptococcus pyogenes strain K9521		1314	WGS	K9521	EMM84.1			MLST.Streptococcus_pyogenes.780				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711827	GCA_900985545.1	CAAHRV000000000		SC	WGS						11		1792932	38.281116	1786		1705.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1330	Streptococcus pyogenes strain K9612		1314	WGS	K9612	EMM99.5			MLST.Streptococcus_pyogenes.781				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711737	GCA_900985505.1	CAAHRP000000000		SC	WGS						12		1713517	38.365677	1689		1617.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1349	Streptococcus pyogenes strain K9612		1314	WGS	K9612	EMM99.5			MLST.Streptococcus_pyogenes.781				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711736	GCA_900985695.1	CAAHSI000000000		SC	WGS						12		1712798	38.364384	1688		1614.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1320	Streptococcus pyogenes strain K9679		1314	WGS	K9679	EMM112.5			MLST.Streptococcus_pyogenes.777				2019-04-09T00:00:00Z		PRJEB3313	SAMEA1711591	GCA_900985405.1	CAAHRF000000000		SC	WGS						13		1817822	38.35282	1837		1746.0		sterile site		2002	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1079	Streptococcus pyogenes strain K9887		1314	WGS	K9887	EMM119.2			MLST.Streptococcus_pyogenes.239				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238155	GCA_900982995.1	CAAHHY000000000		SC	WGS						10		1824020	38.21115	1823		1729.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1077	Streptococcus pyogenes strain K9927		1314	WGS	K9927	EMM223.0			MLST.Streptococcus_pyogenes.613				2019-04-09T00:00:00Z		PRJEB3313	SAMEA2238156	GCA_900982975.1	CAAHHT000000000		SC	WGS						13		1741606	38.25879	1707		1617.0		skin, soft tissue infection		2003	Kenya	Kenya						Human, Homo sapiens																			www.sanger.ac.uk/resources/downloads/bacteria/s-pyogenes This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.845	Streptococcus pyogenes strain KS030		1314	Complete	KS030				MLST.Streptococcus_pyogenes.15	genotype:emm3/ST15			2017-12-15T00:00:00Z		PRJDB5912	SAMD00084336	GCA_003609955.1	AP018337		Laboratory of Bacterial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases	Complete	NextSeq; PacBio RSII	700x	HGAP Assembly v. 3.0; Pilon v1.18	1.0		1		1900008	38.578102	2002		1898.0		endotracheal aspirates culture, the strain was designated as KS030	isolated from endotracheal aspirates culture, the strain was designated as KS030	2017	Japan	Japan						Human, Homo sapiens																		streptococcal toxic shock syndrome (STSS)	A young patient was diagnosed as Streptococcal Toxic Shock Syndrome (STSS) with severe pneumonia, impaired renal function, and rhabdomyolysis. Streptococcus pyogenes (GAS) was isolated from endotracheal aspirates culture, the strain was designated as KS030.	
1314.2826	Streptococcus pyogenes strain KUN-0012590		1314	Complete	KUN-0012590								2020-08-08T00:00:00Z		PRJDB10330	SAMD00238719	GCA_014192005.1	AP023389		Department of Microbiology, Graduate School of Medicine, Kyoto University	Complete	Illumina MiSeq; Oxford Nanopore	526x	Unicycler v. 0.4.8	1.0	0.0	1		1854597	38.5384	1870		1780.0				2007	Japan	Japan:Kyoto						Human, Homo sapiens									Positive	Cocci									We determined complete genome sequence of three Streptococcus species, S. pyogenes, S. suis, and S. dysgalactiae. Among these three species, S. pyogenes and S. dysagalactiae have recognized as causative agents occasionally causing sever disease (ex. toxic shock syndrome) to human. On the other hand, S. suis is one of the major zoonotic agent and cause a variety of infections in individuals working in close contact with swine or pork products. In this study, we focus on the gene sets or genomic regions contributing to their pathogenicity, based on the complete genome sequence of three Streptococcus species.	
1314.2833	Streptococcus pyogenes strain KUN-0014944		1314	Complete	KUN-0014944				MLST.Streptococcus_pyogenes.646				2020-08-08T00:00:00Z		PRJDB10330	SAMD00238720	GCA_014192175.1	AP023390		Department of Microbiology, Graduate School of Medicine, Kyoto University	Complete	Illumina MiSeq; Oxford Nanopore	547x	Unicycler v. 0.4.8	1.0	0.0	1		1747400	38.558887	1688		1611.0				2009	Japan	Japan:Kyoto						Human, Homo sapiens									Positive	Cocci									We determined complete genome sequence of three Streptococcus species, S. pyogenes, S. suis, and S. dysgalactiae. Among these three species, S. pyogenes and S. dysagalactiae have recognized as causative agents occasionally causing sever disease (ex. toxic shock syndrome) to human. On the other hand, S. suis is one of the major zoonotic agent and cause a variety of infections in individuals working in close contact with swine or pork products. In this study, we focus on the gene sets or genomic regions contributing to their pathogenicity, based on the complete genome sequence of three Streptococcus species.	
1314.165	Streptococcus pyogenes strain Lacen1		1314	WGS	Lacen1				MLST.Streptococcus_pyogenes.28				2014-05-07T00:00:00Z		PRJNA242686	SAMN02708609	GCF_000685485.1	JHFA00000000		Universidade Catolica de Brasilia	WGS	Illumina GAII	342.0x	Velvet v. 2.2.4			39		1793962	38.35	1834				blood			Brazil	Brazil: Brasilia						Human, Homo sapiens			various																The aim of this study was to compare the genome assemblies of 4 lethal and 1 non-lethal S.pyogenes samples	collected_by:LACEN
1314.164	Streptococcus pyogenes strain Lacen2		1314	WGS	Lacen2				MLST.Streptococcus_pyogenes.28				2014-05-07T00:00:00Z		PRJNA242686	SAMN02708610	GCF_000685505.1	JHTP00000000		Universidade Catolica de Brasilia	WGS	Illumina GAII	304.0x	Velvet v. 2.2.4			100		1762823	38.37	1814				Blood			Brazil	Brazil: Brasilia						Human, Homo sapiens			various																The aim of this study was to compare the genome assemblies of 4 lethal and 1 non-lethal S.pyogenes samples	collected_by:LACEN
1314.167	Streptococcus pyogenes strain Lacen3		1314	WGS	Lacen3				MLST.Streptococcus_pyogenes.28				2014-05-07T00:00:00Z		PRJNA242686	SAMN02708611	GCF_000685565.1	JHTQ00000000		Universidade Catolica de Brasilia	WGS	Illumina GAII	319.0x	Velvet v. 2.2.4			72		1794996	38.35	1839				Blood			Brazil	Brazil: Brasilia						Human, Homo sapiens			various																The aim of this study was to compare the genome assemblies of 4 lethal and 1 non-lethal S.pyogenes samples	collected_by:LACEN
1314.166	Streptococcus pyogenes strain Lacen4		1314	WGS	Lacen4				MLST.Streptococcus_pyogenes.28				2014-05-07T00:00:00Z		PRJNA242686	SAMN02708612	GCF_000685545.1	JHTO00000000		Universidade Catolica de Brasilia	WGS	Illumina GAII	433.0x	Velvet v. 2.2.4			50		1795205	38.37	1829				Blood			Brazil	Brazil: Brasilia						Human, Homo sapiens			various																The aim of this study was to compare the genome assemblies of 4 lethal and 1 non-lethal S.pyogenes samples	collected_by:LACEN
1314.163	Streptococcus pyogenes strain Lacen5		1314	WGS	Lacen5				MLST.Streptococcus_pyogenes.37				2014-05-07T00:00:00Z		PRJNA242686	SAMN02708613	GCF_000685525.1	JHTN00000000		Universidade Catolica de Brasilia	WGS	Illumina GAII	322.0x	Velvet v. 2.2.4			98		1815423	38.36	1903				Oropharynx			Brazil	Brazil: Brasilia						Human, Homo sapiens			various																The aim of this study was to compare the genome assemblies of 4 lethal and 1 non-lethal S.pyogenes samples	collected_by:LACEN
1314.2962	Streptococcus pyogenes strain M08500		1314	Complete	M08500					genotype:emm66ST874			2021-03-30T00:00:00Z		PRJNA684347	SAMN18435893	GCA_017638465.1	CP072112		Queensland Health Forensic and Scientific Services	Complete	Illumina NextSeq; Oxford Nanopore GridION	248.0x	Unicycler v. v0.4.9b	1.0	0.0	1		1852911	38.553444	1850		1752.0		Blood culture		2020	Australia	Australia						Homo sapiens			Sepsis																Streptococcus pyogenes WGS	collected_by:Queensland Health
1314.2925	Streptococcus pyogenes strain M11318		1314	Complete	M11318				MLST.Streptococcus_pyogenes.28	genotype:emm1ST28			2021-03-02T00:00:00Z		PRJNA684347	SAMN18034722	GCA_017132795.1	CP070994		Queensland Health Forensic and Scientific Services	Complete	Illumina NextSeq; Oxford Nanopore GridION	50.0x	Unicycler v. V0.4.8	1.0	0.0	1		1831274	38.498936	1836		1743.0		Tissue		2018	Australia	Australia						Homo sapiens			Streptococcal infections																Streptococcus pyogenes WGS	collected_by:Queensland Health
1314.195	Streptococcus pyogenes strain M28PF1		1314	Complete	M28PF1				MLST.Streptococcus_pyogenes.52				2015-07-30T00:00:00Z	26184934	PRJNA284654	SAMN03733610	GCF_001020185.1	CP011535		INSERM	Complete	Illumina	100x	Velvet v. 2012; Geneious Pro v. 5.5.9	1.0		1		1896976	38.35	1899		1765.0		vaginal swab		2009	France	France: Alencon						Human, Homo sapiens			puerperal fever										Mesophilic	37 C		Microaerophilic	HostAssociated	Puerperal fever	etiological agent of streptococcal invasive diseases	collected_by:Centre National de Reference des Streptocoqques
1314.534	Streptococcus pyogenes strain M3-b		1314	Complete	M3-b	serovar s			MLST.Streptococcus_pyogenes.15				2016-02-26T00:00:00Z		PRJDB1740	SAMD00000355	GCA_002355175.1	AP014596		National Center for Global Health and Medicine	Complete		20x	GS De Novo Assembler v. 2.7	1.0		1		1893821	38.54	1958		1926.0		patient of a STSS case	derived from a patient of a STSS case	1994	Japan	Japan:Aichi					env_biome:clinical	Human, Homo sapiens																			Streptococcus pyogenes cause a wide variety of infectious diseases, from relatively benign to life threatening. S. pyogenes can be subtyped according to the serotypes of the M proteins expressed on the cell surface. Particular M types of GAS have been associated with certain diseases, which suggests that there are differences in the expression of pathogenic traits among S. pyogeneswith different M types. M1 and M3 S. pyogenes have been found predominantly in patients with streptococcal toxic shock syndrome (STSS), a life-threatening in Japan, the United States, and Europe S. pyogenes str. M3-b is one of the isolates derived from a patient of a STSS case. In this study, complete whole genome sequence of S. progenes str. M3-b to analyze genes related to the virulence.	
1314.472	Streptococcus pyogenes strain M3KCL		1314	WGS	M3KCL	serovar M3			MLST.Streptococcus_pyogenes.315				2017-04-28T00:00:00Z		PRJNA359497	SAMN06192242	GCA_002114055.1	MTSW00000000		Purdue University	WGS	IonTorrent	1.03x	Kbase v. June 2016			60		1864059	38.42	1981				blood	isolated from the blood of a human patient	2009	USA	United States						Human, Homo sapiens																			Streptococcus pyogenes, also known as Group A Streptococcus (GAS), is a strict human pathogen and almost 10% children carry this pathogen in their pharynx without signs or symptoms (Shaikh, Leonard et al., 2010). This pathogen causes diverse diseases from mild, self-limiting superficial infections to toxigenic or invasive diseases. The diseases include strep throat, impetigo, scarlet fever, streptococcal toxic shock syndrome, rheumatic fever, and necrotizing fasciitis (Cunningham, 2000). We sequenced a serotype M3 strain isolated from the blood of a human patient. Often, serotype M3 strains cause an epidemic of invasive disease (Beres, Sylva et al., 2004). When we compared the genome sequence with publically available genome sequences of two serotype M3 strains, MGAS315 and SSI-1, the sequence of this strain was closer to the MGAS315 strain. However, unlike MGAS315, this strain secrets the cysteine protease SpeB, a major virulence factor in the GAS pathogenesis. It appears that this strain has not developed antibiotic resistance and is sensitive to the antibiotics of ampicillin, clindamycin, cefazolin, erythromycin, cefoxitin, penicillin, cefotaxime, vancomycin, levofloxacin, tetracycline, ciprofloxacin, teicoplanin	sample_type:Cell Culture
1314.2853	Streptococcus pyogenes strain M4C20		1314	WGS	M4C20								2021-02-09T00:00:00Z		PRJNA695586	SAMN17619770	GCA_016858325.1	JAFCYZ000000000		Emory University	WGS	Oxford Nanopore MinION; IonTorrent	10.0x	Canu v. 1.8; SPAdes v. 3.13.0	0.0	0.0	10		1927778	38.72801	3298		1878.0		hospital		2016	USA	USA: San Diego						Homo sapiens			Sepsis																Immunosuppressive drugs have been associated with development of invasive infections by group A Streptococcus (GAS). We provide the whole-genome sequence of an invasive emm4 serotype of GAS from a pediatric patient undergoing IL-6 immunotherapy who developed sepsis. Notably, this isolate lacks cov/csr frameshift mutations that often confer hypervirulence.	collected_by:Hal Hoffman, MD
1314.966	Streptococcus pyogenes strain M75		1314	Complete	M75				MLST.Streptococcus_pyogenes.150				2019-02-04T00:00:00Z		PRJNA504701	SAMN10397505	GCA_004135875.1	CP033621		University of Melbourne	Complete	PacBio	105.0x	PacBio SMRT Pipe v. 2.3.0	1.0		1		1852894	38.60604	1910		1810.0		throat		2011	Australia	Australia: Melbourne						Human, Homo sapiens			Pharyngitis																A multifaceted characterisation of a controlled human infection model candidate strain, M75 611024, compared to two other GAS strains: GAS M12 611025, and CDC SS-496, an M1 strain administered to 88 subjects in 1970s pharyngitis controlled human infection model studies (SS-496). This study provides the rationale for the initial deployment of M75 611025 in a modern controlled human infection model, with the aim of safely and successfully causing pharyngitis in healthy adult volunteers.	collected_by:Murdoch Children's Research Institute
1314.202	Streptococcus pyogenes strain MEW123		1314	Complete	MEW123				MLST.Streptococcus_pyogenes.52				2016-01-25T00:00:00Z		PRJNA308987	SAMN04419117	GCF_001535565.1	CP014139	NZ_CP014139.1	University of Michigan	Complete	PacBio	300	Celera PBcR v. 8.3rc2; BWA-MEM v. 0.7.12;	1.0		1		1878699	38.29	1894		1738.0		throat		2012	USA	USA: St. Louis, MO						Human, Homo sapiens														C					Whole genome sequencing and assembly of Streptococcus pyogenes bacterial isolates important for understanding of human disease.	sample_type:whole organism
1314.201	Streptococcus pyogenes strain MEW427		1314	Complete	MEW427				MLST.Streptococcus_pyogenes.39				2016-01-25T00:00:00Z		PRJNA308988	SAMN04419118	GCF_001535505.1	CP014138		University of Michigan	Complete	PacBio	300	Celera PBcR v. 8.3rc2; BWA-MEM v. 0.7.12;	1.0		1		1814455	38.51	1869		1691.0		throat		2015	USA	USA: Ann Arbor, MI						Human, Homo sapiens														C					Whole genome sequencing and assembly of Streptococcus pyogenes strain MEW427, a strain relevant to human disease pathogenesis.;many frameshifted proteins	sample_type:whole organism
1314.968	Streptococcus pyogenes strain MGAS10786		1314	Complete	MGAS10786	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555729	GCA_004153965.1	CP031637		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	189.5 (6.5 & 183.0)x	Unicycler/SPAdes/PILON v.	1.0		1		1937069	38.380203	1999		1895.0		normally sterile site		1998	Canada	Canada: Ontario						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:Public Health Ontario
1314.990	Streptococcus pyogenes strain MGAS10826		1314	Complete	MGAS10826	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555766	GCA_004154405.1	CP031636		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	265.2 (44.1 & 221.1)x	Unicycler/SPAdes/PILON v.	1.0		1		1852263	38.33543	1866		1782.0		normally sterile site		2000	Canada	Canada: Ontario						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:Public Health Ontario
1314.260	Streptococcus pyogenes strain MGAS11027		1314	Complete	MGAS11027	M89			MLST.Streptococcus_pyogenes.407				2016-05-02T00:00:00Z		PRJNA167314	SAMN03792044	GCF_001635895.1	CP013838	NZ_CP013838.1	The Methodist Hospital Research Institute	Complete	Sanger dideoxy sequencing; Illumina	>100 fold	MIRA v. 3; Sequencher v. 5; SPAdes v.	1.0		1		1786874	38.55	1787		1682.0		pharynx		2002	USA	USA: Texas						Human, Homo sapiens			pharyngitis																Streptococcus pyogenes (a.k.a. Group A Streptococcus, GAS) is a genetically diverse human pathogen (having > 150 serotypes/M types) that commonly causes superficial infections of the throat (pharyngitis/strep-throat) and skin (impetigo). Less commonly GAS also causes fulminant invasive infections, such as necrotizing fasciitis (flesh-eating disease) and necrotizing pneumonia, that have high attendant morbidity and mortality. Serotype M89 strains are a prevalent cause of GAS pharyngeal and invasive infections. The whole genome sequence of strain MGAS11027, a pharyngeal infection isolate, was undertaken to gain insight in the genetic basis of GAS serotype M89 pathogenesis.	collected_by:CDC Active Bacterial Core Surveillance;passage_history:minimally passaged
1314.989	Streptococcus pyogenes strain MGAS11052		1314	Complete	MGAS11052	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555770	GCA_004154385.1	CP031635		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	267.8 (25.1 & 242.7)x	Unicycler/SPAdes/PILON v.	1.0		1		1907750	38.24348	1917		1832.0		normally sterile site		2000	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.985	Streptococcus pyogenes strain MGAS11108		1314	Complete	MGAS11108	Emm28			MLST.Streptococcus_pyogenes.456				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555796	GCA_004154305.1	CP031634		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	221.0 (50.1 & 170.9)x	Unicycler/SPAdes/PILON v.	1.0		1		1853812	38.346607	1866		1783.0		normally sterile site		2001	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.984	Streptococcus pyogenes strain MGAS11115		1314	Complete	MGAS11115	Emm28			MLST.Streptococcus_pyogenes.456				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555801	GCA_004154285.1	CP031633		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	186.9 (32.3 & 154.7)x	Unicycler/SPAdes/PILON v.	1.0		1		1851403	38.338924	1873		1788.0		normally sterile site		2002	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.2770	Streptococcus pyogenes strain MGAS2221		1314	Complete	MGAS2221	emm1			MLST.Streptococcus_pyogenes.28	genotype:M1T1			2020-04-20T00:00:00Z		PRJNA562873	SAMN12657656	GCA_012572265.1	CP043530		Houston Methodist Research Institute	Complete	Oxford Nanopore GridION & Illumina	1875.0x	Unicycler v. 0.4.8-beta	1.0	0.0	1		1835779	38.53514	1824		1741.0				1988	Australia	Australia						Human, Homo sapiens			septic scarlet fever																Streptococcus pyogenes (aka Group A Streptococcus, GAS) strain MGAS2221 is genetically representative of global pandemic M1T1 strains and is wild-type forall major global virulence regulators	collected_by:not collected;passage_history:minamal
1314.261	Streptococcus pyogenes strain MGAS23530		1314	Complete	MGAS23530	M89			MLST.Streptococcus_pyogenes.101				2016-05-02T00:00:00Z		PRJNA287028	SAMN03775331	GCF_001635935.1	CP013839	NZ_CP013839.1	Houston Methodist Research Institute	Complete	Sanger dideoxy sequencing; Illumina	>100 fold	SPAdes v. 3.5.0; Sequencher v. 5	1.0		1		1709394	38.51	1682		1593.0		throat swab		1997	Italy	Italy						Human, Homo sapiens			pharyngitis											C			HostAssociated	pharyngitis	Streptococcus pyogenes (a.k.a. Group A Streptococcus, GAS) is a genetically diverse human pathogen (having > 220 serotypes/M types as of 6/15/2015) that commonly causes superficial infections of the throat (pharyngitis/strep-throat) and skin (impetigo). Less commonly GAS also causes fulminant invasive infections, such as necrotizing fasciitis (flesh-eating disease) and necrotizing pneumonia, that have high attendant morbidity and mortality. Serotype M89 strains are a prevalent cause of GAS pharyngeal and invasive infections. The whole genome sequence of strain MGAS23530, a pharyngeal infection isolate, was undertaken to gain insight in the genetic basis of GAS serotype M89 pathogenesis.	collected_by:Universidad de Camerino;passage_history:minimal
1314.262	Streptococcus pyogenes strain MGAS27061		1314	Complete	MGAS27061	serovar M89			MLST.Streptococcus_pyogenes.101				2016-05-02T00:00:00Z		PRJNA266333	SAMN03161558	GCF_001635975.1	CP013840	NZ_CP013840.1	Houston Methodist Research Institute	Complete	Sanger dideoxy sequencing; Illumina	318 fold	SPAdes v. 3.5.0; Sequencher v. 5	1.0		1		1741348	38.52	1719		1626.0				2008	USA	USA: Georgia						Human, Homo sapiens			invasive infection						Positive	Cocci	No								Investigation into the epidemic emergence of GAS serotype M89 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.893	Streptococcus pyogenes strain MGAS27961		1314	Complete	MGAS27961	Emm28			MLST.Streptococcus_pyogenes.52				2019-01-10T00:00:00Z		PRJNA434389	SAMN08555909	GCA_004010855.1	CP032665		Houston Methodist Research Institute	Complete	Oxford Nanopore MiniION; Illumina NextSeq	110.0x	Unicycler/SPAdes/PILON v. 0.4.6/3.12/1.22	1.0		1		1853912	38.34303	1880		1789.0		normally sterile site		2005	USA	USA: Minnesota						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.988	Streptococcus pyogenes strain MGAS28078		1314	Complete	MGAS28078	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556024	GCA_004154365.1	CP031632		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	194.2 (45.5 & 148.8)x	Unicycler/SPAdes/PILON v.	1.0		1		1880780	38.37222	1894		1811.0		normally sterile site		2010	USA	USA: Georgia						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.894	Streptococcus pyogenes strain MGAS28085		1314	Complete	MGAS28085	Emm28			MLST.Streptococcus_pyogenes.52				2019-01-10T00:00:00Z		PRJNA434389	SAMN08556030	GCA_004010875.1	CP032666		Houston Methodist Research Institute	Complete	Oxford Nanopore MiniION; Illumina NextSeq	244.0x	Unicycler/SPAdes/PILON v. 0.4.6/3.12/1.22	1.0		1		1851471	38.34227	1867		1783.0		normally sterile site		2009	USA	USA: New Mexico						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.983	Streptococcus pyogenes strain MGAS28191		1314	Complete	MGAS28191	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556116	GCA_004154265.1	CP031631		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	188.5 (22.3 & 166.2)x	Unicycler/SPAdes/PILON v.	1.0		1		1892473	38.36155	1919		1832.0		normally sterile site		1999	USA	USA: Connecticut						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.982	Streptococcus pyogenes strain MGAS28271		1314	Complete	MGAS28271	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556190	GCA_004154245.1	CP031630		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	201.7 (18.1 & 183.7)x	Unicycler/SPAdes/PILON v.	1.0		1		1842830	38.362736	1856		1771.0		normally sterile site		2011	USA	USA: Minnesota						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.981	Streptococcus pyogenes strain MGAS28278		1314	Complete	MGAS28278	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556197	GCA_004154225.1	CP031629		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	152.2 (6.8 & 145.4)x	Unicycler/SPAdes/PILON v.	1.0		1		1893446	38.375957	1921		1832.0		normally sterile site		2011	USA	USA: New York						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.980	Streptococcus pyogenes strain MGAS28330		1314	Complete	MGAS28330	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556245	GCA_004154205.1	CP031628		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	126.9 (16.7 & 110.1)x	Unicycler/SPAdes/PILON v.	1.0		1		1851619	38.35184	1865		1776.0		normally sterile site		1998	USA	USA: Maryland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.979	Streptococcus pyogenes strain MGAS28360		1314	Complete	MGAS28360	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556272	GCA_004154185.1	CP031627		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	127.6 (25.1 & 102.5)x	Unicycler/SPAdes/PILON v.	1.0		1		1893041	38.372757	1930		1833.0		normally sterile site		2000	USA	USA: New York						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.987	Streptococcus pyogenes strain MGAS28386		1314	Complete	MGAS28386	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556297	GCA_004154345.1	CP031626		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	192.7 (80.4 & 112.2)x	Unicycler/SPAdes/PILON v.	1.0		1		1837594	38.356026	1841		1758.0		normally sterile site		2002	USA	USA: Minnesota						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.978	Streptococcus pyogenes strain MGAS28533		1314	Complete	MGAS28533	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08556433	GCA_004154165.1	CP031625		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	156.4 (28.7 & 127.7)x	Unicycler/SPAdes/PILON v.	1.0		1		1893263	38.349136	1935		1851.0		normally sterile site		2006	USA	USA: New Mexico						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.977	Streptococcus pyogenes strain MGAS28650		1314	Complete	MGAS28650	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562449	GCA_004154145.1	CP031624		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	474.7 (71.3 & 403.4)x	Unicycler/SPAdes/PILON v.	1.0		1		1851876	38.339554	1870		1784.0		normally sterile site		2008	USA	USA: Oregon						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.976	Streptococcus pyogenes strain MGAS28669		1314	Complete	MGAS28669	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562467	GCA_004154125.1	CP031623		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	186.4 (57.7 & 128.7)x	Unicycler/SPAdes/PILON v.	1.0		1		1905059	38.343063	1949		1858.0		normally sterile site		2008	USA	USA: Maryland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.975	Streptococcus pyogenes strain MGAS28686		1314	Complete	MGAS28686	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562482	GCA_004154105.1	CP031622		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	246.0 (121.0 & 125.0)x	Unicycler/SPAdes/PILON v.	1.0		1		1894087	38.347553	1937		1851.0		normally sterile site		2008	USA	USA: New Mexico						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.974	Streptococcus pyogenes strain MGAS28746		1314	Complete	MGAS28746	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562542	GCA_004154085.1	CP031621		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	147.1 (27.7 & 119.4)x	Unicycler/SPAdes/PILON v.	1.0		1		1853620	38.343998	1874		1785.0		normally sterile site		2012	USA	USA: New Mexico						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:CDC Active Bacterial Core Surveillance
1314.986	Streptococcus pyogenes strain MGAS29064		1314	Complete	MGAS29064	Emm28			MLST.Streptococcus_pyogenes.458				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562766	GCA_004154325.1	CP031620		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	226.3 (107.8 & 118.5)x	Unicycler/SPAdes/PILON v.	1.0		1		1839848	38.360615	1844		1759.0		normally sterile site		2015	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.973	Streptococcus pyogenes strain MGAS29284		1314	Complete	MGAS29284	Emm28			MLST.Streptococcus_pyogenes.458				2019-02-11T00:00:00Z		PRJNA434389	SAMN08562978	GCA_004154065.1	CP031619		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	352.2 (10.7 & 341.5)x	Unicycler/SPAdes/PILON v.	1.0		1		1946265	38.37047	2008		1918.0		normally sterile site		2011	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.972	Streptococcus pyogenes strain MGAS29326		1314	Complete	MGAS29326	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08563018	GCA_004154045.1	CP031618		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	106.0 (64.7 & 41.3)x	Unicycler/SPAdes/PILON v.	1.0		1		1940684	38.272278	1969		1883.0		normally sterile site		2010	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.971	Streptococcus pyogenes strain MGAS29409		1314	Complete	MGAS29409	Emm28			MLST.Streptococcus_pyogenes.458				2019-02-11T00:00:00Z		PRJNA434389	SAMN08563099	GCA_004154025.1	CP031617		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	279.5 (15.7 & 263.8)x	Unicycler/SPAdes/PILON v.	1.0		1		1894040	38.374584	1932		1839.0		normally sterile site		2008	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.970	Streptococcus pyogenes strain MGAS7888		1314	Complete	MGAS7888	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555522	GCA_004154005.1	CP031640		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	204.5 (27.9 & 176.6)x	Unicycler/SPAdes/PILON v.	1.0		1		1962429	38.161533	1995		1898.0		normally sterile site		1994	Canada	Canada: Ontario						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:Public Health Ontario
1314.969	Streptococcus pyogenes strain MGAS7914		1314	Complete	MGAS7914	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555548	GCA_004153985.1	CP031639		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	167.3 (19.9 & 147.4)x	Unicycler/SPAdes/PILON v.	1.0		1		1885126	38.370857	1914		1832.0		normally sterile site		1995	Canada	Canada: Ontario						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:Public Health Ontario
1314.967	Streptococcus pyogenes strain MGAS8347		1314	Complete	MGAS8347	Emm28			MLST.Streptococcus_pyogenes.52				2019-02-11T00:00:00Z		PRJNA434389	SAMN08555653	GCA_004153945.1	CP031638		Houston Methodist Research Institute	Complete	Oxford Nanopore MinION & Illumina	162.3 (15.4 & 146.9)x	Unicycler/SPAdes/PILON v.	1.0		1		1833822	38.41714	1822		1741.0		normally sterile site		1995	Finland	Finland						Human, Homo sapiens			invasive infection																Population genomic sequencing of 2,101 Streptococcus pyogenes Emm-type 28 strains	collected_by:National Public Health Laboratory
1314.3104	Streptococcus pyogenes strain MSPY1		1314	WGS	MSPY1	serovar s			MLST.Streptococcus_pyogenes.101				2021-10-13T00:00:00Z		PRJNA657283	SAMN15824174		JACSDN000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	480x	Unicycler v. 0.4.6	0.0	0.0	16		1706687	38.37587	1677		1589.0		wound		2018	USA	USA:Houston						Homo sapiens			SSTI																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.3160	Streptococcus pyogenes strain MSPY1		1314	Duplicate	MSPY1	serovar s			MLST.Streptococcus_pyogenes.101				2021-10-13T00:00:00Z		PRJNA657283	SAMN15824174		JACSDN000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	480x	Unicycler v. 0.4.6	0.0	0.0	16		1706687	38.37587	1677		1589.0		wound		2018	USA	USA:Houston						Homo sapiens			SSTI																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.3175	Streptococcus pyogenes strain MSPY1		1314	Duplicate	MSPY1	serovar s			MLST.Streptococcus_pyogenes.101				2021-10-13T00:00:00Z		PRJNA657283	SAMN15824174		JACSDN000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	480x	Unicycler v. 0.4.6	0.0	0.0	16		1706687	38.37587	1677		1589.0		wound		2018	USA	USA:Houston						Homo sapiens			SSTI																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.212	Streptococcus pyogenes strain MTB313		1314	Complete	MTB313	serovar M1			MLST.Streptococcus_pyogenes.28				2015-06-04T00:00:00Z	25883280	PRJDB1654	SAMD00000328	GCA_001547815.1	AP014572		Kitasato Institute of Life Sciences	Complete	454 GS Jr; ABI 3730	15x		1.0		1		1745332	38.52	1852		1758.0		the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis	isolated on sheep-blood agar plates at the same time from the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis	2011	Japan	Japan: Hikone-shi				0m	env_biome:urban biome	Human, Homo sapiens			acute streptococcal meningitis																Two Streptococcus pyogenes serotype M1 (emm1) strains with mucoid (MTB313) and nonmucoid (MTB314) colony morphologies of were isolated on sheep-blood agar plates at the same time from the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis. The whole-genome sequencing and comparative genomic analysis of MTB313 and MTB314 revealed that only MTB313 carried the amber codon within rocA (a positive regulator of covR). It is common knowledge that the CovR/CovS two-component regulatory system (also known as CsrR/CsrS) suppresses the expression of multiple virulence genes including hasA (hyaluronic acid [HA] capsule synthesis), whereas the covR/covS mutation enhances the expression of speB (cysteine protease) and does not affect the streptolysisn O (SLO) expression. First, MAT101 was generated from MTB313 by introducing pRocA, which contained the full-length rocA of MTB314 in the cloning plasmid pLZ12-Km2. Simultaneously, MAT100 was also generated by introducing pLZ12-Km2 into MTB313. Then, MTB313 and MAT100 showed the large quantities of cell-associated HA in the cell pellets and the small quantities of SpeB associated with low activities in the culture supernatants. In contrast, MTB314 and MAT101 showed the opposite results. Meanwhile, the SLO production was much the same among these four strains in the culture supernatants. Finally, when the mortality rates by two weeks of these four strains were examined in a CD46-expressing transgenic mouse model of subcutaneous infection into both hind footpads, the higher mortalities were observed in the MTB313- or MAT100-infected mice than in the MTB314- or MAT101-infected mice. These results clearly indicate that the point mutation in the rocA gene of S. pyogenes led to the high-pathogenicity phenotype associated with the suppression of covR expression, which occurred within the patient.;many frameshifted proteins;validation errors	
1314.213	Streptococcus pyogenes strain MTB314		1314	Complete	MTB314	serovar M1			MLST.Streptococcus_pyogenes.28				2015-06-04T00:00:00Z	25883280	PRJDB1668	SAMD00000332	GCF_001547835.1	AP014585	NZ_AP014585.1	Kitasato Institute of Life Sciences	Complete	454 GS Jr; ABI 3730	40x		1.0		1		1744827	38.51	1737		1658.0		the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis	isolated on sheep-blood agar plates at the same time from the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis	2011	Japan	Japan: Hikone-shi				0m	env_biome:urban biome	Human, Homo sapiens			acute streptococcal meningitis																Two Streptococcus pyogenes serotype M1 (emm1) strains with mucoid (MTB313) and nonmucoid (MTB314) colony morphologies of were isolated on sheep-blood agar plates at the same time from the cerebrospinal fluid of a single patient suffering from acute streptococcal meningitis. The whole-genome sequencing and comparative genomic analysis of MTB313 and MTB314 revealed that only MTB313 carried the amber codon within rocA (a positive regulator of covR). It is common knowledge that the CovR/CovS two-component regulatory system (also known as CsrR/CsrS) suppresses the expression of multiple virulence genes including hasA (hyaluronic acid [HA] capsule synthesis), whereas the covR/covS mutation enhances the expression of speB (cysteine protease) and does not affect the streptolysisn O (SLO) expression. First, MAT101 was generated from MTB313 by introducing pRocA, which contained the full-length rocA of MTB314 in the cloning plasmid pLZ12-Km2. Simultaneously, MAT100 was also generated by introducing pLZ12-Km2 into MTB313. Then, MTB313 and MAT100 showed the large quantities of cell-associated HA in the cell pellets and the small quantities of SpeB associated with low activities in the culture supernatants. In contrast, MTB314 and MAT101 showed the opposite results. Meanwhile, the SLO production was much the same among these four strains in the culture supernatants. Finally, when the mortality rates by two weeks of these four strains were examined in a CD46-expressing transgenic mouse model of subcutaneous infection into both hind footpads, the higher mortalities were observed in the MTB313- or MAT100-infected mice than in the MTB314- or MAT101-infected mice. These results clearly indicate that the point mutation in the rocA gene of S. pyogenes led to the high-pathogenicity phenotype associated with the suppression of covR expression, which occurred within the patient.	
1314.508	Streptococcus pyogenes strain MUMCMC13		1314	WGS	MUMCMC13				MLST.Streptococcus_pyogenes.28	genotype:ST28			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972301	GCA_002268595.1	NGQP00000000		Christian Medical College	WGS	IonTorrent	169x	AssemblerSPAdes v. 5.0.0.0			60		1861369	38.33	2020		1880.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		6years	Fever, Throat pain																Clinical isolates from Homo sapiens;many frameshifted proteins	
1314.502	Streptococcus pyogenes strain MUMCMC2276		1314	WGS	MUMCMC2276				MLST.Streptococcus_pyogenes.36	genotype:ST36			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972308	GCA_002268485.1	NGQI00000000		Christian Medical College	WGS	IonTorrent	184x	AssemblerSPAdes v. 5.0.0.7			41		1725865	38.5	1795		1683.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		7 years 6months	Fever, Throat pain																Clinical isolates from Homo sapiens	collected_by:Dr Satish Shahane, Mumbai
1314.501	Streptococcus pyogenes strain MUMCMC317		1314	WGS	MUMCMC317				MLST.Streptococcus_pyogenes.36	genotype:ST36			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972303	GCA_002268475.1	NGQN00000000		Christian Medical College	WGS	IonTorrent	189x	AssemblerSPAdes v. 5.0.0.2			86		1766009	38.67	1886		1747.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens			Fever, Throat pain																Clinical isolates from Homo sapiens;many frameshifted proteins	
1314.505	Streptococcus pyogenes strain MUMCMC51		1314	WGS	MUMCMC51				MLST.Streptococcus_pyogenes.28	genotype:ST28			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972302	GCA_002268555.1	NGQO00000000		Christian Medical College	WGS	IonTorrent	134x	AssemblerSPAdes v. 5.0.0.1			34		1848520	38.29	1962		1849.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		5years	Fever, Throat pain																Clinical isolates from Homo sapiens	collected_by:Dr Yewale Hospital, Mumbai
1314.503	Streptococcus pyogenes strain MUMCMC616		1314	WGS	MUMCMC616				MLST.Streptococcus_pyogenes.28	genotype:ST28			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972304	GCA_002268515.1	NGQM00000000		Christian Medical College	WGS	IonTorrent	38x	AssemblerSPAdes v. 5.0.0.3			57		1854371	38.24	2095		1859.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		6 years	Fever, Throat pain																Clinical isolates from Homo sapiens;many frameshifted proteins	
1314.506	Streptococcus pyogenes strain MUMCMC650		1314	WGS	MUMCMC650				MLST.Streptococcus_pyogenes.36	genotype:ST36			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972305	GCA_002268575.1	NGQL00000000		Christian Medical College	WGS	IonTorrent	164x	AssemblerSPAdes v. 5.0.0.4			43		1690769	38.41	1767		1638.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens			Fever, Throat pain																Clinical isolates from Homo sapiens	
1314.507	Streptococcus pyogenes strain MUMCMC661		1314	WGS	MUMCMC661				MLST.Streptococcus_pyogenes.36	genotype:ST36			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972306	GCA_002268585.1	NGQK00000000		Christian Medical College	WGS	IonTorrent	174x	AssemblerSPAdes v. 5.0.0.5			54		1850722	38.41	2002		1819.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		6 years 5 months	Fever, Throat pain																Clinical isolates from Homo sapiens;many frameshifted proteins	
1314.504	Streptococcus pyogenes strain MUMCMC662		1314	WGS	MUMCMC662				MLST.Streptococcus_pyogenes.28	genotype:ST28			2017-08-24T00:00:00Z		PRJNA386535	SAMN06972307	GCA_002268525.1	NGQJ00000000		Christian Medical College	WGS	IonTorrent	162x	AssemblerSPAdes v. 5.0.0.6			32		1848415	38.25	2018		1852.0		throat		2017-04	India	India: Mumbai						Human, Homo sapiens		5 years	Fever, Throat pain																Clinical isolates from Homo sapiens;many frameshifted proteins	collected_by:Dr Satish Shahane, Mumbai
1314.758	Streptococcus pyogenes strain NCTC10085		1314	Complete	NCTC10085				MLST.Streptococcus_pyogenes.36				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3881058	GCA_900475645.1	LS483401		SC	Complete				1.0		1		1795272	38.552376	1745		1669.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.815	Streptococcus pyogenes strain NCTC10866		1314	WGS	NCTC10866	Lancefield Group A			MLST.Streptococcus_pyogenes.161		NCTC:10866		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3614268	GCA_900460005.1	UHHP00000000		SC	WGS						6		1985570	38.40162	2046		1930.0		not available: to be reported later		1900-1957	USA	USA: Maryland (State)												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.809	Streptococcus pyogenes strain NCTC10870		1314	WGS	NCTC10870				MLST.Streptococcus_pyogenes.4				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53414668	GCA_900459855.1	UHHD00000000		SC	WGS						3		1834918	38.555454	1854		1770.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.807	Streptococcus pyogenes strain NCTC10871		1314	WGS	NCTC10871				MLST.Streptococcus_pyogenes.11				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53415418	GCA_900459815.1	UHHB00000000		SC	WGS						3		1888267	38.631824	1906		1823.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.816	Streptococcus pyogenes strain NCTC10872		1314	WGS	NCTC10872	Lancefield Group A			MLST.Streptococcus_pyogenes.159		NCTC:10872		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3614269	GCA_900460015.1	UHHK00000000		SC	WGS						3		1994435	38.53467	2113		2033.0		Skin Lesion		1967	USA	USA: Atlanta						Human, Homo sapiens						host_health_state:disease													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.749	Streptococcus pyogenes strain NCTC10874		1314	Complete	NCTC10874				MLST.Streptococcus_pyogenes.126				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3729940	GCA_900475425.1	LS483379		SC	Complete				1.0		1		1764453	38.536644	1725		1643.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.806	Streptococcus pyogenes strain NCTC10875		1314	WGS	NCTC10875				MLST.Streptococcus_pyogenes.33				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53416168	GCA_900459805.1	UHHA00000000		SC	WGS						2		1785661	38.536373	1770		1688.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.747	Streptococcus pyogenes strain NCTC10876		1314	Complete	NCTC10876	Lancefield Group A			MLST.Streptococcus_pyogenes.176		NCTC:10876		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3662939	GCA_900475175.1	LS483360		SC	Complete				1.0		1		1906305	38.451874	1927		1836.0		Foot Lesion		1900-1967								Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.761	Streptococcus pyogenes strain NCTC10877		1314	Complete	NCTC10877				MLST.Streptococcus_pyogenes.172				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3956099	GCA_900475785.1	LS483421		SC	Complete				1.0		1		1789295	38.51288	1744		1661.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.750	Streptococcus pyogenes strain NCTC10879		1314	Complete	NCTC10879				MLST.Streptococcus_pyogenes.31				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3871783	GCA_900475455.1	LS483389		SC	Complete				1.0		1		1908146	38.48647	1920		1840.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.756	Streptococcus pyogenes strain NCTC10880		1314	Complete	NCTC10880	Lancefield Group A			MLST.Streptococcus_pyogenes.2		NCTC:10880		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3662931	GCA_900475565.1	LS483394		SC	Complete				1.0		1		1785401	38.593403	1750		1668.0		Throat		1966	Netherlands	Netherlands: Leiden						Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.765	Streptococcus pyogenes strain NCTC12044		1314	Complete	NCTC12044				MLST.Streptococcus_pyogenes.124				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3956097	GCA_900475925.1	LS483430		SC	Complete				1.0		1		1756874	38.55177	1705		1638.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.723	Streptococcus pyogenes strain NCTC12045		1314	Complete	NCTC12045	Group A, Type 65			MLST.Streptococcus_pyogenes.127		NCTC:12045		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542444	GCA_900474825.1	LS483326		SC	Complete				1.0		1		1756406	38.645164	1707		1633.0		not available: to be reported later		1900-1988														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.728	Streptococcus pyogenes strain NCTC12046		1314	Complete	NCTC12046	Lancefield Group A			MLST.Streptococcus_pyogenes.44		NCTC:12046		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572427	GCA_900474885.1	LS483336		SC	Complete				1.0		1		1875632	38.556816	1874		1794.0		not available: to be reported later		1900-1986	USA	United States												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.732	Streptococcus pyogenes strain NCTC12047		1314	Complete	NCTC12047	Lancefield Group A, Type 67			MLST.Streptococcus_pyogenes.61		NCTC:12047		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572429	GCA_900474935.1	LS483337		SC	Complete				1.0		1		1805495	38.474102	1784		1698.0		not available: to be reported later		1900-1974														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.730	Streptococcus pyogenes strain NCTC12048		1314	Complete	NCTC12048	Lancefield Group A					NCTC:12048		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572431	GCA_900474915.1	LS483333		SC	Complete				1.0		1		1793034	38.44411	1754		1676.0		not available: to be reported later		1900-1974														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.811	Streptococcus pyogenes strain NCTC12049		1314	WGS	NCTC12049	Lancefield Group A			MLST.Streptococcus_pyogenes.129		NCTC:12049		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3572433	GCA_900459875.1	UHHL00000000		SC	WGS						2		1815687	38.619156	1794		1714.0		not available: to be reported later		1900-1974														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.731	Streptococcus pyogenes strain NCTC12050		1314	Complete	NCTC12050	Lancefield Group A			MLST.Streptococcus_pyogenes.24		NCTC:12050		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572435	GCA_900474925.1	LS483334		SC	Complete				1.0		1		1851237	38.588955	1815		1730.0		not available: to be reported later		1900-1974														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.808	Streptococcus pyogenes strain NCTC12051		1314	WGS	NCTC12051	not available: to be reported later			MLST.Streptococcus_pyogenes.130		NCTC:12051		2018-07-31T00:00:00Z		PRJEB6403	SAMEA3542445	GCA_900459825.1	UHHH00000000		SC	WGS						2		1786441	38.431103	1757		1670.0		not available: to be reported later		1900-1974	Egypt	Egypt: Cairo												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.735	Streptococcus pyogenes strain NCTC12052		1314	Complete	NCTC12052	Lancefield Group A			MLST.Streptococcus_pyogenes.131		NCTC:12052		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594345	GCA_900474975.1	LS483352		SC	Complete				1.0		1		1857727	38.53209	1869		1789.0		not available: to be reported later		1900-1965														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.802	Streptococcus pyogenes strain NCTC12054		1314	WGS	NCTC12054	not available: to be reported later			MLST.Streptococcus_pyogenes.120		NCTC:12054		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3542446	GCA_900459745.1	UHHM00000000		SC	WGS						2		1863737	38.501354	1865		1781.0		not available: to be reported later		1900-1967	Trinidad and Tobago	Trinidad and Tobago												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.725	Streptococcus pyogenes strain NCTC12057		1314	Complete	NCTC12057	Lancefield Group A			MLST.Streptococcus_pyogenes.63		NCTC:12057		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594346	GCA_900474845.1	LS483331		SC	Complete				1.0		1		1848740	38.50374	1782		1705.0		not available: to be reported later		1900-1972	United Kingdom	United Kingdom: Blackpool												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.727	Streptococcus pyogenes strain NCTC12058		1314	Complete	NCTC12058	Lancefield Group A			MLST.Streptococcus_pyogenes.253		NCTC:12058		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594347	GCA_900474865.1	LS483329		SC	Complete				1.0		1		1768863	38.619102	1728		1655.0		not available: to be reported later		1900-1972	United Kingdom	United Kingdom: Stockton												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.718	Streptococcus pyogenes strain NCTC12059		1314	Complete	NCTC12059	not available: to be reported later			MLST.Streptococcus_pyogenes.132		NCTC:12059		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542447	GCA_900474745.1	LS483315		SC	Complete				1.0		1		1808384	38.559013	1778		1698.0		not available: to be reported later		1900-1974														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.896	Streptococcus pyogenes strain NCTC12060		1314	Complete	NCTC12060	not available: to be reported later			MLST.Streptococcus_pyogenes.538		NCTC:12060		2018-12-19T00:00:00Z		PRJEB6403	SAMEA3542448	GCA_900636425.1	LR134272		SC	Complete				1.0		1		1768145	38.654804	1785		1700.0		not available: to be reported later		1975	United Kingdom	United Kingdom: Shrewsbury												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.820	Streptococcus pyogenes strain NCTC12061		1314	WGS	NCTC12061	Lancefield Group A			MLST.Streptococcus_pyogenes.330		NCTC:12061		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3594348	GCA_900460085.1	UHHO00000000		SC	WGS						2		1837322	38.558346	1809		1728.0		not available: to be reported later		1900-1981	United Kingdom	United Kingdom: Winchester												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.738	Streptococcus pyogenes strain NCTC12062		1314	Complete	NCTC12062	Lancefield Group A			MLST.Streptococcus_pyogenes.26		NCTC:12062		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594349	GCA_900475005.1	LS483340		SC	Complete				1.0		1		1827653	38.519455	1806		1724.0		not available: to be reported later		1900-1972	United Kingdom	United Kingdom: Nottingham												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.739	Streptococcus pyogenes strain NCTC12064		1314	Complete	NCTC12064	Lancefield Group A			MLST.Streptococcus_pyogenes.103		NCTC:12064		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594357	GCA_900475035.1	LS483338		SC	Complete				1.0		1		1746380	38.549114	1704		1630.0		not available: to be reported later		1900-1982	United Kingdom	United Kingdom: Telford												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.819	Streptococcus pyogenes strain NCTC12065		1314	WGS	NCTC12065	Lancefield Group A			MLST.Streptococcus_pyogenes.62		NCTC:12065		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3594350	GCA_900460075.1	UHHN00000000		SC	WGS						2		1856280	38.51709	1844		1764.0		not available: to be reported later		1900-1976														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.720	Streptococcus pyogenes strain NCTC12066		1314	Complete	NCTC12066	not available: to be reported later			MLST.Streptococcus_pyogenes.12		NCTC:12066		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542449	GCA_900474775.1	LS483322		SC	Complete				1.0		1		1744145	38.566807	1707		1627.0		not available: to be reported later		1979	United Kingdom	United Kingdom: Exeter												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.744	Streptococcus pyogenes strain NCTC12067		1314	Complete	NCTC12067	Lancefield Group A			MLST.Streptococcus_pyogenes.407		NCTC:12067		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594351	GCA_900475135.1	LS483355		SC	Complete				1.0		1		1752074	38.567665	1714		1634.0		not available: to be reported later		1900-1980														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.745	Streptococcus pyogenes strain NCTC12068		1314	Complete	NCTC12068	Lancefield Group A			MLST.Streptococcus_pyogenes.184		NCTC:12068		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594352	GCA_900475155.1	LS483359		SC	Complete				1.0		1		1751353	38.52947	1683		1598.0		not available: to be reported later		1900-1981														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.724	Streptococcus pyogenes strain NCTC12069		1314	Complete	NCTC12069	not available: to be reported later			MLST.Streptococcus_pyogenes.3		NCTC:12069		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542450	GCA_900474835.1	LS483327		SC	Complete				1.0		1		1808407	38.526836	1796		1722.0		not available: to be reported later		1981	United Kingdom	United Kingdom: Aberdeen												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.729	Streptococcus pyogenes strain NCTC12696		1314	Complete	NCTC12696	Lancefield Group A			MLST.Streptococcus_pyogenes.8		NCTC:12696		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3597589	GCA_900474895.1	LS483332		SC	Complete				1.0		1		1845052	38.482166	1866		1773.0		Pharynx		1900-1992								Human Child						host_health_state:Sore Throat													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.737	Streptococcus pyogenes strain NCTC12840		1314	Complete	NCTC12840	not available: to be reported later					NCTC:12840		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594343	GCA_900474995.1	LS483344		SC	Complete				1.0		1		1838787	38.608116	1855		1773.0		not available: to be reported later		1900-2007														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.803	Streptococcus pyogenes strain NCTC12841		1314	WGS	NCTC12841	not available: to be reported later			MLST.Streptococcus_pyogenes.65		NCTC:12841		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3572413	GCA_900459775.1	UHHQ00000000		SC	WGS						3		1972675	38.606056	2069		1961.0		not available: to be reported later		1900-2007														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.814	Streptococcus pyogenes strain NCTC12842		1314	WGS	NCTC12842				MLST.Streptococcus_pyogenes.42				2018-07-30T00:00:00Z		PRJEB6403	SAMEA4442467	GCA_900459995.1	UHHV00000000		SC	WGS						2		1836428	38.585884	1863		1784.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.760	Streptococcus pyogenes strain NCTC13736		1314	Complete	NCTC13736	Lancefield Group A Emm 22.0			MLST.Streptococcus_pyogenes.46		NCTC:13736		2018-06-17T00:00:00Z		PRJEB6403	SAMEA4012328	GCA_900475765.1	LS483414		SC	Complete				1.0		1		1913208	38.56711	1920		1833.0		Blood Culture		2015	United Kingdom	United Kingdom: Wales						Human, Homo sapiens						host_health_state:Hospital Patient													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.764	Streptococcus pyogenes strain NCTC13737		1314	Complete	NCTC13737	Lancefield Group A Emm 88.6					NCTC:13737		2018-06-17T00:00:00Z		PRJEB6403	SAMEA4017720	GCA_900475875.1	LS483425		SC	Complete				1.0		1		1819726	38.438095	1747		1660.0		Knee aspirate		2012	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:Hospital Patient													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.752	Streptococcus pyogenes strain NCTC13738		1314	Complete	NCTC13738				MLST.Streptococcus_pyogenes.331				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3871791	GCA_900475475.1	LS483382		SC	Complete				1.0		1		1847336	38.563747	1840		1772.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.763	Streptococcus pyogenes strain NCTC13739		1314	Complete	NCTC13739								2018-06-17T00:00:00Z		PRJEB6403	SAMEA53434918	GCA_900475865.1	LS483420		SC	Complete				1.0		1		1785880	38.578403	1739		1660.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.812	Streptococcus pyogenes strain NCTC13740		1314	WGS	NCTC13740								2018-07-30T00:00:00Z		PRJEB6403	SAMEA3871792	GCA_900459925.1	UHGW00000000		SC	WGS						2		1967001	38.518078	1979		1885.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.800	Streptococcus pyogenes strain NCTC13741		1314	WGS	NCTC13741				MLST.Streptococcus_pyogenes.624				2018-07-30T00:00:00Z		PRJEB6403	SAMEA3871793	GCA_900459715.1	UHGX00000000		SC	WGS						3		1892164	38.577736	1913		1826.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.754	Streptococcus pyogenes strain NCTC13742		1314	Complete	NCTC13742				MLST.Streptococcus_pyogenes.63				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3871794	GCA_900475495.1	LS483386		SC	Complete				1.0		1		1934623	38.440254	1902		1818.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.755	Streptococcus pyogenes strain NCTC13743		1314	Complete	NCTC13743				MLST.Streptococcus_pyogenes.89				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3879489	GCA_900475525.1	LS483384		SC	Complete				1.0		1		1846983	38.403385	1821		1735.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.759	Streptococcus pyogenes strain NCTC13744		1314	Complete	NCTC13744	Lancefield Group A, emm 108			MLST.Streptococcus_pyogenes.1088		NCTC:13744		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3879490	GCA_900475705.1	LS483407		SC	Complete				1.0		1		1808803	38.635273	1784		1702.0		Blood Culture		2013	United Kingdom	United Kingdom: London						Human, Homo sapiens						host_health_state:Throat Infection													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.766	Streptococcus pyogenes strain NCTC13745		1314	Complete	NCTC13745				MLST.Streptococcus_pyogenes.101				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3923596	GCA_900475955.1	LS483432		SC	Complete				1.0		1		1834863	38.55171	1817		1745.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.767	Streptococcus pyogenes strain NCTC13751		1314	Complete	NCTC13751				MLST.Streptococcus_pyogenes.150				2018-06-17T00:00:00Z		PRJEB6403	SAMEA4017721	GCA_900475985.1	LS483437		SC	Complete				1.0		1		1891258	38.598858	1926		1836.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.810	Streptococcus pyogenes strain NCTC2218		1314	WGS	NCTC2218	Lancefield Group A			MLST.Streptococcus_pyogenes.28		NCTC:2218		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3539718	GCA_900459865.1	UHHC00000000		SC	WGS						2		1899728	38.460506	1972		1879.0		not available: to be reported later		1926	United Kingdom	United Kingdom: Aberdeen						Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.817	Streptococcus pyogenes strain NCTC2366		1314	WGS	NCTC2366	Lancefield Group A			MLST.Streptococcus_pyogenes.55		NCTC:2366		2018-07-30T00:00:00Z		PRJEB6403	SAMEA3649028	GCA_900460035.1	UHHU00000000		SC	WGS						2		1805104	38.50238	1787		1695.0		not available: to be reported later		1927	United Kingdom	United Kingdom: London												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.742	Streptococcus pyogenes strain NCTC4001		1314	Complete	NCTC4001	Lancefield Group A			MLST.Streptococcus_pyogenes.160		NCTC:4001		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3594360	GCA_900475105.1	LS483353		SC	Complete				1.0		1		1766320	38.593403	1754		1676.0		not available: to be reported later		1900-1933														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.717	Streptococcus pyogenes strain NCTC5163		1314	Complete	NCTC5163	Lancefield Group A, Griffith type 10					NCTC:5163		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3539724	GCA_900474645.1	LS483307		SC	Complete				1.0		1		1921448	38.556286	1979		1895.0		not available: to be reported later		1900-1937	United Kingdom	United Kingdom: London												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.721	Streptococcus pyogenes strain NCTC5164		1314	Complete	NCTC5164	Lancefield Group A, Griffith type 10					NCTC:5164		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542433	GCA_900474795.1	LS483320		SC	Complete				1.0		1		1921169	38.55616	1977		1895.0		not available: to be reported later		1900-1937	United Kingdom	United Kingdom: London												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.2389	Streptococcus pyogenes strain NCTC8193		1314	Complete	NCTC8193	serovar group a			MLST.Streptococcus_pyogenes.99		NCTC:8193		2019-05-10T00:00:00Z		PRJEB6403	SAMEA3222082	GCA_901472475.1	LR590466		SC	Complete				1.0		1		1858171	38.650585	1888		1810.0		not available: not collected		1900-1950	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:puerperal fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.740	Streptococcus pyogenes strain NCTC8195		1314	Complete	NCTC8195	Lancefield Group A, Griffith Type 30			MLST.Streptococcus_pyogenes.65		NCTC:8195		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3632069	GCA_900475075.1	LS483351		SC	Complete				1.0		1		1898595	38.594803	1938		1857.0		not available: to be reported later		1900-1950								Human, Homo sapiens						host_health_state:Puerperal Fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.470	Streptococcus pyogenes strain NCTC8198		1314	Complete	NCTC8198	group a			MLST.Streptococcus_pyogenes.28				2015-05-02T00:00:00Z		PRJEB6403	SAMEA2479569	GCA_002055535.1	LN831034		SC	Complete				1.0		1		1914862	38.5	1967		1891.0		throat		1950	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:disease: scarlet fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.813	Streptococcus pyogenes strain NCTC8199		1314	WGS	NCTC8199				MLST.Streptococcus_pyogenes.84				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53329918	GCA_900459935.1	UHHF00000000		SC	WGS						2		1832467	38.610134	1828		1744.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.751	Streptococcus pyogenes strain NCTC8224		1314	Complete	NCTC8224				MLST.Streptococcus_pyogenes.3				2018-06-17T00:00:00Z		PRJEB6403	SAMEA53411668	GCA_900475465.1	LS483522		SC	Complete				1.0		1		1811249	38.590332	1803		1723.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.716	Streptococcus pyogenes strain NCTC8225		1314	Complete	NCTC8225	Lancefield Group A			MLST.Streptococcus_pyogenes.316		NCTC:8225		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3597579	GCA_900474455.1	LS483298		SC	Complete				1.0		1		1906873	38.43974	1940		1858.0		not available: to be reported later		1900-1951	USA	United States												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.757	Streptococcus pyogenes strain NCTC8227		1314	Complete	NCTC8227				MLST.Streptococcus_pyogenes.47				2018-06-17T00:00:00Z		PRJEB6403	SAMEA3871782	GCA_900475615.1	LS483399		SC	Complete				1.0		1		1822334	38.60829	1824		1753.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.805	Streptococcus pyogenes strain NCTC8229		1314	WGS	NCTC8229				MLST.Streptococcus_pyogenes.32				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53412418	GCA_900459795.1	UHHI00000000		SC	WGS						2		1900776	38.531998	1944		1864.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.746	Streptococcus pyogenes strain NCTC8230		1314	Complete	NCTC8230	Lancefield Group A			MLST.Streptococcus_pyogenes.158		NCTC:8230		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3649042	GCA_900475165.1	LS483356		SC	Complete				1.0		1		1931144	38.569416	1979		1897.0		not available: to be reported later		1900-1951	USA	USA: New York City												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.736	Streptococcus pyogenes strain NCTC8231		1314	Complete	NCTC8231	Lancefield Group A, Griffith Type 44					NCTC:8231		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572417	GCA_900474965.1	LS483345		SC	Complete				1.0		1		1796043	38.52146	1751		1667.0		not available: to be reported later		1927														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.897	Streptococcus pyogenes strain NCTC8232		1314	Complete	NCTC8232	Lancefield Group A, Giffith Type 47					NCTC:8232		2018-12-19T00:00:00Z		PRJEB6403	SAMEA3632070	GCA_900636485.1	LR134284		SC	Complete				1.0		1		1900813	38.56976	1964		1877.0		not available: to be reported later		1934	United Kingdom	United Kingdom: London						Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.722	Streptococcus pyogenes strain NCTC8300		1314	Complete	NCTC8300	Lancefield Group A			MLST.Streptococcus_pyogenes.36		NCTC:8300		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542440	GCA_900474815.1	LS483323		SC	Complete				1.0		1		1797476	38.531364	1747		1670.0		Throat		1900-1950								Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.898	Streptococcus pyogenes strain NCTC8302		1314	Complete	NCTC8302	Lancefield Group A			MLST.Streptococcus_pyogenes.37		NCTC:8302		2018-12-19T00:00:00Z		PRJEB6403	SAMEA3729937	GCA_900636725.1	LR134314		SC	Complete				1.0		1		1834173	38.65186	1817		1745.0		throat		1918	USA	USA: Texas (State)						Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.818	Streptococcus pyogenes strain NCTC8303		1314	WGS	NCTC8303	Lancefield Group A			MLST.Streptococcus_pyogenes.163		NCTC:8303		2018-07-31T00:00:00Z		PRJEB6403	SAMEA3632057	GCA_900460055.1	UHHJ00000000		SC	WGS						5		1870294	38.607674	1916		1824.0		not available: to be reported later		1900-1950	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.762	Streptococcus pyogenes strain NCTC8304		1314	Complete	NCTC8304				MLST.Streptococcus_pyogenes.196				2018-06-17T00:00:00Z		PRJEB6403	SAMEA4557824	GCA_900475795.1	LS483415		SC	Complete				1.0		1		1790372	38.557407	1783		1703.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.801	Streptococcus pyogenes strain NCTC8305		1314	WGS	NCTC8305				MLST.Streptococcus_pyogenes.66				2018-07-31T00:00:00Z		PRJEB6403	SAMEA3879485	GCA_900459725.1	UHHE00000000		SC	WGS						2		1959738	38.601128	2020		1932.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.804	Streptococcus pyogenes strain NCTC8308		1314	WGS	NCTC8308				MLST.Streptococcus_pyogenes.52				2018-07-31T00:00:00Z		PRJEB6403	SAMEA3729938	GCA_900459785.1	UHGY00000000		SC	WGS						2		1839498	38.40401	1795		1715.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.719	Streptococcus pyogenes strain NCTC8314		1314	Complete	NCTC8314	Lancefield Group A, Griffith type 13			MLST.Streptococcus_pyogenes.157		NCTC:8314		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542441	GCA_900474765.1	LS483321		SC	Complete				1.0		1		1862643	38.53664	1879		1783.0		not available: to be reported later		1900-1950														host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.733	Streptococcus pyogenes strain NCTC8316		1314	Complete	NCTC8316	Lancefield Group A			MLST.Streptococcus_pyogenes.75		NCTC:8316		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3597580	GCA_900474945.1	LS483521		SC	Complete				1.0		1		1786462	38.6142	1724		1639.0		not available: to be reported later		1900-1935								Human, Homo sapiens						host_health_state:Sore Throat													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.2390	Streptococcus pyogenes strain NCTC8318		1314	Complete	NCTC8318	group a					NCTC:8318		2019-05-11T00:00:00Z		PRJEB6403	SAMEA3597581	GCA_901482645.1	LR590483		SC	Complete				1.0		1		1819777	38.558517	1799		1720.0		not available: not collected		1800-1934	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:Scarlet fever Outbreak													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.753	Streptococcus pyogenes strain NCTC8320		1314	Complete	NCTC8320				MLST.Streptococcus_pyogenes.42				2018-06-17T00:00:00Z		PRJEB6403	SAMEA53413168	GCA_900475485.1	LS483391		SC	Complete				1.0		1		1863040	38.582584	1899		1825.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.748	Streptococcus pyogenes strain NCTC8322		1314	Complete	NCTC8322	Lancefield Group A			MLST.Streptococcus_pyogenes.55		NCTC:8322		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3662934	GCA_900475335.1	LS483520		SC	Complete				1.0		1		1829590	38.506824	1849		1770.0		not available: to be reported later		1900-1950	United Kingdom	United Kingdom: London												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.741	Streptococcus pyogenes strain NCTC8324		1314	Complete	NCTC8324	Lancefield Group A, Griffith Type 8			MLST.Streptococcus_pyogenes.59		NCTC:8324		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3632058	GCA_900475085.1	LS483347		SC	Complete				1.0		1		1915789	38.526684	1936		1866.0		not available: to be reported later		1932	United Kingdom	United Kingdom: London						Human, Homo sapiens						host_health_state:Scarlet Fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.743	Streptococcus pyogenes strain NCTC8326		1314	Complete	NCTC8326	Lancefield Group A			MLST.Streptococcus_pyogenes.38		NCTC:8326		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3614262	GCA_900475115.1	LS483357		SC	Complete				1.0		1		1891095	38.49188	1923		1830.0		not available: to be reported later		1950	United Kingdom	United Kingdom: London												host_health_state:not available: to be reported later													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.726	Streptococcus pyogenes strain NCTC8328		1314	Complete	NCTC8328	Lancefield Group A			MLST.Streptococcus_pyogenes.156		NCTC:8328		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3572419	GCA_900474855.1	LS483330		SC	Complete				1.0		1		1864452	38.448402	1861		1787.0		not available: to be reported later		1932								Human, Homo sapiens						host_health_state:Scarlet Fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.821	Streptococcus pyogenes strain NCTC8330		1314	WGS	NCTC8330				MLST.Streptococcus_pyogenes.45				2018-07-30T00:00:00Z		PRJEB6403	SAMEA53413918	GCA_900461655.1	UHGZ00000000		SC	WGS						2		1750474	38.598404	1706		1630.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.734	Streptococcus pyogenes strain NCTC8332		1314	Complete	NCTC8332	Lancefiled Group A, Griffith type 10					NCTC:8332		2018-06-17T00:00:00Z		PRJEB6403	SAMEA3542442	GCA_900474955.1	LS483335		SC	Complete				1.0		1		1921449	38.556423	1978		1896.0		not available: to be reported later		1900-1950	United Kingdom	United Kingdom						Human, Homo sapiens						host_health_state:Scarlet Fever													http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.768	Streptococcus pyogenes strain NCTC8370		1314	Complete	NCTC8370								2018-06-17T00:00:00Z		PRJEB6403	SAMEA4364215	GCA_900476015.1	LS483442		SC	Complete				1.0		1		1796907	38.50817	1773		1694.0																															http://www.sanger.ac.uk/resources/downloads/bacteria/nctc/	
1314.192	Streptococcus pyogenes strain NGAS322		1314	Complete	NGAS322				MLST.Streptococcus_pyogenes.188				2015-08-17T00:00:00Z		PRJNA243328	SAMN03274509	GCF_001267805.1	CP010449	NZ_CP010449.1	Public Health Ontario	Complete	SMRT PacBio	114X	Celera v. 7.0; Quiver	1.0		1		1950469	38.32	1959		1812.0																					Positive	Cocci									Closed genome for strains of Streptococcus pyogenes that did not previously contain a closed genome reference.	
1314.196	Streptococcus pyogenes strain NGAS327		1314	Complete	NGAS327				MLST.Streptococcus_pyogenes.5				2015-06-03T00:00:00Z		PRJNA243328	SAMN02715759	GCF_001019695.1	CP007562	NZ_CP007562.1	Public Health Ontario	Complete	PacBio	195.0x	Celera Assembler v. 7.	1.0		1		1702054	38.62	1640		1546.0		human																			Positive	Cocci									Closed genome for strains of Streptococcus pyogenes that did not previously contain a closed genome reference.	
1314.197	Streptococcus pyogenes strain NGAS596		1314	Complete	NGAS596				MLST.Streptococcus_pyogenes.334				2015-06-03T00:00:00Z		PRJNA243328	SAMN02715758	GCF_001019675.1	CP007561	NZ_CP007561.1	Public Health Ontario	Complete	PacBio	220.0x	Celera Assembler v. 7.0	1.0		1		1791306	38.53	1755		1626.0		human																			Positive	Cocci									Closed genome for strains of Streptococcus pyogenes that did not previously contain a closed genome reference.	
1314.193	Streptococcus pyogenes strain NGAS638		1314	Complete	NGAS638				MLST.Streptococcus_pyogenes.182				2015-08-17T00:00:00Z		PRJNA243328	SAMN03274510	GCF_001267845.1	CP010450	NZ_CP010450.1	Public Health Ontario	Complete	SMRT PacBio	308X	Celera v. 7.0; Quiver	1.0		1		1791401	38.56	1774		1654.0																					Positive	Cocci									Closed genome for strains of Streptococcus pyogenes that did not previously contain a closed genome reference.	
1314.198	Streptococcus pyogenes strain NGAS743		1314	Complete	NGAS743				MLST.Streptococcus_pyogenes.62				2015-06-03T00:00:00Z		PRJNA243328	SAMN02715744	GCF_001019635.1	CP007560	NZ_CP007560.1	Public Health Ontario	Complete	PacBio	196.0x	Celera Assembler v. 7.0	1.0		1		1915554	38.5	1941		1807.0		human																			Positive	Cocci									Closed genome for strains of Streptococcus pyogenes that did not previously contain a closed genome reference.	
1314.714	Streptococcus pyogenes strain NGAS979		1314	Complete	NGAS979				MLST.Streptococcus_pyogenes.120			Yes	2018-06-08T00:00:00Z	29780850	PRJNA434749	SAMN08569881	GCA_003203475.1	CP028140		Public Health Ontario	Complete	PacBio	550.0x	HGAP v. AUG-2017	1.0		1		1790938	38.52847	1791		1722.0				2016								Human, Homo sapiens																			Complete genome sequence of emm74 type Streptococcus pyogenes strain NGAS979. Sequencing completed by PacBio.	collected_by:Public Health Ontario
1314.2831	Streptococcus pyogenes strain NIH34		1314	Complete	NIH34				MLST.Streptococcus_pyogenes.15				2020-08-08T00:00:00Z		PRJDB10330	SAMD00238717	GCA_014191695.1	AP023387		Department of Microbiology, Graduate School of Medicine, Kyoto University	Complete	Illumina MiSeq; Oxford Nanopore	514x	Unicycler v. 0.4.8	1.0	0.0	1		1900555	38.58636	1957		1866.0					Japan	Japan:Kochi						Human, Homo sapiens									Positive	Cocci									We determined complete genome sequence of three Streptococcus species, S. pyogenes, S. suis, and S. dysgalactiae. Among these three species, S. pyogenes and S. dysagalactiae have recognized as causative agents occasionally causing sever disease (ex. toxic shock syndrome) to human. On the other hand, S. suis is one of the major zoonotic agent and cause a variety of infections in individuals working in close contact with swine or pork products. In this study, we focus on the gene sets or genomic regions contributing to their pathogenicity, based on the complete genome sequence of three Streptococcus species.	
1314.2832	Streptococcus pyogenes strain NIH35		1314	Complete	NIH35				MLST.Streptococcus_pyogenes.52				2020-08-08T00:00:00Z		PRJDB10330	SAMD00238718	GCA_014191835.1	AP023388		Department of Microbiology, Graduate School of Medicine, Kyoto University	Complete	Illumina MiSeq; Oxford Nanopore	598x	Unicycler v. 0.4.8	1.0	0.0	1		1853362	38.34545	1834		1750.0					Japan	Japan:Kochi						Human, Homo sapiens									Positive	Cocci									We determined complete genome sequence of three Streptococcus species, S. pyogenes, S. suis, and S. dysgalactiae. Among these three species, S. pyogenes and S. dysagalactiae have recognized as causative agents occasionally causing sever disease (ex. toxic shock syndrome) to human. On the other hand, S. suis is one of the major zoonotic agent and cause a variety of infections in individuals working in close contact with swine or pork products. In this study, we focus on the gene sets or genomic regions contributing to their pathogenicity, based on the complete genome sequence of three Streptococcus species.	
1314.2329	Streptococcus pyogenes strain NS1		1314	WGS	NS1	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864309	GCA_900995575.1	CAAJEC000000000		SC	WGS						21		1790029	38.368416	1829		1729.0		skin sore / abscess / burns / IV Site		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2331	Streptococcus pyogenes strain NS10		1314	WGS	NS10	EMM53.0			MLST.Streptococcus_pyogenes.299				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864256	GCA_900995595.1	CAAJEG000000000		SC	WGS						23		1827124	38.280293	1823		1714.0		throat		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1106	Streptococcus pyogenes strain NS100		1314	WGS	NS100	EMM68.2			MLST.Streptococcus_pyogenes.298				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238015	GCA_900983265.1	CAAHIW000000000		SC	WGS						22		1715978	38.30551	1693		1602.0		throat		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2013	Streptococcus pyogenes strain NS10015		1314	WGS	NS10015	EMM97.0			MLST.Streptococcus_pyogenes.197				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407112	GCA_900992415.1	CAAIRY000000000		SC	WGS						11		1775394	38.388382	1763		1680.0		skin sore / abscess / burns / IV Site		1987	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2317	Streptococcus pyogenes strain NS101		1314	WGS	NS101	EMM110.0			MLST.Streptococcus_pyogenes.628				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864215	GCA_900995455.1	CAAJDQ000000000		SC	WGS						18		1780310	38.308205	1769		1686.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2338	Streptococcus pyogenes strain NS1017		1314	WGS	NS1017	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864259	GCA_900995665.1	CAAJEL000000000		SC	WGS						11		1753172	38.373554	1747		1649.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2316	Streptococcus pyogenes strain NS1033		1314	WGS	NS1033	EMM230.0			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864216	GCA_900995445.1	CAAJDM000000000		SC	WGS						14		1791693	38.311714	1794		1712.0		skin		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2334	Streptococcus pyogenes strain NS1036		1314	WGS	NS1036	EMM110.0			MLST.Streptococcus_pyogenes.179				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864254	GCA_900995625.1	CAAJEH000000000		SC	WGS						24		1778117	38.271843	1775		1687.0		skin		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1891	Streptococcus pyogenes strain NS1043		1314	WGS	NS1043	EMM222.0			MLST.Streptococcus_pyogenes.116				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407078	GCA_900991195.1	CAAINF000000000		SC	WGS						10		1751676	38.401493	1754		1671.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2332	Streptococcus pyogenes strain NS1045		1314	WGS	NS1045	EMM60.7			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864253	GCA_900995605.1	CAAJEE000000000		SC	WGS						28		1834886	38.29079	1850		1756.0		skin		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1892	Streptococcus pyogenes strain NS1051		1314	WGS	NS1051	EMM114.2			MLST.Streptococcus_pyogenes.189				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407073	GCA_900991205.1	CAAINH000000000		SC	WGS						27		1866519	38.29221	1870		1770.0		sterile site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2336	Streptococcus pyogenes strain NS1053		1314	WGS	NS1053	EMM60.4			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864252	GCA_900995645.1	CAAJEJ000000000		SC	WGS						19		1801394	38.285282	1781		1700.0		sterile site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2335	Streptococcus pyogenes strain NS1096		1314	WGS	NS1096	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864251	GCA_900995635.1	CAAJEI000000000		SC	WGS						16		1835779	38.341095	1877		1780.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2339	Streptococcus pyogenes strain NS1107		1314	WGS	NS1107	EMM76.4			MLST.Streptococcus_pyogenes.631				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864250	GCA_900995675.1	CAAJEM000000000		SC	WGS						28		1777872	38.302574	1767		1682.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2337	Streptococcus pyogenes strain NS1120		1314	WGS	NS1120	EMM77.0			MLST.Streptococcus_pyogenes.63				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864257	GCA_900995655.1	CAAJEK000000000		SC	WGS						13		1935870	38.285267	1954		1856.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2318	Streptococcus pyogenes strain NS1122		1314	WGS	NS1122	EMM63.3			MLST.Streptococcus_pyogenes.297				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864217	GCA_900995465.1	CAAJDT000000000		SC	WGS						23		1859016	38.239338	1869		1770.0		throat		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2325	Streptococcus pyogenes strain NS1132		1314	WGS	NS1132	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864255	GCA_900995535.1	CAAJDZ000000000		SC	WGS						21		1846639	38.29949	1886		1792.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2330	Streptococcus pyogenes strain NS1133		1314	WGS	NS1133	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864319	GCA_900995585.1	CAAJED000000000		SC	WGS						15		1753944	38.38384	1760		1678.0		Invasive		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2333	Streptococcus pyogenes strain NS1140		1314	WGS	NS1140	EMM57.0			MLST.Streptococcus_pyogenes.348				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864320	GCA_900995615.1	CAAJEF000000000		SC	WGS						18		1778410	38.418476	1770		1685.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1890	Streptococcus pyogenes strain NS1185		1314	WGS	NS1185	EMM80.2			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407064	GCA_900991185.1	CAAING000000000		SC	WGS						14		1767634	38.32943	1761		1672.0		sterile site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1894	Streptococcus pyogenes strain NS1196		1314	WGS	NS1196	EMM60.4			MLST.Streptococcus_pyogenes.193				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407094	GCA_900991225.1	CAAINK000000000		SC	WGS						17		1799506	38.297234	1778		1695.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2319	Streptococcus pyogenes strain NS1210		1314	WGS	NS1210	EMM75.0			MLST.Streptococcus_pyogenes.632				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864218	GCA_900995475.1	CAAJDL000000000		SC	WGS						10		1735571	38.390232	1724		1643.0		sterile site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2342	Streptococcus pyogenes strain NS1216		1314	WGS	NS1216	EMM109.1			MLST.Streptococcus_pyogenes.633				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864318	GCA_900995705.1	CAAJEP000000000		SC	WGS						27		1847903	38.199883	1845		1743.0		sterile site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2344	Streptococcus pyogenes strain NS125		1314	WGS	NS125	EMM95.0			MLST.Streptococcus_pyogenes.604				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864315	GCA_900995725.1	CAAJER000000000		SC	WGS						22		1745728	38.37641	1747		1651.0		Invasive		1993	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2312	Streptococcus pyogenes strain NS13		1314	WGS	NS13	EMM53.0			MLST.Streptococcus_pyogenes.299				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864219	GCA_900995405.1	CAAJDO000000000		SC	WGS						22		1826122	38.2758	1822		1717.0		sterile site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1893	Streptococcus pyogenes strain NS1353		1314	WGS	NS1353	EMM233.1			MLST.Streptococcus_pyogenes.206				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407119	GCA_900991215.1	CAAINI000000000		SC	WGS						24		1758864	38.404186	1753		1667.0		skin sore / abscess / burns / IV Site		1998	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2346	Streptococcus pyogenes strain NS14		1314	WGS	NS14	EMM102.2			MLST.Streptococcus_pyogenes.185				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864258	GCA_900995745.1	CAAJES000000000			WGS						32		1841484	38.436535	1871		1759.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																				
1314.1895	Streptococcus pyogenes strain NS1425		1314	WGS	NS1425	EMM13.0			MLST.Streptococcus_pyogenes.286				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407111	GCA_900991235.1	CAAINJ000000000		SC	WGS						29		1779521	38.334885	1792		1701.0		skin sore / abscess / burns / IV Site		1998	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1896	Streptococcus pyogenes strain NS1438		1314	WGS	NS1438	EMM71.2			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406943	GCA_900991245.1	CAAINL000000000		SC	WGS						24		1727494	38.269505	1713		1602.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1897	Streptococcus pyogenes strain NS1498		1314	WGS	NS1498	EMM217.0			MLST.Streptococcus_pyogenes.594				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406958	GCA_900991255.1	CAAINM000000000		SC	WGS						13		1721477	38.353924	1669		1585.0		skin sore / abscess / burns / IV Site		1998	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1880	Streptococcus pyogenes strain NS16		1314	WGS	NS16	EMM77.0			MLST.Streptococcus_pyogenes.166				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407102	GCA_900991085.1	CAAIMW000000000		SC	WGS						12		1840695	38.27766	1814		1729.0		other		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1898	Streptococcus pyogenes strain NS1691		1314	WGS	NS1691	EMM75.3			MLST.Streptococcus_pyogenes.590				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406983	GCA_900991265.1	CAAINN000000000		SC	WGS						31		1778762	38.27578	1759		1651.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2345	Streptococcus pyogenes strain NS176		1314	WGS	NS176	EMM207.1			MLST.Streptococcus_pyogenes.332				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864314	GCA_900995735.1	CAAJET000000000		SC	WGS						17		1756596	38.30295	1755		1653.0		skin		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2348	Streptococcus pyogenes strain NS178		1314	WGS	NS178	EMM54.1			MLST.Streptococcus_pyogenes.302				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864322	GCA_900995765.1	CAAJEU000000000		SC	WGS						12		1707571	38.38508	1682		1604.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2347	Streptococcus pyogenes strain NS179		1314	WGS	NS179	EMM9.0			MLST.Streptococcus_pyogenes.204				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864295	GCA_900995755.1	CAAJEV000000000			WGS						22		1791309	38.42296	1793		1688.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																				
1314.2349	Streptococcus pyogenes strain NS190		1314	WGS	NS190	EMM92.0			MLST.Streptococcus_pyogenes.312				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864294	GCA_900995775.1	CAAJEW000000000		SC	WGS						17		1737674	38.3904	1714		1618.0		sterile site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2322	Streptococcus pyogenes strain NS192		1314	WGS	NS192	EMM106.0			MLST.Streptococcus_pyogenes.338				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864273	GCA_900995505.1	CAAJDV000000000		SC	WGS						16		1687465	38.446545	1654		1568.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1899	Streptococcus pyogenes strain NS1932		1314	WGS	NS1932	EMM22.0			MLST.Streptococcus_pyogenes.175				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406995	GCA_900991275.1	CAAINO000000000		SC	WGS						21		1763447	38.323013	1733		1640.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1905	Streptococcus pyogenes strain NS1944		1314	WGS	NS1944	EMM18.12			MLST.Streptococcus_pyogenes.535				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407005	GCA_900991335.1	CAAINU000000000		SC	WGS						15		1758731	38.355156	1769		1677.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2327	Streptococcus pyogenes strain NS195		1314	WGS	NS195	EMM19.X			MLST.Streptococcus_pyogenes.370				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864272	GCA_900995555.1	CAAJEB000000000		SC	WGS						31		1808060	38.356735	1850		1755.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1900	Streptococcus pyogenes strain NS1951		1314	WGS	NS1951	EMM90.2			MLST.Streptococcus_pyogenes.418				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407014	GCA_900991285.1	CAAINQ000000000		SC	WGS						19		1732918	38.35421	1712		1626.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2340	Streptococcus pyogenes strain NS196		1314	WGS	NS196	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864297	GCA_900995685.1	CAAJEN000000000		SC	WGS						18		1864783	38.273148	1910		1806.0		throat		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1901	Streptococcus pyogenes strain NS1980		1314	WGS	NS1980	EMM77.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407024	GCA_900991295.1	CAAINR000000000		SC	WGS						18		1773478	38.371212	1765		1677.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1904	Streptococcus pyogenes strain NS1984		1314	WGS	NS1984	EMM82.0			MLST.Streptococcus_pyogenes.26				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407080	GCA_900991325.1	CAAINS000000000		SC	WGS						19		1826601	38.355087	1861		1765.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1903	Streptococcus pyogenes strain NS1988		1314	WGS	NS1988	EMM9.0			MLST.Streptococcus_pyogenes.603				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407048	GCA_900991315.1	CAAINT000000000		SC	WGS						23		1820488	38.353893	1824		1723.0		genital		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1902	Streptococcus pyogenes strain NS1999		1314	WGS	NS1999	EMM75.3			MLST.Streptococcus_pyogenes.590				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407045	GCA_900991305.1	CAAINP000000000		SC	WGS						33		1778996	38.27659	1760		1655.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2326	Streptococcus pyogenes strain NS20		1314	WGS	NS20	EMM75.1			MLST.Streptococcus_pyogenes.607				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864275	GCA_900995545.1	CAAJDY000000000		SC	WGS						12		1855212	38.440792	1862		1770.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1906	Streptococcus pyogenes strain NS2000		1314	WGS	NS2000	EMM77.0			MLST.Streptococcus_pyogenes.63				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407055	GCA_900991345.1	CAAINW000000000		SC	WGS						18		1939014	38.297092	1954		1856.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1907	Streptococcus pyogenes strain NS2012		1314	WGS	NS2012	EMM99.5			MLST.Streptococcus_pyogenes.593				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407103	GCA_900991355.1	CAAINV000000000		SC	WGS						16		1782509	38.427647	1793		1709.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1908	Streptococcus pyogenes strain NS2023		1314	WGS	NS2023	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407118	GCA_900991365.1	CAAINX000000000		SC	WGS						24		1774643	38.44159	1805		1709.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2341	Streptococcus pyogenes strain NS204		1314	WGS	NS204	EMM2.0			MLST.Streptococcus_pyogenes.55				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864296	GCA_900995695.1	CAAJEO000000000		SC	WGS						25		1941235	38.357155	2001		1885.0		sterile site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1882	Streptococcus pyogenes strain NS205		1314	WGS	NS205	EMM56.1			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406957	GCA_900991105.1	CAAIMV000000000		SC	WGS						17		1773838	38.38374	1807		1709.0		sterile site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2343	Streptococcus pyogenes strain NS210		1314	WGS	NS210	EMM22.0			MLST.Streptococcus_pyogenes.202				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864291	GCA_900995715.1	CAAJEQ000000000		SC	WGS						22		1767698	38.347168	1740		1639.0		Invasive		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.713	Streptococcus pyogenes strain NS210		1314	WGS	NS210	22			MLST.Streptococcus_pyogenes.202				2018-05-31T00:00:00Z		PRJNA471286	SAMN09206642	GCA_003177315.1	QFZH00000000		University of Notre Dame	WGS	Illumina	50.0x	Velvet v. 1.2.10			36		1760837	38.327568	1776		1699.0		Patient with Diabetic ulcer		1990	Australia	Australia						Human, Homo sapiens			Diabetic ulcer with fever																The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:not applicable
1314.1911	Streptococcus pyogenes strain NS2128		1314	WGS	NS2128	EMM192.0			MLST.Streptococcus_pyogenes.612				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407088	GCA_900991395.1	CAAINY000000000		SC	WGS						12		1755424	38.380985	1769		1681.0		other		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2328	Streptococcus pyogenes strain NS216		1314	WGS	NS216	EMM229.0			MLST.Streptococcus_pyogenes.614				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864274	GCA_900995565.1	CAAJEA000000000		SC	WGS						18		1738314	38.263386	1721		1633.0		Invasive		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1104	Streptococcus pyogenes strain NS2188		1314	WGS	NS2188	EMM49.3			MLST.Streptococcus_pyogenes.190				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238008	GCA_900983245.1	CAAHIY000000000		SC	WGS						15		1764805	38.2646	1758		1669.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1119	Streptococcus pyogenes strain NS22		1314	WGS	NS22	EMM57.2			MLST.Streptococcus_pyogenes.33				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238027	GCA_900983395.1	CAAHJJ000000000		SC	WGS						20		1804808	38.32668	1845		1759.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2351	Streptococcus pyogenes strain NS223		1314	WGS	NS223	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864313	GCA_900995795.1	CAAJEY000000000		SC	WGS						20		1744389	38.3813	1761		1668.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.709	Streptococcus pyogenes strain NS223		1314	WGS	NS223	91			MLST.Streptococcus_pyogenes.12				2018-05-25T00:00:00Z		PRJNA471549	SAMN09206643	GCA_003171615.1	QFXT00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			53		1749483	38.41295	1807		1728.0		blood		1990	Australia	Australia						Human, Homo sapiens			Infected central venous catheter																The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:not applicable
1314.1909	Streptococcus pyogenes strain NS2231		1314	WGS	NS2231	EMM49.3			MLST.Streptococcus_pyogenes.190				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407098	GCA_900991375.1	CAAINZ000000000		SC	WGS						16		1763890	38.269394	1747		1668.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2353	Streptococcus pyogenes strain NS225		1314	WGS	NS225	EMM99.0			MLST.Streptococcus_pyogenes.141				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864321	GCA_900995815.1	CAAJFA000000000		SC	WGS						11		1741713	38.463455	1715		1637.0		sterile site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2354	Streptococcus pyogenes strain NS226		1314	WGS	NS226	EMM4.5			MLST.Streptococcus_pyogenes.177				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864292	GCA_900995825.1	CAAJFC000000000		SC	WGS						14		1770603	38.423447	1749		1665.0		sterile site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1115	Streptococcus pyogenes strain NS2283		1314	WGS	NS2283	EMM3.22			MLST.Streptococcus_pyogenes.335				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238029	GCA_900983355.1	CAAHJI000000000		SC	WGS						20		1767130	38.225845	1754		1664.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1114	Streptococcus pyogenes strain NS2299		1314	WGS	NS2299	EMM3.22			MLST.Streptococcus_pyogenes.335				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238030	GCA_900983345.1	CAAHJM000000000		SC	WGS						22		1766747	38.225903	1752		1663.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1881	Streptococcus pyogenes strain NS232		1314	WGS	NS232	EMM49.3			MLST.Streptococcus_pyogenes.190				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406946	GCA_900991095.1	CAAIMX000000000		SC	WGS						27		1835988	38.239975	1877		1783.0		throat		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1884	Streptococcus pyogenes strain NS234		1314	WGS	NS234	EMM42.0			MLST.Streptococcus_pyogenes.80				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406981	GCA_900991125.1	CAAIMY000000000		SC	WGS						13		1733548	38.369576	1704		1624.0		throat		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2356	Streptococcus pyogenes strain NS235		1314	WGS	NS235	EMM24.1			MLST.Streptococcus_pyogenes.582				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864298	GCA_900995845.1	CAAJFD000000000		SC	WGS						22		1692413	38.42597	1666		1583.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2321	Streptococcus pyogenes strain NS236		1314	WGS	NS236	EMM77.0			MLST.Streptococcus_pyogenes.63				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864277	GCA_900995495.1	CAAJDU000000000		SC	WGS						12		1894518	38.27174	1886		1795.0		skin sore / abscess / burns / IV Site		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1120	Streptococcus pyogenes strain NS2361		1314	WGS	NS2361	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238031	GCA_900983405.1	CAAHJN000000000		SC	WGS						19		1800365	38.309917	1819		1724.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1883	Streptococcus pyogenes strain NS237		1314	WGS	NS237	EMM97.0			MLST.Streptococcus_pyogenes.203				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407002	GCA_900991115.1	CAAIMZ000000000		SC	WGS						14		1770044	38.355793	1788		1692.0		throat		1994	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2358	Streptococcus pyogenes strain NS239		1314	WGS	NS239	EMM207.1			MLST.Streptococcus_pyogenes.610				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864223	GCA_900995865.1	CAAJFF000000000		SC	WGS						22		1728801	38.282032	1680		1594.0		Invasive		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2313	Streptococcus pyogenes strain NS240		1314	WGS	NS240	EMM183.X			MLST.Streptococcus_pyogenes.166				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864276	GCA_900995415.1	CAAJDS000000000		SC	WGS						15		1720783	38.334454	1705		1610.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1097	Streptococcus pyogenes strain NS2403		1314	WGS	NS2403	EMM3.22			MLST.Streptococcus_pyogenes.335				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238002	GCA_900983175.1	CAAHIT000000000		SC	WGS						20		1767153	38.224384	1754		1666.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1096	Streptococcus pyogenes strain NS2413		1314	WGS	NS2413	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238003	GCA_900983165.1	CAAHIS000000000		SC	WGS						15		1784018	38.374832	1749		1663.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1912	Streptococcus pyogenes strain NS2416		1314	WGS	NS2416	EMM104.0			MLST.Streptococcus_pyogenes.597				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406966	GCA_900991405.1	CAAIOB000000000		SC	WGS						14		1813981	38.372837	1816		1729.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2357	Streptococcus pyogenes strain NS244		1314	WGS	NS244	EMM4.5			MLST.Streptococcus_pyogenes.177				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864222	GCA_900995855.1	CAAJFE000000000		SC	WGS						22		1795607	38.41087	1808		1710.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2359	Streptococcus pyogenes strain NS25		1314	WGS	NS25	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864225	GCA_900995875.1	CAAJFG000000000		SC	WGS						22		1885811	38.291275	1943		1852.0		sterile site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1910	Streptococcus pyogenes strain NS2509		1314	WGS	NS2509	EMM85.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406973	GCA_900991385.1	CAAIOA000000000		SC	WGS						26		1780495	38.307438	1755		1662.0		skin sore / abscess / burns / IV Site		2000	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2362	Streptococcus pyogenes strain NS253		1314	WGS	NS253	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864224	GCA_900995905.1	CAAJFI000000000		SC	WGS						14		1714958	38.357807	1701		1611.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2361	Streptococcus pyogenes strain NS265		1314	WGS	NS265	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864290	GCA_900995895.1	CAAJFJ000000000		SC	WGS						19		1741104	38.37921	1758		1662.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1916	Streptococcus pyogenes strain NS2663		1314	WGS	NS2663	EMM53.0			MLST.Streptococcus_pyogenes.363				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407025	GCA_900991445.1	CAAIOF000000000		SC	WGS						24		1780940	38.388985	1818		1709.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1915	Streptococcus pyogenes strain NS2664		1314	WGS	NS2664	EMM89.14			MLST.Streptococcus_pyogenes.812				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406961	GCA_900991435.1	CAAIOE000000000		SC	WGS						20		1809605	38.359806	1846		1746.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1913	Streptococcus pyogenes strain NS2671		1314	WGS	NS2671	EMM102.7			MLST.Streptococcus_pyogenes.287				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406945	GCA_900991415.1	CAAIOC000000000		SC	WGS						16		1799139	38.39678	1806		1712.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1914	Streptococcus pyogenes strain NS2676		1314	WGS	NS2676	EMM232.0			MLST.Streptococcus_pyogenes.185				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406936	GCA_900991425.1	CAAIOD000000000		SC	WGS						15		1744675	38.445522	1710		1620.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1917	Streptococcus pyogenes strain NS2679		1314	WGS	NS2679	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406985	GCA_900991455.1	CAAIOG000000000		SC	WGS						17		1760144	38.333626	1755		1669.0		skin sore / abscess / burns / IV Site		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1111	Streptococcus pyogenes strain NS27		1314	WGS	NS27	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238019	GCA_900983315.1	CAAHJF000000000		SC	WGS						16		1747745	38.393734	1753		1668.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1918	Streptococcus pyogenes strain NS2763		1314	WGS	NS2763	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406967	GCA_900991465.1	CAAIOH000000000		SC	WGS						21		1799859	38.312946	1822		1724.0		sterile site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1920	Streptococcus pyogenes strain NS2811		1314	WGS	NS2811	EMM9.0			MLST.Streptococcus_pyogenes.204				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407085	GCA_900991485.1	CAAIOJ000000000		SC	WGS						20		1801655	38.38554	1788		1694.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2350	Streptococcus pyogenes strain NS282		1314	WGS	NS282	EMM207.1			MLST.Streptococcus_pyogenes.332				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864293	GCA_900995785.1	CAAJEX000000000		SC	WGS						16		1755962	38.29426	1749		1653.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2352	Streptococcus pyogenes strain NS297		1314	WGS	NS297	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864299	GCA_900995805.1	CAAJEZ000000000		SC	WGS						20		1815047	38.41876	1829		1743.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1094	Streptococcus pyogenes strain NS2985		1314	WGS	NS2985	EMM105.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238004	GCA_900983155.1	CAAHIP000000000		SC	WGS						19		1806469	38.323746	1807		1707.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2314	Streptococcus pyogenes strain NS3		1314	WGS	NS3	EMM98.0			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864308	GCA_900995425.1	CAAJDP000000000		SC	WGS						18		1714753	38.380257	1716		1629.0		Invasive		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1919	Streptococcus pyogenes strain NS3003		1314	WGS	NS3003	EMM225.0			MLST.Streptococcus_pyogenes.48				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407092	GCA_900991475.1	CAAIOI000000000		SC	WGS						20		1759039	38.338833	1754		1652.0		skin sore / abscess / burns / IV Site		2001	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2355	Streptococcus pyogenes strain NS32		1314	WGS	NS32	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864228	GCA_900995835.1	CAAJFB000000000		SC	WGS						13		1758778	38.41244	1766		1680.0		sterile site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1922	Streptococcus pyogenes strain NS3275		1314	WGS	NS3275	EMM8.0			MLST.Streptococcus_pyogenes.602				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407100	GCA_900991505.1	CAAIOK000000000		SC	WGS						18		1747498	38.374123	1717		1640.0		skin sore / abscess / burns / IV Site		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1921	Streptococcus pyogenes strain NS3309		1314	WGS	NS3309	EMM86.1			MLST.Streptococcus_pyogenes.4				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407115	GCA_900991495.1	CAAIOL000000000		SC	WGS						14		1749047	38.40368	1749		1663.0		joint / synovial fluid		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1924	Streptococcus pyogenes strain NS3332		1314	WGS	NS3332	EMM108.0			MLST.Streptococcus_pyogenes.304				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407071	GCA_900991525.1	CAAION000000000		SC	WGS						11		1759883	38.386074	1765		1686.0		skin sore / abscess / burns / IV Site		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1923	Streptococcus pyogenes strain NS3335		1314	WGS	NS3335	EMM39.4			MLST.Streptococcus_pyogenes.268				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407052	GCA_900991515.1	CAAIOM000000000		SC	WGS						29		1845764	38.371807	1914		1813.0		skin sore / abscess / burns / IV Site		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1885	Streptococcus pyogenes strain NS343		1314	WGS	NS343	EMM225.0			MLST.Streptococcus_pyogenes.48				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407017	GCA_900991135.1	CAAINA000000000		SC	WGS						15		1758091	38.338802	1745		1653.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1926	Streptococcus pyogenes strain NS3473		1314	WGS	NS3473	EMM82.0			MLST.Streptococcus_pyogenes.26				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407041	GCA_900991535.1	CAAIOO000000000		SC	WGS						17		1789155	38.35347	1807		1710.0		genital		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1857	Streptococcus pyogenes strain NS35		1314	WGS	NS35	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864220	GCA_900990855.1	CAAILY000000000		SC	WGS						10		1817476	38.235706	1830		1738.0		Invasive		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1862	Streptococcus pyogenes strain NS351		1314	WGS	NS351	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864234	GCA_900990905.1	CAAIMC000000000		SC	WGS						16		1865754	38.06646	1876		1779.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1936	Streptococcus pyogenes strain NS3523		1314	WGS	NS3523	EMM197.0			MLST.Streptococcus_pyogenes.615				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407037	GCA_900991645.1	CAAIOZ000000000		SC	WGS						9		1745385	38.45587	1733		1652.0		other		2002	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1861	Streptococcus pyogenes strain NS365		1314	WGS	NS365	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864235	GCA_900990895.1	CAAIMD000000000		SC	WGS						18		1861869	38.273216	1898		1799.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1949	Streptococcus pyogenes strain NS3785		1314	WGS	NS3785	EMM12.0			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407032	GCA_900991775.1	CAAIPK000000000		SC	WGS						15		1794801	38.39579	1784		1699.0		throat		2003	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1110	Streptococcus pyogenes strain NS38		1314	WGS	NS38	EMM57.2			MLST.Streptococcus_pyogenes.33				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238020	GCA_900983305.1	CAAHJE000000000		SC	WGS						13		1751357	38.35267	1759		1676.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1958	Streptococcus pyogenes strain NS3844		1314	WGS	NS3844	EMM25.1			MLST.Streptococcus_pyogenes.192				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407023	GCA_900991865.1	CAAIPV000000000		SC	WGS						21		1805823	38.322414	1815		1724.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1967	Streptococcus pyogenes strain NS3850		1314	WGS	NS3850	EMM11.0			MLST.Streptococcus_pyogenes.584				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407010	GCA_900991955.1	CAAIQE000000000		SC	WGS						19		1848157	38.416702	1874		1791.0		other		2003	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1968	Streptococcus pyogenes strain NS3870		1314	WGS	NS3870	EMM75.1			MLST.Streptococcus_pyogenes.609				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407004	GCA_900991965.1	CAAIQF000000000		SC	WGS						12		1862534	38.39626	1850		1762.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1108	Streptococcus pyogenes strain NS3965		1314	WGS	NS3965	EMM49.3			MLST.Streptococcus_pyogenes.190				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238017	GCA_900983285.1	CAAHJB000000000		SC	WGS						16		1856414	38.100826	1870		1773.0		skin sore / abscess / burns / IV Site		1800-2018	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1864	Streptococcus pyogenes strain NS414		1314	WGS	NS414	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864232	GCA_900990925.1	CAAIMG000000000		SC	WGS						20		1805022	38.38208	1827		1738.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1971	Streptococcus pyogenes strain NS4147		1314	WGS	NS4147	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406987	GCA_900991995.1	CAAIQI000000000		SC	WGS						16		1855347	38.2453	1892		1792.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1865	Streptococcus pyogenes strain NS415		1314	WGS	NS415	EMM4.5			MLST.Streptococcus_pyogenes.177				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864227	GCA_900990915.1	CAAIMF000000000		SC	WGS						20		1766300	38.39177	1746		1664.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1970	Streptococcus pyogenes strain NS4150		1314	WGS	NS4150	EMM22.0			MLST.Streptococcus_pyogenes.46				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406972	GCA_900991985.1	CAAIQH000000000		SC	WGS						28		1811473	38.463505	1861		1765.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1969	Streptococcus pyogenes strain NS4155		1314	WGS	NS4155	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406951	GCA_900991975.1	CAAIQG000000000		SC	WGS						22		1728144	38.27442	1714		1607.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1102	Streptococcus pyogenes strain NS426		1314	WGS	NS426	EMM239.0			MLST.Streptococcus_pyogenes.92				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238014	GCA_900983225.1	CAAHIZ000000000		SC	WGS						27		1858893	38.40101	1913		1815.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1863	Streptococcus pyogenes strain NS43		1314	WGS	NS43	EMM25.0			MLST.Streptococcus_pyogenes.600				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864226	GCA_900990935.1	CAAIME000000000		SC	WGS						32		1833810	38.33002	1875		1772.0		throat		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1866	Streptococcus pyogenes strain NS436		1314	WGS	NS436	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864229	GCA_900990945.1	CAAIMI000000000		SC	WGS						21		1805560	38.385708	1823		1738.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1925	Streptococcus pyogenes strain NS4505		1314	WGS	NS4505	EMM110.0			MLST.Streptococcus_pyogenes.179				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406940	GCA_900991545.1	CAAIOP000000000		SC	WGS						25		1778480	38.278965	1773		1681.0		skin sore / abscess / burns / IV Site		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1927	Streptococcus pyogenes strain NS4517		1314	WGS	NS4517	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406956	GCA_900991555.1	CAAIOQ000000000		SC	WGS						24		1743127	38.4169	1750		1659.0		skin sore / abscess / burns / IV Site		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1928	Streptococcus pyogenes strain NS4518		1314	WGS	NS4518	EMM12.1			MLST.Streptococcus_pyogenes.36				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406970	GCA_900991565.1	CAAIOS000000000		SC	WGS						22		1798030	38.380615	1810		1715.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1867	Streptococcus pyogenes strain NS452		1314	WGS	NS452	EMM25.0			MLST.Streptococcus_pyogenes.191				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864221	GCA_900990955.1	CAAIMH000000000		SC	WGS						13		1796292	38.350014	1810		1716.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1868	Streptococcus pyogenes strain NS455		1314	WGS	NS455	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864237	GCA_900990965.1	CAAIMJ000000000		SC	WGS						10		1714849	38.3509	1693		1610.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.707	Streptococcus pyogenes strain NS455		1314	WGS	NS455	52			MLST.Streptococcus_pyogenes.180				2018-05-25T00:00:00Z		PRJNA471549	SAMN09206644	GCA_003171575.1	QFXS00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			35		1714937	38.35651	1738		1665.0		blood		1990	Australia	Australia						Human, Homo sapiens																			The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:not applicable
1314.1929	Streptococcus pyogenes strain NS4618		1314	WGS	NS4618	EMM76.6			MLST.Streptococcus_pyogenes.291				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406988	GCA_900991575.1	CAAIOR000000000		SC	WGS						20		1779428	38.317146	1771		1687.0		throat		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1932	Streptococcus pyogenes strain NS4624		1314	WGS	NS4624	EMM19.4			MLST.Streptococcus_pyogenes.616				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406982	GCA_900991605.1	CAAIOT000000000		SC	WGS						13		1767026	38.4545	1779		1691.0		skin sore / abscess / burns / IV Site		2004	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1930	Streptococcus pyogenes strain NS4697		1314	WGS	NS4697	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406997	GCA_900991585.1	CAAIOU000000000		SC	WGS						14		1800622	38.383514	1824		1738.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1933	Streptococcus pyogenes strain NS4706		1314	WGS	NS4706	EMM13.0			MLST.Streptococcus_pyogenes.286				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407009	GCA_900991615.1	CAAIOW000000000		SC	WGS						29		1807102	38.36482	1848		1750.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1931	Streptococcus pyogenes strain NS4716		1314	WGS	NS4716	EMM91.1			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407029	GCA_900991595.1	CAAIOV000000000		SC	WGS						17		1745853	38.391262	1758		1665.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1095	Streptococcus pyogenes strain NS4729		1314	WGS	NS4729	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238005	GCA_900983145.1	CAAHIR000000000		SC	WGS						21		1853146	38.335457	1883		1791.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1858	Streptococcus pyogenes strain NS473		1314	WGS	NS473	EMM232.0			MLST.Streptococcus_pyogenes.110				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864231	GCA_900990865.1	CAAILZ000000000		SC	WGS						24		1789136	38.356155	1809		1715.0		Invasive		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1859	Streptococcus pyogenes strain NS474		1314	WGS	NS474	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864249	GCA_900990875.1	CAAIMA000000000		SC	WGS						17		1861768	38.268967	1895		1801.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1935	Streptococcus pyogenes strain NS4743		1314	WGS	NS4743	EMM58.8			MLST.Streptococcus_pyogenes.549				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407039	GCA_900991635.1	CAAIOY000000000		SC	WGS						23		1822248	38.318714	1835		1735.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1860	Streptococcus pyogenes strain NS476		1314	WGS	NS476	EMM80.X							2019-04-09T00:00:00Z		PRJEB2232	SAMEA864248	GCA_900990885.1	CAAIMB000000000		SC	WGS						10		1723842	38.32921	1693		1616.0		Invasive		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1934	Streptococcus pyogenes strain NS4766		1314	WGS	NS4766	EMM183.2			MLST.Streptococcus_pyogenes.586				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407046	GCA_900991625.1	CAAIOX000000000		SC	WGS						11		1796685	38.384937	1821		1729.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1937	Streptococcus pyogenes strain NS4797		1314	WGS	NS4797	EMM100.0			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406934	GCA_900991655.1	CAAIPA000000000		SC	WGS						21		1840341	38.356045	1898		1809.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1117	Streptococcus pyogenes strain NS48		1314	WGS	NS48	EMM57.2			MLST.Streptococcus_pyogenes.33				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238025	GCA_900983375.1	CAAHJK000000000		SC	WGS						14		1751168	38.35396	1757		1674.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1939	Streptococcus pyogenes strain NS4800		1314	WGS	NS4800	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406942	GCA_900991675.1	CAAIPB000000000		SC	WGS						23		1833247	38.402485	1861		1761.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1940	Streptococcus pyogenes strain NS4804		1314	WGS	NS4804	EMM81.2			MLST.Streptococcus_pyogenes.608				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406959	GCA_900991685.1	CAAIPC000000000		SC	WGS						18		1843487	38.25497	1853		1768.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2360	Streptococcus pyogenes strain NS488		1314	WGS	NS488	EMM12.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA864233	GCA_900995885.1	CAAJFH000000000		SC	WGS						22		1794113	38.38434	1798		1703.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1938	Streptococcus pyogenes strain NS4883		1314	WGS	NS4883	EMM103.0			MLST.Streptococcus_pyogenes.611				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406974	GCA_900991665.1	CAAIPD000000000		SC	WGS						19		1776958	38.303852	1772		1686.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2366	Streptococcus pyogenes strain NS495		1314	WGS	NS495	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864238	GCA_900995945.1	CAAJFN000000000		SC	WGS						9		1750811	38.367554	1748		1650.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1101	Streptococcus pyogenes strain NS4972		1314	WGS	NS4972	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238006	GCA_900983215.1	CAAHIN000000000		SC	WGS						22		1853343	38.338127	1879		1792.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1941	Streptococcus pyogenes strain NS4982		1314	WGS	NS4982	EMM42.0			MLST.Streptococcus_pyogenes.80				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406980	GCA_900991695.1	CAAIPE000000000		SC	WGS						11		1732722	38.366165	1702		1624.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1942	Streptococcus pyogenes strain NS4984		1314	WGS	NS4984	EMM124.0			MLST.Streptococcus_pyogenes.544				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406994	GCA_900991705.1	CAAIPF000000000		SC	WGS						13		1728897	38.33045	1698		1619.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1943	Streptococcus pyogenes strain NS4985		1314	WGS	NS4985	EMM14.4			MLST.Streptococcus_pyogenes.118				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407007	GCA_900991715.1	CAAIPG000000000		SC	WGS						17		1730547	38.439697	1734		1640.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2367	Streptococcus pyogenes strain NS50		1314	WGS	NS50	EMM218.1			MLST.Streptococcus_pyogenes.292				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864239	GCA_900995955.1	CAAJFO000000000		SC	WGS						11		1725550	38.242996	1711		1625.0		sterile site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2315	Streptococcus pyogenes strain NS50.1		1314	WGS	NS50.1	EMM108.0			MLST.Streptococcus_pyogenes.304				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864279	GCA_900995435.1	CAAJDR000000000		SC	WGS						19		1802953	38.986732	1821		1739.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1886	Streptococcus pyogenes strain NS501		1314	WGS	NS501	EMM14.4			MLST.Streptococcus_pyogenes.118				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407027	GCA_900991145.1	CAAINB000000000		SC	WGS						20		1722248	38.434826	1724		1626.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1944	Streptococcus pyogenes strain NS5025		1314	WGS	NS5025	EMM105.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407019	GCA_900991725.1	CAAIPH000000000		SC	WGS						17		1769731	38.31198	1749		1650.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1945	Streptococcus pyogenes strain NS5048		1314	WGS	NS5048	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407028	GCA_900991735.1	CAAIPI000000000		SC	WGS						19		1850659	38.333427	1875		1790.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2368	Streptococcus pyogenes strain NS506		1314	WGS	NS506	EMM14.4			MLST.Streptococcus_pyogenes.118				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864230	GCA_900995965.1	CAAJFR000000000		SC	WGS						16		1721263	38.42326	1719		1632.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1946	Streptococcus pyogenes strain NS5128		1314	WGS	NS5128	EMM77.0			MLST.Streptococcus_pyogenes.588				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407049	GCA_900991745.1	CAAIPJ000000000		SC	WGS						13		1776556	38.36838	1765		1683.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1887	Streptococcus pyogenes strain NS514		1314	WGS	NS514	EMM73.0			MLST.Streptococcus_pyogenes.331				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407035	GCA_900991155.1	CAAINC000000000		SC	WGS						16		1773971	38.360096	1786		1712.0		genital		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1947	Streptococcus pyogenes strain NS5146		1314	WGS	NS5146	EMM78.3			MLST.Streptococcus_pyogenes.181				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407082	GCA_900991755.1	CAAIPL000000000		SC	WGS						14		1759083	38.245667	1711		1628.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2372	Streptococcus pyogenes strain NS516		1314	WGS	NS516	EMM110.0			MLST.Streptococcus_pyogenes.596				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864242	GCA_900996005.1	CAAJFY000000000		SC	WGS						17		1768245	38.314472	1758		1672.0		skin		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1103	Streptococcus pyogenes strain NS5268		1314	WGS	NS5268	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238013	GCA_900983235.1	CAAHIX000000000		SC	WGS						21		1853532	38.33724	1874		1791.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.263	Streptococcus pyogenes strain NS53		1314	Complete	NS53	serovar M71			MLST.Streptococcus_pyogenes.318				2016-05-06T00:00:00Z		PRJNA317786	SAMN04625972	GCF_001638845.1	CP015238		University of Notre Dame	Complete	454; Illumina MiSeq	200.0x	Newbler v. 2.9; MIRA v. 3	1.0		1		1765123	38.42	1743		1630.0		nonsterile tissues such as skin		1990	Australia	Australia: Northern Territory						Human, Homo sapiens			febrile																Genome characterization of a serotype M71 strain of Streptococcus pyogenes.	collected_by:Menzies School of Health Research and Royal Darwin Hospital
1314.2305	Streptococcus pyogenes strain NS53		1314	WGS	NS53	EMM71.0			MLST.Streptococcus_pyogenes.318				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864278	GCA_900995335.1	CAAJDE000000000		SC	WGS						24		1722552	38.262474	1714		1606.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2370	Streptococcus pyogenes strain NS534		1314	WGS	NS534	EMM232.0			MLST.Streptococcus_pyogenes.110				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864241	GCA_900995985.1	CAAJFP000000000		SC	WGS						17		1746570	38.35277	1737		1653.0		Invasive		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1948	Streptococcus pyogenes strain NS5340		1314	WGS	NS5340	EMM65.4			MLST.Streptococcus_pyogenes.546				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407068	GCA_900991765.1	CAAIPM000000000		SC	WGS						27		1737540	38.38778	1725		1632.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1856	Streptococcus pyogenes strain NS5341		1314	WGS	NS5341	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864311	GCA_900990845.1	CAAILX000000000		SC	WGS						20		1789388	38.342495	1760		1667.0		sterile site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1855	Streptococcus pyogenes strain NS5347		1314	WGS	NS5347	EMM4.5			MLST.Streptococcus_pyogenes.289				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864280	GCA_900990835.1	CAAILW000000000		SC	WGS						22		1841309	38.29949	1829		1736.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1950	Streptococcus pyogenes strain NS5378		1314	WGS	NS5378	EMM124.0			MLST.Streptococcus_pyogenes.544				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407061	GCA_900991785.1	CAAIPN000000000		SC	WGS						17		1742667	38.31572	1719		1636.0		skin sore / abscess / burns / IV Site		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2376	Streptococcus pyogenes strain NS539		1314	WGS	NS539	EMM76.6			MLST.Streptococcus_pyogenes.291				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864240	GCA_900996045.1	CAAJFU000000000		SC	WGS						15		1776121	38.300037	1773		1687.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1952	Streptococcus pyogenes strain NS5427		1314	WGS	NS5427	EMM63.0			MLST.Streptococcus_pyogenes.598				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407091	GCA_900991805.1	CAAIPP000000000		SC	WGS						24		1881578	38.369244	1943		1834.0		normal skin		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1951	Streptococcus pyogenes strain NS5434		1314	WGS	NS5434	EMM57.2			MLST.Streptococcus_pyogenes.33				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407084	GCA_900991795.1	CAAIPO000000000		SC	WGS						15		1751644	38.356594	1757		1681.0		normal skin		1991	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1953	Streptococcus pyogenes strain NS5496		1314	WGS	NS5496	EMM77.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407122	GCA_900991815.1	CAAIPQ000000000		SC	WGS						12		1829012	38.30762	1815		1715.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2385	Streptococcus pyogenes strain NS5530		1314	WGS	NS5530	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864283	GCA_900996135.1	CAAJGG000000000		SC	WGS						24		1747062	38.359257	1735		1640.0		skin		1993	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1954	Streptococcus pyogenes strain NS5539		1314	WGS	NS5539	EMM33.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407106	GCA_900991825.1	CAAIPR000000000		SC	WGS						21		1790619	38.391865	1819		1722.0		skin sore / abscess / burns / IV Site		1993	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1955	Streptococcus pyogenes strain NS5544		1314	WGS	NS5544	EMM76.0			MLST.Streptococcus_pyogenes.617				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406965	GCA_900991835.1	CAAIPS000000000		SC	WGS						42		1898195	38.358864	2001		1873.0		skin sore / abscess / burns / IV Site		1993	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1956	Streptococcus pyogenes strain NS5568		1314	WGS	NS5568	EMM77.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406975	GCA_900991845.1	CAAIPT000000000		SC	WGS						15		1734964	38.379147	1700		1613.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1957	Streptococcus pyogenes strain NS5578		1314	WGS	NS5578	EMM123.0			MLST.Streptococcus_pyogenes.610				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406939	GCA_900991855.1	CAAIPU000000000		SC	WGS						14		1727069	38.314915	1676		1594.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1960	Streptococcus pyogenes strain NS5582		1314	WGS	NS5582	EMM18.12			MLST.Streptococcus_pyogenes.535				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407021	GCA_900991885.1	CAAIPY000000000		SC	WGS						12		1719512	38.347706	1704		1615.0		throat		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1959	Streptococcus pyogenes strain NS5615		1314	WGS	NS5615	EMM33.0			MLST.Streptococcus_pyogenes.3				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407011	GCA_900991875.1	CAAIPX000000000		SC	WGS						15		1753680	38.416836	1751		1663.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1962	Streptococcus pyogenes strain NS5630		1314	WGS	NS5630	EMM98.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407012	GCA_900991905.1	CAAIPZ000000000		SC	WGS						14		1740037	38.35694	1739		1660.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2311	Streptococcus pyogenes strain NS564		1314	WGS	NS564	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864271	GCA_900995395.1	CAAJDI000000000		SC	WGS						21		1771070	38.271183	1776		1686.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1112	Streptococcus pyogenes strain NS5658		1314	WGS	NS5658	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238021	GCA_900983325.1	CAAHJD000000000		SC	WGS						22		1853228	38.337833	1886		1791.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2377	Streptococcus pyogenes strain NS567		1314	WGS	NS567	EMM193.0			MLST.Streptococcus_pyogenes.108				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864247	GCA_900996055.1	CAAJFW000000000		SC	WGS						23		1766312	38.36707	1796		1683.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1963	Streptococcus pyogenes strain NS5694		1314	WGS	NS5694	EMM230.0			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407003	GCA_900991915.1	CAAIQA000000000		SC	WGS						12		1796404	38.314266	1799		1718.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1961	Streptococcus pyogenes strain NS5749		1314	WGS	NS5749	EMM238.2			MLST.Streptococcus_pyogenes.372				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407031	GCA_900991895.1	CAAIPW000000000		SC	WGS						30		1847462	38.390438	1901		1804.0		skin sore / abscess / burns / IV Site		1987	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1964	Streptococcus pyogenes strain NS5758		1314	WGS	NS5758	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407075	GCA_900991925.1	CAAIQB000000000		SC	WGS						13		1847701	38.30494	1891		1804.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1965	Streptococcus pyogenes strain NS5778		1314	WGS	NS5778	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407057	GCA_900991935.1	CAAIQC000000000		SC	WGS						13		1757837	38.384052	1759		1678.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1966	Streptococcus pyogenes strain NS5779		1314	WGS	NS5779	EMM108.0			MLST.Streptococcus_pyogenes.304				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407047	GCA_900991945.1	CAAIQD000000000		SC	WGS						8		1724785	38.38548	1701		1629.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2363	Streptococcus pyogenes strain NS578		1314	WGS	NS578	EMM232.0			MLST.Streptococcus_pyogenes.110				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864246	GCA_900995915.1	CAAJFK000000000		SC	WGS						23		1786101	38.33305	1805		1714.0				1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1972	Streptococcus pyogenes strain NS5782		1314	WGS	NS5782	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406971	GCA_900992005.1	CAAIQJ000000000		SC	WGS						24		1809453	38.354286	1836		1745.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1973	Streptococcus pyogenes strain NS5789		1314	WGS	NS5789	EMM4.0			MLST.Streptococcus_pyogenes.39				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406953	GCA_900992015.1	CAAIQK000000000		SC	WGS						18		1849410	38.306053	1882		1800.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2364	Streptococcus pyogenes strain NS581		1314	WGS	NS581	EMM42.1			MLST.Streptococcus_pyogenes.80				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864245	GCA_900995925.1	CAAJFM000000000		SC	WGS						10		1731014	38.355553	1703		1625.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2365	Streptococcus pyogenes strain NS59		1314	WGS	NS59	EMM53.0			MLST.Streptococcus_pyogenes.299				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864244	GCA_900995935.1	CAAJFL000000000		SC	WGS						22		1826125	38.272724	1822		1716.0		skin		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1974	Streptococcus pyogenes strain NS5958		1314	WGS	NS5958	EMM56.0			MLST.Streptococcus_pyogenes.115				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406937	GCA_900992025.1	CAAIQL000000000		SC	WGS						15		1774486	38.386272	1811		1712.0		skin sore / abscess / burns / IV Site		2005	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1879	Streptococcus pyogenes strain NS6		1314	WGS	NS6	EMM123.0			MLST.Streptococcus_pyogenes.325				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407116	GCA_900991075.1	CAAIMU000000000		SC	WGS						16		1729376	38.297478	1683		1595.0		sterile site		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1975	Streptococcus pyogenes strain NS6033		1314	WGS	NS6033	EMM87.0			MLST.Streptococcus_pyogenes.541				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407108	GCA_900992035.1	CAAIQM000000000		SC	WGS						21		1831423	38.188686	1812		1717.0		ear		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1976	Streptococcus pyogenes strain NS6078		1314	WGS	NS6078	STG653.1			MLST.Streptococcus_pyogenes.92				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407121	GCA_900992045.1	CAAIQN000000000		SC	WGS						20		1703659	38.409214	1650		1571.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1977	Streptococcus pyogenes strain NS6087		1314	WGS	NS6087	EMM114.2			MLST.Streptococcus_pyogenes.140				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407110	GCA_900992055.1	CAAIQO000000000		SC	WGS						13		1712596	38.423912	1678		1591.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2375	Streptococcus pyogenes strain NS611		1314	WGS	NS611	EMM15.1			MLST.Streptococcus_pyogenes.629				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864243	GCA_900996035.1	CAAJFX000000000		SC	WGS						17		1705575	38.427357	1693		1607.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1978	Streptococcus pyogenes strain NS6142		1314	WGS	NS6142	EMM183.2			MLST.Streptococcus_pyogenes.166				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407087	GCA_900992065.1	CAAIQP000000000		SC	WGS						11		1751715	38.344593	1739		1654.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1979	Streptococcus pyogenes strain NS6185		1314	WGS	NS6185	EMM15.1							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407095	GCA_900992075.1	CAAIQQ000000000		SC	WGS						14		1709776	38.43991	1691		1609.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1981	Streptococcus pyogenes strain NS6187		1314	WGS	NS6187	EMM13.0			MLST.Streptococcus_pyogenes.286				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407070	GCA_900992095.1	CAAIQS000000000		SC	WGS						31		1807832	38.36601	1852		1747.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1980	Streptococcus pyogenes strain NS6221		1314	WGS	NS6221	EMM100.5			MLST.Streptococcus_pyogenes.119				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407077	GCA_900992085.1	CAAIQR000000000		SC	WGS						17		1800986	38.353825	1837		1752.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1982	Streptococcus pyogenes strain NS6263		1314	WGS	NS6263	EMM232.0			MLST.Streptococcus_pyogenes.185				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407063	GCA_900992105.1	CAAIQT000000000		SC	WGS						20		1791566	38.435658	1777		1685.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1983	Streptococcus pyogenes strain NS6441		1314	WGS	NS6441	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407013	GCA_900992115.1	CAAIQU000000000		SC	WGS						15		1799830	38.309284	1820		1727.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1984	Streptococcus pyogenes strain NS6474		1314	WGS	NS6474	EMM44.0			MLST.Streptococcus_pyogenes.178				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406996	GCA_900992125.1	CAAIQV000000000		SC	WGS						12		1822676	38.313686	1846		1760.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1985	Streptococcus pyogenes strain NS6531		1314	WGS	NS6531	EMM91.0			MLST.Streptococcus_pyogenes.12				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407034	GCA_900992135.1	CAAIQW000000000		SC	WGS						19		1745871	38.389763	1753		1666.0		skin sore / abscess / burns / IV Site		2006	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1987	Streptococcus pyogenes strain NS6570		1314	WGS	NS6570	EMM82.1			MLST.Streptococcus_pyogenes.591				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407020	GCA_900992155.1	CAAIQY000000000		SC	WGS						15		1777629	38.338417	1795		1696.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1986	Streptococcus pyogenes strain NS6595		1314	WGS	NS6595	EMM123.0			MLST.Streptococcus_pyogenes.610				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406949	GCA_900992145.1	CAAIQX000000000		SC	WGS						15		1750363	38.30777	1726		1640.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1988	Streptococcus pyogenes strain NS6648		1314	WGS	NS6648	EMM41.2			MLST.Streptococcus_pyogenes.579				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406954	GCA_900992165.1	CAAIQZ000000000		SC	WGS						24		1754286	38.39211	1758		1669.0		sterile site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2369	Streptococcus pyogenes strain NS671		1314	WGS	NS671	EMM81.3			MLST.Streptococcus_pyogenes.183				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864265	GCA_900995975.1	CAAJFQ000000000		SC	WGS						24		1793277	38.20823	1812		1724.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2379	Streptococcus pyogenes strain NS672		1314	WGS	NS672	EMM28.0			MLST.Streptococcus_pyogenes.52				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864266	GCA_900996075.1	CAAJFZ000000000		SC	WGS						14		1817156	38.172176	1829		1737.0		sterile site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1991	Streptococcus pyogenes strain NS6749		1314	WGS	NS6749	EMM54.1			MLST.Streptococcus_pyogenes.302				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406947	GCA_900992195.1	CAAIRC000000000		SC	WGS						15		1740167	38.402866	1723		1646.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1989	Streptococcus pyogenes strain NS6770		1314	WGS	NS6770	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406990	GCA_900992175.1	CAAIRB000000000		SC	WGS						14		1813712	38.401653	1835		1751.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1889	Streptococcus pyogenes strain NS678		1314	WGS	NS678	EMM4.0			MLST.Streptococcus_pyogenes.39				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407060	GCA_900991175.1	CAAINE000000000		SC	WGS						17		1848709	38.31032	1886		1799.0		throat		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1992	Streptococcus pyogenes strain NS6783		1314	WGS	NS6783	EMM65.2			MLST.Streptococcus_pyogenes.585				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406964	GCA_900992205.1	CAAIRD000000000		SC	WGS						25		1723411	38.403145	1715		1622.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2380	Streptococcus pyogenes strain NS684		1314	WGS	NS684	EMM81.2			MLST.Streptococcus_pyogenes.290				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864267	GCA_900996085.1	CAAJGA000000000		SC	WGS						16		1976050	38.142456	2014		1913.0		skin sore / abscess / burns / IV Site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1990	Streptococcus pyogenes strain NS6845		1314	WGS	NS6845	EMM178.0			MLST.Streptococcus_pyogenes.592				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407067	GCA_900992185.1	CAAIRA000000000		SC	WGS						19		1723537	38.38264	1698		1615.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2378	Streptococcus pyogenes strain NS687		1314	WGS	NS687	EMM58.0			MLST.Streptococcus_pyogenes.176				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864260	GCA_900996065.1	CAAJGB000000000		SC	WGS						17		1855824	38.239014	1897		1798.0		other		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1107	Streptococcus pyogenes strain NS6902		1314	WGS	NS6902	EMM49.0			MLST.Streptococcus_pyogenes.371				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238016	GCA_900983275.1	CAAHJA000000000		SC	WGS						17		1799241	38.384537	1824		1730.0		skin sore / abscess / burns / IV Site		1800-2018	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2381	Streptococcus pyogenes strain NS691		1314	WGS	NS691	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864261	GCA_900996095.1	CAAJGC000000000		SC	WGS						17		1719670	38.431328	1705		1620.0		skin sore / abscess / burns / IV Site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1993	Streptococcus pyogenes strain NS6930		1314	WGS	NS6930	EMM99.5			MLST.Streptococcus_pyogenes.593				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407059	GCA_900992215.1	CAAIRE000000000		SC	WGS						15		1782559	38.42543	1797		1712.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2310	Streptococcus pyogenes strain NS696		1314	WGS	NS696	EMM1.0			MLST.Streptococcus_pyogenes.630				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864270	GCA_900995385.1	CAAJDH000000000		SC	WGS						16		1760211	38.378147	1771		1678.0		throat		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1994	Streptococcus pyogenes strain NS6983		1314	WGS	NS6983	EMM74.0			MLST.Streptococcus_pyogenes.120				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407050	GCA_900992225.1	CAAIRG000000000		SC	WGS						16		1759698	38.33277	1753		1666.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1995	Streptococcus pyogenes strain NS6989		1314	WGS	NS6989	EMM101.0			MLST.Streptococcus_pyogenes.182				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407113	GCA_900992235.1	CAAIRF000000000		SC	WGS						18		1793734	38.359867	1825		1744.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2382	Streptococcus pyogenes strain NS702		1314	WGS	NS702	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864262	GCA_900996105.1	CAAJGD000000000		SC	WGS						16		1715591	38.434162	1706		1621.0		throat		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1996	Streptococcus pyogenes strain NS7048		1314	WGS	NS7048	EMM24.1			MLST.Streptococcus_pyogenes.582				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407101	GCA_900992245.1	CAAIRH000000000		SC	WGS						17		1688595	38.395824	1659		1583.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1998	Streptococcus pyogenes strain NS7056		1314	WGS	NS7056	EMM116.1			MLST.Streptococcus_pyogenes.227				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407093	GCA_900992265.1	CAAIRJ000000000		SC	WGS						18		1767399	38.360607	1778		1690.0		skin sore / abscess / burns / IV Site		2007	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1997	Streptococcus pyogenes strain NS7092		1314	WGS	NS7092	EMM78.3			MLST.Streptococcus_pyogenes.181				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407083	GCA_900992255.1	CAAIRI000000000		SC	WGS						16		1759365	38.24505	1713		1627.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1999	Streptococcus pyogenes strain NS7096		1314	WGS	NS7096	EMM53.0			MLST.Streptococcus_pyogenes.11				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407089	GCA_900992275.1	CAAIRK000000000		SC	WGS						29		1726818	38.433544	1723		1635.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2001	Streptococcus pyogenes strain NS7098		1314	WGS	NS7098	EMM86.1			MLST.Streptococcus_pyogenes.4				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406986	GCA_900992295.1	CAAIRL000000000		SC	WGS						17		1749983	38.408657	1756		1664.0		skin sore / abscess / burns / IV Site		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2000	Streptococcus pyogenes strain NS7124		1314	WGS	NS7124	EMM124.0			MLST.Streptococcus_pyogenes.199				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406969	GCA_900992285.1	CAAIRM000000000		SC	WGS						16		1753620	38.333218	1735		1643.0		throat		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2002	Streptococcus pyogenes strain NS7133		1314	WGS	NS7133	EMM165.0			MLST.Streptococcus_pyogenes.112				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407026	GCA_900992305.1	CAAIRN000000000		SC	WGS						20		1788346	38.319725	1780		1693.0		throat		1997	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2004	Streptococcus pyogenes strain NS7158		1314	WGS	NS7158	EMM99.0			MLST.Streptococcus_pyogenes.141				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407022	GCA_900992325.1	CAAIRP000000000		SC	WGS						9		1741610	38.42898	1714		1642.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2003	Streptococcus pyogenes strain NS7160		1314	WGS	NS7160	EMM92.0			MLST.Streptococcus_pyogenes.599				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407033	GCA_900992315.1	CAAIRO000000000		SC	WGS						9		1733447	38.375732	1717		1632.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2006	Streptococcus pyogenes strain NS7168		1314	WGS	NS7168	EMM4.5			MLST.Streptococcus_pyogenes.606				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406992	GCA_900992345.1	CAAIRQ000000000		SC	WGS						22		1862905	38.288918	1871		1779.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2005	Streptococcus pyogenes strain NS7175		1314	WGS	NS7175	EMM192.0			MLST.Streptococcus_pyogenes.612				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407018	GCA_900992335.1	CAAIRR000000000		SC	WGS						14		1756138	38.3881	1766		1681.0		skin sore / abscess / burns / IV Site		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2383	Streptococcus pyogenes strain NS718		1314	WGS	NS718	EMM92.0			MLST.Streptococcus_pyogenes.312				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864263	GCA_900996115.1	CAAJGE000000000		SC	WGS						19		1737397	38.389267	1718		1618.0		skin sore / abscess / burns / IV Site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2007	Streptococcus pyogenes strain NS7185		1314	WGS	NS7185	EMM238.1							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407053	GCA_900992355.1	CAAIRS000000000		SC	WGS						15		1729106	38.341946	1670		1597.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2012	Streptococcus pyogenes strain NS7249		1314	WGS	NS7249	EMM75.3			MLST.Streptococcus_pyogenes.590				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407042	GCA_900992405.1	CAAIRU000000000		SC	WGS						29		1778785	38.275192	1759		1652.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2010	Streptococcus pyogenes strain NS7259		1314	WGS	NS7259	EMM192.0			MLST.Streptococcus_pyogenes.612				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407076	GCA_900992385.1	CAAIRX000000000		SC	WGS						15		1754669	38.383366	1769		1681.0		throat		1999	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2304	Streptococcus pyogenes strain NS730		1314	WGS	NS730	EMM90.5							2019-04-09T00:00:00Z		PRJEB2232	SAMEA864303	GCA_900995325.1	CAAJDD000000000		SC	WGS						10		1750471	38.36804	1763		1652.0		skin sore / abscess / burns / IV Site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2384	Streptococcus pyogenes strain NS731		1314	WGS	NS731	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864264	GCA_900996125.1	CAAJGF000000000		SC	WGS						7		1750643	38.36484	1743		1649.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2374	Streptococcus pyogenes strain NS733		1314	WGS	NS733	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864287	GCA_900996025.1	CAAJFV000000000		SC	WGS						9		1750873	38.366005	1745		1647.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2371	Streptococcus pyogenes strain NS736		1314	WGS	NS736	EMM221.0			MLST.Streptococcus_pyogenes.113				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864286	GCA_900995995.1	CAAJFS000000000		SC	WGS						20		1805505	38.40413	1838		1752.0		skin		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2373	Streptococcus pyogenes strain NS755		1314	WGS	NS755	EMM90.5			MLST.Streptococcus_pyogenes.184				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864281	GCA_900996015.1	CAAJFT000000000		SC	WGS						9		1750302	38.366352	1747		1648.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1116	Streptococcus pyogenes strain NS76		1314	WGS	NS76	EMM98.1			MLST.Streptococcus_pyogenes.205				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238022	GCA_900983365.1	CAAHJL000000000		SC	WGS						12		1759129	38.392033	1761		1675.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2008	Streptococcus pyogenes strain NS7970		1314	WGS	NS7970	EMM41.2			MLST.Streptococcus_pyogenes.296				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407081	GCA_900992365.1	CAAIRV000000000		SC	WGS						24		1782181	38.370064	1811		1717.0		skin sore / abscess / burns / IV Site		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1878	Streptococcus pyogenes strain NS8		1314	WGS	NS8	EMM85.0			MLST.Streptococcus_pyogenes.109				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407107	GCA_900991065.1	CAAIMT000000000		SC	WGS						16		1784198	38.377846	1750		1664.0		skin sore / abscess / burns / IV Site		1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2309	Streptococcus pyogenes strain NS80		1314	WGS	NS80	EMM70.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA864304	GCA_900995375.1	CAAJDJ000000000		SC	WGS						16		1801575	38.315857	1857		1757.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2308	Streptococcus pyogenes strain NS803		1314	WGS	NS803	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864301	GCA_900995365.1	CAAJDK000000000		SC	WGS						22		1797891	38.391045	1807		1711.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2386	Streptococcus pyogenes strain NS804		1314	WGS	NS804	EMM97.1			MLST.Streptococcus_pyogenes.216				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864269	GCA_900996145.1	CAAJGH000000000		SC	WGS						12		1758600	38.37623	1749		1663.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2011	Streptococcus pyogenes strain NS8042		1314	WGS	NS8042	EMM89.0			MLST.Streptococcus_pyogenes.142				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407066	GCA_900992395.1	CAAIRW000000000		SC	WGS						14		1729001	38.3695	1710		1630.0		throat		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1098	Streptococcus pyogenes strain NS81		1314	WGS	NS81	EMM55.0			MLST.Streptococcus_pyogenes.100				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238007	GCA_900983185.1	CAAHIQ000000000		SC	WGS						24		1852525	38.30383	1884		1797.0		skin sore / abscess / burns / IV Site		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2009	Streptococcus pyogenes strain NS8145		1314	WGS	NS8145	EMM22.0			MLST.Streptococcus_pyogenes.175				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407099	GCA_900992375.1	CAAIRT000000000		SC	WGS						21		1763306	38.3263	1725		1638.0		throat		1995	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2306	Streptococcus pyogenes strain NS83		1314	WGS	NS83	EMM232.1			MLST.Streptococcus_pyogenes.288				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864302	GCA_900995345.1	CAAJDG000000000		SC	WGS						25		1747922	38.36349	1740		1642.0		Invasive		1992	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2387	Streptococcus pyogenes strain NS833		1314	WGS	NS833	EMM221.0			MLST.Streptococcus_pyogenes.113				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864285	GCA_900996155.1	CAAJGI000000000		SC	WGS						19		1807167	38.414886	1834		1751.0		skin		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2388	Streptococcus pyogenes strain NS836		1314	WGS	NS836	EMM221.0			MLST.Streptococcus_pyogenes.113				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864284	GCA_900996165.1	CAAJGJ000000000		SC	WGS						21		1806210	38.404713	1839		1754.0		skin		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.710	Streptococcus pyogenes strain NS88.3		1314	WGS	NS88.3	98			MLST.Streptococcus_pyogenes.205				2018-05-25T00:00:00Z		PRJNA471549	SAMN09206648	GCA_003171625.1	QFXO00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			48		1753984	38.36637	1822		1756.0		blood		1990	Australia	Australia						Human, Homo sapiens			Invasive																The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:not applicable
1314.1888	Streptococcus pyogenes strain NS909		1314	WGS	NS909	EMM81.0			MLST.Streptococcus_pyogenes.117				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407051	GCA_900991165.1	CAAIND000000000		SC	WGS						18		1817297	38.31104	1806		1712.0		sterile site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1854	Streptococcus pyogenes strain NS930		1314	WGS	NS930	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864288	GCA_900990825.1	CAAILV000000000		SC	WGS						14		1719696	38.427956	1711		1624.0		throat		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2320	Streptococcus pyogenes strain NS931		1314	WGS	NS931	EMM65.0			MLST.Streptococcus_pyogenes.111				2019-04-09T00:00:00Z		PRJEB2232	SAMEA864307	GCA_900995485.1	CAAJDN000000000		SC	WGS						14		1719844	38.434834	1744		1658.0		skin sore / abscess / burns / IV Site		1996	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.447	Streptococcus pyogenes strain PEI-B-P-20		1314	WGS	PEI-B-P-20				MLST.Streptococcus_pyogenes.28				2017-02-17T00:00:00Z		PRJEB11503	SAMEA4470459	GCF_900108785.1	FUVE00000000		IFH_MS	WGS						113		1763120	38.57	1818																																	To further characterize the first WHO international repository for transfusion relevant nacteria strains, we determined the whole genome sequences of the first four species of this collection, namely Staphylococcus epidermidis, Streptococcus pyogenes, Klebsiella pneumoniae, and Escherichia coli.	
1314.1048	Streptococcus pyogenes strain PS003		1314	Complete	PS003	M77					102.100.100.25708		2019-01-10T00:00:00Z		PRJEB29800	SAMEA5096236	GCA_900619615.1	LR130239		Bioplatforms Australia	Complete				1.0		1		1909563	38.466915	1873				urine		2010-07-05	Australia	Australia						Human, Homo sapiens						host_health_state:diseased													The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.The pathogens included in this initiative are: Escherichia coli, Klebsiella pneumoniae complex, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. The following project contains the complete genomes and sequence data for Streptococcus pyogenes.	
1314.1049	Streptococcus pyogenes strain PS006		1314	Complete	PS006	M28			MLST.Streptococcus_pyogenes.52		102.100.100.25709		2019-01-10T00:00:00Z		PRJEB29800	SAMEA5096237	GCA_900619625.1	LR130240		Bioplatforms Australia	Complete				1.0		1		1854706	38.349743	1832				urine		2010-07-06	Australia	Australia						Human, Homo sapiens						host_health_state:diseased													The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.The pathogens included in this initiative are: Escherichia coli, Klebsiella pneumoniae complex, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. The following project contains the complete genomes and sequence data for Streptococcus pyogenes.	
1314.851	Streptococcus pyogenes strain RLGH		1314	Complete	RLGH				MLST.Streptococcus_pyogenes.39				2018-11-23T00:00:00Z		PRJNA505351	SAMN10416088	GCA_003814385.1	CP033908		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; PacBio	50.0x	SPAdes v. 3.10.0	1.0		1		1903972	38.541584	1975		1875.0					USA	USA: North Carolina						Human, Homo sapiens	male	38	Cellulitis																Whole genome sequencing of type emm4 GAS clinical strains	collected_by:Duke University Medical Center
1314.895	Streptococcus pyogenes strain S119		1314	Complete	S119	emm1			MLST.Streptococcus_pyogenes.28			Yes	2018-11-30T00:00:00Z		PRJEB27939	SAMEA4805863	GCA_900608505.1	LR031521		IP	Complete				1.0		1		1877450	38.5451	1885		1816.0		Blood culture	isolated from a blood culture	2008	France	France						Human, Homo sapiens						host_health_state:diseased													The streptococcus pyogenes strain S119 is an invasive emm1 type strain isolated from a blood culture. Its complete genome sequence was performed using Illumina sequencing and served as reference sequence to characterize the transcriptional landscape in S. pyogenes by using dRNA-sequencing and strand-specific RNA-sequencing. ncRNAs and promoters were annotated;Invasive strain isolated from a blood culture	
1314.715	Streptococcus pyogenes strain S2_012_000_R3_95		1314	WGS	S2_012_000_R3_95								2018-06-18T00:00:00Z		PRJNA376580	SAMN07426595	GCA_003240915.1	QFNT00000000			WGS	Illumina HiSeq	000.0	IDBA_UD v. 1.1.1			182		2044028	41.81425	2155		1911.0		hospital NICU surfaces and sink samples		2013-10-01	USA	USA: Pittsburgh					env_biome:hospital																				This data was generated to recover genomes from hospital (NICU) surfaces and sinks.;derived from metagenome	sample_type:metagenomic assembly
1314.2590	Streptococcus pyogenes strain S417		1314	WGS	S417				MLST.Streptococcus_pyogenes.36				2020-01-10T00:00:00Z		PRJNA598017	SAMN13696974	GCA_009846875.1	WUWP00000000		Peking University	WGS	Illumina NovaSeq	12.0x	SPAdes v. 3.13.1	0.0	0.0	96		2094142	38.53042	2157				no	isolated from a patient with sepsis shock	2017-04-24	China	China						Human, Homo sapiens	male	58	infection			host_description:healthly;host_disease_outcome:death;host_disease_stage:shock;host_health_state:seriously ill;host_subject_id:1461150900													Streptococcus pyogenes S417 was isolated from a patient with sepsis shock.	collected_by:Xiumei Xiao
1314.846	Streptococcus pyogenes strain SASM4-Duke		1314	Complete	SASM4-Duke	serovar M4			MLST.Streptococcus_pyogenes.39				2018-10-12T00:00:00Z		PRJNA300859	SAMN04230441	GCA_003640605.1	CP031770		Baylor College of Medicine	Complete	Illumina MiSeq; PacBio	200.0x	SPAdes v. 3.12.0	1.0		1		1903997	38.541344	1976		1875.0		blood			USA	USA: North Carolina						Human, Homo sapiens	female	48	Bacteremia											C					Clinical isolates of serotype M4 GAS	collected_by:Duke University Medical Center
1314.473	Streptococcus pyogenes strain SC05		1314	WGS	SC05				MLST.Streptococcus_pyogenes.28				2017-05-19T00:00:00Z		PRJNA381156	SAMN06671863	GCA_002115435.1	NBYS00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina MiSeq	59.0x	SPAdes v. NOV-2015			25		1805776	38.39	1884		1797.0		Vaginal cavity	recovered from differents sites of infections	2012-12-05	Brazil	Brazil: Porto Alegre						Human, Homo sapiens	female	8 years old	Vaginal Infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:ISCMPA
1314.957	Streptococcus pyogenes strain SC06		1314	WGS	SC06				MLST.Streptococcus_pyogenes.28				2019-01-30T00:00:00Z		PRJNA381156	SAMN10769258	GCA_004122835.1	SDMF00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			57		1816816	38.476105	1929		1841.0		pleural liquid	recovered from differents sites of infections	2012-05-12	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			pleural drainage																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.958	Streptococcus pyogenes strain SC08		1314	WGS	SC08				MLST.Streptococcus_pyogenes.28				2019-01-30T00:00:00Z		PRJNA381156	SAMN10769259	GCA_004122875.1	SDMG00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			90		1852114	38.380142	1977		1883.0		sputum	recovered from differents sites of infections	2013-09-26	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			pulmonary infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.960	Streptococcus pyogenes strain SC18		1314	WGS	SC18								2019-01-30T00:00:00Z		PRJNA381156	SAMN10769263	GCA_004122895.1	SDMH00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			47		1804267	38.4151	1867		1777.0		postoperative wound infection	recovered from differents sites of infections	2015-05-08	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			wound infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.959	Streptococcus pyogenes strain SC21		1314	WGS	SC21				MLST.Streptococcus_pyogenes.190				2019-01-30T00:00:00Z		PRJNA381156	SAMN10769285	GCA_004122885.1	SDMI00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			942		2301490	38.546722	3129		2909.0		sputum	recovered from differents sites of infections	2015-08-26	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			pulmonary infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.953	Streptococcus pyogenes strain SC23		1314	WGS	SC23				MLST.Streptococcus_pyogenes.365				2019-01-27T00:00:00Z		PRJNA381156	SAMN10769286	GCA_004114635.1	SDAT00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			269		1929836	38.577682	2164		2055.0		bronchoalveolar lavage	recovered from differents sites of infections	2016-03-30	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			pulmonary infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.1113	Streptococcus pyogenes strain SDog		1314	WGS	SDog	EMM70.0			MLST.Streptococcus_pyogenes.10				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238026	GCA_900983335.1	CAAHJG000000000		SC	WGS						14		1800931	38.3153	1820		1727.0				1990	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.991	Streptococcus pyogenes strain SP1336		1314	Complete	SP1336	M12			MLST.Streptococcus_pyogenes.36				2019-02-13T00:00:00Z	30721938	PRJNA486857	SAMN09867132	GCA_004193935.1	CP031738		University of Melbourne	Complete	PacBio	105.0x	PacBio SMRT Pipe v. 2.3.0	1.0		1		1878827	38.525208	1936		1843.0		throat		2017	Australia	Australia: Gold Coast, QLD						Human, Homo sapiens			Scarlet Fever																Complete genome of M12 Streptococcus pyogenes associated with Scarlet Fever in an Australian patient	collected_by:Gold Coast Health
1314.1046	Streptococcus pyogenes strain SP444		1314	Complete	SP444	M4			MLST.Streptococcus_pyogenes.39		102.100.100.25706		2019-01-10T00:00:00Z		PRJEB29800	SAMEA5096234	GCA_900619595.1	LR130237		Bioplatforms Australia	Complete				1.0		1		1823047	38.545742	1799				blood		2008-04-28	Australia	Australia						Human, Homo sapiens						host_health_state:diseased													The Antibiotic Resistant Sepsis Pathogens Framework Initiative aims to develop a framework dataset of 5 sepsis pathogens (5 strains each) using an integrated application of genomic, transcriptomic, metabolomic and proteomic technologies.The pathogens included in this initiative are: Escherichia coli, Klebsiella pneumoniae complex, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. The following project contains the complete genomes and sequence data for Streptococcus pyogenes.	
1314.2429	Streptococcus pyogenes strain SPY2006		1314	WGS	SPY2006				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996166	GCA_008122095.1	SJLO00000000		Rostock University Medical Center	WGS	Illumina HiSeq	78.8892x	SPAdes v. 2000-12-03T00:00:00			32		1808015	38.384747	1891		1808.0		biopsy		2016-12-01	Denmark	Denmark: Copenhagen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2430	Streptococcus pyogenes strain SPY2015		1314	WGS	SPY2015				MLST.Streptococcus_pyogenes.62				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996167	GCA_008122125.1	SJLN00000000		Rostock University Medical Center	WGS	Illumina HiSeq	68.584x	SPAdes v. 2000-12-03T00:00:00			79		1883884	38.340736	2031		1936.0		biopsy		2016-12-01	Denmark	Denmark: Copenhagen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2419	Streptococcus pyogenes strain SPY2017		1314	WGS	SPY2017				MLST.Streptococcus_pyogenes.52				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996168	GCA_008121705.1	SJLM00000000		Rostock University Medical Center	WGS	Illumina HiSeq	49.8079x	SPAdes v. 2000-12-03T00:00:00			36		1913977	38.2665	2013		1908.0		biopsy		2016-12-01	Denmark	Denmark: Copenhagen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2420	Streptococcus pyogenes strain SPY2028		1314	WGS	SPY2028				MLST.Streptococcus_pyogenes.15				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996169	GCA_008121715.1	SJLL00000000		Rostock University Medical Center	WGS	Illumina HiSeq	31.0267x	SPAdes v. 2000-12-03T00:00:00			643		2154046	39.56155	2770		2584.0		biopsy		2016-12-01	Denmark	Denmark: Copenhagen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2418	Streptococcus pyogenes strain SPY3005		1314	WGS	SPY3005				MLST.Streptococcus_pyogenes.101				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996170	GCA_008121695.1	SJLK00000000		Rostock University Medical Center	WGS	Illumina HiSeq	66.3499x	SPAdes v. 2000-12-03T00:00:00			136		1778010	38.503326	1872		1766.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2417	Streptococcus pyogenes strain SPY3012		1314	WGS	SPY3012				MLST.Streptococcus_pyogenes.63				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996171	GCA_008121685.1	SJLJ00000000		Rostock University Medical Center	WGS	Illumina HiSeq	75.1817x	SPAdes v. 2000-12-03T00:00:00			164		2018057	38.465317	2209		2067.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2415	Streptococcus pyogenes strain SPY5003		1314	WGS	SPY5003				MLST.Streptococcus_pyogenes.63				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996172	GCA_008121625.1	SJLI00000000		Rostock University Medical Center	WGS	Illumina HiSeq	13.6686x	SPAdes v. 2000-12-03T00:00:00			565		2072479	38.52806	2509		2364.0		biopsy		2016-07-04	Sweden	Sweden: Gothenburg						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2412	Streptococcus pyogenes strain SPY5004		1314	WGS	SPY5004				MLST.Streptococcus_pyogenes.52				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996173	GCA_008121595.1	SJLH00000000		Rostock University Medical Center	WGS	Illumina HiSeq	16.1493x	SPAdes v. 2000-12-03T00:00:00			166		1998853	38.25739	2222		2098.0		biopsy		2016-07-04	Sweden	Sweden: Gothenburg						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2428	Streptococcus pyogenes strain SPY5006A		1314	WGS	SPY5006A				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996174	GCA_008122075.1	SJLG00000000		Rostock University Medical Center	WGS	Illumina HiSeq	29.0102x	SPAdes v. 2000-12-03T00:00:00			80		1837335	38.3377	1968		1875.0		biopsy		2016-07-04	Sweden	Sweden: Gothenburg						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2426	Streptococcus pyogenes strain SPY5006B		1314	WGS	SPY5006B				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996175	GCA_008122055.1	SJLF00000000		Rostock University Medical Center	WGS	Illumina HiSeq	72.9108x	SPAdes v. 2000-12-03T00:00:00			61		1823838	38.438942	1938		1851.0		biopsy		2016-07-04	Sweden	Sweden: Gothenburg						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2427	Streptococcus pyogenes strain SPY5006C		1314	WGS	SPY5006C				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996176	GCA_008122065.1	SJLE00000000		Rostock University Medical Center	WGS	Illumina HiSeq	23.8922x	SPAdes v. 2000-12-03T00:00:00			95		1844084	38.316692	1984		1884.0		biopsy		2016-07-04	Sweden	Sweden: Gothenburg						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2409	Streptococcus pyogenes strain SPY5448		1314	WGS	SPY5448				MLST.Streptococcus_pyogenes.28				2019-06-19T00:00:00Z		PRJNA524111	SAMN10996177	GCA_006364945.1	VCIF00000000		Rostock University Medical Center	WGS	Illumina HiSeq	30x	SPAdes v. 2000-12-03T00:00:00			216		1896038	39.134766	2130		2018.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2408	Streptococcus pyogenes strain SPY5626		1314	WGS	SPY5626				MLST.Streptococcus_pyogenes.15				2019-06-19T00:00:00Z		PRJNA524111	SAMN10996178	GCA_006364905.1	VCIE00000000		Rostock University Medical Center	WGS	Illumina HiSeq	30x	SPAdes v. 2000-12-03T00:00:00			87		1854127	38.54272	2024		1929.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2414	Streptococcus pyogenes strain SPY6004		1314	WGS	SPY6004				MLST.Streptococcus_pyogenes.15				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996179	GCA_008121615.1	SJLD00000000		Rostock University Medical Center	WGS	Illumina HiSeq	31.4699x	SPAdes v. 2000-12-03T00:00:00			109		1906082	38.410046	2132		2007.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2423	Streptococcus pyogenes strain SPY6013		1314	WGS	SPY6013				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996180	GCA_008121975.1	SJLC00000000		Rostock University Medical Center	WGS	Illumina HiSeq	63.3439x	SPAdes v. 2000-12-03T00:00:00			220		1890102	38.932556	2115		2000.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2424	Streptococcus pyogenes strain SPY6016		1314	WGS	SPY6016				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996181	GCA_008121985.1	SJLB00000000		Rostock University Medical Center	WGS	Illumina HiSeq	44.2192x	SPAdes v. 2000-12-03T00:00:00			340		1945491	38.859444	2264		2129.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2425	Streptococcus pyogenes strain SPY6018		1314	WGS	SPY6018				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996182	GCA_008122015.1	SJLA00000000		Rostock University Medical Center	WGS	Illumina HiSeq	67.9729x	SPAdes v. 2000-12-03T00:00:00			224		1892635	38.944275	2115		2002.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2421	Streptococcus pyogenes strain SPY6025		1314	WGS	SPY6025				MLST.Streptococcus_pyogenes.28				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996183	GCA_008121955.1	SJKZ00000000		Rostock University Medical Center	WGS	Illumina HiSeq	57.1598x	SPAdes v. 2000-12-03T00:00:00			172		1885482	38.540012	2057		1942.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2422	Streptococcus pyogenes strain SPY6026		1314	WGS	SPY6026				MLST.Streptococcus_pyogenes.39				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996184	GCA_008121965.1	SJKY00000000		Rostock University Medical Center	WGS	Illumina HiSeq	158.429x	SPAdes v. 2000-12-03T00:00:00			63		1804414	38.367302	1888		1801.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2407	Streptococcus pyogenes strain SPY6028		1314	WGS	SPY6028				MLST.Streptococcus_pyogenes.39				2019-06-19T00:00:00Z		PRJNA524111	SAMN10996185	GCA_006364895.1	VCID00000000		Rostock University Medical Center	WGS	Illumina HiSeq	60.3289x	SPAdes v. 2000-12-03T00:00:00			545		2117857	38.721924	2606		2372.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2416	Streptococcus pyogenes strain SPY6033		1314	WGS	SPY6033				MLST.Streptococcus_pyogenes.338				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996186	GCA_008121655.1	SJKX00000000		Rostock University Medical Center	WGS	Illumina HiSeq	152.023x	SPAdes v. 2000-12-03T00:00:00			55		1775098	38.574207	1842		1750.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2413	Streptococcus pyogenes strain SPY6040		1314	WGS	SPY6040				MLST.Streptococcus_pyogenes.52				2019-08-28T00:00:00Z		PRJNA524111	SAMN10996187	GCA_008121605.1	SJKW00000000		Rostock University Medical Center	WGS	Illumina HiSeq	119.71x	SPAdes v. 2000-12-03T00:00:00			129		1925041	38.371494	2085		1959.0		biopsy		2016-10-01	Norway	Norway: Bergen						Human, Homo sapiens																			Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2405	Streptococcus pyogenes strain SPY8003		1314	WGS	SPY8003				MLST.Streptococcus_pyogenes.15				2019-06-19T00:00:00Z		PRJNA524111	SAMN10996188	GCA_006364855.1	VCIC00000000		Rostock University Medical Center	WGS	Illumina HiSeq	30x	SPAdes v. 2000-12-03T00:00:00			107		1882007	38.607613	2068		1962.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.2406	Streptococcus pyogenes strain SPY8157		1314	WGS	SPY8157				MLST.Streptococcus_pyogenes.28				2019-06-19T00:00:00Z		PRJNA524111	SAMN10996189	GCA_006364865.1	VCIB00000000		Rostock University Medical Center	WGS	Illumina HiSeq	30x	SPAdes v. 2000-12-03T00:00:00			99		1838870	38.5819	1975		1886.0		biopsy		2016-12-01	Sweden	Sweden: Stockholm						Human, Homo sapiens			NSTI																Novel genomic isolates of S. pyogenes and S. dysgalactiae subsp. equisimilis associated to necrotising fasciitis (NSTI) obtained from several European hospitals.	collected_by:Itzek A
1314.662	Streptococcus pyogenes strain SPYOINFP20011		1314	WGS	SPYOINFP20011				MLST.Streptococcus_pyogenes.28				2017-11-23T00:00:00Z		PRJEB22834	SAMEA104325094	GCA_900231885.1	OEIP00000000		HELMHOLTZ CENTER FOR INFECTION RESEARCH	WGS						42		1813097	38.38779	1853		1755.0												Human, Homo sapiens																			Genome comparison of Streptococcus pyogenes and Streptococcus dysgalactiae subspecies equisimilis (SDSE) strains related to Necrotizing fasciitis	
1314.711	Streptococcus pyogenes strain SS1448		1314	WGS	SS1448	86			MLST.Streptococcus_pyogenes.9				2018-05-30T00:00:00Z		PRJNA471549	SAMN09206645	GCA_003176935.1	QFXR00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			55		1783456	38.37863	1882		1798.0				1976	Trinidad and Tobago	Trinidad and Tobago: Trinidad						Human, Homo sapiens			Rheumatic fever																The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:Colindale Lab, UK
1314.712	Streptococcus pyogenes strain SS1572		1314	WGS	SS1572	223			MLST.Streptococcus_pyogenes.536				2018-05-30T00:00:00Z		PRJNA471549	SAMN09206646	GCA_003176945.1	QFXQ00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			32		1766875	38.302765	1798		1719.0		Sterile site		1971	Egypt	Egypt						Human, Homo sapiens																			The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:Dr. D. Bessen
1314.708	Streptococcus pyogenes strain SS1574		1314	WGS	SS1574	224			MLST.Streptococcus_pyogenes.96				2018-05-25T00:00:00Z		PRJNA471549	SAMN09206647	GCA_003171595.1	QFXP00000000		University of Notre Dame	WGS	Illumina MiSeq	50x	velvet v. 1.2.10			31		1742552	38.379803	1799		1718.0				1972	Trinidad and Tobago	Trinidad and Tobago: Trinidad						Human, Homo sapiens			Impetigo																The skin isolates will be used for identifying genetic factors involved in the pathogenic mechanisms of skin infection of GAS.	collected_by:not applicable
1314.275	Streptococcus pyogenes strain SST1019-1		1314	WGS	SST1019-1				MLST.Streptococcus_pyogenes.974				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988143	GCF_001638335.1	LRGF00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			26		1773428	38.36	1775		1666.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-08	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.274	Streptococcus pyogenes strain SST1020-1		1314	WGS	SST1020-1				MLST.Streptococcus_pyogenes.10				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988139	GCF_001638325.1	LRGG00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			20		1792762	38.29	1831		1715.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-08	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.276	Streptococcus pyogenes strain SST1021-1		1314	WGS	SST1021-1				MLST.Streptococcus_pyogenes.10				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988140	GCF_001638345.1	LRGH00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			16		1801299	38.34	1827		1716.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.277	Streptococcus pyogenes strain SST1023-1		1314	WGS	SST1023-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988121	GCF_001638385.1	LRGI00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			14		1743826	38.29	1746		1638.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-11	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.278	Streptococcus pyogenes strain SST1024-1		1314	WGS	SST1024-1				MLST.Streptococcus_pyogenes.11				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988123	GCF_001638405.1	LRGJ00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			26		1768435	38.41	1798		1686.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-11	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.280	Streptococcus pyogenes strain SST1028-1		1314	WGS	SST1028-1				MLST.Streptococcus_pyogenes.10				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988118	GCF_001638435.1	LRGK00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			21		1791360	38.3	1821		1710.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-17	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.281	Streptococcus pyogenes strain SST2088-1		1314	WGS	SST2088-1				MLST.Streptococcus_pyogenes.974				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988144	GCF_001638465.1	LRGL00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			21		1775966	38.36	1778		1672.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-08	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.271	Streptococcus pyogenes strain SST2090-1		1314	WGS	SST2090-1								2016-05-06T00:00:00Z		PRJNA292736	SAMN03988125	GCF_001638255.1	LRGM00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			399		1443667	37.7	1829		1653.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.;genome length too small	collected_by:Menzies School of Health Research
1314.279	Streptococcus pyogenes strain SST2091-1		1314	WGS	SST2091-1				MLST.Streptococcus_pyogenes.304				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988134	GCF_001638415.1	LRGN00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			14		1781836	38.38	1806		1702.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.283	Streptococcus pyogenes strain SST2092-1		1314	WGS	SST2092-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988135	GCF_001638505.1	LRGO00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			17		1743816	38.29	1746		1644.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.272	Streptococcus pyogenes strain SST2093-1		1314	WGS	SST2093-1				MLST.Streptococcus_pyogenes.304				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988136	GCF_001638265.1	LRGP00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			15		1756132	38.44	1746		1650.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.284	Streptococcus pyogenes strain SST2094-1		1314	WGS	SST2094-1				MLST.Streptococcus_pyogenes.304				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988137	GCF_001638525.1	LRGQ00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			11		1756070	38.43	1750		1649.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.273	Streptococcus pyogenes strain SST2095-1		1314	WGS	SST2095-1				MLST.Streptococcus_pyogenes.176				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988138	GCF_001638275.1	LRGR00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			19		1878702	38.29	1954		1821.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.282	Streptococcus pyogenes strain SST2096-1		1314	WGS	SST2096-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988126	GCF_001638485.1	LRGS00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			17		1747406	38.32	1739		1643.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.286	Streptococcus pyogenes strain SST2097-1		1314	WGS	SST2097-1								2016-05-06T00:00:00Z		PRJNA292736	SAMN03988127	GCF_001638565.1	LRGT00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			373		1432679	37.83	1793		1619.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.;genome length too small	collected_by:Menzies School of Health Research
1314.285	Streptococcus pyogenes strain SST2098-1		1314	WGS	SST2098-1				MLST.Streptococcus_pyogenes.182				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988141	GCF_001638545.1	LRGU00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			15		1756972	38.4	1764		1667.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-09	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.287	Streptococcus pyogenes strain SST2099-1		1314	WGS	SST2099-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988131	GCF_001638575.1	LRGV00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			15		1741024	38.28	1743		1637.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-10	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.288	Streptococcus pyogenes strain SST2102-1		1314	WGS	SST2102-1				MLST.Streptococcus_pyogenes.304				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988132	GCF_001638585.1	LRGW00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			10		1750481	38.38	1755		1657.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-10	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.290	Streptococcus pyogenes strain SST2103-1		1314	WGS	SST2103-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988133	GCF_001638625.1	LRGX00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			13		1745425	38.29	1746		1644.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-10	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.291	Streptococcus pyogenes strain SST2229-1		1314	WGS	SST2229-1				MLST.Streptococcus_pyogenes.974				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988128	GCF_001638655.1	LRGY00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			22		1774159	38.36	1772		1665.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-10	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.289	Streptococcus pyogenes strain SST2232-1		1314	WGS	SST2232-1				MLST.Streptococcus_pyogenes.176				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988124	GCF_001638645.1	LRGZ00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			32		1880503	38.34	1954		1819.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-11	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.294	Streptococcus pyogenes strain SST2233-1		1314	WGS	SST2233-1				MLST.Streptococcus_pyogenes.641				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988145	GCF_001638725.1	LRHA00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			11		1812778	38.29	1837		1723.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.292	Streptococcus pyogenes strain SST2235-1		1314	WGS	SST2235-1				MLST.Streptococcus_pyogenes.641				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988146	GCF_001638675.1	LRHB00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			17		1812526	38.28	1839		1730.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.295	Streptococcus pyogenes strain SST2236-1		1314	WGS	SST2236-1				MLST.Streptococcus_pyogenes.641				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988147	GCF_001638745.1	LRHC00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			29		1815817	38.28	1862		1740.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.293	Streptococcus pyogenes strain SST2237-1		1314	WGS	SST2237-1				MLST.Streptococcus_pyogenes.10				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988119	GCF_001638695.1	LRHD00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			19		1790770	38.29	1817		1709.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.296	Streptococcus pyogenes strain SST2238-1		1314	WGS	SST2238-1				MLST.Streptococcus_pyogenes.641				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988148	GCF_001638755.1	LRHE00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			19		1810918	38.28	1839		1723.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.297	Streptococcus pyogenes strain SST2240-1		1314	WGS	SST2240-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988129	GCF_001638775.1	LRHF00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			16		1742559	38.28	1743		1640.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.298	Streptococcus pyogenes strain SST2241-1		1314	WGS	SST2241-1				MLST.Streptococcus_pyogenes.205				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988130	GCF_001638805.1	LRHG00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			15		1832398	38.33	1860		1751.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-14	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.265	Streptococcus pyogenes strain SST2242-1		1314	WGS	SST2242-1				MLST.Streptococcus_pyogenes.182				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988142	GCF_001638885.1	LRHH00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			16		1751340	38.37	1767		1666.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-17	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.266	Streptococcus pyogenes strain SST2243-1		1314	WGS	SST2243-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988120	GCF_001638895.1	LRHI00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			14		1741874	38.28	1751		1643.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-17	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.264	Streptococcus pyogenes strain SST2245-1		1314	WGS	SST2245-1				MLST.Streptococcus_pyogenes.332				2016-05-06T00:00:00Z		PRJNA292736	SAMN03988122	GCF_001638865.1	LRHJ00000000		Menzies School of Health Research	WGS	Illumina HiSeq	133.0x	Velvet v. JULY-2015			17		1740786	38.28	1734		1636.0		skin	isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting	2011-11-18	Australia	Australia: Darwin, Northern Territory						Human, Homo sapiens			pyoderma											C					Streptococcus pyogenes isolated from pyoderma to investigate transmission within and between households in a remote Indigenous community setting.	collected_by:Menzies School of Health Research
1314.500	Streptococcus pyogenes strain ST36		1314	WGS	ST36				MLST.Streptococcus_pyogenes.36				2017-08-14T00:00:00Z		PRJNA386535	SAMN07270556	GCA_002250425.1	NJPV00000000		Christian Medical College	WGS	IonTorrent	174.0x	AssemblerSPAdes v. 5.0.0.5			43		1745757	38.43	1802		1708.0				2017-04	India	India: Mumbai						Human, Homo sapiens		6 years 5 months	Fever, Throat pain																Clinical isolates from Homo sapiens	
1314.2828	Streptococcus pyogenes strain ST62		1314	Complete	ST62				MLST.Streptococcus_pyogenes.62				2020-08-17T00:00:00Z		PRJNA553829	SAMN12251807	GCA_014218035.1	CP041615		Federal University of Rio de Janeiro	Complete	Illumina HiSeq	64.0x	Newbler v. 3.0	1.0	0.0	1		1918724	38.5186	1994		1910.0		oropharynx		1997	Brazil	Brazil						Human, Homo sapiens			not reported																Streptococcus pyogenes 37-97hp	collected_by:Bernadete Carvalho
1314.375	Streptococcus pyogenes strain STAB09014		1314	Complete	STAB09014				MLST.Streptococcus_pyogenes.52				2016-07-05T00:00:00Z		PRJNA278400	SAMN03418290	GCF_001678885.1	CP011069	NZ_CP011069.1	Universite de Rennes 1	Complete	Illumina	19,000	CLC Genomic Workbench v. 6.5.1	1.0		1		1862487	38.36	1845		1707.0		1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis)	isolated from a 1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis) in French Brittany	2009							env_biome:not applicable	Human, Homo sapiens		5 year																	STAB905 was isolated from a 1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis) in French Brittany.	
1314.509	Streptococcus pyogenes strain STAB090229		1314	Complete	STAB090229				MLST.Streptococcus_pyogenes.150	genotype:emm75			2017-08-01T00:00:00Z		PRJNA377855	SAMN06473357	GCA_002238295.1	CP020027		university of rennes1	Complete	Illumina; PCR + Sanger	800.0x	CLC Genomics v. 6.5	1.0		1		1846347	38.57	1913		1810.0		Hospital		2009-02-28	France	France						Human, Homo sapiens	female	28	endometritisis																virulence factor determination	collected_by:S. Kayal
1314.516	Streptococcus pyogenes strain STAB090229		1314	Duplicate	STAB090229				MLST.Streptococcus_pyogenes.150	genotype:emm75			2017-08-01T00:00:00Z		PRJNA377855	SAMN06473357	GCA_002238295.1	CP020027		university of rennes1	Complete	Illumina; PCR + Sanger	800.0x	CLC Genomics v. 6.5	1.0		1		1846347	38.57	1913		1810.0		Hospital		2009-02-28	France	France						Human, Homo sapiens	female	28	endometritisis																virulence factor determination	collected_by:S. Kayal
1314.2536	Streptococcus pyogenes strain STAB09023		1314	Complete	STAB09023				MLST.Streptococcus_pyogenes.101				2019-12-10T00:00:00Z		PRJNA524538	SAMN11029189	GCA_009738475.1	CP036530		university of rennes1	Complete	Illumina HiSeq + PCR + sanger	817.0x	CLC genomics workbench v. 6	1.0	0.0	1		1741943	38.521122	1727		1662.0		genital		2009	France	France						Human, Homo sapiens																			Genomics comparative and determination of virulence factors	sample_type:cell culture;collected_by:S.Kayal
1314.189	Streptococcus pyogenes strain STAB10015		1314	Complete	STAB10015				MLST.Streptococcus_pyogenes.52				2015-07-30T00:00:00Z	26184948	PRJNA278400	SAMN03418291	GCF_001023495.1	CP011068	NZ_CP011068.1	Universite de Rennes 1	Complete	Illumina	1,900	CLC Genomic Workbench v. 6.5.1	1.0		1		1950454	38.25	1949		1810.0		1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis)	isolated from a 1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis) in French Brittany	2010							env_biome:not applicable	Human, Homo sapiens		5 year																	STAB905 was isolated from a 1,5 year-old girl (2009) and STAB1001 from a 3,3 years-old boy (2010) with perianal streptococcal cellulitis (anusitis) in French Brittany.	
1314.2535	Streptococcus pyogenes strain STAB10048		1314	Complete	STAB10048				MLST.Streptococcus_pyogenes.101				2019-12-10T00:00:00Z		PRJNA524780	SAMN11032819	GCA_009738495.1	CP036531		university rennes1	Complete	Illumina HiSeq + PCR + sanger	980.0x	CLC genomics workbench v. 6	1.0	0.0	1		1742165	38.521324	1727		1662.0		Facial cutaneous		2010	France	France						Human, Homo sapiens																			complet sequence of an invasive streptococcus pyogenes M/emm89	sample_type:cell culture
1314.515	Streptococcus pyogenes strain STAB120304		1314	Duplicate	STAB120304				MLST.Streptococcus_pyogenes.150	genotype:emm75			2017-08-01T00:00:00Z		PRJNA378587	SAMN06554460	GCA_002238315.1	CP020082		university of rennes1	Complete	Illumina; PCR + sanger	700.0x	CLC Genomics workbench v. 6	1.0		1		1890354	38.6	1971		1868.0		throat		2012-03-04	France	France						Human, Homo sapiens	male	42	asymptomatic																virulence factor determination	collected_by:S. Kayal
1314.510	Streptococcus pyogenes strain STAB120304		1314	Complete	STAB120304				MLST.Streptococcus_pyogenes.150	genotype:emm75			2017-08-01T00:00:00Z		PRJNA378587	SAMN06554460	GCA_002238315.1	CP020082		university of rennes1	Complete	Illumina; PCR + sanger	700.0x	CLC Genomics workbench v. 6	1.0		1		1890354	38.6	1971		1868.0		throat		2012-03-04	France	France						Human, Homo sapiens	male	42	asymptomatic																virulence factor determination	collected_by:S. Kayal
1314.267	Streptococcus pyogenes strain STAB13021		1314	Complete	STAB13021				MLST.Streptococcus_pyogenes.44				2016-05-09T00:00:00Z		PRJNA310843	SAMN04456596	GCF_001640945.1	CP014278		university of rennes1	Complete	Illumina		CLC genomic workbench v. 6			1		1810516	38.5	1810		1701.0		Hospital		2013-11-27	France	France:Brittany						Human, Homo sapiens	female	41	skin abcess											37 C		Facultative	HostAssociated		sequencing of virulent strains	collected_by:Samer Kayal
1314.492	Streptococcus pyogenes strain STAB14018		1314	Complete	STAB14018				MLST.Streptococcus_pyogenes.150				2017-06-02T00:00:00Z		PRJNA312571	SAMN04500791	GCA_002163545.1	CP014542		university of rennes1	Complete	Illumina	2000	CLC genomic workbench v. 6	1.0		1		1890465	38.6	1934		1804.0		Blood		2014-05-09	France	France: Brittany						Human, Homo sapiens	female	81	Bacteriemia, sepcis			host_disease_stage:sepsis								C				sepsis	sequencing of virulent strains	collected_by:Samer kayal
1314.663	Streptococcus pyogenes strain TJ11-001		1314	Complete	TJ11-001				MLST.Streptococcus_pyogenes.36				2018-03-30T00:00:00Z		PRJNA445523	SAMN08793275	GCA_003025365.1	CP028148		National Institute for Communicable Disease Control and Prevention, China CDC	Complete	Illumina HiSeq; Oxford Nanopore	320.0x	Unicycler v. MAR-2018	1.0		1		1939844	38.47995	1927				swab throat		2011-07	China	China						Human, Homo sapiens			scarlet fever																complete genome of a scarlet fever isolate from China	collected_by:ICDC, China CDC
1314.3170	Streptococcus pyogenes strain TSPY1026		1314	Complete	TSPY1026	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824163	GCA_020827075.1	CP060646		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	270x	Unicycler v. 0.4.6	1.0	0.0	1		1890384	38.44023	1868		1757.0		skin		2016	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3185	Streptococcus pyogenes strain TSPY1026		1314	Duplicate	TSPY1026	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824163	GCA_020827075.1	CP060646		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	270x	Unicycler v. 0.4.6	1.0	0.0	1		1890384	38.44023	1868		1757.0		skin		2016	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3105	Streptococcus pyogenes strain TSPY125		1314	WGS	TSPY125	serovar s							2021-10-13T00:00:00Z		PRJNA657283	SAMN15824173		JACSDO000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	140x	Unicycler v. 0.4.6	0.0	0.0	14		1726049	38.22962	1698		1626.0		wound		2013	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.3161	Streptococcus pyogenes strain TSPY125		1314	Duplicate	TSPY125	serovar s							2021-10-13T00:00:00Z		PRJNA657283	SAMN15824173		JACSDO000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	140x	Unicycler v. 0.4.6	0.0	0.0	14		1726049	38.22962	1698		1626.0		wound		2013	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.3176	Streptococcus pyogenes strain TSPY125		1314	Duplicate	TSPY125	serovar s							2021-10-13T00:00:00Z		PRJNA657283	SAMN15824173		JACSDO000000000		UTHSC/McGovern Medical School	WGS	Illumina MiSeq	140x	Unicycler v. 0.4.6	0.0	0.0	14		1726049	38.22962	1698		1626.0		wound		2013	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC, BCM
1314.3168	Streptococcus pyogenes strain TSPY1309		1314	Complete	TSPY1309	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824165	GCA_020827035.1	CP060644		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	290x	Unicycler v. 0.4.6	1.0	0.0	1		1781254	38.614986	1732		1634.0		skin		2017	USA	USA:Houston						Homo sapiens			Abscess																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3183	Streptococcus pyogenes strain TSPY1309		1314	Duplicate	TSPY1309	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824165	GCA_020827035.1	CP060644		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	290x	Unicycler v. 0.4.6	1.0	0.0	1		1781254	38.614986	1732		1634.0		skin		2017	USA	USA:Houston						Homo sapiens			Abscess																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3166	Streptococcus pyogenes strain TSPY1312		1314	Complete	TSPY1312	serovar s			MLST.Streptococcus_pyogenes.378				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824167	GCA_020826995.1	CP060642		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	147x	Unicycler v. 0.4.6	1.0	0.0	1		1845647	38.508987	1828		1728.0		throat		2017	USA	USA:Houston						Homo sapiens			Abscess																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3181	Streptococcus pyogenes strain TSPY1312		1314	Duplicate	TSPY1312	serovar s			MLST.Streptococcus_pyogenes.378				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824167	GCA_020826995.1	CP060642		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	147x	Unicycler v. 0.4.6	1.0	0.0	1		1845647	38.508987	1828		1728.0		throat		2017	USA	USA:Houston						Homo sapiens			Abscess																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3169	Streptococcus pyogenes strain TSPY1349		1314	Complete	TSPY1349	serovar s			MLST.Streptococcus_pyogenes.161				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824164	GCA_020827055.1	CP060645		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	260x	Unicycler v. 0.4.6	1.0	0.0	1		1902845	38.422836	1901		1793.0		throat		2017	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3184	Streptococcus pyogenes strain TSPY1349		1314	Duplicate	TSPY1349	serovar s			MLST.Streptococcus_pyogenes.161				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824164	GCA_020827055.1	CP060645		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	260x	Unicycler v. 0.4.6	1.0	0.0	1		1902845	38.422836	1901		1793.0		throat		2017	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3171	Streptococcus pyogenes strain TSPY136		1314	Complete	TSPY136	serovar s			MLST.Streptococcus_pyogenes.46				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824162	GCA_020827095.1	CP060647		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	420x	Unicycler v. 0.4.6	1.0	0.0	1		1780403	38.63597	1753		1666.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3186	Streptococcus pyogenes strain TSPY136		1314	Duplicate	TSPY136	serovar s			MLST.Streptococcus_pyogenes.46				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824162	GCA_020827095.1	CP060647		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	420x	Unicycler v. 0.4.6	1.0	0.0	1		1780403	38.63597	1753		1666.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3162	Streptococcus pyogenes strain TSPY141		1314	Complete	TSPY141	serovar s			MLST.Streptococcus_pyogenes.184				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824172	GCA_020826915.1	CP060638		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	102x	Unicycler v. 0.4.6	1.0	0.0	1		1878218	38.412262	1872		1768.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3177	Streptococcus pyogenes strain TSPY141		1314	Duplicate	TSPY141	serovar s			MLST.Streptococcus_pyogenes.184				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824172	GCA_020826915.1	CP060638		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	102x	Unicycler v. 0.4.6	1.0	0.0	1		1878218	38.412262	1872		1768.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3163	Streptococcus pyogenes strain TSPY153		1314	Complete	TSPY153	serovar s			MLST.Streptococcus_pyogenes.75				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824171	GCA_020826935.1	CP060639		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	186x	Unicycler v. 0.4.6	1.0	0.0	1		1970284	38.53424	1989		1866.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3178	Streptococcus pyogenes strain TSPY153		1314	Duplicate	TSPY153	serovar s			MLST.Streptococcus_pyogenes.75				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824171	GCA_020826935.1	CP060639		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	186x	Unicycler v. 0.4.6	1.0	0.0	1		1970284	38.53424	1989		1866.0		throat		2013	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.961	Streptococcus pyogenes strain TSPY155		1314	Complete	TSPY155								2019-01-31T00:00:00Z		PRJNA494557	SAMN10172638	GCA_004123995.1	CP032699		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	394.0x	Unicycler v. 0.4.6; Canu v. 1.7.1	1.0		1		1882327	38.488903	1898		1818.0		Abscess (retropharyngeal)		2013	USA	USA:Houston						Human, Homo sapiens			Invasive																Whole genome sequencing of antibiotic resistant strains of group A Streptococcus	collected_by:UTHSC/BCM
1314.965	Streptococcus pyogenes strain TSPY165		1314	Complete	TSPY165				MLST.Streptococcus_pyogenes.133				2019-01-31T00:00:00Z		PRJNA494557	SAMN10172669	GCA_004124135.1	CP033336		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	263.0x	Unicycler v. 0.4.6; Canu v. 1.7.1	1.0		1		1812036	38.51204	1844		1765.0		Otitis media		2013	USA	USA:Houston						Human, Homo sapiens			Invasive																Whole genome sequencing of antibiotic resistant strains of group A Streptococcus	collected_by:UTHSC/BCM
1314.2969	Streptococcus pyogenes strain TSPY1687		1314	Complete	TSPY1687				MLST.Streptococcus_pyogenes.36				2021-04-27T00:00:00Z		PRJNA608028	SAMN14162572	GCA_018140985.1	CP049187		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	120.0x	Unicycler v. 0.4.6	1.0	0.0	1		1866140	38.467907	1847		1759.0		Pharyngeal		2018	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing of emm12 group A streptococcal strains derived from multiple disease states	collected_by:UTHSC/BCM
1314.964	Streptococcus pyogenes strain TSPY208		1314	Complete	TSPY208				MLST.Streptococcus_pyogenes.49				2019-01-31T00:00:00Z		PRJNA494557	SAMN10172651	GCA_004124115.1	CP033335		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	250.0x	Unicycler v. 0.4.6; Canu v. 1.7.1	1.0		1		1801696	38.688046	1828		1735.0		Pharyngeal		2014	USA	USA:Houston						Human, Homo sapiens			Pharyngitis																Whole genome sequencing of antibiotic resistant strains of group A Streptococcus	collected_by:UTHSC/BCM
1314.3165	Streptococcus pyogenes strain TSPY210		1314	Complete	TSPY210	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824169	GCA_020826975.1	CP060641		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	158x	Unicycler v. 0.4.6	1.0	0.0	1		1841971	38.520206	1844		1725.0		blood		2014	USA	USA:Houston						Homo sapiens			Invasive																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3180	Streptococcus pyogenes strain TSPY210		1314	Duplicate	TSPY210	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824169	GCA_020826975.1	CP060641		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	158x	Unicycler v. 0.4.6	1.0	0.0	1		1841971	38.520206	1844		1725.0		blood		2014	USA	USA:Houston						Homo sapiens			Invasive																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3173	Streptococcus pyogenes strain TSPY270		1314	Complete	TSPY270	serovar s			MLST.Streptococcus_pyogenes.167				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824160	GCA_020827135.1	CP060649		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	330x	Unicycler v. 0.4.6	1.0	0.0	1		1852565	38.427963	1834		1738.0		skin		2014	USA	USA:Houston						Homo sapiens			SSTI																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3188	Streptococcus pyogenes strain TSPY270		1314	Duplicate	TSPY270	serovar s			MLST.Streptococcus_pyogenes.167				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824160	GCA_020827135.1	CP060649		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	330x	Unicycler v. 0.4.6	1.0	0.0	1		1852565	38.427963	1834		1738.0		skin		2014	USA	USA:Houston						Homo sapiens			SSTI																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3172	Streptococcus pyogenes strain TSPY383		1314	Complete	TSPY383	serovar s			MLST.Streptococcus_pyogenes.28				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824161	GCA_020827115.1	CP060648		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	130x	Unicycler v. 0.4.6	1.0	0.0	1		1827693	38.463352	1838		1744.0		throat		2014	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3187	Streptococcus pyogenes strain TSPY383		1314	Duplicate	TSPY383	serovar s			MLST.Streptococcus_pyogenes.28				2021-11-10T00:00:00Z		PRJNA657283	SAMN15824161	GCA_020827115.1	CP060648		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	130x	Unicycler v. 0.4.6	1.0	0.0	1		1827693	38.463352	1838		1744.0		throat		2014	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3167	Streptococcus pyogenes strain TSPY416		1314	Complete	TSPY416	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824166	GCA_020827015.1	CP060643		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	1090x	Unicycler v. 0.4.6	1.0	0.0	1		1791351	38.482742	1749		1651.0		skin		2014	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3182	Streptococcus pyogenes strain TSPY416		1314	Duplicate	TSPY416	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824166	GCA_020827015.1	CP060643		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	1090x	Unicycler v. 0.4.6	1.0	0.0	1		1791351	38.482742	1749		1651.0		skin		2014	USA	USA:Houston						Homo sapiens			Cellulitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.963	Streptococcus pyogenes strain TSPY453		1314	Complete	TSPY453				MLST.Streptococcus_pyogenes.63				2019-01-31T00:00:00Z		PRJNA494557	SAMN10172674	GCA_004124075.1	CP033337		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	211.0x	Unicycler v. 0.4.6; Canu v. 1.7.1	1.0		1		1976011	38.422207	2026		1931.0		Cellulitis		2014	USA	USA:Houston						Human, Homo sapiens			SSTI																Whole genome sequencing of antibiotic resistant strains of group A Streptococcus	collected_by:UTHSC/BCM
1314.3070	Streptococcus pyogenes strain TSPY515		1314	Complete	TSPY515				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14235194	GCA_019342885.1	CP049687		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	120x	Unicycler v. 0.4.6	1.0	0.0	1		1866277	38.55703	1876		1776.0		Abscess (skin)		2014	USA	USA						Homo sapiens			SSTI																Emergence of a novel emm4 GAS clone in the human population	collected_by:BCM/UTHSC
1314.962	Streptococcus pyogenes strain TSPY556		1314	Complete	TSPY556				MLST.Streptococcus_pyogenes.82				2019-01-31T00:00:00Z		PRJNA494557	SAMN10172691	GCA_004124015.1	CP032700,CP032701		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	285.0x	Unicycler v. 0.4.6; Canu v. 1.7.1	1.0	1.0	2		1833100	38.362064	1846		1765.0		Abscess (lymph node)		2015	USA	USA:Houston						Human, Homo sapiens			Invasive																Whole genome sequencing of antibiotic resistant strains of group A Streptococcus	collected_by:UTHSC/BCM
1314.3068	Streptococcus pyogenes strain TSPY637		1314	Complete	TSPY637				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14235203	GCA_019342865.1	CP049686		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	130x	Unicycler v. 0.4.6	1.0	0.0	1		1823857	38.54019	1820		1715.0		throat		2015	USA	USA						Homo sapiens			Pharyngitis																Emergence of a novel emm4 GAS clone in the human population	collected_by:BCM/UTHSC
1314.3164	Streptococcus pyogenes strain TSPY764		1314	Complete	TSPY764	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824170	GCA_020826955.1	CP060640		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	111x	Unicycler v. 0.4.6	1.0	0.0	1		1758170	38.558956	1705		1604.0		throat		2015	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3179	Streptococcus pyogenes strain TSPY764		1314	Duplicate	TSPY764	serovar s							2021-11-10T00:00:00Z		PRJNA657283	SAMN15824170	GCA_020826955.1	CP060640		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	111x	Unicycler v. 0.4.6	1.0	0.0	1		1758170	38.558956	1705		1604.0		throat		2015	USA	USA:Houston						Homo sapiens			Pharyngitis																Genome sequencing and assembly of multiple serotypes of group A Streptococcus for epigenetic studies	collected_by:UTHSC/BCM
1314.3081	Streptococcus pyogenes strain TSPY767		1314	Complete	TSPY767				MLST.Streptococcus_pyogenes.39				2021-08-04T00:00:00Z		PRJNA609136	SAMN14235217	GCA_019448315.1	CP055246		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; Oxford Nanopore GridION	750.0x	Unicycler v. 0.4.6	1.0	0.0	1		1860158	38.507805	1882		1771.0		throat		2015	USA	USA						Homo sapiens			Pharyngitis																Emergence of a novel emm4 GAS clone in the human population	collected_by:BCM/UTHSC
1314.3067	Streptococcus pyogenes strain TSPY806		1314	Complete	TSPY806				MLST.Streptococcus_pyogenes.39				2021-07-26T00:00:00Z		PRJNA609136	SAMN14235221	GCA_019342845.1	CP049685		UTHSC/McGovern Medical School	Complete	Illumina MiSeq; ONT GridION	513x	Unicycler v. 0.4.6	1.0	0.0	1		1866006	38.561024	1878		1772.0		Cellulitis		2016	USA	USA						Homo sapiens			SSTI																Emergence of a novel emm4 GAS clone in the human population	collected_by:BCM/UTHSC
1314.476	Streptococcus pyogenes strain WB136		1314	WGS	WB136				MLST.Streptococcus_pyogenes.176				2017-05-19T00:00:00Z		PRJNA381156	SAMN06671848	GCA_002115505.1	NBYV00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina MiSeq	69.0x	SPAdes v. NOV-2015			20		1842632	38.28	1921		1826.0		blood	recovered from differents sites of infections	2011-08-03	Brazil	Brazil: Porto Alegre						Human, Homo sapiens	male		Bacteremia																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:ISCMPA
1314.956	Streptococcus pyogenes strain WB147		1314	WGS	WB147				MLST.Streptococcus_pyogenes.46				2019-01-30T00:00:00Z		PRJNA381156	SAMN10769257	GCA_004122745.1	SDME00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			88		1801174	38.49406	1924		1839.0		oropharynx	recovered from differents sites of infections	2011-12-12	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			oropharynx infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.475	Streptococcus pyogenes strain WB151		1314	WGS	WB151				MLST.Streptococcus_pyogenes.53				2017-05-19T00:00:00Z		PRJNA381156	SAMN06671862	GCA_002115485.1	NBYU00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina MiSeq	48.0x	SPAdes v. NOV-2015			38		1806404	38.34	1846		1772.0		skin	recovered from differents sites of infections	2012-01-17	Brazil	Brazil: Porto Alegre						Human, Homo sapiens	male		Skin lesion																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:ISCMPA
1314.474	Streptococcus pyogenes strain WB155		1314	WGS	WB155				MLST.Streptococcus_pyogenes.59				2017-05-19T00:00:00Z		PRJNA381156	SAMN06671861	GCA_002115465.1	NBYT00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina MiSeq	49.0x	SPAdes v. NOV-2015			22		1861224	38.34	1941		1855.0		Oropharynx	recovered from differents sites of infections	2012-05-12	Brazil	Brazil: Porto Alegre						Human, Homo sapiens	male		Pharyngitis																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:ISCMPA
1314.955	Streptococcus pyogenes strain WB75a		1314	WGS	WB75a								2019-01-30T00:00:00Z		PRJNA381156	SAMN10769256	GCA_004122715.1	SDMD00000000		UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE	WGS	Illumina HiSeq	30.0x	SPAdes v. 3.12.0			53		1728182	38.33676	1763		1693.0		blood	recovered from differents sites of infections	2004-07-09	Brazil	Brazil:Porto Alegre						Human, Homo sapiens			blood infection																Streptococcus pyogenes (Group A beta-hemolytic Streptococcus, GAS) is usually a coloniser of the human oropharynx and skin. However, under specific circumstances, these microorganisms have the hability to cause diverse clinical manifestations ranging from mild diseases such as pharyngo-tonsillitis and erysipelas to severe and invasive diseases such as necrotising fasciitis, pneumonia and streptococcal toxic shock syndrome. The goal of this project are the knowledge about GAS pathogenesis and molecular epidemiology of human isolates recovered from differents sites of infections.	collected_by:UFCSPA
1314.1118	Streptococcus pyogenes strain YARB5		1314	WGS	YARB5	EMM52.1			MLST.Streptococcus_pyogenes.180				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238028	GCA_900983385.1	CAAHJH000000000		SC	WGS						12		1722878	38.394592	1699		1612.0		skin sore		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1121	Streptococcus pyogenes strain YARC4		1314	WGS	YARC4	EMM92.0			MLST.Streptococcus_pyogenes.82				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238032	GCA_900983415.1	CAAHJO000000000		SC	WGS						17		1736934	38.43022	1715		1630.0		skin sore		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1122	Streptococcus pyogenes strain YARG2		1314	WGS	YARG2	EMM11.0			MLST.Streptococcus_pyogenes.547				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238033	GCA_900983425.1	CAAHJP000000000		SC	WGS						15		1808568	38.39326	1825		1740.0		skin sore		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1123	Streptococcus pyogenes strain YARG4		1314	WGS	YARG4	EMM124.0			MLST.Streptococcus_pyogenes.544				2019-04-09T00:00:00Z		PRJEB2232	SAMEA2238034	GCA_900983435.1	CAAHJR000000000		SC	WGS						17		1743892	38.31748	1729		1639.0		Skin sore		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.1015	Streptococcus pyogenes strain emm1		1314	Complete	emm1				MLST.Streptococcus_pyogenes.28				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793313	GCA_005164585.1	CP035441		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1834762	38.52914	1874		1801.0		blood			India	India						Human, Homo sapiens			Invasive disease																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1019	Streptococcus pyogenes strain emm100		1314	Complete	emm100				MLST.Streptococcus_pyogenes.119				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793301	GCA_005165265.1	CP035453		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1839531	38.546566	1889		1800.0		blood		2006	Fiji	Fiji						Human, Homo sapiens			Invasive disease																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.996	Streptococcus pyogenes strain emm105		1314	Complete	emm105								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793323	GCA_005161125.1	CP035431		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1800116	38.488243	1795		1716.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1010	Streptococcus pyogenes strain emm11		1314	Complete	emm11				MLST.Streptococcus_pyogenes.547				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793322	GCA_005163565.1	CP035432		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1809631	38.584774	1827		1737.0		throat		2011	New Zealand	New Zealand						Human, Homo sapiens			Throat																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1007	Streptococcus pyogenes strain emm123		1314	Complete	emm123				MLST.Streptococcus_pyogenes.325				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793302	GCA_005163085.1	CP035452		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1768816	38.477943	1731		1661.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1000	Streptococcus pyogenes strain emm124		1314	Complete	emm124				MLST.Streptococcus_pyogenes.199				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793314	GCA_005161825.1	CP035440		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1790668	38.500603	1798		1706.0		throat		1997	Australia	Australia						Human, Homo sapiens			Throat																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1020	Streptococcus pyogenes strain emm197		1314	Complete	emm197								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793299	GCA_005165385.1	CP035455		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1797172	38.612553	1842		1763.0		throat		2013	New Zealand	New Zealand						Human, Homo sapiens			Rheumatic fever																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1025	Streptococcus pyogenes strain emm1_NS6		1314	WGS	emm1_NS6				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292275	GCA_005472315.1	SSAD00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			32		1846182	38.41864	1961		1873.0		throat		2007	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1040	Streptococcus pyogenes strain emm1_NS7		1314	WGS	emm1_NS7				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292277	GCA_005472655.1	SSAO00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			32		1846182	38.41864	1961		1873.0		throat		2008	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.954	Streptococcus pyogenes strain emm1_S1		1314	WGS	emm1_S1				MLST.Streptococcus_pyogenes.28				2019-04-21T00:00:00Z		PRJNA497706	SAMN10265283	GCA_004118185.2	RIZE00000000		University of Antwerpen	WGS	Illumina MiSeq	70.0x	SPAdes v. 3.10			73		1770449	38.428844	1869		1790.0		blood		1999	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1041	Streptococcus pyogenes strain emm1_S10		1314	WGS	emm1_S10				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292269	GCA_005472665.1	SSAS00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			36		1792315	38.38479	1875		1797.0		blood		2005	Belgium	Belgium						Human, Homo sapiens			Wound infection, Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1030	Streptococcus pyogenes strain emm1_S11		1314	WGS	emm1_S11				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292270	GCA_005472455.1	SSAR00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			26		1794882	38.363464	1872		1794.0		blood		2005	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1031	Streptococcus pyogenes strain emm1_S12		1314	WGS	emm1_S12				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292272	GCA_005472465.1	SSAQ00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			33		1828588	38.370205	1926		1842.0		finger		2007	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1034	Streptococcus pyogenes strain emm1_S13		1314	WGS	emm1_S13								2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292276	GCA_005472505.1	SSAP00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			153		1795639	38.45752	1966		1872.0		blood		2008	Belgium	Belgium						Human, Homo sapiens			STSS																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1027	Streptococcus pyogenes strain emm1_S14		1314	WGS	emm1_S14				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292280	GCA_005472375.1	SSAN00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			43		1793046	38.37255	1876		1797.0		blood		2009	Belgium	Belgium						Human, Homo sapiens			STSS, pneumonia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1038	Streptococcus pyogenes strain emm1_S15		1314	WGS	emm1_S15				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292283	GCA_005472605.1	SSAM00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			40		1780718	38.35944	1867		1792.0		Wound (not sterile)		2010	Belgium	Belgium						Human, Homo sapiens			STSS, fasciitis																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1026	Streptococcus pyogenes strain emm1_S16		1314	WGS	emm1_S16				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292286	GCA_005472365.1	SSAL00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			76		1752336	38.426563	1844		1770.0		muscle		2012	Belgium	Belgium						Human, Homo sapiens			STSS, myositis																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1039	Streptococcus pyogenes strain emm1_S17		1314	WGS	emm1_S17				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292287	GCA_005472615.1	SSAK00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			56		1775344	38.39531	1866		1788.0		blood		2012	Belgium	Belgium						Human, Homo sapiens			STSS																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1028	Streptococcus pyogenes strain emm1_S18		1314	WGS	emm1_S18				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292290	GCA_005472385.1	SSAJ00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			30		1788666	38.370403	1854		1780.0				2013	Belgium	Belgium						Human, Homo sapiens			STSS, Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1037	Streptococcus pyogenes strain emm1_S19		1314	WGS	emm1_S19				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292291	GCA_005472595.1	SSAI00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			36		1827570	38.385895	1926		1845.0		blood		2013	Belgium	Belgium						Human, Homo sapiens			Septicemia, cellulitis																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.952	Streptococcus pyogenes strain emm1_S2		1314	WGS	emm1_S2				MLST.Streptococcus_pyogenes.28				2019-04-21T00:00:00Z		PRJNA497706	SAMN10265285	GCA_004118175.2	RIZF00000000		University of Antwerpen	WGS	Illumina MiSeq	70.0x	SPAdes v. 3.10			36		1763498	38.42311	1848		1764.0		muscle		2012	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1029	Streptococcus pyogenes strain emm1_S20		1314	WGS	emm1_S20				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292292	GCA_005472395.1	SSAH00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			35		1791093	38.369434	1871		1796.0		throat		2013	Belgium	Belgium						Human, Homo sapiens			STSS, pneumonia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1024	Streptococcus pyogenes strain emm1_S21		1314	WGS	emm1_S21				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292293	GCA_005472355.1	SSAG00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			65		1779172	38.402332	1879		1796.0		tissue from tooth extraction		2013	Belgium	Belgium						Human, Homo sapiens			Septicimia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1036	Streptococcus pyogenes strain emm1_S22		1314	WGS	emm1_S22				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292294	GCA_005472565.1	SSAF00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			22		1783913	38.371407	1855		1782.0				2013	Belgium	Belgium						Human, Homo sapiens			TSS, cellulitis, fasciitis																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1022	Streptococcus pyogenes strain emm1_S23		1314	WGS	emm1_S23				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292295	GCA_005472265.1	SSAE00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			36		1785997	38.366024	1866		1788.0		blood		2013	Belgium	Belgium						Human, Homo sapiens			Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1023	Streptococcus pyogenes strain emm1_S3		1314	WGS	emm1_S3								2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11287988	GCA_005472275.1	SSBF00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12.0			20		1663711	38.284954	1729		1655.0		blood		1999-03	Belgium	Belgium						Human, Homo sapiens			BSI																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1035	Streptococcus pyogenes strain emm1_S4		1314	WGS	emm1_S4				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292261	GCA_005472555.1	SSAY00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			72		1764860	38.41802	1861		1778.0		blood		1999	Belgium	Belgium						Human, Homo sapiens			Erysipelas																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1044	Streptococcus pyogenes strain emm1_S5		1314	WGS	emm1_S5				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292262	GCA_005472725.1	SSAX00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			21		1796532	38.36316	1875		1797.0		blood		1999	Belgium	Belgium						Human, Homo sapiens																			Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1032	Streptococcus pyogenes strain emm1_S6		1314	WGS	emm1_S6				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292263	GCA_005472475.1	SSAW00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			49		1794403	38.416027	1878		1790.0		throat		1999	Belgium	Belgium						Human, Homo sapiens			STSS																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1033	Streptococcus pyogenes strain emm1_S7		1314	WGS	emm1_S7				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292266	GCA_005472495.1	SSAV00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			36		1847213	38.415817	1948		1859.0		blood		2001	Belgium	Belgium						Human, Homo sapiens			Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1043	Streptococcus pyogenes strain emm1_S8		1314	WGS	emm1_S8				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292267	GCA_005472715.1	SSAU00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			36		1847213	38.415817	1948		1859.0		blood		2003	Belgium	Belgium						Human, Homo sapiens			Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.1042	Streptococcus pyogenes strain emm1_S9		1314	WGS	emm1_S9				MLST.Streptococcus_pyogenes.28				2019-05-17T00:00:00Z	31065672	PRJNA497706	SAMN11292268	GCA_005472695.1	SSAT00000000		University of Antwerpen	WGS	Illumina MiSeq	80x	SPAdes v. 12			27		1803739	38.390144	1887		1805.0		blood		2004	Belgium	Belgium						Human, Homo sapiens			Septicemia																Group A Streptococcus (GAS) causes infections ranging from pharyngitis to toxic shock syndrome. During the last two decades, there has been a public health concern of severe invasive infections caused by GAS of the emm1 genotype. This study investigated the longitudinal genomic evolution of emm1 GAS strains in Belgium over a 19-year period and studied the genetic variations between invasive and non-invasive strains.	
1314.999	Streptococcus pyogenes strain emm22.8		1314	Complete	emm22.8				MLST.Streptococcus_pyogenes.360				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793316	GCA_005161605.1	CP035438		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1950616	38.319946	2023		1919.0		skin			India	India						Human, Homo sapiens			Skin																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1006	Streptococcus pyogenes strain emm230		1314	Complete	emm230				MLST.Streptococcus_pyogenes.205				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793303	GCA_005162865.1	CP035451		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1826832	38.484657	1846		1775.0		skin		2005	Australia	Australia						Human, Homo sapiens			Skin sore / abscess / burns / IV Site																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1016	Streptococcus pyogenes strain emm25		1314	Complete	emm25				MLST.Streptococcus_pyogenes.191				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793312	GCA_005164705.1	CP035442		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1835714	38.492653	1870		1785.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1008	Streptococcus pyogenes strain emm54		1314	Complete	emm54				MLST.Streptococcus_pyogenes.302				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793300	GCA_005163245.1	CP035454		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1742565	38.564186	1739		1664.0		skin		1994	Australia	Australia						Human, Homo sapiens			Skin sore / abscess / burns / IV Site																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.995	Streptococcus pyogenes strain emm55		1314	Complete	emm55				MLST.Streptococcus_pyogenes.100				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793324	GCA_005160925.1	CP035430		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1899479	38.51946	1940		1848.0		skin		2005	Australia	Australia						Human, Homo sapiens			Acute post-streptococcal glomerulonephritis																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1003	Streptococcus pyogenes strain emm56		1314	Complete	emm56				MLST.Streptococcus_pyogenes.115				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793305	GCA_005162405.1	CP035449		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1825427	38.55235	1876		1785.0		skin		2005	Australia	Australia						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.992	Streptococcus pyogenes strain emm57		1314	Complete	emm57				MLST.Streptococcus_pyogenes.348				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793328	GCA_005160445.1	CP035426		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1756622	38.589237	1736		1676.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1001	Streptococcus pyogenes strain emm58		1314	Complete	emm58				MLST.Streptococcus_pyogenes.176				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793311	GCA_005161985.1	CP035443		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1888806	38.40188	1934		1845.0		blood		1995	Australia	Australia						Human, Homo sapiens			Invasive disease																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.997	Streptococcus pyogenes strain emm64.3		1314	Complete	emm64.3								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793319	GCA_005161325.1	CP035435		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1779766	38.563663	1811		1743.0		throat		2003	Brazil	Brazil						Human, Homo sapiens			Pharyngitis																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1011	Streptococcus pyogenes strain emm65		1314	Complete	emm65				MLST.Streptococcus_pyogenes.716				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793321	GCA_005163705.1	CP035433		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1789855	38.566364	1785		1709.0		blood		1998	Kenya	Kenya						Human, Homo sapiens			Invasive disease																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1021	Streptococcus pyogenes strain emm68.2		1314	Complete	emm68.2								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793308	GCA_005222545.1	CP035446		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1747924	38.533024	1729		1659.0		throat		2004	Brazil	Brazil						Human, Homo sapiens			Pharyngitis																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1004	Streptococcus pyogenes strain emm70		1314	Complete	emm70				MLST.Streptococcus_pyogenes.10				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793306	GCA_005162565.1	CP035448		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1826467	38.471485	1850		1773.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.993	Streptococcus pyogenes strain emm74		1314	Complete	emm74				MLST.Streptococcus_pyogenes.120				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793327	GCA_005160565.1	CP035427		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1861037	38.46576	1903		1827.0		throat		2014	New Zealand	New Zealand						Human, Homo sapiens			Rheumatic fever																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1012	Streptococcus pyogenes strain emm75.1		1314	Complete	emm75.1				MLST.Streptococcus_pyogenes.607				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793320	GCA_005163865.1	CP035434		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1887700	38.604755	1906		1814.0		skin		1991	Australia	Australia						Human, Homo sapiens			Skin sore / abscess / burns / IV Site																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1014	Streptococcus pyogenes strain emm77		1314	Complete	emm77				MLST.Streptococcus_pyogenes.588				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793315	GCA_005164305.1	CP035439		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1806314	38.538925	1811		1739.0		throat		2005	Australia	Australia						Human, Homo sapiens			Throat																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.998	Streptococcus pyogenes strain emm78.3		1314	Complete	emm78.3								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793317	GCA_005161465.1	CP035437		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1806521	38.44035	1799		1723.0		throat		2002	New Zealand	New Zealand						Human, Homo sapiens			Rheumatic fever																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1013	Streptococcus pyogenes strain emm89.14		1314	Complete	emm89.14				MLST.Streptococcus_pyogenes.380				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793318	GCA_005164025.1	CP035436		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1806344	38.53773	1832		1746.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore.																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1017	Streptococcus pyogenes strain emm90.5		1314	Complete	emm90.5				MLST.Streptococcus_pyogenes.184				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793310	GCA_005164885.1	CP035444		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1764969	38.54402	1745		1666.0		blood		2014	New Zealand	New Zealand						Human, Homo sapiens			Invasive disease																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1018	Streptococcus pyogenes strain emm92		1314	Complete	emm92								2019-05-06T00:00:00Z		PRJNA454341	SAMN10793309	GCA_005165045.1	CP035445		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1758778	38.48297	1764		1683.0		throat		2006	Fiji	Fiji						Human, Homo sapiens			Throat																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1005	Streptococcus pyogenes strain emm93.4		1314	Complete	emm93.4				MLST.Streptococcus_pyogenes.814				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793304	GCA_005162725.1	CP035450		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1701466	38.597126	1675		1613.0		skin		2006	Fiji	Fiji						Human, Homo sapiens			Skin sore																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.1002	Streptococcus pyogenes strain emm97.1		1314	Complete	emm97.1				MLST.Streptococcus_pyogenes.283				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793307	GCA_005162245.1	CP035447		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1812090	38.40201	1810		1743.0		Soft tissue		2007	Kenya	Kenya						Human, Homo sapiens			Soft tissue																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.2843	Streptococcus pyogenes strain emm9ST603		1314	Complete	emm9ST603				MLST.Streptococcus_pyogenes.603				2020-12-20T00:00:00Z		PRJNA684347	SAMN17054563	GCA_016126835.1	CP065927		Queensland Health Forensic and Scientific Services	Complete	Illumina NextSeq; Oxford Nanopore GridION	100.0x	Unicycler v. DEC-2020	1.0	0.0	1		1862424	38.544605	1836		1727.0		bone		2020	Australia	Australia						Human, Homo sapiens			Streptococcal Infections																Streptococcus pyogenes WGS	collected_by:Queensland Health
1314.1009	Streptococcus pyogenes strain emmNA		1314	Complete	emmNA				MLST.Streptococcus_pyogenes.612				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793325	GCA_005163385.1	CP035429		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1788166	38.554363	1834		1748.0		throat		1999	Australia	Australia						Human, Homo sapiens			Throat																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.994	Streptococcus pyogenes strain emmSTG866.1		1314	Complete	emmSTG866.1				MLST.Streptococcus_pyogenes.450				2019-05-06T00:00:00Z		PRJNA454341	SAMN10793326	GCA_005160785.1	CP035428		University of Melbourne	Complete	PacBio	80x	HGAP v. 2	1.0		1		1816007	38.416317	1816		1736.0		Soft tissue		2005	Kenya	Kenya						Human, Homo sapiens			Soft tissue																Complete genomes of 30 globally distributed Group A Streptococcus isolates	collected_by:Davies_et_al
1314.2715	Streptococcus pyogenes strain iGAS205		1314	WGS	iGAS205								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828814	GCA_011319335.1	JAAABS000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1856380	38.326042	1857				blood		2009	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2718	Streptococcus pyogenes strain iGAS218		1314	WGS	iGAS218								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828815	GCA_011327435.1	JAAABT000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1856963	38.328712	1856				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2731	Streptococcus pyogenes strain iGAS220		1314	WGS	iGAS220								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828816	GCA_011380045.1	JAAABU000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1856672	38.32982	1857				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2730	Streptococcus pyogenes strain iGAS221		1314	WGS	iGAS221								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828817	GCA_011380015.1	JAAABV000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1856381	38.32613	1855				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2729	Streptococcus pyogenes strain iGAS222		1314	WGS	iGAS222								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828818	GCA_011380005.1	JAAABW000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1856483	38.32801	1856				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2720	Streptococcus pyogenes strain iGAS226		1314	WGS	iGAS226								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828819	GCA_011327415.1	JAAABX000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1856300	38.32484	1856				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2721	Streptococcus pyogenes strain iGAS228		1314	WGS	iGAS228								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828820	GCA_011327395.1	JAAABY000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	21		1856542	38.328247	1857				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2722	Streptococcus pyogenes strain iGAS230		1314	WGS	iGAS230								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828821	GCA_011327365.1	JAAABZ000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	22		1856511	38.326946	1853				blood		2010	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2724	Streptococcus pyogenes strain iGAS239		1314	WGS	iGAS239								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828822	GCA_011379955.1	JAAACA000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1856440	38.325127	1855				blood		2011	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2719	Streptococcus pyogenes strain iGAS245		1314	WGS	iGAS245								2020-03-16T00:00:00Z		PRJNA600655	SAMN13828823	GCA_011327335.1	JAAACB000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1856515	38.326595	1856				blood		2011	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2726	Streptococcus pyogenes strain iGAS260		1314	WGS	iGAS260								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828824	GCA_011379935.1	JAAACC000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1856097	38.325745	1852				tissue		2012	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2725	Streptococcus pyogenes strain iGAS300		1314	WGS	iGAS300								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828825	GCA_011379945.1	JAAACD000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1857212	38.330196	1859				blood		2014	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2727	Streptococcus pyogenes strain iGAS302		1314	WGS	iGAS302				MLST.Streptococcus_pyogenes.176				2020-03-17T00:00:00Z		PRJNA600655	SAMN13828826	GCA_011379925.1	JAAACE000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1890185	38.15923	1902				blood		2014	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2723	Streptococcus pyogenes strain iGAS307		1314	WGS	iGAS307								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828827	GCA_011379905.1	JAAACF000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	20		1856520	38.32644	1856				blood		2015	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2728	Streptococcus pyogenes strain iGAS326		1314	WGS	iGAS326								2020-03-17T00:00:00Z		PRJNA600655	SAMN13828828	GCA_011379865.1	JAAACG000000000		Haukeland University Hospital	WGS	Illumina MiSeq	80x	SPAdes v. 3.9	0.0	0.0	19		1854300	38.324974	1852				blood		2016	Norway	Norway: Bergen						Human, Homo sapiens																			Epidemiologic surveillance of trends in antimicrobial resistance in beta-hemolytic streptococci in western Norway. Whole genome sequencing of resistant isolates to elucidate resistance genes and associated mobile genetic elements.	sample_type:Cell culture
1314.2849	Streptococcus pyogenes strain iGAS376		1314	Complete	iGAS376				MLST.Streptococcus_pyogenes.99				2021-01-06T00:00:00Z		PRJNA685009	SAMN17141633	GCA_016549355.1	CP067010		University of Glasgow	Complete	Illumina; Oxford Nanopore MinION	101x	Unicycler hybrid assembly v. 0.4.8	1.0	0.0	1		1897124	38.60138	1936		1824.0		blood		2018-06-07	United Kingdom	United Kingdom: Scotland						Human, Homo sapiens			Invasive group A Streptococcus infection																Complete genomes of three invasive isolates of S. pyogenes emm5.23	collected_by:Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus Reference Laboratory
1314.2850	Streptococcus pyogenes strain iGAS391		1314	Complete	iGAS391				MLST.Streptococcus_pyogenes.99				2021-01-06T00:00:00Z		PRJNA685009	SAMN17141634	GCA_016549375.1	CP067009		University of Glasgow	Complete	Illumina; Oxford Nanopore MinION	237x	Unicycler hybrid assembly v. 0.4.8	1.0	0.0	1		1897129	38.600906	1933		1824.0		blood		2019-03-21	United Kingdom	United Kingdom: Scotland						Human, Homo sapiens			Invasive group A Streptococcus infection																Complete genomes of three invasive isolates of S. pyogenes emm5.23	collected_by:Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus Reference Laboratory
1314.2848	Streptococcus pyogenes strain iGAS426		1314	Complete	iGAS426				MLST.Streptococcus_pyogenes.99				2021-01-06T00:00:00Z		PRJNA685009	SAMN17141635	GCA_016549335.1	CP067008		University of Glasgow	Complete	Illumina; Oxford Nanopore MinION	199x	Unicycler hybrid assembly v. 0.4.8	1.0	0.0	1		1897111	38.60122	1936		1824.0		blood		2015-02-27	United Kingdom	United Kingdom: Scotland						Human, Homo sapiens			Invasive group A Streptococcus infection																Complete genomes of three invasive isolates of S. pyogenes emm5.23	collected_by:Scottish Haemophilus, Legionella, Meningococcus & Pneumococcus Reference Laboratory
1314.2014	Streptococcus pyogenes strain patientB		1314	WGS	patientB	EMM1.0			MLST.Streptococcus_pyogenes.28				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1407120	GCA_900992425.1	CAAIRZ000000000		SC	WGS						16		1799987	38.376167	1824		1736.0		vaginal swab		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2015	Streptococcus pyogenes strain patientC		1314	WGS	patientC	EMM77.0							2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406938	GCA_900992435.1	CAAISA000000000		SC	WGS						12		1875098	38.31368	1868		1775.0		vaginal swab		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2016	Streptococcus pyogenes strain patientG		1314	WGS	patientG	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406948	GCA_900992445.1	CAAISB000000000		SC	WGS						15		1706390	38.39494	1661		1591.0		vaginal swab		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2018	Streptococcus pyogenes strain patientH		1314	WGS	patientH	EMM75.0			MLST.Streptococcus_pyogenes.150				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406976	GCA_900992465.1	CAAISD000000000		SC	WGS						9		1822500	38.46343	1844		1752.0		sterile site		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2017	Streptococcus pyogenes strain patientI		1314	WGS	patientI	EMM89.0			MLST.Streptococcus_pyogenes.101				2019-04-09T00:00:00Z		PRJEB2232	SAMEA1406989	GCA_900992455.1	CAAISC000000000		SC	WGS						16		1747076	38.402107	1741		1652.0		vaginal swab		2010	Australia	Australia						Human, Homo sapiens																			http://www.sanger.ac.uk/resources/downloads/bacteria/streptococcus-pyogenes.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/	
1314.2709	Streptococcus pyogenes strain spy-1326		1314	WGS	spy-1326				MLST.Streptococcus_pyogenes.36				2020-02-12T00:00:00Z		PRJNA598017	SAMN14047987	GCA_010499535.1	JAAGRT000000000		Peking University	WGS	Illumina NovaSeq	10x	SOAPdenovo v. 2.03	0.0	0.0	83		2004671	38.558548	2098		1955.0		wound	isolated from a patient with sepsis shock	2019-01-06	China	China						Human, Homo sapiens			wound infection																Streptococcus pyogenes S417 was isolated from a patient with sepsis shock.	collected_by:puh3
1314.2708	Streptococcus pyogenes strain spy-1397		1314	WGS	spy-1397								2020-02-12T00:00:00Z		PRJNA598017	SAMN14047988	GCA_010499515.1	JAAGRU000000000		Peking University	WGS	Illumina NovaSeq	10x	SOAPdenovo v. 2.03	0.0	0.0	49		1995610	38.41199	2082		1938.0		wound	isolated from a patient with sepsis shock	2019-02-26	China	China						Human, Homo sapiens			wound infection																Streptococcus pyogenes S417 was isolated from a patient with sepsis shock.	collected_by:puh3
1314.2707	Streptococcus pyogenes strain spy-498		1314	WGS	spy-498								2020-02-12T00:00:00Z		PRJNA598017	SAMN14047986	GCA_010499565.1	JAAGRS000000000		Peking University	WGS	Illumina NovaSeq	10x	SOAPdenovo v. 2.03	0.0	0.0	58		2002928	38.4525	2083		1939.0		wound	isolated from a patient with sepsis shock	2017-08-28	China	China						Human, Homo sapiens			wound infection																Streptococcus pyogenes S417 was isolated from a patient with sepsis shock.	collected_by:puh3
1314.498	Streptococcus pyogenes strain spy0390		1314	WGS	spy0390				MLST.Streptococcus_pyogenes.99				2017-08-14T00:00:00Z	28680421	PRJNA382215	SAMN06701846	GCA_002250265.1	NCTM00000000		Shanghai CDC	WGS	Illumina HiSeq	1600x	SOAPdenovo v. 2.04			38		1953330	38.46	2115		1997.0		Pleural effusion		2013-10-08	China	China						Human, Homo sapiens		20	pneumonia																pathogenic bacteria	collected_by:Chen Mingliang of Shanghai CDC
1314.499	Streptococcus pyogenes strain spy0392		1314	WGS	spy0392				MLST.Streptococcus_pyogenes.99				2017-08-14T00:00:00Z	28680421	PRJNA382215	SAMN06701847	GCA_002250335.1	NCTL00000000		Shanghai CDC	WGS	Illumina HiSeq	1600x	SOAPdenovo v. 2.04			39		1934710	38.39	2097		1987.0		sputum		2013-10-08	China	China						Human, Homo sapiens		27	pneumonia																pathogenic bacteria	collected_by:Chen Mingliang of Shanghai CDC
